WO2016106266A1 - TGFβ RECEPTOR ANTAGONISTS - Google Patents
TGFβ RECEPTOR ANTAGONISTS Download PDFInfo
- Publication number
- WO2016106266A1 WO2016106266A1 PCT/US2015/067252 US2015067252W WO2016106266A1 WO 2016106266 A1 WO2016106266 A1 WO 2016106266A1 US 2015067252 W US2015067252 W US 2015067252W WO 2016106266 A1 WO2016106266 A1 WO 2016106266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- pyridin
- halogen
- independently
- Prior art date
Links
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 108091005735 TGF-beta receptors Proteins 0.000 title 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 196
- 238000000034 method Methods 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 392
- 229910052739 hydrogen Inorganic materials 0.000 claims description 234
- 239000001257 hydrogen Substances 0.000 claims description 234
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 159
- -1 -OH Chemical group 0.000 claims description 134
- 229910052736 halogen Inorganic materials 0.000 claims description 110
- 150000002367 halogens Chemical class 0.000 claims description 110
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 82
- 125000003282 alkyl amino group Chemical group 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 61
- 125000000623 heterocyclic group Chemical group 0.000 claims description 57
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 56
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 50
- 125000003545 alkoxy group Chemical group 0.000 claims description 48
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 39
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 239000005557 antagonist Substances 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 17
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 12
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- VRPRBQAJAQCSCW-BMSJAHLVSA-N N-[4-[3-[5-(trideuteriomethoxy)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(OC=1C=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)([2H])([2H])[2H] VRPRBQAJAQCSCW-BMSJAHLVSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- XODSKPZUYKGNMW-UHFFFAOYSA-N N-[4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O XODSKPZUYKGNMW-UHFFFAOYSA-N 0.000 claims description 4
- UKJWABCHVCNLAX-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-ethoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2OCC)C1=CC(=NC=C1)NC(C)=O)F UKJWABCHVCNLAX-UHFFFAOYSA-N 0.000 claims description 4
- TWGKOZPGDCIKQA-BMSJAHLVSA-N N-[4-[6-fluoro-3-[5-(trideuteriomethoxy)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC([2H])([2H])[2H] TWGKOZPGDCIKQA-BMSJAHLVSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- YAURUPNGLRUZTR-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(C)=O)F YAURUPNGLRUZTR-UHFFFAOYSA-N 0.000 claims description 3
- SDIWHZMLILEDAK-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC SDIWHZMLILEDAK-UHFFFAOYSA-N 0.000 claims description 3
- SDIWHZMLILEDAK-BMSJAHLVSA-N N-[4-[6-chloro-3-[5-(trideuteriomethoxy)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC([2H])([2H])[2H] SDIWHZMLILEDAK-BMSJAHLVSA-N 0.000 claims description 3
- MCOHDLNMMNXGOH-UHFFFAOYSA-N N-[4-[6-fluoro-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC MCOHDLNMMNXGOH-UHFFFAOYSA-N 0.000 claims description 3
- OUXSSNKXGXEJMO-UHFFFAOYSA-N N-[4-[6-methoxy-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC OUXSSNKXGXEJMO-UHFFFAOYSA-N 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- VWSFKHLXKXHRDY-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)F VWSFKHLXKXHRDY-UHFFFAOYSA-N 0.000 claims description 2
- YAURUPNGLRUZTR-BMSJAHLVSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-6-(trideuteriomethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound [2H]C([2H])([2H])OC1=CC2=C(N=C1)C(=C(N2)C1=CC(NC(C)=O)=NC=C1)C1=NC(=CC=C1)C(F)F YAURUPNGLRUZTR-BMSJAHLVSA-N 0.000 claims description 2
- LZIKYNOAPPEQMG-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-6-ethoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)OCC)C1=CC(=NC=C1)NC(C)=O)F LZIKYNOAPPEQMG-UHFFFAOYSA-N 0.000 claims description 2
- OLYCUNOTKFNETC-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(1-hydroxyethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C(C)O)C1=CC(=NC=C1)NC(C)=O)F OLYCUNOTKFNETC-UHFFFAOYSA-N 0.000 claims description 2
- BXHURORUSAJJMH-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C(C)(C)O)C1=CC(=NC=C1)NC(C)=O)F BXHURORUSAJJMH-UHFFFAOYSA-N 0.000 claims description 2
- DYOHQLYHPIZXHG-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2CO)C1=CC(=NC=C1)NC(C)=O)F DYOHQLYHPIZXHG-UHFFFAOYSA-N 0.000 claims description 2
- CDVFGEXFOAGXJO-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(methylaminomethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2CNC)C1=CC(=NC=C1)NC(C)=O)F CDVFGEXFOAGXJO-UHFFFAOYSA-N 0.000 claims description 2
- OLYCUNOTKFNETC-LLVKDONJSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-[(1R)-1-hydroxyethyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2[C@@H](C)O)C1=CC(=NC=C1)NC(C)=O)F OLYCUNOTKFNETC-LLVKDONJSA-N 0.000 claims description 2
- PRIWSHXIEAISOK-UHFFFAOYSA-N N-[4-[6-methoxy-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC PRIWSHXIEAISOK-UHFFFAOYSA-N 0.000 claims description 2
- OUXSSNKXGXEJMO-BMSJAHLVSA-N N-[4-[6-methoxy-3-[5-(trideuteriomethoxy)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound [2H]C([2H])([2H])OC1=CN=C(C=C1)C1=C(NC2=C1N=CC(OC)=C2)C1=CC(NC(C)=O)=NC=C1 OUXSSNKXGXEJMO-BMSJAHLVSA-N 0.000 claims description 2
- IHDQOIQCCCQCNA-UHFFFAOYSA-N N-[4-[7-(1-hydroxyethyl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound OC(C)C1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC IHDQOIQCCCQCNA-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 229930192474 thiophene Chemical group 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 39
- 125000001475 halogen functional group Chemical group 0.000 claims 28
- AQUKDYPRJZEQSG-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-[(dimethylamino)methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2CN(C)C)C1=CC(=NC=C1)NC(C)=O)F AQUKDYPRJZEQSG-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 214
- 229910001868 water Inorganic materials 0.000 description 206
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 177
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 161
- 238000005481 NMR spectroscopy Methods 0.000 description 154
- 238000004128 high performance liquid chromatography Methods 0.000 description 154
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 147
- 239000002245 particle Substances 0.000 description 145
- 239000000203 mixture Substances 0.000 description 138
- 239000003643 water by type Substances 0.000 description 133
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 96
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 91
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 77
- 238000007429 general method Methods 0.000 description 74
- 238000006243 chemical reaction Methods 0.000 description 73
- 239000007787 solid Substances 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 66
- 239000000243 solution Substances 0.000 description 64
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 49
- 239000000047 product Substances 0.000 description 43
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 125000005843 halogen group Chemical group 0.000 description 33
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 31
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 30
- 239000005695 Ammonium acetate Substances 0.000 description 30
- 235000019257 ammonium acetate Nutrition 0.000 description 30
- 229940043376 ammonium acetate Drugs 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 29
- 239000012071 phase Substances 0.000 description 29
- 239000000725 suspension Substances 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 229940045207 immuno-oncology agent Drugs 0.000 description 24
- 239000002584 immunological anticancer agent Substances 0.000 description 24
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 238000003818 flash chromatography Methods 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 102000009618 Transforming Growth Factors Human genes 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 229910000024 caesium carbonate Inorganic materials 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000013058 crude material Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 13
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- WULVUFYZVYHTFX-UHFFFAOYSA-N 2-bromo-5-methoxypyridine Chemical compound COC1=CC=C(Br)N=C1 WULVUFYZVYHTFX-UHFFFAOYSA-N 0.000 description 7
- JWTZSVLLPKTZJP-UHFFFAOYSA-N 2-bromo-6-chloropyridine Chemical compound ClC1=CC=CC(Br)=N1 JWTZSVLLPKTZJP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 238000001023 centrifugal evaporation Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 229910002666 PdCl2 Inorganic materials 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 239000012391 XPhos Pd G2 Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000001270 agonistic effect Effects 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 5
- WULVUFYZVYHTFX-FIBGUPNXSA-N 2-bromo-5-(trideuteriomethoxy)pyridine Chemical compound [2H]C([2H])([2H])OC1=CC=C(Br)N=C1 WULVUFYZVYHTFX-FIBGUPNXSA-N 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 125000006575 electron-withdrawing group Chemical group 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- BZUUVQCSPHPUQA-UHFFFAOYSA-N 2-bromo-5-chloropyridine Chemical compound ClC1=CC=C(Br)N=C1 BZUUVQCSPHPUQA-UHFFFAOYSA-N 0.000 description 4
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical compound COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
- ZIDIKYIZXMYHAW-UHFFFAOYSA-N 2-bromo-6-fluoropyridine Chemical compound FC1=CC=CC(Br)=N1 ZIDIKYIZXMYHAW-UHFFFAOYSA-N 0.000 description 3
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- IUVCEWDTRHWINV-UHFFFAOYSA-N N-[4-[5-methoxy-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC1=CC=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC IUVCEWDTRHWINV-UHFFFAOYSA-N 0.000 description 3
- RCAVIUHVCFAMEU-UHFFFAOYSA-N N-[4-[6-(2-methoxyethoxy)-3-(5-methoxypyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COCCOC=1C=C2C(=NC=1)C(=C(N2COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC RCAVIUHVCFAMEU-UHFFFAOYSA-N 0.000 description 3
- JNWGLODSPWWDAX-UHFFFAOYSA-N N-[4-[6-(2-methoxyethoxy)-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COCCOC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC JNWGLODSPWWDAX-UHFFFAOYSA-N 0.000 description 3
- CAYIFMSNPBNWOA-UHFFFAOYSA-N N-[4-[6-bromo-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound BrC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC CAYIFMSNPBNWOA-UHFFFAOYSA-N 0.000 description 3
- MAMWDDXCRNOMEK-UHFFFAOYSA-N N-[4-[6-hydroxy-3-(5-methoxypyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound OC=1C=C2C(=NC=1)C(=C(N2COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC MAMWDDXCRNOMEK-UHFFFAOYSA-N 0.000 description 3
- 102000004473 OX40 Ligand Human genes 0.000 description 3
- 108010042215 OX40 Ligand Proteins 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000012457 nonaqueous media Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 150000003248 quinolines Chemical group 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- VHGBUYMPBFPXQM-UHFFFAOYSA-N 2,5-dibromopyridin-3-amine Chemical compound NC1=CC(Br)=CN=C1Br VHGBUYMPBFPXQM-UHFFFAOYSA-N 0.000 description 2
- WPRGYCGIBOKQEI-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-N-(1,3-dihydroxypropan-2-yl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound ClC1=CC(=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC)C(=O)NC(CO)CO WPRGYCGIBOKQEI-UHFFFAOYSA-N 0.000 description 2
- KUHSAAHTEMAJTF-UHFFFAOYSA-N 2-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=CC=N1 KUHSAAHTEMAJTF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BQFKHNMQEDTHEZ-UHFFFAOYSA-N 2-[2-(2-acetamidopyridin-4-yl)-3-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[3,2-b]pyridin-1-yl]acetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=C(C2=NC=CC=C2N1CC(=O)N)C1=NC(=CC=C1)C(F)F BQFKHNMQEDTHEZ-UHFFFAOYSA-N 0.000 description 2
- SURKZMFXICWLHU-UHFFFAOYSA-N 2-bromo-4-chloropyridine Chemical compound ClC1=CC=NC(Br)=C1 SURKZMFXICWLHU-UHFFFAOYSA-N 0.000 description 2
- ZTBGDNNRDRISQZ-UHFFFAOYSA-N 2-bromo-6-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=CC(Br)=N1 ZTBGDNNRDRISQZ-UHFFFAOYSA-N 0.000 description 2
- KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- BIEFUCZKSQLACW-UHFFFAOYSA-N 4-[6-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]-N-methylpyridin-2-amine Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC)C1=NC=C(C=C1)F BIEFUCZKSQLACW-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100037354 Ectodysplasin-A Human genes 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- VMPHXSISAWQRSW-UHFFFAOYSA-N N-[4-[2-(3-amino-5-bromopyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=C(C=1)Br)C#CC1=CC(=NC=C1)NC(C)=O VMPHXSISAWQRSW-UHFFFAOYSA-N 0.000 description 2
- VWNMDKXCUZBYCS-UHFFFAOYSA-N N-[4-[3-(5-methoxypyridin-2-yl)-6-methylsulfonyl-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)C=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC VWNMDKXCUZBYCS-UHFFFAOYSA-N 0.000 description 2
- GEAUWSQFJFAMAS-UHFFFAOYSA-N N-[4-[3-(6-chloropyridin-2-yl)-5-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC=2C1=NC(=CC=2)F)C1=CC(=NC=C1)NC(C)=O GEAUWSQFJFAMAS-UHFFFAOYSA-N 0.000 description 2
- XKKNZDFGIGAVTQ-UHFFFAOYSA-N N-[4-[3-(6-chloropyridin-2-yl)-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)F)C1=CC(=NC=C1)NC(C)=O XKKNZDFGIGAVTQ-UHFFFAOYSA-N 0.000 description 2
- VLNVOPKYHBOXFG-UHFFFAOYSA-N N-[4-[3-(6-chloropyridin-2-yl)-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(C)=O VLNVOPKYHBOXFG-UHFFFAOYSA-N 0.000 description 2
- YSHDTTAGUZFYTD-UHFFFAOYSA-N N-[4-[3-(6-methylpyridin-2-yl)-7-(oxan-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CC1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C1CCOCC1)C1=CC(=NC=C1)NC(C)=O YSHDTTAGUZFYTD-UHFFFAOYSA-N 0.000 description 2
- VIACTSRPMZXABM-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]-2-(dimethylamino)acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(CN(C)C)=O)F VIACTSRPMZXABM-UHFFFAOYSA-N 0.000 description 2
- WXVWCPGMODJNGF-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(2-pyrrolidin-1-ylethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2OCCN1CCCC1)C1=CC(=NC=C1)NC(C)=O)F WXVWCPGMODJNGF-UHFFFAOYSA-N 0.000 description 2
- WBOZMWGWWGFJRK-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(oxan-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C1CCOCC1)C1=CC(=NC=C1)NC(C)=O)F WBOZMWGWWGFJRK-UHFFFAOYSA-N 0.000 description 2
- BLXKIOOFUHGYTL-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-ethenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C=C)C1=CC(=NC=C1)NC(C)=O)F BLXKIOOFUHGYTL-UHFFFAOYSA-N 0.000 description 2
- RQYTVKRCADDCJX-UHFFFAOYSA-N N-[4-[6-bromo-3-(5-methoxypyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound BrC=1C=C2C(=NC=1)C(=C(N2COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC RQYTVKRCADDCJX-UHFFFAOYSA-N 0.000 description 2
- WQNNRNJKXPUYGN-UHFFFAOYSA-N N-[4-[6-chloro-3-(6-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)Cl)C1=CC(=NC=C1)NC(C)=O WQNNRNJKXPUYGN-UHFFFAOYSA-N 0.000 description 2
- LMIFLQXRWUDCAE-UHFFFAOYSA-N N-[4-[6-cyano-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(#N)C=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC LMIFLQXRWUDCAE-UHFFFAOYSA-N 0.000 description 2
- DGVJUAZFHAGZKY-UHFFFAOYSA-N N-[4-[7-(6-chloropyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC2=NC=CN=C21)C1=CC(=NC=C1)NC(C)=O DGVJUAZFHAGZKY-UHFFFAOYSA-N 0.000 description 2
- ZNAJAAFVZVFSRM-UHFFFAOYSA-N N-[4-[7-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)F ZNAJAAFVZVFSRM-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GMDXVMCDNRSXGV-UHFFFAOYSA-N methyl 2-(2-acetamidopyridin-4-yl)-5-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylate Chemical compound ClC1=CC(=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)F)C(=O)OC GMDXVMCDNRSXGV-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- XDRVJGRCLHDJIS-UHFFFAOYSA-N n-(4-ethynylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(C#C)=CC=N1 XDRVJGRCLHDJIS-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- DIIFZCPZIRQDIJ-UHFFFAOYSA-N (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid Chemical compound CC1=NOC(C)=C1B(O)O DIIFZCPZIRQDIJ-UHFFFAOYSA-N 0.000 description 1
- ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 description 1
- XDDGKNRSCDEWBR-UHFFFAOYSA-N (6-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=CC(Br)=N1 XDDGKNRSCDEWBR-UHFFFAOYSA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ZNLTYQPDGSUUGG-UHFFFAOYSA-N 2,3-difluoro-5-iodopyridine Chemical compound FC1=CC(I)=CN=C1F ZNLTYQPDGSUUGG-UHFFFAOYSA-N 0.000 description 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 1
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 1
- RTNMAMGONCCJAS-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-N-methyl-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=C(C2=NC=CC(=C2N1)C(=O)NC)C=1C=NC(=CC=1)OC RTNMAMGONCCJAS-UHFFFAOYSA-N 0.000 description 1
- CGUVOIWEZZTAGE-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-3-bromo-5-chloro-N-(1,3-dihydroxypropan-2-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=C(C2=NC(=CC(=C2N1)C(=O)NC(CO)CO)Cl)Br CGUVOIWEZZTAGE-UHFFFAOYSA-N 0.000 description 1
- WKZOAJGMVBWXKK-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-3-bromo-5-chloro-N-methyl-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=C(C2=NC(=CC(=C2N1)C(=O)NC)Cl)Br WKZOAJGMVBWXKK-UHFFFAOYSA-N 0.000 description 1
- AAIJRYOSVTUGHF-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=CC2=NC(=CC(=C2N1)C(=O)O)Cl AAIJRYOSVTUGHF-UHFFFAOYSA-N 0.000 description 1
- NCQNUHVMBPKOEQ-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-3-(6-methoxypyridin-3-yl)-N-methyl-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound ClC1=CC(=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC)C(=O)NC NCQNUHVMBPKOEQ-UHFFFAOYSA-N 0.000 description 1
- ASVGSIRUWDRMLZ-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-N-(1,3-dihydroxypropan-2-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=CC2=NC(=CC(=C2N1)C(=O)NC(CO)CO)Cl ASVGSIRUWDRMLZ-UHFFFAOYSA-N 0.000 description 1
- HZLCPNVJPJZOSE-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-N-(1,3-dihydroxypropan-2-yl)-3-pyridin-3-yl-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound ClC1=CC(=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC=CC=1)C(=O)NC(CO)CO HZLCPNVJPJZOSE-UHFFFAOYSA-N 0.000 description 1
- IDQVYZPWHWIHKS-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-5-chloro-N-methyl-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=CC2=NC(=CC(=C2N1)C(=O)NC)Cl IDQVYZPWHWIHKS-UHFFFAOYSA-N 0.000 description 1
- BIGIPEDTAGYZGQ-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-N-(1,3-dihydroxypropan-2-yl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxamide Chemical compound OCC(CO)NC(=O)C1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC BIGIPEDTAGYZGQ-UHFFFAOYSA-N 0.000 description 1
- VRZZMRYGHFNKEN-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)acetamide Chemical compound CN1CCN(CC(N)=O)CC1 VRZZMRYGHFNKEN-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- XOGMOLVFPVRVFY-UHFFFAOYSA-N 2-[(6-bromopyridin-2-yl)amino]ethanol Chemical compound OCCNC1=CC=CC(Br)=N1 XOGMOLVFPVRVFY-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 150000003930 2-aminopyridines Chemical class 0.000 description 1
- JMDIWBIWPAAWHP-UHFFFAOYSA-N 2-bromo-4-ethylpyridine Chemical compound CCC1=CC=NC(Br)=C1 JMDIWBIWPAAWHP-UHFFFAOYSA-N 0.000 description 1
- AWBDARKONATUHX-UHFFFAOYSA-N 2-bromo-4-methoxypyridine Chemical compound COC1=CC=NC(Br)=C1 AWBDARKONATUHX-UHFFFAOYSA-N 0.000 description 1
- LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
- AZOXQBMBDRLSCQ-UHFFFAOYSA-N 2-bromo-5-chloropyridin-3-amine Chemical compound NC1=CC(Cl)=CN=C1Br AZOXQBMBDRLSCQ-UHFFFAOYSA-N 0.000 description 1
- CVYWULFZGZRVCV-UHFFFAOYSA-N 2-bromo-5-methoxypyridin-3-amine Chemical compound COC1=CN=C(Br)C(N)=C1 CVYWULFZGZRVCV-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- ZRXQHWYUAIXKRL-UHFFFAOYSA-N 2-bromo-5-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CC=C(Br)N=C1 ZRXQHWYUAIXKRL-UHFFFAOYSA-N 0.000 description 1
- DOWNSQADAFSSAR-UHFFFAOYSA-N 2-bromo-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC(Br)=N1 DOWNSQADAFSSAR-UHFFFAOYSA-N 0.000 description 1
- PDCBQYZKWWAKCG-UHFFFAOYSA-N 2-bromo-6-chloro-4-methylpyridine Chemical compound CC1=CC(Cl)=NC(Br)=C1 PDCBQYZKWWAKCG-UHFFFAOYSA-N 0.000 description 1
- QFPSGSIVZKURDU-UHFFFAOYSA-N 2-bromo-6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1Br QFPSGSIVZKURDU-UHFFFAOYSA-N 0.000 description 1
- BUPDRKSRZCMGRP-UHFFFAOYSA-N 2-bromo-6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C(Br)=N1 BUPDRKSRZCMGRP-UHFFFAOYSA-N 0.000 description 1
- HKDVVTLISGIPFE-UHFFFAOYSA-N 2-bromopyridin-3-amine Chemical compound NC1=CC=CN=C1Br HKDVVTLISGIPFE-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- PPKPMWTWNSWRQG-UHFFFAOYSA-N 2-chloro-N-[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClCC(=O)NC1=NC=CC(=C1)C1=C(C2=NC=C(C=C2N1)Cl)C1=NC=C(C=C1)F PPKPMWTWNSWRQG-UHFFFAOYSA-N 0.000 description 1
- GYZNHUNWABYAPO-UHFFFAOYSA-N 2-fluoro-5-iodopyridine Chemical compound FC1=CC=C(I)C=N1 GYZNHUNWABYAPO-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- BWRNWWSQZROEOA-UHFFFAOYSA-N 2-morpholin-4-ylacetamide Chemical compound NC(=O)CN1CCOCC1 BWRNWWSQZROEOA-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 150000003929 3-aminopyridines Chemical class 0.000 description 1
- AEVSSZHXGJAPIE-UHFFFAOYSA-N 3-chloropyrazin-2-amine Chemical compound NC1=NC=CN=C1Cl AEVSSZHXGJAPIE-UHFFFAOYSA-N 0.000 description 1
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
- MKYMPPMHOCMKMQ-UHFFFAOYSA-N 4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-amine Chemical compound COC1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)N MKYMPPMHOCMKMQ-UHFFFAOYSA-N 0.000 description 1
- ZZWRNAJRXWCWHG-UHFFFAOYSA-N 4-[3-[6-(difluoromethyl)pyridin-2-yl]-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-amine Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)N)F ZZWRNAJRXWCWHG-UHFFFAOYSA-N 0.000 description 1
- HQNFQAWAAUSMLW-UHFFFAOYSA-N 4-[6-methoxy-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-amine Chemical compound COC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)N)C1=NC=C(C=C1)OC HQNFQAWAAUSMLW-UHFFFAOYSA-N 0.000 description 1
- RKMJFRYVUHOZJX-UHFFFAOYSA-N 4-[6-methoxy-3-(6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-amine Chemical compound COC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)N)C1=NC(=CC=C1)C RKMJFRYVUHOZJX-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- GTLFLMZOABSJSV-UHFFFAOYSA-N 4-chloropyridin-3-amine Chemical compound NC1=CN=CC=C1Cl GTLFLMZOABSJSV-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- RPFAUCIXZGMCFN-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)C=N1 RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 1
- PEAOEIWYQVXZMB-UHFFFAOYSA-N 5-bromo-2-chloropyridine Chemical compound ClC1=CC=C(Br)C=N1 PEAOEIWYQVXZMB-UHFFFAOYSA-N 0.000 description 1
- JLCVSFDCHKCISN-UHFFFAOYSA-N 5-bromo-2-fluoro-3-methylpyridine Chemical compound CC1=CC(Br)=CN=C1F JLCVSFDCHKCISN-UHFFFAOYSA-N 0.000 description 1
- DWVCZDMMGYIULX-UHFFFAOYSA-N 5-bromo-2-methoxypyrimidine Chemical compound COC1=NC=C(Br)C=N1 DWVCZDMMGYIULX-UHFFFAOYSA-N 0.000 description 1
- DMSHUVBQFSNBBL-UHFFFAOYSA-N 5-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=C(C#N)N=C1 DMSHUVBQFSNBBL-UHFFFAOYSA-N 0.000 description 1
- CXWLXKZIXLOBCC-UHFFFAOYSA-N 5-chloro-2-iodopyridine Chemical compound ClC1=CC=C(I)N=C1 CXWLXKZIXLOBCC-UHFFFAOYSA-N 0.000 description 1
- NTXRNCUPGYOZCN-UHFFFAOYSA-N 5-iodo-2-methoxypyridine Chemical compound COC1=CC=C(I)C=N1 NTXRNCUPGYOZCN-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- PSZRCSVBLJMQLL-UHFFFAOYSA-N 6-bromo-3-chloro-2-methylpyridine Chemical compound CC1=NC(Br)=CC=C1Cl PSZRCSVBLJMQLL-UHFFFAOYSA-N 0.000 description 1
- BFQONZCQHGIKIY-UHFFFAOYSA-N 6-bromo-3-fluoro-2-methylpyridine Chemical compound CC1=NC(Br)=CC=C1F BFQONZCQHGIKIY-UHFFFAOYSA-N 0.000 description 1
- ZTEATMVVGQUULZ-UHFFFAOYSA-N 6-bromoisoquinoline Chemical compound C1=NC=CC2=CC(Br)=CC=C21 ZTEATMVVGQUULZ-UHFFFAOYSA-N 0.000 description 1
- PTEFNEALEPSHLC-UHFFFAOYSA-N 6-bromopyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1 PTEFNEALEPSHLC-UHFFFAOYSA-N 0.000 description 1
- HNEBPTAKURBYRM-UHFFFAOYSA-N 6-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=CC(C#N)=N1 HNEBPTAKURBYRM-UHFFFAOYSA-N 0.000 description 1
- IFIHYLCUKYCKRH-UHFFFAOYSA-N 6-bromoquinoline Chemical compound N1=CC=CC2=CC(Br)=CC=C21 IFIHYLCUKYCKRH-UHFFFAOYSA-N 0.000 description 1
- DPRIHFQFWWCIGY-UHFFFAOYSA-N 8-bromoisoquinoline Chemical compound C1=NC=C2C(Br)=CC=CC2=C1 DPRIHFQFWWCIGY-UHFFFAOYSA-N 0.000 description 1
- PIWNKSHCLTZKSZ-UHFFFAOYSA-N 8-bromoquinoline Chemical compound C1=CN=C2C(Br)=CC=CC2=C1 PIWNKSHCLTZKSZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 229940121697 CD27 agonist Drugs 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 229940122551 CD40 antagonist Drugs 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- FBMLZMFEJDIAFW-UHFFFAOYSA-N CN1C(=C(C2=NC=CC=C21)C1=NC=C(C=C1)F)C1=CC(=NC=C1)NC(C)=O Chemical compound CN1C(=C(C2=NC=CC=C21)C1=NC=C(C=C1)F)C1=CC(=NC=C1)NC(C)=O FBMLZMFEJDIAFW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100039536 Calcium-activated chloride channel regulator 1 Human genes 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010008773 Choroid melanoma Diseases 0.000 description 1
- AWMJAJOFLPHUNK-UHFFFAOYSA-N ClC1=C2C(=NC=C1)C(=C(N2COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)C(F)F Chemical compound ClC1=C2C(=NC=C1)C(=C(N2COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)C(F)F AWMJAJOFLPHUNK-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- IXGPIPMAZKCLDZ-UHFFFAOYSA-N FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2C=1CCOCC=1)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F Chemical compound FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2C=1CCOCC=1)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F IXGPIPMAZKCLDZ-UHFFFAOYSA-N 0.000 description 1
- CSYIIVFFBCKADK-UHFFFAOYSA-N FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2C=C)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F Chemical compound FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2C=C)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F CSYIIVFFBCKADK-UHFFFAOYSA-N 0.000 description 1
- UESIWFXNYBNTRJ-UHFFFAOYSA-N FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2OCC)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F Chemical compound FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2OCC)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F UESIWFXNYBNTRJ-UHFFFAOYSA-N 0.000 description 1
- YDIFCMDYJRFGDW-UHFFFAOYSA-N FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2OCCN1CCCC1)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F Chemical compound FC(C1=CC=CC(=N1)C1=C(N(C=2C1=NC=CC=2OCCN1CCCC1)COCC[Si](C)(C)C)C1=CC(=NC=C1)NC(C)=O)F YDIFCMDYJRFGDW-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000650134 Homo sapiens WAS/WASL-interacting protein family member 2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- YQFKBIALUMYKTG-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-4-chloropyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=CC(=C1NC(C(F)(F)F)=O)Cl YQFKBIALUMYKTG-UHFFFAOYSA-N 0.000 description 1
- QVVQFLCKUXGKMS-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-5-bromopyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=C(C=C1NC(C(F)(F)F)=O)Br QVVQFLCKUXGKMS-UHFFFAOYSA-N 0.000 description 1
- ZHLWDQIYUXPDPO-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-5-chloropyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=C(C=C1NC(C(F)(F)F)=O)Cl ZHLWDQIYUXPDPO-UHFFFAOYSA-N 0.000 description 1
- YVXJWUVWLMOOHK-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-5-fluoropyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=C(C=C1NC(C(F)(F)F)=O)F YVXJWUVWLMOOHK-UHFFFAOYSA-N 0.000 description 1
- VSXSSYNXBRCEFL-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-5-methoxypyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=C(C=C1NC(C(F)(F)F)=O)OC VSXSSYNXBRCEFL-UHFFFAOYSA-N 0.000 description 1
- VRLYGTRLTZYCIW-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-6-fluoropyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC(=CC=C1NC(C(F)(F)F)=O)F VRLYGTRLTZYCIW-UHFFFAOYSA-N 0.000 description 1
- MUFXDVLIRIEPAA-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]-6-methoxypyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC(=CC=C1NC(C(F)(F)F)=O)OC MUFXDVLIRIEPAA-UHFFFAOYSA-N 0.000 description 1
- JWUVCYYINYIQIV-UHFFFAOYSA-N N-[2-[2-(2-acetamidopyridin-4-yl)ethynyl]pyridin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC1=NC=CC=C1NC(C(F)(F)F)=O JWUVCYYINYIQIV-UHFFFAOYSA-N 0.000 description 1
- XZUCEQJWZLWWLC-UHFFFAOYSA-N N-[4-(1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound N1C(=CC2=NC=CC=C21)C1=CC(=NC=C1)NC(C)=O XZUCEQJWZLWWLC-UHFFFAOYSA-N 0.000 description 1
- BQMKJTHVDAHUDO-UHFFFAOYSA-N N-[4-(3-bromo-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound BrC1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O BQMKJTHVDAHUDO-UHFFFAOYSA-N 0.000 description 1
- RBEIWSNMLPAJOG-UHFFFAOYSA-N N-[4-(3-isoquinolin-6-yl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound C1=NC=CC2=CC(=CC=C12)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O RBEIWSNMLPAJOG-UHFFFAOYSA-N 0.000 description 1
- MSODGBYTOVGICZ-UHFFFAOYSA-N N-[4-(3-pyrimidin-2-yl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound N1=C(N=CC=C1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O MSODGBYTOVGICZ-UHFFFAOYSA-N 0.000 description 1
- XOSKNJGMSZZNEP-UHFFFAOYSA-N N-[4-(3-quinolin-6-yl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound N1=CC=CC2=CC(=CC=C12)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O XOSKNJGMSZZNEP-UHFFFAOYSA-N 0.000 description 1
- WTHZTFUSIMAWAX-UHFFFAOYSA-N N-[4-(3-quinolin-8-yl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound N1=CC=CC2=CC=CC(=C12)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O WTHZTFUSIMAWAX-UHFFFAOYSA-N 0.000 description 1
- VKMFQVXRVBWJDN-UHFFFAOYSA-N N-[4-(6-cyano-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound C(#N)C=1C=C2C(=NC=1)C=C(N2)C1=CC(=NC=C1)NC(C)=O VKMFQVXRVBWJDN-UHFFFAOYSA-N 0.000 description 1
- NURJHMUKGBIAGY-UHFFFAOYSA-N N-[4-(6-cyano-3-iodo-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]acetamide Chemical compound C(#N)C=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)I NURJHMUKGBIAGY-UHFFFAOYSA-N 0.000 description 1
- APDOGLQCFZOURF-UHFFFAOYSA-N N-[4-[2-(3-amino-4-chloropyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=CC=1Cl)C#CC1=CC(=NC=C1)NC(C)=O APDOGLQCFZOURF-UHFFFAOYSA-N 0.000 description 1
- AUBITVYYPDQAKS-UHFFFAOYSA-N N-[4-[2-(3-amino-5-chloropyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=C(C=1)Cl)C#CC1=CC(=NC=C1)NC(C)=O AUBITVYYPDQAKS-UHFFFAOYSA-N 0.000 description 1
- LCIGTFDIEYECPI-UHFFFAOYSA-N N-[4-[2-(3-amino-5-fluoropyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=C(C=1)F)C#CC1=CC(=NC=C1)NC(C)=O LCIGTFDIEYECPI-UHFFFAOYSA-N 0.000 description 1
- SVCQEXKVGHNJCI-UHFFFAOYSA-N N-[4-[2-(3-amino-5-methoxypyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=C(C=1)OC)C#CC1=CC(=NC=C1)NC(C)=O SVCQEXKVGHNJCI-UHFFFAOYSA-N 0.000 description 1
- ISKXVGVCEZPZIL-UHFFFAOYSA-N N-[4-[2-(3-amino-6-fluoropyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC(=CC=1)F)C#CC1=CC(=NC=C1)NC(C)=O ISKXVGVCEZPZIL-UHFFFAOYSA-N 0.000 description 1
- SPJUJLLFEHLRSB-UHFFFAOYSA-N N-[4-[2-(3-amino-6-methoxypyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC(=CC=1)OC)C#CC1=CC(=NC=C1)NC(C)=O SPJUJLLFEHLRSB-UHFFFAOYSA-N 0.000 description 1
- OEWMVILYOZJGJW-UHFFFAOYSA-N N-[4-[2-(3-aminopyrazin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=CN=1)C#CC1=CC(=NC=C1)NC(C)=O OEWMVILYOZJGJW-UHFFFAOYSA-N 0.000 description 1
- JPHFFKUDHIBYOW-UHFFFAOYSA-N N-[4-[2-(3-aminopyridin-2-yl)ethynyl]pyridin-2-yl]acetamide Chemical compound NC=1C(=NC=CC=1)C#CC1=CC(=NC=C1)NC(C)=O JPHFFKUDHIBYOW-UHFFFAOYSA-N 0.000 description 1
- IOAMUBPTUJQQIT-UHFFFAOYSA-N N-[4-[3-(4-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC(=NC=C1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O IOAMUBPTUJQQIT-UHFFFAOYSA-N 0.000 description 1
- MLSCQPLLIBIVCC-UHFFFAOYSA-N N-[4-[3-(4-ethylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(C)C1=CC(=NC=C1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O MLSCQPLLIBIVCC-UHFFFAOYSA-N 0.000 description 1
- JSSSLIAPOKPKMC-UHFFFAOYSA-N N-[4-[3-(4-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC1=CC(=NC=C1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O JSSSLIAPOKPKMC-UHFFFAOYSA-N 0.000 description 1
- BWKMWNMSBIREOE-UHFFFAOYSA-N N-[4-[3-(4-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CC1=CC(=NC=C1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O BWKMWNMSBIREOE-UHFFFAOYSA-N 0.000 description 1
- LCGMMFUNUMGQHO-UHFFFAOYSA-N N-[4-[3-(5,6-difluoropyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=C(C=NC=1F)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O LCGMMFUNUMGQHO-UHFFFAOYSA-N 0.000 description 1
- XKBQEEMXWRKMJM-UHFFFAOYSA-N N-[4-[3-(5-chloro-6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=CC(=NC=1C)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O XKBQEEMXWRKMJM-UHFFFAOYSA-N 0.000 description 1
- VCVRXCQLVOMSMK-UHFFFAOYSA-N N-[4-[3-(5-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O VCVRXCQLVOMSMK-UHFFFAOYSA-N 0.000 description 1
- FJZQOTRNXBTFRF-UHFFFAOYSA-N N-[4-[3-(5-chloropyridin-2-yl)-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=CC(=NC=1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(C)=O FJZQOTRNXBTFRF-UHFFFAOYSA-N 0.000 description 1
- DCBTZROHQFRGGP-UHFFFAOYSA-N N-[4-[3-(5-fluoro-4-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C(=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)C DCBTZROHQFRGGP-UHFFFAOYSA-N 0.000 description 1
- FERHSHBURLOYFA-UHFFFAOYSA-N N-[4-[3-(5-fluoro-6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=CC(=NC=1C)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O FERHSHBURLOYFA-UHFFFAOYSA-N 0.000 description 1
- HIBSCUPNVKNRSL-UHFFFAOYSA-N N-[4-[3-(5-fluoro-6-methylpyridin-2-yl)-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=CC(=NC=1C)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(C)=O HIBSCUPNVKNRSL-UHFFFAOYSA-N 0.000 description 1
- CSGOCRBKBMMOAS-UHFFFAOYSA-N N-[4-[3-(5-fluoropyridin-2-yl)-6-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=CC(=NC=1)C1=C(NC=2C1=NC=C(C=2)OC)C1=CC(=NC=C1)NC(C)=O CSGOCRBKBMMOAS-UHFFFAOYSA-N 0.000 description 1
- VRPRBQAJAQCSCW-UHFFFAOYSA-N N-[4-[3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC=1C=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O VRPRBQAJAQCSCW-UHFFFAOYSA-N 0.000 description 1
- LIKDYDWODKJNQN-UHFFFAOYSA-N N-[4-[3-(5-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CC=1C=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O LIKDYDWODKJNQN-UHFFFAOYSA-N 0.000 description 1
- JVSJQDBKLPJNNG-UHFFFAOYSA-N N-[4-[3-(5-methylsulfonylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)C=1C=CC(=NC=1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O JVSJQDBKLPJNNG-UHFFFAOYSA-N 0.000 description 1
- HZGVFWWUNGOCPZ-UHFFFAOYSA-N N-[4-[3-(6-chloro-4-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC(=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)C HZGVFWWUNGOCPZ-UHFFFAOYSA-N 0.000 description 1
- JPVHYXJAJWPADW-UHFFFAOYSA-N N-[4-[3-(6-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O JPVHYXJAJWPADW-UHFFFAOYSA-N 0.000 description 1
- UDFWAZASNLHOLI-UHFFFAOYSA-N N-[4-[3-(6-chloropyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O UDFWAZASNLHOLI-UHFFFAOYSA-N 0.000 description 1
- HUWIXZYCOANMNI-UHFFFAOYSA-N N-[4-[3-(6-cyanopyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(#N)C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O HUWIXZYCOANMNI-UHFFFAOYSA-N 0.000 description 1
- SSALSHZHAFBGJI-UHFFFAOYSA-N N-[4-[3-(6-cyanopyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(#N)C1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O SSALSHZHAFBGJI-UHFFFAOYSA-N 0.000 description 1
- OBFLSUILMNVBKU-UHFFFAOYSA-N N-[4-[3-(6-fluoro-5-methylpyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=C(C=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)C OBFLSUILMNVBKU-UHFFFAOYSA-N 0.000 description 1
- ZRPGPXPEWHIVDN-UHFFFAOYSA-N N-[4-[3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O ZRPGPXPEWHIVDN-UHFFFAOYSA-N 0.000 description 1
- MTOKESMTTXYGSQ-UHFFFAOYSA-N N-[4-[3-(6-fluoropyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O MTOKESMTTXYGSQ-UHFFFAOYSA-N 0.000 description 1
- ILRSFFCYCYFCCO-UHFFFAOYSA-N N-[4-[3-(6-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O ILRSFFCYCYFCCO-UHFFFAOYSA-N 0.000 description 1
- WNEDBWIYXAKWNS-UHFFFAOYSA-N N-[4-[3-(6-methoxypyridin-3-yl)-1-methylpyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC1=CC=C(C=N1)C1=C(N(C=2C1=NC=CC=2)C)C1=CC(=NC=C1)NC(C)=O WNEDBWIYXAKWNS-UHFFFAOYSA-N 0.000 description 1
- UDICEJRTGFQQJQ-UHFFFAOYSA-N N-[4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]cyclopropanecarboxamide Chemical compound COC1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(=O)C1CC1 UDICEJRTGFQQJQ-UHFFFAOYSA-N 0.000 description 1
- XPASUDUUTHMDBC-UHFFFAOYSA-N N-[4-[3-(6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound CC1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O XPASUDUUTHMDBC-UHFFFAOYSA-N 0.000 description 1
- UJMHLVXHPYYMAD-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2C1CCN(CC1)C)C1=CC(=NC=C1)NC(C)=O)F UJMHLVXHPYYMAD-UHFFFAOYSA-N 0.000 description 1
- XTMQTSSCKOHAMM-UHFFFAOYSA-N N-[4-[3-[6-(difluoromethyl)pyridin-2-yl]-7-[(4-methylpiperazin-1-yl)methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2CN1CCN(CC1)C)C1=CC(=NC=C1)NC(C)=O)F XTMQTSSCKOHAMM-UHFFFAOYSA-N 0.000 description 1
- WNFMSQWPTWVOOP-UHFFFAOYSA-N N-[4-[3-[6-(trifluoromethyl)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=CC(=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)(F)F WNFMSQWPTWVOOP-UHFFFAOYSA-N 0.000 description 1
- ULXMHLYSEKNPLJ-UHFFFAOYSA-N N-[4-[3-[6-(trifluoromethyl)pyridin-3-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC(C1=CC=C(C=N1)C1=C(NC=2C1=NC=CC=2)C1=CC(=NC=C1)NC(C)=O)(F)F ULXMHLYSEKNPLJ-UHFFFAOYSA-N 0.000 description 1
- YQOIIOXDNZPVEC-UHFFFAOYSA-N N-[4-[5-fluoro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=CC=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)F YQOIIOXDNZPVEC-UHFFFAOYSA-N 0.000 description 1
- RHXPRFOIVWVKRF-UHFFFAOYSA-N N-[4-[5-fluoro-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=CC=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC RHXPRFOIVWVKRF-UHFFFAOYSA-N 0.000 description 1
- XVEZAFWEPKTWAR-UHFFFAOYSA-N N-[4-[5-fluoro-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC1=CC=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC XVEZAFWEPKTWAR-UHFFFAOYSA-N 0.000 description 1
- NQMFEEFUCBGNDS-UHFFFAOYSA-N N-[4-[6-(aminomethyl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound NCC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC NQMFEEFUCBGNDS-UHFFFAOYSA-N 0.000 description 1
- DNQQPPYTAUTABF-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)Cl DNQQPPYTAUTABF-UHFFFAOYSA-N 0.000 description 1
- PXAQKOXWMVQEQR-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-fluoro-4-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C(=C1)C)F PXAQKOXWMVQEQR-UHFFFAOYSA-N 0.000 description 1
- HYPGMFMXFARARN-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1-(4-methylphenyl)sulfonylpyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]-N-methylacetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2S(=O)(=O)C1=CC=C(C)C=C1)C1=CC(=NC=C1)N(C(C)=O)C)C1=NC=C(C=C1)F HYPGMFMXFARARN-UHFFFAOYSA-N 0.000 description 1
- XYKUHZHMBRNVPC-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1-(4-methylphenyl)sulfonylpyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2S(=O)(=O)C1=CC=C(C)C=C1)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)F XYKUHZHMBRNVPC-UHFFFAOYSA-N 0.000 description 1
- RTEMXTJQBFNYGT-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]-2-morpholin-4-ylacetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(CN1CCOCC1)=O)C1=NC=C(C=C1)F RTEMXTJQBFNYGT-UHFFFAOYSA-N 0.000 description 1
- OCRDCGDRQOHDJO-UHFFFAOYSA-N N-[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)F OCRDCGDRQOHDJO-UHFFFAOYSA-N 0.000 description 1
- WWNMOXCJRHFOHF-UHFFFAOYSA-N N-[4-[6-chloro-3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)F WWNMOXCJRHFOHF-UHFFFAOYSA-N 0.000 description 1
- QBFWNBXVXXUDGC-UHFFFAOYSA-N N-[4-[6-chloro-3-(6-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)OC QBFWNBXVXXUDGC-UHFFFAOYSA-N 0.000 description 1
- IARUBRTUSKVTCX-UHFFFAOYSA-N N-[4-[6-chloro-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC IARUBRTUSKVTCX-UHFFFAOYSA-N 0.000 description 1
- DUJWQXKVMVMMLE-UHFFFAOYSA-N N-[4-[6-chloro-3-(6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)C DUJWQXKVMVMMLE-UHFFFAOYSA-N 0.000 description 1
- MDOVXBHJJCUXMT-UHFFFAOYSA-N N-[4-[6-chloro-3-[6-(2-hydroxyethylamino)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)NCCO MDOVXBHJJCUXMT-UHFFFAOYSA-N 0.000 description 1
- PGGXARIWJJEHLM-UHFFFAOYSA-N N-[4-[6-chloro-3-[6-(hydroxymethyl)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)CO PGGXARIWJJEHLM-UHFFFAOYSA-N 0.000 description 1
- BNKKENJECSYBSJ-UHFFFAOYSA-N N-[4-[6-cyano-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(#N)C=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC BNKKENJECSYBSJ-UHFFFAOYSA-N 0.000 description 1
- TWGKOZPGDCIKQA-UHFFFAOYSA-N N-[4-[6-fluoro-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound FC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC TWGKOZPGDCIKQA-UHFFFAOYSA-N 0.000 description 1
- GVZZIOKFMGJTOH-UHFFFAOYSA-N N-[4-[6-methoxy-3-(6-methylpyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound COC=1C=C2C(=NC=1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)C GVZZIOKFMGJTOH-UHFFFAOYSA-N 0.000 description 1
- UYZDUNUBKRWWRK-UHFFFAOYSA-N N-[4-[7-(aminomethyl)-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound NCC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC UYZDUNUBKRWWRK-UHFFFAOYSA-N 0.000 description 1
- VVLBQFNGDPTBAM-UHFFFAOYSA-N N-[4-[7-chloro-3-(5-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)Cl VVLBQFNGDPTBAM-UHFFFAOYSA-N 0.000 description 1
- OLRRPWHYCDVBCG-UHFFFAOYSA-N N-[4-[7-chloro-3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)OC OLRRPWHYCDVBCG-UHFFFAOYSA-N 0.000 description 1
- MYIGOJMQCLDISW-UHFFFAOYSA-N N-[4-[7-chloro-3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)F MYIGOJMQCLDISW-UHFFFAOYSA-N 0.000 description 1
- QHHLTVVQCBKXOJ-UHFFFAOYSA-N N-[4-[7-chloro-3-[6-(difluoromethyl)pyridin-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC(=CC=C1)C(F)F QHHLTVVQCBKXOJ-UHFFFAOYSA-N 0.000 description 1
- XVNNJGCOYHKASN-UHFFFAOYSA-N N-[4-[7-cyano-3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]acetamide Chemical compound C(#N)C1=C2C(=NC=C1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C=1C=NC(=CC=1)OC XVNNJGCOYHKASN-UHFFFAOYSA-N 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000018795 RELT Human genes 0.000 description 1
- 108010052562 RELT Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000016946 TWEAK Receptor Human genes 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100027540 WAS/WASL-interacting protein family member 2 Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LSOUOGVELKEZKB-UHFFFAOYSA-N [2-[[4-[6-chloro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl]amino]-2-oxoethyl] acetate Chemical compound C(C)(=O)OCC(=O)NC1=NC=CC(=C1)C1=C(C2=NC=C(C=C2N1)Cl)C1=NC=C(C=C1)F LSOUOGVELKEZKB-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- COERJHDMQUPDCV-UHFFFAOYSA-N [K].FB(F)F Chemical compound [K].FB(F)F COERJHDMQUPDCV-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003306 cell dissemination Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- JOCOZHZEDRHLJN-UHFFFAOYSA-N ethyl 2-[2-(2-acetamidopyridin-4-yl)ethynyl]-6-chloro-3-[(2,2,2-trifluoroacetyl)amino]pyridine-4-carboxylate Chemical compound C(C)(=O)NC1=NC=CC(=C1)C#CC=1C(=C(C(=O)OCC)C=C(N=1)Cl)NC(C(F)(F)F)=O JOCOZHZEDRHLJN-UHFFFAOYSA-N 0.000 description 1
- BCEJHBNXETYHCO-UHFFFAOYSA-N ethyl 3-amino-2-bromo-6-chloropyridine-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=C(N=C1Br)Cl BCEJHBNXETYHCO-UHFFFAOYSA-N 0.000 description 1
- BIFLTHWDFNLOTD-UHFFFAOYSA-N ethyl 3-aminopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1N BIFLTHWDFNLOTD-UHFFFAOYSA-N 0.000 description 1
- ZYJCTOLZHAXVCQ-UHFFFAOYSA-N ethyl 5-amino-2-chloropyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC(Cl)=NC=C1N ZYJCTOLZHAXVCQ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000002742 malignant choroid melanoma Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- RQUNOBPZIUYGDU-UHFFFAOYSA-N methyl 2-(2-acetamidopyridin-4-yl)-5-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylate Chemical compound C(C)(=O)NC1=NC=CC(=C1)C1=CC2=NC(=CC(=C2N1)C(=O)OC)Cl RQUNOBPZIUYGDU-UHFFFAOYSA-N 0.000 description 1
- UPZFCGJLDZGJAC-UHFFFAOYSA-N methyl 2-(2-acetamidopyridin-4-yl)-5-chloro-3-(5-chloropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylate Chemical compound ClC1=CC(=C2C(=N1)C(=C(N2)C1=CC(=NC=C1)NC(C)=O)C1=NC=C(C=C1)Cl)C(=O)OC UPZFCGJLDZGJAC-UHFFFAOYSA-N 0.000 description 1
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- SJGPVMWAWFCTQG-UHFFFAOYSA-N n'-(2-hydroxyethyl)acetohydrazide Chemical compound CC(=O)NNCCO SJGPVMWAWFCTQG-UHFFFAOYSA-N 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- LFMGMKPLBDZJLP-UHFFFAOYSA-N n-(4-bromopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(Br)=CC=N1 LFMGMKPLBDZJLP-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YOCOCWDLQJRROV-UHFFFAOYSA-N n-[4-(2-trimethylsilylethynyl)pyridin-2-yl]acetamide Chemical compound CC(=O)NC1=CC(C#C[Si](C)(C)C)=CC=N1 YOCOCWDLQJRROV-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Polymers 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- TGF The active form of TGF is a dimer that signals through the formation of a membrane bound heterotetramer composed of the serine threonine type 1 and type 2 receptors, TGF R-l (ALK5) and TGF R-2, respectively.
- TGF R-l ALK5
- TGF R-2 TGF R-2
- the type 2 constitutively activated receptors phosphorylate the type 1 receptors in the glycine and serine rich "GS region" activating a signaling cascade through the intracellular signaling effector molecules, Smad2 or Smad3.
- TGF R-l phosphorylates the receptor Smad2 and/or Smad3 (RSmads) that form a complex with Smad4 (Shi and Massague, Cell 2003, 113:685-700).
- R 2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C 6 )alkyl, (Ci-C 6 )alkoxy or -SO2 (Ci-C 6 )alkyl;
- R 5 and R 6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
- n 0, 1, 2, 3, or 4;
- R is AA, or a heterocylic or heterobicyclic group substituted with 0-4 R 2 ;
- X 1 , X 2 , X 3 and X 4 are independently -CR 4 or -N-, wherein at least one is -N-;
- R 1 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 8 )cycloalkyl, -CONHR 9 , -COOR 9 , -COR 9 or - SO2R 9 , any of which except the hydrogen is substituted with 0-3 R x ;
- W is hydrogen, halogen, -OH, (Ci-C 3 )alkyl, halo(Ci-C 3 )alkyl, hydroxy(Ci- C 3 )alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
- R 7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN;
- R 8 is hydrogen, (Ci-C 6 )alkyl, (C3-C 8 )cycloalkyl, -CONHR 9 , -COOR 9 , -COR 9 or -
- R x is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C 3 )alkyl, or -CN;
- R 2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C 3 )alkyl, (Ci-C 3 )alkoxy or -SO2 (Ci-C3)alkyl;
- R 2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C 3 )alkoxy or -SO2 (Ci-C3)alkyl;
- R 5 and R 6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl; or
- R 3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C 6 )alkyl, (C2-C 6 )alkenyl, (Ci-C 6 )alkoxy, (C3-C 8 )cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR 5 R 6 , -CONR 5 R 6 , -COOR 4 , -COR 4 , -SO2R 4 , -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 R y ;
- R 1 is hydrogen, (Ci-C 3 )alkyl, (C3-C 6 )cycloalkyl, -CONHR 9 , -COOR 9 , -COR 9 or - SO2R 9 , any of which except the hydrogen is substituted with 0-3 R x ;
- R 3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C 3 )alkyl, (C2-C 6 )alkenyl, (Ci-C 3 )alkoxy, (C3-C 8 )cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR 5 R 6 , -CONR 5 R 6 , -COOR 4 , -COR 4 , -SO2R 4 , -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 R y ;
- R 9 is hydrogen, (Ci-C6)alkyl, (C 3 -C8)cycloalkyl, heterocyclylalkyl-,
- R x is hydrogen, halogen, -OH, halo(Ci-C 3 )alkyl, hydroxy(Ci-C 3 )alkyl, -amino(Ci- C 3 )alkyl, or -CN;
- R 7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
- R 1 is -COR 9 ;
- R 7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
- n 0, 1 or 2;
- the compounds of formula (I) of the invention are TGFBR antagonists and have potential utility in the treatment of diseases and conditions for which a TGFBR antagonist is indicated.
- a method for treatment of a chronic autoimmune and/or inflammatory condition in a subject in need thereof which comprises administering a therapeutically effective amount of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
- Types of cancers that may be treated with the compounds of this invention include, but are not limited to, brain cancers, skin cancers, bladder cancers, ovarian cancers, breast cancers, gastric cancers, pancreatic cancers, prostate cancers, colon cancers, blood cancers, lung cancers and bone cancers.
- Examples of such cancer types include neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familiar adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tong carcinoma, salivary gland carcinoma, gastric carcinoma,
- the compound(s) of the invention are sequentially administered prior to administration of the immuno-oncology agent. In another aspect, compound(s) of the invention are administered concurrently with the immunology-oncology agent. In yet another aspect, compound(s) of the invention are sequentially administered after administration of the immuno-oncology agent.
- compounds of the invention may be co-formulated with an immuno-oncology agent.
- the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators).
- the immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF- ⁇ , VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.
- a cytokine that inhibits T cell activation e.g., IL-6, IL-10, TGF- ⁇ , VEGF, and other immunosuppressive cytokines
- a cytokine that stimulates T cell activation for stimulating an immune response.
- agents that can be combined with compounds of the invention for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells.
- compounds of the invention can be combined with antagonists of KIR, such as lirilumab.
- compounds of the invention can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-Ll/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
- agonistic agents that ligate positive costimulatory receptors e.g., blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency
- the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody.
- PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514;
- the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody.
- Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (W012/32433).
- the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody.
- GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WOl 1/028683).
- the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody.
- the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody.
- Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or di calcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by
- alkoxy refers to an -O-alkyl group.
- C ⁇ alkoxy (or alkyloxy), is intended to include Ci, C 2 , C3, C4, C5, and C alkoxy groups.
- Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and i-butoxy.
- alkylthio or “thioalkoxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.
- cycloalkyl refers to cyclized alkyl groups.
- C3-6 cycloalkyl is intended to include C3, C4, C5, and C cycloalkyl groups.
- Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl.
- Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl”.
- cycloalkenyl refers to cyclized alkenyl groups.
- C 4- 6 cycloalkenyl is intended to include C 4 , C5, and Ce cycloalkenyl groups.
- aromatic heterocyclic group or "heteroaryl” is intended to mean stable monocyclic and poly cyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
- Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4- thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodi
- EWG electron withdrawing group
- EWGs include, but are not limited to, CF 3 , CF 2 CF 3 , CN, halogen, haloalkyl, N0 2 , sulfone, sulfoxide, ester, sulfonamide, carboxamide, alkoxy, alkoxyether, alkenyl, alkynyl, OH, C(0)alkyl, CO2H, phenyl, heteroaryl, -O-phenyl, and -O- heteroaryl.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, gly colic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric
- organic acids such as acetic, propionic, succinic, gly colic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenylace
- compounds of formula I may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i. e. , a compound of formula I) is a prodrug within the scope and spirit of the invention.
- a prodrug within the scope and spirit of the invention.
- Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:
- esters of compounds of formula I include C ⁇ alkyl, C ⁇ alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C i- alkanoyloxy-C ⁇ alkyl (e.g. , acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl),
- the present invention is intended to include all isotopes of atoms occurring in the present compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include deuterium and tritium.
- the isotopes of hydrogen can be denoted as 3 ⁇ 4 (hydrogen), 2 H (deuterium) and 3 ⁇ 4 (tritium). They are also commonly denoted as D for deuterium and T for tritium.
- CD3 denotes a methyl group wherein all of the hydrogen atoms are deuterium.
- Isotopes of carbon include 13 C and 14 C.
- the term "pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
- bases include, but are not limited to, alkali metals (e.g. , sodium) hydroxides, alkaline earth metals (e.g. , magnesium), hydroxides, ammonia, and compounds of formula NW ⁇ 4 + , wherein W is Ci-4 alkyl, and the like.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
- the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
- the compounds of this invention may be prepared using the reactions and techniques described in this section.
- the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being affected.
- all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.
- Deprotection may be accomplished by treatment with tetrabutylammonium fluoride in a solvent such as THF or other means known to one skilled in the art to afford compounds of formula iv.
- a solvent such as THF or other means known to one skilled in the art to afford compounds of formula iv.
- the reaction of compounds of formula iv with suitably substituted 3-aminopyridines (v, X halogen) in the presence of a catalyst such as Pd(PPh3)2Ch with an additive such as Cul in the presence of a base such as triethylamine in an appropriate solvent such as
- Example 1A A mixture of Example 1A (4.2 g, 19.3 mmol), ethynyltrimethylsilane (2.28 g, 23.2 mmol), bis(triphenylphosphine)palladium(II) dichlororide (0.27 g, 0.39 mmol) and copper(I) iodide (0.15 g, 0.77 mmol) in TEA (20 mL, 143 mmol) was purged with nitrogen and heated to 76 °C for 2.5 h, and then cooled to room temperature. The mixture was filtered through a short silica gel column, eluting with EtOAc.
- Example IB (2.89 g, 94%) as a light yellow solid.
- Example IE (12.5 mg, 31%) as a white solid.
- Example 4 was prepared from Example ID and 2-fluoro-5-iodopyridine by the general methods shown for Example 1.
- Example 8 was prepared from Example ID and 2-bromopyrimidine by the general methods shown for Example 1.
- Example 9 was prepared from Example ID and 5-bromo-2-chloropyridine by the general methods shown for Example 1.
- Example 10 was prepared from Example ID and 2,3-difluoro-5-iodopyridine by the general methods shown for Example 1.
- Example 12 was prepared from Example ID and 5-bromopicolinonitrile by the general methods shown for Example 1.
- MS (ES): m/z 355 [M+H] + ; 3 ⁇ 4 NMR (500 MHz, DMSO-de) ⁇ ppm 10.70 (br. s., 1H), 8.84 (s, 1H), 8.58 (br. s., 1H), 8.41 (br.
- Example 14 may also be prepared by the alternative Method B:
- Example 15
- Example 17 was prepared from Example ID and 6-bromoisoquinoline by the general methods shown for Example 1.
- Example 20 was prepared from Example ID and 5-bromo-lH-indole by the general methods shown for Example 1.
- MS (ES): m/z 368 [M+H] + ; 3 ⁇ 4 NMR (500 MHz, DMSO-de) ⁇ ppm 11.33 (br.
- Example 21 was prepared from Example ID and 8-bromoquinoline by the general methods shown for Example 1.
- Example 22 was prepared from Example ID and 6-bromoquinoline by the general methods shown for Example 1.
- Example 25 was prepared from Example ID and 2-bromo-5- (methylsulfonyl)pyridine by the general methods shown for Example 1.
- Example 26 was prepared from Example ID and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1.
- MS (ES): m/z 360 [M+H] + ; 3 ⁇ 4 NMR (500 MHz, DMSO-de) ⁇ ppm 13.40 (br.
- Example 27 was prepared from Example ID and 5-bromo-2-methoxypyrimidine by the general methods shown for Example 1.
- Example 28 was prepared from Example ID and 2-bromo-4-methoxy pyridine by the general methods shown for Example 1.
- Example 32 was prepared from Example ID and 2-bromo-4-chloropyridine by the general methods shown for Example 1.
- Example 33 was prepared from Example ID and 6-bromo-3-chloro-2- methylpyridine by the general methods shown for Example 1.
- Example 34 A was prepared from Example IB and 2-bromo-6-fluoropyridin-3- amine by similar methods as shown for Example 1C.
- Example 34B was prepared from Example 34A by methods similar to those shown for Example ID.
- Example 34 was prepared from Example 34B and 2-bromo-6-chloropyridine by the general methods shown for Example 1.
- Example 36 was prepared from Example 34B and 5-iodo-2-methoxypyridine by the general methods shown for Example 1.
- Example 38A was prepared from Example IB and 2-bromo-5-fluoropyridin-3- by the methods shown for Example 1 C.
- Example 38 was prepared from Example 38B and 2-bromo-6-chloropyridine by the general methods shown for Example 1.
- Example 39 was prepared from Example 38B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1.
- Example 40 was prepared from Example 38B and 5-bromo-2-methoxypyridine by the general methods shown for Example 1.
- Example 41 A was prepared from Example IB and 2-bromo-5-chloropyridin-3- amine by the methods similar to those shown for Example 1C.
- Example 41B was prepared from Example 41 A by the methods similar to those shown for Example ID.
- Example 41 was prepared from Example 41 B and 2-bromo-6-chloropyridine by the general methods shown for Example 1.
- Example 42 was prepared from Example 41 B and 2-bromo-5-fluoropyridine by the general methods shown for Example 1.
- Example 43 was prepared from Example 41B and 5-bromo-2-methoxypyridine by the general methods shown for Example 1.
- Example 47 was prepared from Example 41 B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1.
- Example 48A was prepared from Example IB and 2-bromo-5-methoxypyridin-3- amine by methods similar to those shown for Example 1C.
- Example 48B was prepared from Example 48A by methods similar to those shown for Example ID.
- Example 49 was prepared from Example 48B and 2-bromo-5-fluoropyridine by the general methods shown for Example 1.
- Example 51 was prepared from Example 48B and 6-bromo-3-fluoro-2- methylpyridine by the general methods shown for Example 1.
- Example 14 To a solution of Example 14 (38 mg, 0.106 mmol) in MeOH (8 mL) was added IN NaOH (1.057 mL, 1.057 mmol). The mixture was then heated at 80 °C for 1.5 h, and then concentrated. The solid residue was suspended in water, collected by filtration, and dried to give the title product (27.4 mg, 80%) as a white solid.
- Example 52 To a solution of Example 52 (12.1 mg, 0.038 mmol) and TEA (10.6 ⁇ , 0.076 mmol) in THF (0.6 mL) was added a solution of cyclopropanecarbonyl chloride (6.8 mg, 0.065 mmol) in THF (70 ⁇ ). The reaction was stirred for 2 h, and then concentrated NH4OH (1 drop) was added. The resulting reaction mixture was stirred at room temperature overnight.
- the mixture was diluted with DMF and purified by preparative HPLC (Column: Waters XBridge C I 8, 19 x 200 mm, 5- ⁇ particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-55% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.) to give Example 53 (4.0 mg, 23%).
- Example 14 To a solution of Example 14 (12 mg, 0.033 mmol) in DMF (0.5 mL) was added CS2CO3 (21.76 mg, 0.067 mmol), followed by a solution of methyl iodide (2.088 ⁇ , 0.033 mmol) in DMF (0.5 mL).
- Example 55B was prepared from 55A by methods similar to those shown for Example ID.
- Example 55 was prepared from Example 55B and 2-bromo-6-chloropyridine by the general methods shown for Example 1.
- Example 56B (2.45 g, 8.77 mmol) and Example IB (1.544 g, 9.64 mmol) in DMF (18 mL) were added Cul (0.134 g, 0.701 mmol) and TEA (12.2 mL, 88 mmol). The reaction mixture was purged with nitrogen, followed bythe addition of PdCl 2 (PPh 3 )2 (0.369 g, 0.526 mmol). The resulting mixture was heated at 78 °C for 2 h under nitrogen. The reaction mixture was then cooled to room temperature and diluted with ethyl acetate and saturated aqueous NaHC0 3 solution.
- Example 58A was prepared from Example 56E and 2-aminopropane-l,3-diol by similar method shown for Example 56F. .
- Example 58B was prepared using similar methods as those shown for Example 56G.
- MS (ES): m/z 482.0, 484.0 [M+H] + .
- Example 58 was prepared from Example 58B by the general method shown for Example 56 ⁇ .
- MS (ES): m/z 51 1.2 [M+H] + .
- Example 59 was prepared from Example 58C by similar methods shown for Example 57.
- reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then concentrated in vacuo to a small volume. To the reaction mixture was added IN NaOH solution and ethyl acetate. The organic layer was separated and washed with a saturated NaHC0 3 solution, dried over MgS0 4 , and then filtered. The filtrate was concentrated in vacuo. The residue was purified by silica gel flash chromatography, eluting with 15% ethyl acetate in hexane to give the desired product as a white solid (1.65 g, 51 %).
- Example 61 A (1.55 g, 7.47 mmol) and Example IB (1.257 g, 7.85 mmol) in DMF (6 mL) were added Cul (0.142 g, 0.747 mmol) and TEA (10.41 mL, 74.7 mmol). The reaction mixture was purged with nitrogen, and treated with
- Example 61B To a suspension of Example 61B (0.95 g, 3.31 mmol) in DCE (12 mL) at ice bath temperature was added TEA (1.62 mL, 11.60 mmol), followed by the addition of trifluoroacetic anhydride (0.74 mL, 5.30 mmol) slowly. The reaction mixture was stirred at 0 °C for 20 min. To the mixture was added more TEA (1.0 mL) and trifluoroacetic anhydride (0.45 mL) and the reaction mixture was stirred at 0 °C for another 40 min. The reaction mixture was quenched with a cold saturated NaHC0 5 solution and the resulting mixture was extracted with ethyl acetate (2x).
- Example 61C A mixture of Example 61C (30 mg, 0.078 mmol), CS2CO3 (77 mg, 0.235 mmol) and 2-bromo-5-fiuoropyridine (17.93 mg, 0.102 mmol) in acetonitrile (2 mL) in a sealed tube was purged with nitrogen, and treated with Pd(PPh3)4 (9.06 mg, 7.84 ⁇ ). The reaction mixture was heated at 100 °C for 1.5 h and then cooled to room temperature. The reaction mixture was diluted with MeOH and ethyl acetate and filtered. The filtrate was concentrated in vacuo.
- Example 62 was prepared from Example 61 C and 2-bromo-5-methoxy pyridine by the general method shown for Example 61.
- Example 63 was prepared from Example 61 C and 2-bromo-5-chloropyridine by the general method shown for Example 61.
- Example 64 was prepared from Example 61 C and 2-bromo-6-fluoropyridine by the general method shown for Example 61. .
- Example 65 was prepared from Example 41 B and 2-bromo-6-methoxy pyridine by the general methods shown for Example 1.
- Example 66 was prepared from Example 41 B and 2-bromo-6-methylpyridine by the general methods shown for Example 1. .
- Example 67 was prepared from Example 41 B and (6-bromopyridin-2-yl)methanol by the general methods shown for Example 1. .
- Example 68 was prepared from Example 41B and 2-((6-bromopyridin-2- yl)amino)ethanol by the general methods shown for Example 1.
- Example 56C To a suspension of Example 56C (0.2 g, 0.557 mmol) in DCE (4 mL) and diethyl ether (10 mL) was added CaCC (0.223 g, 2.230 mmol) at ice bath temperature. To the reaction mixture was added TFAA (0.17 mL, 1.226 mmol) slowly and the reaction mixture was stirred at ice bath temperature for 2 h. To the reaction mixture was added cold water and ethyl acetate. The organic layer was separated and washed with brine and dried over MgS0 4 . The mixture was filtered and the filtrate was concentrated in vacuo.
- Example 69 was prepared from Example 69A and 2-bromo-5-fluoropyridine by the general methods shown for Example 1.
- Example 70 was prepared from Example 69A and 2-bromo-5-chloropyridine by the general methods shown for Example 1.
- Example 72A To a suspension of Example 72A (60 mg, 0.177 mmol) in DCE (3 mL) were added acetoxyacetyl chloride (0.06 mL, 0.54 mmol) and TEA (0.1 mL, 0.71 mmol). The reaction was stirred at room temperature for 2 h. To the reaction mixture was added 0.5 mL of an ammonia hydroxide solution and the mixture was stirred at room temperature for 1 h. The resulting reaction mixture was concentrated in vacuo.
- Example 72A To a suspension of Example 72A (1 15 mg, 0.338 mmol) in DCE (7 niL) were added chloroacetyl chloride (0.14 mL, 1.70 mmol) and TEA (0.25 mL, 1.70 mmol) slowly. The reaction was stirred at room temperature for 1 h. To the reaction mixture was added 1 mL of ammonia hydroxide solution and the mixture was stirred at room temperature for 0.5 h. The reaction mixture was then diluted with CHC1 3 : 2-propanol
- Example 74A 35 mg, 0.084 mmol
- acetonitrile 2 mL
- morpholine 0.074 mL, 0.841 mmol
- Ag 2 0 39.0 mg, 0.168 mmol
- Example 75 was prepared from Example 74A and 2-aminoethanol by the general methods shown for Example 74.
- Example 76A (80 mg, 0.283 mmol) in Ether:DCM (1 : 1) (4 mL) was added dropwise a solution of 2,2,2-trifluoroacetic anhydride (0.039 mL, 0.283 mmol) in DCM (1 mL) at -10 °C. The reaction mixture was stirred for 30min at -10 °C to 0 °C. The reaction mixture was then diluted with EtOAc, washed with water, and then with satutared aqueous NaCl, dried with MgSCn and concentrated to yield Example 76B (90 mg, 0.238 mmol, 84 % yield) as an off white solid which was used for the next step without further purification.
- Example 76 was preapared from Example 76B and 5-bromo-2-methoxypyridine following the general method for Example 1.
- Example 77 was preapared from Example 76B and 2-bromo-6-chloropyridine following the general method for example 1.
- the reaction mixture was concentrated in vacuo. To the residue was added 20 mL of iPrOH, the mixture was sonicated and the solid was filtered and washed with iPrOH. The resulting solid was triturated with CH2CI2 and collected by filtration. The filtrate was concentrated and the residue was triturated with CH2CI2 to obtain a second crop of the title compound. Both solids were combined to obtain 2 g of yellow solid. The filtrate was further concentrated in vacuo and the residue was purified by column chromatography on S1O2 (gradient hexane/EtOAc) to obtain 640 mg of the title compound, total 2.64 g (93% yield) as a yellow solid.
- Example 78A 300 mg, 0.91 mmol
- Zn(CN) 2 106 mg, 0.91 mmol
- DMF dimethyl methoxylate
- PdCk dppf
- Pd2dba3 80 mg, 0.087 mmol
- the reaction mixture was again purged with N2 and heated at 85 °C for 6 h.
- the reaction mixture was partially concentrated in vacuo and the residue was passed through a column of S1O2 (gradient CH2CI2 to 10% MeOH in CH2CI2) to obtain the title compound (135 mg, 0.487 mmol, 54 % yield) as a yellow solid.
- MS (ES): m/z 278 [M+H] + ; 3 ⁇ 4 NMR (400 MHz,
- Example 78B A mixture of Example 78B (530 mg, 1.911 mmol), CS2CO3 (685 mg, 2.103 mmol) and Pd(Ph3P)4 (110 mg, 0.096 mmol) in 12 mL DMF was purged with ⁇ 2 and the mixture was heated 150 °C for 20 minutes, and then cooled to room temperature. The reaction mixture was partially concentrated in vacuo, and the residue was mixed with 15 mL
- Example 78C 600 mg, 2.164 mmol
- DMF 15 mL
- N-iodosuccinimde 487 mg, 2.164 mmol
- the reaction mixture was partially concentrated in vacuo, and the residue was triturated with water and the solid was filtered to obtain the title compound (620 mg, 1.538 mmol, 71.1 % yield) as a light brown solid.
- MS (ES): m/z 403.9
- Example 78D A mixture of Example 78D (35 mg, 0.087 mmol), 2-methoxy-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine(30.6 mg, 0.130 mmol) and 0.2 mL 3M K3PO4 in DMF (2 mL) was purged with ⁇ 2. The mixture was treated with PdCl2(dppf) (25.4 mg, 0.035 mmol), purged with ⁇ 2 and heated at 80 °C for 60 min. The reaction mixture was concentrated to a volume of 1 mL and 3 mL MeOH was added.
- Example 78 A mixture of Example 78 (50 mg, 0.130 mmol) and 20% Pd(OH)2 on carbon (10 mg) in MeOH (12 mL) was stirred under 1 atm of H2 at room temperature. After 4 h additional 20% Pd(OH)2 on carbon (20 mg) was added and stirring was continued under 1 atm H2.
- Example 80 and Example 81 were prepared following similar procedures as described in Examples 78 and 79.
- Example 72A To a solution of Example 72A (0.45 g, 1.18 mmol) in DMF (8 mL) were added CS2CO3 (0.85 g, 2.59 mmol) and ⁇ -toluenesulfonyl chloride (0.22 mL, 1.18 mmol). The reaction mixture was stirred at room temperature over night. To the reaction mixture was added ethyl acetate and a saturated NaHC0 3 solution. The organic layer was extracted with ethyl acetate (2x) and the combined organic layers were washed with saturated NaHC0 3 solution, dried over MgS0 4 and filtered. The filtrate was concentrated in vacuo.
- Example 82A To a suspension of Example 82A (50 mg, 0.093 mmol) in THF (1 mL) was added methyl iodide (0.017 mL, 0.280 mmol) in DMF (0.6 mL) and CS2CO3 (61 mg, 0.187 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with ethyl acetate and saturated NaHC0 3 solution. The organic layer was separated and dried over MgS0 4 and filtered. The filtrate was concentrated in vacuo to give the desired product, which was used in the next step without purification.
- Example 83A was prepared from Example IB and 2,5-dibromopyridin-3-amine by methods similar to those shown for Example 1C.
- Example 83 was prepared from Example 83B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1.
- Example 52 To a suspension of Example 52 (28.8 mg, 0.091 mmol) in CH2CI2 (2 mL) was added TEA (0.038mL, 0.272 mmol) and methyl chloroformate (0.014 mL, 0.182 mmol). The mixture was stirred at room temperature overnight, and then MeOH (1 mL) and concentrated NH4OH (1 drop) were added. The resulting reaction mixture was stirred at room temperature ovemight.
- Example 84 (10.5 mg, 31 %).
- Example 72A To a suspension of Example 72A (68 mg, 0.20 mmol) in DCE (3 mL) were added methyl chloroformate (0.04 mL, 0.52 mmol) and 4-methylmorpholine (0.13 mL, 1.20 mmol). The reaction mixture was stirred at room temperature for 1 h. Additional methyl chloroformate (0.04 mL, 0.52 mmol) and 4-methylmorpholine (0.13 mL, 1.201 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for another 0.5 h. To the mixture was added ammonium hydroxide (0.6 mL) and MeOH (3 mL). The resulting mixture was stirred at room temperature for 20 h.
- reaction mixture was then diluted with a saturated NaHC0 3 solution and CHC1 3 : 2-propanol (2.5 : 1). The layers were separated and the aqueous layer was extracted with CHC1 3 : 2- propanol (2.5 : 1). The combined organic layers were dried over MgS0 4 and filtered. The filtrate was concentrated in vacuo to give a yellow solid. To the extract was added DCM, the mixture was sonicated and then filtered to give the desired product as a yellow solid (35 mg, 42%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates generally to compounds of formula (I) that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Description
TGFp RECEPTOR ANTAGONISTS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority from U.S. Provisional Application No. 62/095,328 filed December 22, 2014, the disclosures of which are incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
The invention relates generally to compounds that modulate the activity of TGF R-l and TGF R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
BACKGROUND OF THE INVENTION
TGF is a multifunctional cytokine that regulates a wide variety of biological processes that include cell proliferation and differentiation, migration and adhesion, extracellular matrix modification including tumor stroma and immunosuppression, angiogenesis and desmoplasia (Ling and Lee, Current Pharmaceutical Biotech. 2011, 12:2190-2202), processes supporting tumor progression and late stage disease.
The active form of TGF is a dimer that signals through the formation of a membrane bound heterotetramer composed of the serine threonine type 1 and type 2 receptors, TGF R-l (ALK5) and TGF R-2, respectively. Upon binding of two type 1 and two type 2 receptors, the type 2 constitutively activated receptors phosphorylate the type 1 receptors in the glycine and serine rich "GS region" activating a signaling cascade through the intracellular signaling effector molecules, Smad2 or Smad3. TGF R-l phosphorylates the receptor Smad2 and/or Smad3 (RSmads) that form a complex with Smad4 (Shi and Massague, Cell 2003, 113:685-700). These complexes then translocate to the nucleus where they elicit a wide variety of transcriptional responses resulting in altered gene expression (Weiss and Attisano, WIREs Developmental Biology, 2013, 2:47-63). The TGF proteins are prototypic members of a large family of related factors in mammals with a number of these also identified in other phyla. Generally, two groups have been characterized, the TGF -like and BMP-like ligands. In addition, in vertebrates, seven typel receptors and five type 2 receptors have been identified. An
additional layer of complexity in ligand/receptor binding is the potential of co-receptors known as type 3 that facilitate ligand binding to the type 1 and 2 receptor complex. These type 3 receptors, also known as Betaglycan and Endoglin are comprised of large extracellular domains and short cytoplasmic tails and bind different TGF family members (Bernabeu et al, Biochem Biophys Acta 2009, 1792:954-73). Although type 3 receptors facilitate signaling, cleavage of the extracellular domain can generate soluble proteins that sequester ligands and can potentially inhibit signaling (Bernabeu et al, Biochem Biophys Acta 2009, 1792:954-73). While multiple redundancies in this large family present challenges to identifying a selective inhibitor, TGF R-l and -2 are relatively selective targets for TGF ligand engagement.
Alteration in TGF signaling are associated with a wide variety of human disorders including fibrosis, inflammatory, skeletal, muscular and cardiovascular disorders as well as cancer (Harradine, et al,2006, Annals of Medicine 38:403-14). In human cancer, TGF signaling alterations can occur in the germline or arise
spontaneously in various cancer types. TGF is also a potent inducer of angiogenesis, which provides a critical support system for solid tumors as well as a mechanism for tumor cell dissemination (Buijs et al., 2011, Curr Pharmaceutical Biotech, 12:2121-37). Therefore multiple strategies to inhibit TGF signaling have been exploited in various disease states.
SUMMARY OF THE INVENTION
In a first aspect of the present invention, there is provided a compound of formula
(I)
(I)
wherein:
( 2),
R is or a heterocylic or heterobicyclic group substituted with 0-4 R2;
X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect, there is provided a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
In another aspect, there is provided a compound of the invention or a
pharmaceutically acceptable salt thereof for use in therapy. In particular, for use in the treatment of a disease or condition for which a TGFBR antagonist is indicated.
In another aspect, there is provided a method of treating cancers, fibrosis, inflammatory, skeletal, muscular and cardiovascular disorders which comprise administering to a subject in need thereof a therapeutically effective amount of a TGFBR antagonist.
DETAILED DESCRIPTION OF THE INVENTION a first aspect of the present invention, there is provided a compound of formul
(I)
wherein:
(R2)m
R is AA, or a heterocylic or heterobicyclic group substituted with 0-4 R2; X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-; R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In a second aspect within the scope of the first aspect of the invention, there is provided a compound of formula (II)
(Π)
wherein:
X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In a third aspect within the scope of the first and second aspects of the invention, there is provided a compound of formula (II)
(II)
wherein:
X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -arnino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1 , 2, 3, or 4;
n is 0, 1 , 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In a fourth aspect within the scope of the first, second and third aspects of the invention, there is provided a compound of formula (II)
(II)
wherein:
X1 and X2 are independently -CH or -N-;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or■ SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C3)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN; R8 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In a fifth aspect of the invention, there is provided a compound of formula (II)
(Π)
wherein:
X1 and X2 are independently -CH or -N-;
R1 is hydrogen, (Ci-C3)alkyl, (C4-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
Ry is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN; R8 is hydrogen, (Ci-C3)alkyl, or -COR9;
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1 or 2;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In a sixth aspect of the invention, there is provided a compound of formula (III)
(III)
wherein:
R is a heterocylic or heterobicyclic group substituted with 0-4 R2;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect of the invention, there is provided a compound of formula (III)
(III)
wherein:
R is a heterocylic or heterobicyclic group substituted with 0-4 R2;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl,
O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -arnino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN;
R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1 , 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect of the invention, there is provided a compound of formula (III)
(III)
wherein:
R is thiazole, thiadiazole, thiophene, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R2;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect of the invention there is provided a compound of formula (III)
(III)
wherein:
R is thiazole, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R2; R1 is -COR9 substituted with 0-2 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, halogen, -CN, (Ci-C3)alkyl, (Ci- C3)alkoxy, (C3-C6)cycloalkyl, 5-6 membered heteroaryl, heterocyclo, -NR5R6, - CONR5R6, -COOR4, -SO2R4 or (Ci-C3)alkylamino substituted with 0-2 R^;
Ry is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is -COR9;
R9 is hydrogen, (Ci-C3)alkyl or (C3-C6)cycloalkyl;
n is 0, 1 or 2;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect of the invention there is provided a compound of formula (III)
(III)
wherein:
R is thiazole, isoquinoline, indole or quinoline substituted with 0-4 R2;
R1 is -COR9;
R2 is independently one or more hydrogen, halogen, -CF3, -CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, halogen, -CN or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is hydrogen;
R9 is hydrogen or (Ci-C3)alkyl;
n is 0, 1 or 2;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect, there is provided a compound selected from the exemplified examples within the scope of the first aspect, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect, there is provided a compound selected from any subset list of compounds within the scope of any of the above aspects.
In another aspect, there is provided a compound according to claim 1 selected from the following list:
N- {4-[6-Fluoro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin- 2-yl}acetamide,
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} -2- { [3-(morpholin-4-yl)propyl] amino} acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-(methoxy-d3)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-ethoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethoxy-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide,
N-(4-{3 6-(Difluoromethyl)pyridin-2-yl]-7-[(dimethylamino)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(l-hydroxyethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(lR)-l -hydroxyethyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(l S)-l-hydroxyethyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(methylamino)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-(7-(l-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide, or
N-(4-(6-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
In another aspect, there is provided a compound according to claim 1 selected from the following list:
N-{4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide,
N-{4-[6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl}acetamide,
N-(4-(3-(5-(Methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide,
N-(4-(6-Chloro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(6-Fluoro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide, 106
N-(4-(6-Methoxy-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide, or
N-(4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
OTHER EMBODIMENTS OF THE INVENTION
In another embodiment, the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
In another embodiment, the invention provides a process for making a compound of the invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
In another embodiment, the invention provides a method for the treatment and/or prophylaxis of various types of cancer, comprising administering to a patient in need of such treatment and/or prophylaxis a therapeutically effective amount of one or more compounds of the invention, alone, or, optionally, in combination with another compound of the invention and/or at least one other type of therapeutic agent.
In another embodiment, the invention provides a method for the treatment and/or prophylaxis of various types of cancer, including without limitation, small cell lung cancer, non-small cell lung cancer, colorectal cancer, multiple myeloma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), pancreatic cancer, liver cancer, hepatocellular cancer, neuroblastoma, other solid tumors or other hematological cancers.
In another embodiment, the invention provides a method for the treatment and/or prophylaxis of various types of cancer, including without limitation, small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.
In another embodiment, the invention provides a method for the treatment and/or prophylaxis of Marian's syndrome and associated diseases, disorders and conditions associated with aberrant TGF-β expression.
In another embodiment, the invention provides a method for the treatment and/or prophylaxis of fibrosis such as hepatic or pulmonary fibrosis.
In another embodiment, the invention provides a compound of the present invention for use in therapy.
In another embodiment, the invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.
THERAPEUTIC APPLICATIONS
The compounds of formula (I) of the invention are TGFBR antagonists and have potential utility in the treatment of diseases and conditions for which a TGFBR antagonist is indicated.
In one embodiment there is provided a method for the treatment of a disease or condition, for which a TGFBR antagonists is indicated, in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
In another embodiment there is provided a method for treatment of a chronic autoimmune and/or inflammatory condition, in a subject in need thereof which comprises administering a therapeutically effective amount of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
In a further embodiment there is provided a method for treatment of cancer in a subject in need thereof which comprises administering a therapeutically effective amount of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
In one embodiment the subject in need thereof is a mammal, particularly a human.
TGFBR antagonists are believed to be useful in the treatment of a variety of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and in the prevention and treatment of viral infections.
TGFBR antagonists may be useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis.
TGFBR antagonists may be useful in the treatment of cancer, including hematological, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.
The term "diseases or conditions for which a TGFBR antagonists is indicated" is intended to include any of or all of the above disease states.
While it is possible that for use in therapy, a compound of formula (I) as well as pharmaceutically acceptable salts thereof may be administered as the compound itself, it is more commonly presented as a pharmaceutical composition.
Pharmaceutical compositions may be presented in unit dose forms containing a predetermined amount of active ingredient pep unit dose. Preferred unit dosage
compositions are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of an active ingredient. Such unit doses may therefore be administered more than once a day. Preferred unit dosage compositions are those containing a daily dose or sub- dose (for administration more than once a day), as herein above recited, or an appropriate fraction thereof, of an active ingredient.
Types of cancers that may be treated with the compounds of this invention include, but are not limited to, brain cancers, skin cancers, bladder cancers, ovarian cancers, breast cancers, gastric cancers, pancreatic cancers, prostate cancers, colon cancers, blood cancers, lung cancers and bone cancers. Examples of such cancer types include neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familiar adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tong carcinoma, salivary gland carcinoma, gastric carcinoma,
adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, renal carcinoma, kidney parenchymal carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroid melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmocytoma.
In addition to apoptosis defects found in tumors, defects in the ability to eliminate self- reactive cells of the immune system due to apoptosis resistance are considered to play a key role in the pathogenesis of autoimmune diseases. Autoimmune diseases are characterized in that the cells of the immune system produce antibodies against its own organs and molecules or directly attack tissues resulting in the destruction of the latter. A failure of those self-reactive cells to undergo apoptosis leads to the manifestation of the
disease. Defects in apoptosis regulation have been identified in autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis.
Compounds of the invention are useful for the treatment of certain types of cancer by themselves or in combination or co-administration with other therapeutic agents or radiation therapy. Thus, in one embodiment, the compounds of the invention are coadministered with radiation therapy or a second therapeutic agent with cytostatic or antineoplastic activity. Suitable cytostatic chemotherapy compounds include, but are not limited to (i) antimetabolites; (ii) DNA-fragmenting agents, (iii) DNA-crosslinking agents, (iv) intercalating agents (v) protein synthesis inhibitors, (vi) topoisomerase I poisons, such as camptothecin or topotecan; (vii) topoisomerase II poisons, (viii) microtubule-directed agents, (ix) kinase inhibitors (x) miscellaneous investigational agents (xi) hormones and (xii) hormone antagonists. It is contemplated that compounds of the invention may be useful in combination with any known agents falling into the above 12 classes as well as any future agents that are currently in development. In particular, it is contemplated that compounds of the invention may be useful in combination with current Standards of Care as well as any that evolve over the foreseeable future. Specific dosages and dosing regimens would be based on physicians' evolving knowledge and the general skill in the art.
Further provided herein are methods of treatment wherein compounds of the invention are administered with one or more immuno-oncology agents. The immuno- oncology agents used herein, also known as cancer immunotherapies, are effective to enhance, stimulate, and/or up-regulate immune responses in a subject. In one aspect, the administration of a compound of the invention with an immuno-oncology agent has a synergic effect in inhibiting tumor growth.
In one aspect, the compound(s) of the invention are sequentially administered prior to administration of the immuno-oncology agent. In another aspect, compound(s) of the invention are administered concurrently with the immunology-oncology agent. In yet another aspect, compound(s) of the invention are sequentially administered after administration of the immuno-oncology agent.
In another aspect, compounds of the invention may be co-formulated with an immuno-oncology agent.
Immuno-oncology agents include, for example, a small molecule drug, antibody, or other biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not
limited to, cancer vaccines, antibodies, and cytokines. In one aspect, the antibody is a monoclonal antibody. In another aspect, the monoclonal antibody is humanized or human.
In one aspect, the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators).
Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7- 1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane bound ligands that bind to co- stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L,
TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fnl4, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTfiR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin α/ΤΝΡβ, TNFR2, TNF a, LT R, Lymphotoxin a 1β2, FAS, FASL, RELT, DR6, TROY, NGFR.
In another aspect, the immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.
In one aspect, T cell responses can be stimulated by a combination of a compound of the invention and one or more of (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
Other agents that can be combined with compounds of the invention for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of
activating receptors on NK cells. For example, compounds of the invention can be combined with antagonists of KIR, such as lirilumab.
Yet other agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WOl 1/70024, WOl 1/107553, WO 11/131407, WO 13/87699, WO 13/119716, WO 13/132044) or FPA-008
(WOl 1/140249; W013169264; WO14/036357).
In another aspect, compounds of the invention can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-Ll/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
In one aspect, the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.
In another aspect, the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514;
WO2012/145493). The immuno-oncology agent may also include pidilizumab (CT-011), though its specificity for PD-1 binding has been questioned. Another approach to target the PD-1 receptor is the recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgGl, called AMP-224
In another aspect, the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody. Suitable PD-L1 antibodies include, for example,
MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS-936559 (WO2007/005874), and MSB0010718C (WO2013/79174).
In another aspect, the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS- 986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601,
WO09/44273).
In another aspect, the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (W012/32433).
In another aspect, the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WOl 1/028683).
In another aspect, the immuno-oncology agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598, WO08/36653, WO08/36642), indoximod, or NLG-919 (WO09/73620, WO09/1156652, WOl 1/56652, W012/142237).
In another aspect, the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.
In another aspect, the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody. Suitable OX40L antagonists include, for example, RG-7888 (WO06/029879).
In another aspect, the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.
In another aspect, the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab.
In another aspect, the immuno-oncology agent is MGA271 (to B7H3)
(WOl 1/109400).
The combination therapy is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form having a fixed ratio of each therapeutic agent or in multiple, single dosage forms for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. Combination therapy also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment.) Where the combination therapy further comprises a non-drug treatment, the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. This invention encompasses all combinations of preferred aspects of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional embodiments. It is also understood that each individual element of the embodiments is its own independent embodiment. Furthermore, any element of an embodiment is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.
PHARMACEUTICAL COMPOSITIONS AND DOSING
The invention also provides pharmaceutically acceptable compositions which comprise a therapeutically effective amount of one or more of the compounds of Formula
I, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents, and optionally, one or more additional therapeutic agents described above. As described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained release formulation; (3) topical application, for example, as a cream, ointment, or a controlled release patch or spray applied to the skin; (4) intravaginally or
intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) trans dermally; or (8) nasally.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol
and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or
polyanhydrides; and (22) other non-toxic compatible substances employed in
pharmaceutical formulations.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxy toluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the patient being treated and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety -nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an
aforementioned formulation renders orally bioavailable a compound of the present invention.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, troches and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or di calcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may
also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above described excipients.
Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol,
ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal
administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and
polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
Pharmaceutical compositions of this invention suitable for parenteral
administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of
the inj ectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is
accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsuled matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
When the compounds of the present invention are administered as
pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of
absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.01 to about 50 mg per kilogram of body weight per day.
If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain aspects of the invention, dosing is one administration per day.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).
DEFINITIONS
Unless specifically stated otherwise herein, references made in the singular may also include the plural. For example, "a" and "an" may refer to either one, or one or more.
Unless otherwise indicated, any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates thereof where such
isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the invention. Many geometric isomers of C=C double bonds, C=N double bonds, ring systems, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. Cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. The present compounds can be isolated in optically active or racemic forms. Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by
chromatography or fractional crystallization. Depending on the process conditions the end products of the present invention are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the invention. If so desired, one form of a compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present invention may be separated into the individual isomers. Compounds of the present invention, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the invention.
When a substituent is noted as "optionally substituted", the substituents are selected from, for example, substituents such as alkyl, cycloalkyl, aryl, heterocyclo, halo, hydroxy, alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or arylalkyl; alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thiol, alkylthio, arylthio, arylalkylthio, alkylthiono, arylthiono, arylalkylthiono, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfonamido, e.g. -SO2NH2, substituted sulfonamido, nitro, cyano, carboxy, carbamyl, e.g. -CONH2, substituted carbamyl e.g. -CONHalkyl, -
CONHaryl, -CONHarylalkyl or cases where there are two substituents on the nitrogen selected from alkyl, aryl or arylalkyl; alkoxycarbonyl, aryl, substituted aryl, guanidino, heterocyclyl, e.g., indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl and the like, and substituted heterocyclyl, unless otherwise defined.
For purposes of clarity and in accordance with standard convention in the art, the symbol ¾ is used in formulas and tables to show the bond that is the point of attachment of the moiety or substituent to the core/nucleus of the structure.
Additonally, for purposes of clarity, where a substituent has a dash (-) that is not between two letters or symbols; this is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom.
Additionally, for purposes of clarity, when there is no substituent shown at the end of a solid line, this indicates that there is a methyl (CH3) group connected to the bond.
As used herein, the term "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "Ci-Ce alkyl" denotes alkyl having 1 to 6 carbon atoms. Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g. , n-propyl and isopropyl), butyl (e.g. , n-butyl, isobutyl, i-butyl), and pentyl (e.g. , n-pentyl, isopentyl, neopentyl).
The term "alkenyl" denotes a straight- or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length. For example, "C2-C8 alkenyl" contains from two to eight carbon atoms. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1 -methyl-2-buten- 1-yl, heptenyl, octenyl and the like.
The term "alkynyl" denotes a straight- or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length. For example, "C2-C8 alkenyl" contains from two to eight carbon atoms. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1- butynyl, heptynyl, octynyl and the like.
The term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. "C^ alkoxy" (or alkyloxy), is intended to include Ci, C2, C3, C4, C5, and C alkoxy groups. Example
alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and i-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.
The term "aryl", either alone or as part of a larger moiety such as "aralkyl", "aralkoxy", or aryloxyalkyl", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to 15 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. In certain embodiments of the invention, "aryl" refers to an aromatic ring system which includes, but not limited to phenyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl and terahydronaphthyl. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Non-limiting examples include benzyl, phenethyl and the like. The fused aryls may be connected to another group either at a suitable position on the cycloalkyl ring or the aromatic ring. For example:
Arrowed lines drawn from the ring system indicate that the bond may be attached to any of the suitable ring atoms.
The term "cycloalkyl" refers to cyclized alkyl groups. C3-6 cycloalkyl is intended to include C3, C4, C5, and C cycloalkyl groups. Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl". The term "cycloalkenyl" refers to cyclized alkenyl groups. C4-6 cycloalkenyl is intended to include C4, C5, and Ce cycloalkenyl groups. Example cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
The term "cycloalkylalkyl"refers to a cycloalkyl or substituted cycloalkyl bonded to an alkyl group connected to the core of the compound.
"Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl also include
"fluoroalkyl" that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.
"Haloalkoxy" or "haloalkyloxy" represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. For example, "C^ haloalkoxy", is intended to include Ci, C2, C3, C4, C5, and C haloalkoxy groups. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2- trifluoroethoxy, and pentafluorothoxy. Similarly, "haloalkylthio" or "thiohaloalkoxy" represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and pentafluoroethyl- S-.
The term "benzyl," as used herein, refers to a methyl group on which one of the hydrogen atoms is replaced by a phenyl group.
As used herein, the term "heterocycle," "heterocyclyl," or "heterocyclic group" is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated, or fully unsaturated, and that contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any polycyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e. , N→0 and S(0)p, wherein p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (i.e. , N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be
substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. When the term "heterocycle" is used, it is intended to include heteroaryl.
Examples of heterocycles include, but are not limited to, acridinyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl,
benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3-Z>]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl,
1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl, oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-l ,2,5-thiadiazinyl, 1 ,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1 ,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclic group" is intended to mean a stable 9- or 10-membered heterocyclic ring system which contains
two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a
5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a
6- membered heteroaryl ring or a benzo ring, each fused to a second ring. The second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).
The bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, lH-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,
5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro-benzofuranyl, chromanyl,
1,2,3,4-tetrahydro-quinoxalinyl and 1,2,3,4-tetrahydro-quinazolinyl.
As used herein, the term "aromatic heterocyclic group" or "heteroaryl" is intended to mean stable monocyclic and poly cyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4- thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl and benzodioxane. Heteroaryl groups are substituted or unsubstituted. The nitrogen atom is substituted or unsubstituted (i.e. , N or NR wherein R is H or another substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→0 and S(0)p, wherein p is 0, 1 or 2).
Bridged rings are also included in the definition of heterocycle. A bridged ring occurs when one or more, preferably one to three, atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. Examples of bridged rings include, but are not
limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
The term "heterocyclylalkyfrefers to a heterocyclyl or substituted heterocyclyl bonded to an alkyl group connected to the core of the compound.
The term "counter ion" is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate or a positively charged species such as sodium (Na+), potassium (K+), ammonium (RnNHm+ where n=0-4 and m=0-4) and the like.
The term "electron withdrawing group" (EWG) refers to a substituent which polarizes a bond, drawing electron density towards itself and away from other bonded atoms. Examples of EWGs include, but are not limited to, CF3, CF2CF3, CN, halogen, haloalkyl, N02, sulfone, sulfoxide, ester, sulfonamide, carboxamide, alkoxy, alkoxyether, alkenyl, alkynyl, OH, C(0)alkyl, CO2H, phenyl, heteroaryl, -O-phenyl, and -O- heteroaryl. Preferred examples of EWG include, but are not limited to, CF3, CF2CF3, CN, halogen, SO^C^ alkyl), CONHCC^ alkyl), CONCC^ alkyl)2, and heteroaryl. More preferred examples of EWG include, but are not limited to, CF3 and CN.
As used herein, the term "amine protecting group" means any group known in the art of organic synthesis for the protection of amine groups which is stable to an ester reducing agent, a disubstituted hydrazine, R4-M and R7-M, a nucleophile, a hydrazine reducing agent, an activator, a strong base, a hindered amine base and a cyclizing agent. Such amine protecting groups fitting these criteria include those listed in Wuts, P. G. M. and Greene, T.W. Protecting Groups in Organic Synthesis, 4th Edition, Wiley (2007) and The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Examples of amine protecting groups include, but are not limited to, the following: (1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; (2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls,
l-(p-biphenyl)-l-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); (3) aliphatic carbamate types such as fert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; (4) cyclic alkyl carbamate types such
as cyclopentyloxycarbonyl and adamantyloxycarbonyl; (5) alkyl types such as triphenylmethyl and benzyl; (6) trialkylsilane such as trimethylsilane; (7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl; and (8) alkyl types such as triphenylmethyl, methyl, and benzyl; and substituted alkyl types such as
2,2,2-trichloroethyl, 2-phenylethyl, and i-butyl; and trialkylsilane types such as trimethylsilane.
As referred to herein, the term "substituted" means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g. , C=C, C=N, or N=N).
In cases wherein there are nitrogen atoms (e.g. , amines) on compounds of the present invention, these may be converted to N-oxides by treatment with an oxidizing agent (e.g. , mCPBA and/or hydrogen peroxides) to afford other compounds of this invention. Thus, shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N-)0) derivative.
When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R, then said group may optionally be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom in which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts
of acidic groups such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, gly colic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,
methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington: The Science and Practice of Pharmacy, 22nd Edition, Allen, L. V. Jr., Ed. ; Pharmaceutical Press, London, UK (2012), the disclosure of which is hereby incorporated by reference.
In addition, compounds of formula I may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i. e. , a compound of formula I) is a prodrug within the scope and spirit of the invention. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:
a) Bundgaard, H., ed., Design of Prodrugs, Elsevier (1985), and Widder, K. et al, eds., Methods in Enzymology, 1 12:309-396, Academic Press (1985);
b) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs," A Textbook of Drug Design and Development, pp. 113-191 , Krosgaard-Larsen, P. et al., eds., Harwood Academic Publishers (1991);
c) Bundgaard, ., Adv. Drug Deliv. Rev , 8: 1 -38 (1992);
d) Bundgaard, H. et al, J. Pharm. Set , 77:285 (1988);
e) Kakeya, N. et al, Chem. Pharm. Bull , 32:692 (1984); and
f) Rautio, J (Editor). Prodrugs and Targeted Delivery ftlethods and
Principles in Medicinal Chemistry), Vol 47, Wiley -VCH, 2011.
Compounds containing a carboxy group can form physiologically hydrolyzable esters that serve as prodrugs by being hydrolyzed in the body to yield formula I compounds per se. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes.
Parenteral administration may be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula I include C ^alkyl, C^alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C i- alkanoyloxy-C^alkyl (e.g. , acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl),
C^alkoxycarbonyloxy-C ^alkyl (e.g. , methoxycarbonyl-oxymethyl or
ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl,
(5 -methy 1-2-oxo-l , 3 -dioxolen-4-yl)-methyl), and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.
Preparation of prodrugs is well known in the art and described in, for example, King, F.D., ed., Medicinal Chemistry: Principles and Practice, The Royal Society of
Chemistry, Cambridge, UK (2nd edition, reproduced, 2006); Testa, B. et al, Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology, VCHA and Wiley-VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., The Practice of Medicinal Chemistry, 3rd edition, Academic Press, San Diego, CA (2008).
The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. The isotopes of hydrogen can be denoted as ¾ (hydrogen), 2H (deuterium) and ¾ (tritium). They are also commonly denoted as D for deuterium and T for tritium. In the application, CD3 denotes a methyl group wherein all of the hydrogen atoms are deuterium. Isotopes of carbon include 13C and 14C.
Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
The term "solvate" means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. The solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered arrangement. The solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
As used herein, the term "patient" refers to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g. , murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably refers to humans.
As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent, i.e., a compound of the invention, that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. The term also includes within its scope amounts effective to enhance normal physiological function
As used herein, the term "treating" includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
As used herein, the term "pharmaceutical composition" refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
Examples of bases include, but are not limited to, alkali metals (e.g. , sodium) hydroxides, alkaline earth metals (e.g. , magnesium), hydroxides, ammonia, and compounds of formula NW~4+, wherein W is Ci-4 alkyl, and the like.
For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
METHODS OF PREPARATION
The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
The compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being affected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the
compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts {Protective Groups In Organic Synthesis, Third Edition, Wiley and Sons, 1999).
Compounds of Formula (I) may be prepared by reference to the methods illustrated in the following Schemes. As shown therein the end product is a compound having the same structural formula as Formula (I). It will be understood that any compound of Formula (I) may be produced by the schemes by the suitable selection of reagents with appropriate substitution. Solvents, temperatures, pressures, and other reaction conditions may readily be selected by one of ordinary skill in the art. Starting materials are commercially available or readily prepared by one of ordinary skill in the art. Constituents of compounds are as defined herein or elsewhere in the specification.
The synthesis of the compounds of Formula (I) can be made using the methods summarized in Schemes 1 to 4.
Scheme 1
Compounds of general formula ii may be prepared from suitably substituted 2- aminopyridines i (X = halogen or other appropriate functionality) by treatment with an
acylating agent such as acetic anhydride (LG = -OAc) in the presence of a base such as DMAP using a suitable solvent such as dimethylformamide at an appropriate temperature. Treatment of compound ii with a protected acetylene such as trimethylsilylacetylene in the presence of a catalyst such as Pd(PPh3)2Ch with an additive such as Cul in the presence of a base such as triethylamine at elevated temperature may be used to effect transformation to compounds of formula iii. Deprotection may be accomplished by treatment with tetrabutylammonium fluoride in a solvent such as THF or other means known to one skilled in the art to afford compounds of formula iv. The reaction of compounds of formula iv with suitably substituted 3-aminopyridines (v, X = halogen) in the presence of a catalyst such as Pd(PPh3)2Ch with an additive such as Cul in the presence of a base such as triethylamine in an appropriate solvent such as
dimethylformamide at elevated temperature may be used to produce compounds of formula vi. Further, treatment of compounds of formula vi with trifluoracetic anhydride, or other appropriate acylating reagent in a solvent such as dichloromethane in the presence of a base such as triethylamine at an appropriate temperature may be used to afford compounds of formula vii. Cyclization of compounds of formula vii in the presence of an appropriately substituted heteroaryl halide (R-X) in the presence of a catalyst such as Pd(PPh3)4 and a base such as CS2CO3 in an appropriate solvent such as acetonitrile at an elevated temperature such as 100 °C may afford compounds of formula viii. Compounds of formula viii may be further elaborated to compounds of general formula ix by treatment with an appropriately functionalized reagent (Rs-X) where X is leaving group, for example halogen, in the presence of a base such as triethylamine in an appropriate solvent such as dimethylformamide.
Scheme 2
Alternatively, as described in Scheme 2, compounds of formula vi may be cyclized directly through treatment with an appropriate reagent such as Cul in an appropriate solvent such as DMF at elevated temperature to afford compounds of formula x. Additionally, compounds of formula x may be prepared by treatment of compounds of formula vii with a catalyst such as Pd(PPh3)4 in the presence of a base such as CS2CO3 in an appropriate solvent such as acetonitrile at elevated temperatures such as 100 °C. Compounds of formula x may be treated with a halogenating reagent, such as N- bromosuccinimide in a solvent such as dimethylformamide to provide compounds of formula xi. Compounds of formula xi may be further elaborated to afford compounds of formula viii by treatment with an organometallic reagent, such as a boronic acid (M = B(OH)2) or boronate ester in the presence of a catalyst such as PdCl2(dppf) with a base such as K2CO3 in an appropriate solvent such as 1,4-dioxane.
Scheme 3
Compounds of formula viii may also be further elaborated as described in Scheme 3. Treatment of compounds of formula viii with a base, such as sodium hydroxide, in a solvent such as water or a mixture of water and methanol, at elevated temperature may provide free amines of formula xii. Reaction of compounds of formula xii with an appropriately substituted reagent containing a leaving group, for example halogen (LG =
Hal), in the presence of a base in an appropriate solvent such as dimethylformamide may provide compounds of formula xiii. Alternatively, compounds of formula xiii may be treated with a carboxylic acid (LG = OH) and a peptide coupling reagent such as EDC to afford compounds of general formula xiii.
Scheme 4
Alternatively, compounds of formula viii may be selectively protected by several methods known to one skilled in the art. For example, treatment with a sulfonyl chloride (PG-LG = pTsCl) in the presence of a base such as triethylamine in an appropriate solvent such as dimethylformamide may be used to afford compounds of general formula xiv. Reaction of compounds of formula xiv with an appropriately substituted reagent containing a leaving group, for example halogen (LG = Hal), in the presence of a base in an appropriate solvent such as dimethylformamide may provide compounds of formula xv. Protecting group removal may be effected in many ways known to one skilled in the art, for example by treatment with a base such as sodium hydroxide in a solvent or solvent mixture such as aqueous methanol to afford compounds of general formula xiii.
The invention is further defined in the following Examples. It should be understood that the Examples are given by way of illustration only. From the above discussion and the Examples, one skilled in the art can ascertain the essential
characteristics of the invention, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the invention to various uses and conditions. As a result, the invention is not limited by the illustrative examples set forth herein below, but rather is defined by the claims appended hereto.
Abbreviations
AC2O acetic anhydride
ACN Acetonitrile
CH3CN Acetonitrile
CS2CO3 cesium carbonate
DCM dichloromethane
DMAP dimethylaminopyridine
DMF dimethylformamide
DMSO dimethyl sulfoxide
Et3N triethyl amine
EtOAc ethyl acetate
g Gram
h hour(s)
H2O Water
HPLC high pressure liquid chromatography
K2CO3 potassium carbonate
LCMS Liquid Chromatography -Mass Spectroscopy
Mel methyl iodide
MeOH Methanol
min minute(s)
MgS04 magnesium sulfate
mL Milliliter
mmol Millimolar
NaHCOs sodium bicarbonate
NaOH sodium hydroxide
NBS N-bromosuccinamide
NH4OAC ammonium acetate
NH4OH ammonium hydroxide
PdCl2(dppf) [ΐ,ΐ '- bis(diphenylphosphino)ferrocene]dichloropalladium
Pd(Ph3P)4 tetrakis(triphenylphosphine)palladium
RT retention time
Abbreviations
TBAF tetrabutylammonium fluoride
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
AC2O acetic anhydride
Example 1
N- {4-[3-(6-Me lpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
1A): N-(4-Bromopyridin-2-yl)acetamide
To a mixture of 4-bromopyridin-2-amine (3.8 g, 22 mmol) in AC2O (20 mL) was added DMAP (0.054 g, 0.44 mmol). The mixture was heated in a sealed pressure reaction vessel at 140 °C for lh, and then cooled to room temperature. The reaction mixture was poured into ice-water, and the resulting mixture was adjusted to pH = 8.4 with NH4OH. The resulting precipitate was collected by filtration, washed with water and dried to afford Example 1A (4.2 g, 88%). HPLC: RT = 0.587 min (H20/MeOH with 0.1 % TFA, Chromolith SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES):
m/z = 217 [M+H]+; ¾ NMR (400 MHz, Chloroform-d) δ ppm 10.71 (br. s., 1H), 8.32 (d, J=.1.8 Hz, 1H), 8.22 (d, J = 5.5 Hz, 1H), 7.35 (dd, J = 5.3, 1.8 Hz, 1H), 2.11 (s, 3H).
IB): N-(4-Ethynylpyridin-2-yl)acetamide
A mixture of Example 1A (4.2 g, 19.3 mmol), ethynyltrimethylsilane (2.28 g, 23.2 mmol), bis(triphenylphosphine)palladium(II) dichlororide (0.27 g, 0.39 mmol) and copper(I) iodide (0.15 g, 0.77 mmol) in TEA (20 mL, 143 mmol) was purged with nitrogen and heated to 76 °C for 2.5 h, and then cooled to room temperature. The mixture was filtered through a short silica gel column, eluting with EtOAc. The filtrate was concentrated to give N-(4-((trimethylsilyl)ethynyl)pyridin-2-yl)acetamide (5.10 g, 114%). The above solid was dissolved in THF (60 mL), and treated with TBAF (12.6 g, 48.2 mmol) in one portion. The reaction mixture was stirred at room temperature for 2 h and then concentrated to dryness. The residue was treated with water and extracted with EtOAc (3 x). The combined extracts were washed with brine, dried (MgS04), and then concentrated. The residue was purified by silica gel flash chromatography (12 g column, EtOAc/DCM = 0-100%) to afford Example IB (2.89 g, 94%) as a light yellow solid. HPLC: RT = 0.43 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 161 [M+H]+; ¾ NMR
(400MHz, Chloroform-d) δ ppm 8.32 (s, 1H), 8.24 (dd, J=5.1, 0.7 Hz, 1H), 8.05 (br. s., 1H), 7.11 (dd, J=5.1, 1.5 Hz, 1H), 3.30 (s, 1H), 2.23 (s, 3H).
1C): N-(4-((3-Aminopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
A mixture of 2-bromopyridin-3-amine (3.40 g, 19.7 mmol), Example IB (3 g, 18.7 mmol), bis(triphenylphosphine)palladium(II) dichloride (0.13 g, 0.19mmol) and copper(I) iodide (0.11 g, 0.56 mmol) in TEA (24 mL) and DMF (8 mL) was purged with N2, and then heated at 76 °C for 1 h. The reaction mixture was cooled to room
temperature, and then concentrated and the residue was purified by silica gel flash chromatography (40 g column, MeOH/DCM = 0-12%) to afford Example 1C (5.5 g) as a yellow solid. HPLC: RT = 0.953 min (H20/MeOH with 0.1% TFA, Chromolith
SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 253 [M+H]+; ¾ NMR (400 MHz, Chloroform-d) δ ppm 8.38 (s, 1H), 8.28 (dd, J=5.1, 0.9 Hz, 1H), 8.08 (dd, J=4.5, 1.4 Hz, 1H), 7.96 (br. s., 1H), 7.23 (dd, J=5.2, 1.4 Hz, 1H), 7.16 - 7.10 (m, 1H), 7.09 - 7.04 (m, 1H), 4.34 (br. s., 2H), 2.25 (s, 3H).
ID): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)pyridin-3-yl)-2,2,2-trifluoroacetamide
To a suspension of Example 1C (335 mg, 1.33 mmol) in CH2CI2 (15 mL) was added TEA, and the mixture was cooled to 0 °C. Trifluoroacetic anhydride (0.28 mL, 1.99 mmol) was slowly added. The reaction mixture was stirred at 0 °C for 30 min and then diluted with DCM. The solution was washed with sat.aq.NaHCC and brine, dried (MgSCn), and then concentrated. The residue was sonicated with DCM/hexane, and the resulting solid was collected by filtration to afford Example ID (412 mg, 71%) as a yellow solid. HPLC: RT = 1.530 min (H20/MeOH with 0.1% TFA, Chromolith
SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 349 [M+H]+; ¾ NMR (400 MHz, Chloroform-d) δ ppm 8.86 - 8.69 (m, 2H), 8.54 (dd, J=4.8, 1.5 Hz, 1H), 8.45 (s, 1H), 8.35 (dd, J=5.1, 0.9 Hz, 1H), 7.99 (br. s., 1H), 7.44 (dd, J=8.5, 4.7 Hz, 1H), 7.21 (dd, J=5.1, 1.3 Hz, 1H), 2.26 (s, 3H).
Example 1): N-{4-[3-(6-Methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
A mixture of Example ID (40 mg, 0.12 mmol), 2-bromo-6-methylpyridine (23.7mg, 0.14 mmol), Pd(Ph3P)4 (6.6 mg, 5.7 μπιοΐ) and Cs2C03 (112 mg, 0.35 mmol) in acetonitrile (1 mL) was purged with N2. The mixture was then heated at 100 °C in a sealed vial for 2h, and then cooled to room temperature. The solid was filtered off, and rinsed with 10% MeOH/DCM, and the filtrate was concentrated. The residue was dissolved in DMF, and purified by preparative HPLC (YMC-Pack C- 18 30 x 100 mm, eluting with 10% -70% aqueous CEbCN containing 5 mmol NEUOAc over 20 min, 30 mL/min, wavelength = 254 nm) to give Example IE (12.5 mg, 31%) as a white solid. HPLC: RT = 1.040 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD,
4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 344 [M+H]+; ¾ NMR (400 MHz, methanol-d4) δ ppm 8.39 (dd, J=4.6, 1.3 Hz, 1H), 8.31 - 8.21 (m, 2H), 7.97 (dd, J=8.1, 1.3 Hz, 1H), 7.83 (t, J=7.7 Hz, 1H), 7.50 (d, J=7.7 Hz, 1H), 7.32 (dt, J=8.4, 4.2 Hz, 2H), 7.13 (dd, J=5.2, 1.7 Hz, 1H), 2.53 (s, 3H), 2.17 (s, 3H).
Example 2
N-{4-[3-(6-Methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 2 was prepared from Example ID and 2-bromo-6-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.72 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 360 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.73 (s, 1H), 8.67 (d, J=5.0 Hz, 1H), 8.57 - 8.30 (m, 3H), 7.96 (s, 1H), 7.81 - 7.65 (m, 2H), 7.35 - 7.20 (m, 2H), 6.81 (d, J=8.4 Hz, 1H), 2.51 (br. s., 3H), 2.11 (s, 3H).
Example 3
N-{4-[3-(6-Chloropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 3 was prepared from Example ID, and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.77 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 364 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.69 (s, 1H), 8.63 (d, J=5.0 Hz, 1H), 8.42 (d, J=5.0 Hz, 1H), 8.38 - 8.27 (m, 2H), 7.94 - 7.86 (m, 1H), 7.80 (d, J=7.1 Hz, 1H), 7.59 (dd, J=7.9, 5.6 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 7.26 (d, J=4.4 Hz, 1H), 2.10 (s, 3H).
Example 4
N-{4-[3-(6-Fluoropyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 4 was prepared from Example ID and 2-fluoro-5-iodopyridine by the general methods shown for Example 1. HPLC: RT = 0.58 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 348 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.18 (s, IH), 10.61 (s, IH), 8.44 (d, J=4.4 Hz, IH), 8.36 (d, J=5.0 Hz, IH), 8.29 (s, 2H), 8.16 - 8.05 (m, IH), 7.91 (d, J=8.1 Hz, IH), 7.34 - 7.21 (m, 2H), 7.17 (d, J=5.0 Hz, IH), 2.09 (s, 3H).
Example 5
N-{4-[3-(5-Chloropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 5 was prepared from Example ID and 5-chloro-2-iodopyridine by the general methods shown for Example 1. HPLC: RT = 0.85 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 364 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ
ppm 10.77 (s, 1H), 8.75 - 8.62 (m, 2H), 8.55 - 8.43 (m, 2H), 8.37 (s, 1H), 8.00 - 7.91 (m, 1H), 7.75 - 7.58 (m, 2H), 7.30 (d, J=4.4 Hz, 1H), 2.12 (s, 3H).
Example 6
N- {4-[3-(5-Fluoropyridin-2-yl)-lH-pyiTolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
Example 6 was prepared from Example ID and 2-bromo-5-fiuoropyridine by the general methods shown for Example 1. HPLC: RT = 0.70 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 348 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.77 (s, 1H), 8.75 - 8.63 (m, 2H), 8.57 (d, J=8.4 Hz, 1H), 8.48 (d, J=5.4 Hz, 1H), 8.34 (s, 1H), 7.84 - 7.70 (m, 2H), 7.56 (dd, J=8.1, 3.7 Hz, 1H), 7.31 (d, J=5.0 Hz, 1H), 2.11 (s, 3H).
Example 7
N-(4- {3-[6-(Trifluoromethyl)pyridin-2-yl]-lH-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2- yl)acetamide
Example 7 was prepared from Example ID and 2-bromo-6- (trifluoromethyl)pyridine by the general methods shown for Example 1. HPLC: RT =
0.87 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μτη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 398 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.63 (s, IH), 8.62 (d, J=4.4 Hz, IH), 8.41 - 8.30 (m, 2H), 8.29 - 8.20 (m, 2H), 8.17 (t, J=7.7 Hz, IH), 7.84 - 7.78 (m, IH), 7.53 (dd, J=8.1, 5.0 Hz, IH), 7.26 (d, J=4.4 Hz, IH), 2.08 (s, 3H).
Example 8
N-{4-[3-(Pyrimidin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 8 was prepared from Example ID and 2-bromopyrimidine by the general methods shown for Example 1. HPLC: RT = 0.54 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 331 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.77 (s, IH), 8.86 (d, J=5.0 Hz, 2H), 8.78 (d, J=5.7 Hz, IH), 8.71 (d, J=8.4 Hz, IH), 8.54 - 8.45 (m, 2H), 7.85 (dd, J=8.1, 6.1 Hz, IH), 7.50 - 7.41 (m, 2H), 2.13 (s, 3H).
Example 9
N-{4-[3-(6-Chloropyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 9 was prepared from Example ID and 5-bromo-2-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.64 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 364 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.24 (s, IH), 10.63 (s, IH), 8.52 - 8.40 (m, 2H), 8.36 (d, J=5.0 Hz, IH), 8.30 (s, IH), 8.00 (dd, J=8.4, 2.4 Hz, IH), 7.91 (d, J=8.1 Hz, IH), 7.55 (d, J=8.1 Hz, IH), 7.29 (dd, J=8.2, 4.5 Hz, IH), 7.16 (d, J=4.4 Hz, IH), 2.09 (s, 3H).
Example 10
N-{4-[3-(5,6-Difluoropyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 10 was prepared from Example ID and 2,3-difluoro-5-iodopyridine by the general methods shown for Example 1. HPLC: RT = 0.70 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 366 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.28 (s, IH), 10.61 (s, IH), 8.46 (d, J=4.4 Hz, IH), 8.38 (d, J=5.0 Hz, IH), 8.27 (br. s., IH), 8.17 (t, J=9.8 Hz, IH), 8.08 (s, IH), 7.92 (d, J=8.4 Hz, IH), 7.30 (dd, J=8.1, 4.4 Hz, IH), 7.25 (d, J=4.7 Hz, IH), 2.08 (s, 3H).
Example 11
N-{4-[3-(6-Fluoro-5-methylpyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 11 was prepared from Example ID and 5-bromo-2-fluoro-3- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.70 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 362 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.60 (s, 1H), 8.43 (d, J=3.7 Hz, 1H), 8.37 - 8.25 (m, 2H), 8.10 - 7.94 (m, 2H), 7.90 (d, J=7.7 Hz, 1H), 7.28 (dd, J=8.1, 4.7 Hz, 1H), 7.16 (d, J=4.4 Hz, 1H), 2.28 (s, 3H), 2.09 (s, 3H).
Example 12
N-{4-[3-(6-Cyanopyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 12 was prepared from Example ID and 5-bromopicolinonitrile by the general methods shown for Example 1. HPLC: RT = 0.58 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 355 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.70 (br. s., 1H), 8.84 (s, 1H), 8.58 (br. s., 1H), 8.41 (br. s., 1H), 8.29 - 8.16 (m, 3H), 8.11 (d, J=8.1 Hz, 1H), 7.95 (s, 1H), 7.53 (br. s., 1H), 7.20 (d, J=4.0 Hz, 1H), 2.09 (s, 3H).
Example 13
N-(4- {3-[6-(Trifluoromethyl)pyridin-3-yl]-lH-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2- yl)acetamide
Example 13 was prepared from Example ID and 5-bromo-2- (trifluoromethyl)pyridine by the general methods shown for Example 1. HPLC: RT = 0.78 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μτη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 398 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.36 (s, IH), 10.64 (s, IH), 8.84 (s, IH), 8.47 (d, J=4.4 Hz, IH), 8.37 (d, J=5.0 Hz, IH), 8.30 (s, IH), 8.23 (d, J=8.1 Hz, IH), 7.94 (m, 2H), 7.32 (dd, J=8.2, 4.5 Hz, IH), 7.18 (d, J=4.7 Hz, IH), 2.08 (s, 3H).
Example 14
N- {4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Method A:
Example 14 was prepared from Example ID and 5-bromo-2-methoxypyridine by the general methods shown for Example 1. HPLC: RT = 0.62 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 360 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.01 (s, 1H), 10.58 (s, 1H), 8.41 (dd, J=4.5, 1.4 Hz, 1H), 8.37 - 8.29 (m, 2H), 8.26 (d, J=2.0 Hz, 1H), 7.87 (dd, J=8.1, 1.3 Hz, 1H), 7.80 (dd, J=8.5, 2.3 Hz, 1H), 7.25 (dd, J=8.3, 4.5 Hz, 1H), 7.13 (dd, J=5.1, 1.5 Hz, 1H), 6.87 (d, J=8.6 Hz, 1H), 2.10 (s, 3H).
Example 14 may also be prepared by the alternative Method B:
14A): N-(4-(lH-Pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example ID (5 g, 14.36 mmol), Pd(Ph3P)4 (0.829 g, 0.718 mmol) and CS2CO3 (9.36 g, 28.7 mmol) in acetonitrile (60 mL) was purged with N2. The mixture was then heated at 100 °C in a sealed pressure reaction vessel overnight, and then cooled to room temperature. The reaction mixture was diluted with MeOH/DCM, and directly loaded onto celite, and then purified by silica gel flash chromatography (80 g column, MeOH/DCM=0-10%) to give Example 14A (2.37 g, 65%). HPLC: RT = 0.850 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 253 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.03 (s, 1H), 10.57 (s, 1H), 8.53 (s, 1H), 8.39 (ddd, J=6.8, 5.0, 1.0 Hz, 2H), 7.82 (dt, J=8.0, 1.2 Hz, 1H), 7.61 (dd, J=5.3, 1.5 Hz, 1H), 7.21 - 7.11 (m, 2H), 2.15 (s, 3H).
To a suspension of Example 14A (6.55 g, 26.0 mmol) in DMF (70 mL) at 0 °C was added NBS (4.62 g, 26.0 mmol). The reaction was then stirred at room temperature for 30 min, quenched with MeOH, and then concentrated. The residue was treated with MeOH, and the solid precipitate was collected by filtration and dried to give Example 14B (7.7 g, 90%) as a light yellow solid. HPLC: RT = 0.953 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6x50mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z= 332 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.31 (s, 1H), 10.67 (s, 1H), 8.76 (s, 1H), 8.58 - 8.33 (m, 2H), 7.88 (dd, J=8.4, 1.3 Hz, 1H), 7.60 (dd, J=5.3, 1.8 Hz, 1H), 7.30 (dd, J=8.3, 4.5 Hz, 1H), 2.15 (s, 3H).
Example 14): N-{4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
A mixture of Example 14B (7.5 g, 22.65 mmol), (6-methoxypyridin-3-yl)boronic acid (8.66 g, 56.6 mmol), PdCl2(dppf)-CH2Cl2 adduct (0.555 g, 0.679 mmol) and 2M
K2C03 (34.0 mL, 67.9 mmol) in 1,4-Dioxane (200 mL) was purged with N2. The mixture was heated to reflux for 5h and then cooled to room temperature. The reaction mixture was then diluted with EtOAc, washed with brine, dried and concentrated. The residue was purified by silica gel flash chromatography (120 g column, MeOH/ DCM=0-10%) to give Example 14 (3.85 g, 47%) as an off white solid.
Example 15
N-{4-[3-(6-Cyanopyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 15 was prepared from Example ID and 6-bromopicolinonitrile by the general methods shown for Example 1. HPLC: RT = 0.74 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 355 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.55 (s, IH), 8.54 (d, J=8.1 Hz, IH), 8.49 (d, J=4.0 Hz, IH), 8.36 (d, J=5.0 Hz, IH), 8.25 (s, IH), 8.10 (t, J=7.9 Hz, IH), 7.98 - 7.90 (m, IH), 7.85 (d, J=7.4 Hz, IH), 7.32 (dd, J=8.2, 4.5 Hz, IH), 7.25 (d, J=5.0 Hz, IH), 2.08 (s, 3H).
Example 16
N-{4-[3-(6-Fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 16 was prepared from Example ID and 2-bromo-6-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 0.73 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 348 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.75 (s, IH), 8.67 (d, J=5.0 Hz, IH), 8.52 - 8.41 (m, 2H), 8.33 (s, IH), 8.03 (q,
J=8.1 Hz, IH), 7.68 (dd, J=7.9, 5.6 Hz, IH), 7.58 (d, J=7.1 Hz, IH), 7.30 (d, J=4.0 Hz, IH), 7.16 (d, J=9.8 Hz, IH), 2.11 (s, 3H).
Example 17
N- {4-[3-(Isoquinolin-6-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 17 was prepared from Example ID and 6-bromoisoquinoline by the general methods shown for Example 1. HPLC: RT = 0.55 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.62 (s, IH), 9.30 (s, IH), 8.53 - 8.43 (m, 2H), 8.38 (s, IH), 8.29 (d, J=5.4 Hz, IH), 8.24 (s, IH), 8.08 (d, J=8.4 Hz, IH), 7.93 (d, J=8.1 Hz, IH), 7.82 (d, J=5.7 Hz, IH), 7.71 (d, J=8.4 Hz, IH), 7.30 (dd, J=8.1 , 4.4 Hz, IH), 7.09 (d, J=5.0 Hz, IH), 2.07 (s, 3H).
Example 18
N- {4-[3-(5-Methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
Example 18 was prepared from Example ID and 2-bromo-5-methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.72 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 344 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.80 (s, IH), 8.73 - 8.64 (m, 2H), 8.49 (d, J=5.0 Hz, IH), 8.45 (d, J=8.1 Hz, IH), 8.36 (s, IH), 7.91 (d, J=7.7 Hz, IH), 7.67 (dd, J=8.1, 5.4 Hz, IH), 7.52 (d, J=8.4 Hz, IH), 7.32 (d, J=4.0 Hz, IH), 2.42 (s, 3H), 2.12 (s, 3H).
Example 19
N- {4- [3 -(Isoquinolin-8-y 1)- 1 H-py rrolo [3,2-b] py ridin-2-y l]py ridin-2-y 1 } acetamide
Example 19 was prepared from Example ID and 8-bromoisoquinoline by the general methods shown for Example 1. HPLC: RT = 0.56 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.46 (s, IH), 8.88 (s, IH), 8.46 (d, J=5.7 Hz, IH), 8.31 (d, J=3.7 Hz, IH), 8.25 (s, IH), 8.13 (d, J=5.4 Hz, IH), 8.02 (d, J=8.4 Hz, IH), 7.96 (s, IH), 7.91 (d, J=5.7 Hz, IH), 7.82 (t, J=7.6 Hz, IH), 7.57 (d, J=6.7 Hz, IH), 7.28 (dd, J=8.2, 4.5 Hz, IH), 6.90 (d, J=4.4 Hz, IH), 2.02 (s, 3H).
Example 20
N- {4- [3 -(1 H-Indol-5 -yl)-l H-pyrrolo [3,2-b]py ridin-2-y 1] py ridin-2-y 1 } acetamide
Example 20 was prepared from Example ID and 5-bromo-lH-indole by the general methods shown for Example 1. HPLC: RT = 0.81 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 368 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.33 (br. s., IH), 10.69 (s, IH), 8.62 (d, J=8.1 Hz, IH), 8.55 (d, J=5.7 Hz, IH), 8.45 (s, IH), 8.26 (d, J=5.4 Hz, IH), 7.77 - 7.67 (m, 2H), 7.53 - 7.41 (m, 2H), 7.06 (d, J=8.1 Hz, IH), 6.98 (d, J=4.7 Hz, IH), 6.50 (br. s., IH), 2.10 (s, 3H).
Example 21
N-{4-[3-(Quinolin-8-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 21 was prepared from Example ID and 8-bromoquinoline by the general methods shown for Example 1. HPLC: RT = 0.64 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.37 (s, IH), 8.58 (d, J=2.7 Hz, IH), 8.41 (d, J=8.1 Hz, IH), 8.26 (d, J=4.4 Hz, IH), 8.20 (br. s., IH), 8.08 - 7.99 (m, 2H), 7.93 (d, J=8.1 Hz, IH), 7.81 (d, J=6.7 Hz, IH), 7.70 (t, J=7.6 Hz, IH), 7.46 (dd, J=8.4, 4.0 Hz, IH), 7.23 (dd, J=8.1, 4.4 Hz, IH), 6.83 (d, J=5.0 Hz, IH), 2.01 (s, 3H).
Example 22
N-{4-[3-(Quinolin-6-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
Example 22 was prepared from Example ID and 6-bromoquinoline by the general methods shown for Example 1. HPLC: RT = 0.54 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.15 (s, IH), 10.61 (s, IH), 8.89 (d, J=2.7 Hz, IH), 8.46 (d, J=3.7 Hz, IH), 8.42 - 8.32 (m, 2H), 8.27 (d, J=5.4 Hz, IH), 8.22 (s, IH), 7.99 (d, J=8.8 Hz, IH), 7.93 (d, J=8.1 Hz, IH), 7.79 (dd, J=8.8, 1.3 Hz, IH), 7.53 (dd, J=8.2, 4.2 Hz, IH), 7.30 (dd, J=8.2, 4.5 Hz, IH), 7.09 (d, J=4.4 Hz, IH), 2.07 (s, 3H).
Example 23
N- {4-[3-(5-Fluoro-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 23 was prepared from Example ID and 6-bromo-3-fiuoro-2- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.80 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μηι
particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 362 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.56 (s, IH), 8.49 (d, J=4.4 Hz, IH), 8.38 - 8.28 (m, 2H), 8.05 - 7.89 (m, 2H), 7.68 (t, J=9.1 Hz, IH), 7.35 (dd, J=8.1, 4.7 Hz, IH), 7.25 (d, J=5.4 Hz, IH), 2.33 (d, J=2.4 Hz, 3H), 2.10 (s, 3H).
Example 24
N-{4-[3-(5-Fluoro-4-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 24 was prepared from Example ID and 2-bromo-5-fiuoro-4- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 362 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.74 (s, IH), 8.65 (d, J=5.0 Hz, IH), 8.59 - 8.49 (m, 2H), 8.46 (d, J=5.4 Hz, IH), 8.35 (s, IH), 7.71 (dd, J=8.1, 5.7 Hz, IH), 7.54 (d, J=5.7 Hz, IH), 7.29 (d, J=4.7 Hz, IH), 2.26 (s, 3H), 2.11 (s, 3H).
Example 25
Example 25 was prepared from Example ID and 2-bromo-5- (methylsulfonyl)pyridine by the general methods shown for Example 1. HPLC: RT = 0.63 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.61 (s, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.61 (d, J=8.4 Hz, 1H), 8.53 (d, J=4.7 Hz, 1H), 8.43 - 8.32 (m, 2H), 8.29 (s, 1H), 7.94 (d, J=8.1 Hz, 1H), 7.33 (dd, J=8.1, 4.7 Hz, 1H), 7.25 (d, J=5.0 Hz, 1H), 3.45 - 3.35 (m, 3H), 2.10 (s, 3H).
Example 26
N-{4-[3-(5-Methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 26 was prepared from Example ID and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.70 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 360 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 13.40 (br. s., 1H), 10.77 (s, 1H), 8.68 (d, J=5.7 Hz, 1H), 8.58 (d, J=8.4 Hz, 1H), 8.53 - 8.46 (m, 2H), 8.39 (s, 1H), 7.75 (dd, J=8.1, 5.7 Hz, 1H), 7.53 (dd, J=8.8, 3.1 Hz, 1H), 7.41 (d, J=8.8 Hz, 1H), 7.30 (dd, J=5.1, 1.5 Hz, 1H), 3.91 (s, 3H), 2.12 (s, 3H).
Example 27
N-{4-[3 2-Methoxypyrimidin-5-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 27 was prepared from Example ID and 5-bromo-2-methoxypyrimidine by the general methods shown for Example 1. HPLC: RT = 0.55 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 361 [M+H]+; ¾ NMR (500 MHz, DMSO- de) δ ppm 10.63 (s, IH), 8.68 (s, IH), 8.47 (d, J=4.0 Hz, IH), 8.37 (d, J=5.0 Hz, IH), 8.32 (s, IH), 8.03 (d, J=8.1 Hz, IH), 7.37 (dd, J=8.1, 4.7 Hz, IH), 7.21 (d, J=4.0 Hz, IH), 3.97 (s, 3H), 2.09 (s, 3H).
Example 28
N-{4-[3-(4-Methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 28 was prepared from Example ID and 2-bromo-4-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.58 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 360 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ
ppm 10.57 (s, IH), 8.48 (d, J=4.0 Hz, IH), 8.38 - 8.19 (m, 3H), 7.90 (d, J=8.4 Hz, IH), 7.72 (d, J=2.0 Hz, IH), 7.28 (dd, J=8.1 , 4.4 Hz, IH), 7.18 (d, J=5.0 Hz, IH), 6.91 (d, J=3.4 Hz, IH), 3.89 (s, 3H), 2.10 (s, 3H).
Example 29
N- {4-[3-(4-Ethylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 29 was prepared from Example ID and 2-bromo-4-ethylpyridine by the general methods shown for Example 1. HPLC: RT = 0.93 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 358 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.57 (s, IH), 8.49 (d, J=4.0 Hz, IH), 8.38 (d, J=5.0 Hz, IH), 8.35 - 8.26 (m, 2H), 7.98 - 7.87 (m, 2H), 7.31 (dd, J=7.9, 4.5 Hz, IH), 7.17 (dd, J=16.7, 4.5 Hz, 2H), 2.70 (q, J=7.5 Hz, 2H), 2.10 (s, 3H), 1.23 (t, J=7.6 Hz, 3H).
Example 30
N- {4-[3-(6-Chloro-4-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 30 was prepared from Example ID and 2-bromo-6-chloro-4- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.
(H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.67 (s, IH), 8.62 (d, J=4.7 Hz, IH), 8.40 (d, J=5.0 Hz, IH), 8.36 - 8.21 (m, 2H), 7.72 (br. s., IH), 7.62 - 7.48 (m, IH), 7.33 (s, IH), 7.24 (d, J=4.0 Hz, IH), 2.36 (s, 3H), 2.11 (s, 3H).
Example 31
N-{4-[3-(4-Methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 31 was prepared from Example ID and 2-bromo-4-methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.57 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 344 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.54 (s, IH), 8.47 (d, J=4.0 Hz, IH), 8.35 - 8.21 (m, 3H), 7.94 (s, IH), 7.89 (d, J=7.7 Hz, IH), 7.27 (dd, J=8.2, 4.5 Hz, IH), 7.12 (dd, J=10.3, 5.2 Hz, 2H), 2.40 (s, 3H), 2.10 (s, 3H).
Example 32
N-{4-[3-(4-Chloropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
Example 32 was prepared from Example ID and 2-bromo-4-chloropyridine by the general methods shown for Example 1. HPLC: RT = 1.02 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 364 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.74 (s, 1H), 8.71 - 8.54 (m, 2H), 8.46 (d, J=5.0 Hz, 1H), 8.37 (br. s., 2H), 7.86 (br. s., 1H), 7.69 - 7.57 (m, 1H), 7.51 (d, J=3.7 Hz, 1H), 7.31 (d, J=4.0 Hz, 1H), 2.12 (s, 3H).
Example 33
N-{4-[3-(5-Chloro-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 33 was prepared from Example ID and 6-bromo-3-chloro-2- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.98 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.73 (s, 1H), 8.67 (d, J=5.0 Hz, 1H), 8.54 - 8.40 (m, 2H), 8.36 (s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.73 - 7.63 (m, 1H), 7.46 (d, J=7.7 Hz, 1H), 7.30 (d, J=4.4 Hz, 1H), 2.61 (s, 3H), 2.11 (s, 3H).
Example 34
N-{4-[3-(6-Chloropyridin-2-yl)-5-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
34A): N-(4-((3-Amino-6-fluoropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
Example 34 A was prepared from Example IB and 2-bromo-6-fluoropyridin-3- amine by similar methods as shown for Example 1C. HPLC: RT = 1.27 min (EhO/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 271 [M+H]+.
34B): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-6-fluoropyridin-3-yl)-2,2,2- trifluoroacetamide
Example 34B was prepared from Example 34A by methods similar to those shown for Example ID. HPLC: RT = 1.69 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 367 [M+H]+ , ¾ NMR (400 MHz, Chloroform-d) δ ppm 8.82 (br. s., 1H), 8.58 (dd, J=9.5, 2.6 Hz, 1H), 8.49 - 8.30 (m, 3H), 8.05 (br. s., 1H), 7.20 (dd, J=5.2, 1.4 Hz, 1H), 2.26 (s, 3H).
N-{4-[3-(6-Chloropyridin-2-yl)-5-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 34 was prepared from Example 34B and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.98 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.39 (s, IH), 10.57 (s, IH), 8.50 (s, IH), 8.34 (d, J=5.0 Hz, IH), 8.28 (s, IH), 8.16 (d, J=7.4 Hz, IH), 7.92 (t, J=7.7 Hz, IH), 7.80 (dd, J=9.3, 2.2 Hz, IH), 7.36 (d, J=7.7 Hz, IH), 7.21 (d, J=5.0 Hz, IH), 2.09 (s, 3H).
Example 35
N- {4-[5-Fluoro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 35 was prepared from Example 34B and 2-bromo-5-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 0.91 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min,
wavelength = 220 nm); MS (ES): m/z = 366 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.37 (s, IH), 10.54 (s, IH), 8.46 (d, J=3.0 Hz, IH), 8.31 (d, J=5.0 Hz, IH), 8.23 (s, IH), 8.06 (t, J=7.9 Hz, IH), 7.98 (dd, J=8.6, 4.5 Hz, IH), 7.83 (td, J=8.8, 3.0 Hz, IH), 7.15 (d, J=4.4 Hz, IH), 7.02 (d, J=8.8 Hz, IH), 2.08 (s, 3H).
Example 36
N-{4-[5-Fluoro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 36 was prepared from Example 34B and 5-iodo-2-methoxypyridine by the general methods shown for Example 1. HPLC: RT = 0.96 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.28 (s, IH), 10.60 (s, IH), 8.40 - 8.25 (m, 2H), 8.19 (d, J=1.7 Hz, IH), 8.04 (t, J=7.9 Hz, IH), 7.72 (dd, J=8.6, 2.2 Hz, IH), 7.10 (d, J=5.4 Hz, IH), 7.00 (d, J=8.8 Hz, IH), 6.88 (d, J=8.4 Hz, IH), 3.88 (s, 3H), 2.09 (s, 3H).
Example 37
Example 37 was prepared from Example 34B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.82 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.24 (s, IH), 10.55 (s, IH), 8.28 (d, J=5.4 Hz, 2H), 8.21 (d, J=2.7 Hz, IH), 8.04 (t, J=8.1 Hz, IH), 7.85 (d, J=8.4 Hz, IH), 7.52 (dd, J=8.6, 2.9 Hz, IH), 7.11 (d, J=4.0 Hz, IH), 6.99 (d, J=8.4 Hz, IH), 3.86 (s, 3H), 2.09 (s, 3H).
Example 38
N-{4-[3-(6-Chloropyridin-2-yl)-6-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
38A): N-(4-((3-Amino-5-fluoropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
Example 38A was prepared from Example IB and 2-bromo-5-fluoropyridin-3- by the methods shown for Example 1 C. HPLC: RT =1.25 min (H20/MeOH with
0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 271 [M+H]+ , ¾ NMR (400 MHz, DMSO-de) δ 10.60 (s, IH), 8.36 (d, J=5.3 Hz, IH), 8.23 (s, IH), 7.79 (d, J=2.6 Hz, IH), 7.35 (dd, J=5.1, 1.3 Hz, IH), 6.95 (dd, J=l l. l, 2.5 Hz, IH), 6.17 (s, 2H), 2.12 (s, 3H).
38B): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-fluoropyridin-3-yl)-2,2,2- trifluoroacetamide
Example 38B was prepared from Example 38A by the methods shown for Example ID. HPLC: RT = 1.69 min (H20/MeOH with 0.1% TFA, Chromolith
SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 367 [M+H]+ , ¾ NMR (400 MHz, DMSO-de) δ ppm 11.74 (s, IH), 10.67 (s, IH), 8.70 (d, J=2.9 Hz, IH), 8.41 (dd, J=5.1, 0.7 Hz, IH), 8.24 (s, IH), 8.09 (dd, J=9.1, 2.8 Hz, IH), 7.19 (dd, J=5.1, 1.3 Hz, IH), 2.12 (s, 3H).
N-{4-[3-(6-Chloropyridin-2-yl)-6-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 38 was prepared from Example 38B and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.98 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.57 (s, IH), 8.50 (s, IH), 8.34 (d, J=5.4 Hz, IH), 8.28 (s, IH), 8.16 (d, J=7.7 Hz, IH), 7.93 (t, J=7.7 Hz, IH), 7.80 (dd, J=9.3, 2.5 Hz, IH), 7.36 (d, J=7.7 Hz, IH), 7.21 (d, J=5.4 Hz, IH), 2.09 (s, 3H).
Example 39
N-{4-[6-Fluoro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 39 was prepared from Example 38B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.77 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.15 (s, IH), 10.54 (s, IH), 8.45 (s, IH), 8.35 - 8.24 (m, 2H), 8.21 (d, J=2.7 Hz, IH), 7.95 (d, J=8.4 Hz, IH), 7.74 (dd, J=9.4, 2.4 Hz, IH), 7.50 (dd, J=8.6, 2.9 Hz, IH), 7.12 (d, J=4.4 Hz, IH), 3.86 (s, 3H), 2.10 (s, 3H).
Example 40
Example 40 was prepared from Example 38B and 5-bromo-2-methoxypyridine by the general methods shown for Example 1. HPLC: RT = 0.88 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.24 (s, IH), 10.67 (s, IH), 8.43 (s, IH), 8.33 (d, J=5.0 Hz, IH), 8.29 (s, IH), 8.24 (d, J=2.0 Hz, IH), 7.81 - 7.72 (m, 2H), 7.13 (d, J=5.0 Hz, IH), 6.88 (d, J=8.8 Hz, IH), 3.88 (s, IH), 2.10 (s, IH).
Example 41
N- {4-[3-(6-Chloropyridin-2-yl)-6-chloro-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
41 A): N-(4-((3-Amino-5-chloropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
Example 41 A was prepared from Example IB and 2-bromo-5-chloropyridin-3- amine by the methods similar to those shown for Example 1C. HPLC: RT = 1.53 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 287 [M+H]+ , ¾ NMR (400 MHz, DMSO-de) δ 10.61 (s, IH), 8.36 (d, J=5.1 Hz, IH), 8.24 (s, IH), 7.80 (d, J=2.0 Hz, IH), 7.36 (dd, J=5.1, 1.5 Hz, IH), 7.20 (d, J=2.2 Hz, IH), 6.14 (s, 2H), 2.12 (s, 3H).
4 IB): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-chloropyridin-3-yl)-2,2,2- trifluoroacetamide
Example 41B was prepared from Example 41 A by the methods similar to those shown for Example ID. HPLC: RT = 1.93 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 383 [M+H]+ , ¾ NMR (400 MHz, DMSO-d) δ ppm 11.73 (s, IH), 10.68 (s, IH), 8.72 (d, J=2.2 Hz, IH), 8.41 (dd, J=5.1, 0.7 Hz, IH), 8.25 (d, J=2.2 Hz, 2H), 7.20 (dd, J=5.2, 1.4 Hz, IH), 2.12 (s, 3H).
Example 41): N-{4-[3-(6-Chloropyridin-2-yl)-6-chloro-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
Example 41 was prepared from Example 41 B and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 1.14 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 398 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.45 (s, IH), 10.59 (s, IH), 8.49 (d, J=2.0 Hz, IH), 8.35 (d, J=5.4 Hz, IH), 8.30 (s, IH), 8.16 (d, J=7.7 Hz, IH), 8.00 (d, J=2.0 Hz, IH), 7.93 (t, J=7.7 Hz, IH), 7.37 (d, J=7.7 Hz, IH), 7.22 (d, J=4.0 Hz, IH), 2.10 (s, IH).
Example 42
N-{4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 42 was prepared from Example 41 B and 2-bromo-5-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 0.95 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.34 (s, IH), 10.57 (s, IH), 8.47 (dd, J=4.9, 2.5 Hz, 2H), 8.33 (d, J=5.0 Hz, IH), 8.27 (s, IH), 8.10 (dd, J=8.6, 4.5 Hz, IH), 7.98 (d, J=2.0 Hz, IH), 7.83 (td, J=8.8, 2.7 Hz, IH), 7.17 (d, J=4.7 Hz, IH), 2.09 (s, IH).
Example 43
Example 43 was prepared from Example 41B and 5-bromo-2-methoxypyridine by the general methods shown for Example 1. HPLC: RT = 1.03 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.29 (s, IH), 10.68 (s, IH), 8.42 (s, IH), 8.34 (d, J=5.4 Hz, IH), 8.30 (s, IH), 8.24 (s, IH), 7.98 (s, IH), 7.77 (d, J=8.4 Hz, IH), 7.14 (d, J=4.7 Hz, IH), 6.88 (d, J=8.4 Hz, IH), 3.88 (s, 3H), 2.10 (s, 3H).
Example 44
N-{4-[6-Chloro-3-(5-fluoro-4-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
Example 44 was prepared from Example 41 B and 2-bromo-5-fiuoro-4- methylpyridine by the general methods shown for Example 1. HPLC: RT = 1.03 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 396 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.32 (s, IH), 10.56 (s, IH), 8.46 (br. s., IH), 8.34 (s, IH), 8.31 (d, J=5.0 Hz, IH), 8.26 (br. s., IH), 7.98 (d, J=1.7 Hz, IH), 7.94 (d, J=6.1 Hz, IH), 7.14 (d, J=4.4 Hz, IH), 2.36 (s, IH), 2.09 (s, IH).
Example 45
N-{4-[6-Chloro-3-(6-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 45 was prepared from Example 41 B and 2-bromo-6-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 1.03 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.44 (s, IH), 10.59 (s, IH), 8.48 (s, IH), 8.36 (d, J=5.0 Hz, IH), 8.26 (s, IH), 8.07 (d, J=4.4 Hz, 2H), 8.00 (d, J=\ Hz, IH), 7.22 (d, J=4.7 Hz, IH), 7.03 (d, J=7.1 Hz, IH), 2.09 (s, 3H).
Example 46
N-{4-[6-Chloro-3-(5-chloropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 46 was prepared from Example 41 B and 2-bromo-5-chloropyridine by the general methods shown for Example 1. HPLC: RT = 1.15 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 398 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ
ppm 10.61 (s, 1H), 8.47 (br. s., 2H), 8.33 (d, J=5.4 Hz, 1H), 8.25 (br. s., 1H), 8.1 1 (d, J=8.4 Hz, 1H), 8.04 - 7.97 (m, 2H), 7.18 (d, J=5.0 Hz, 1H), 2.09 (s, 3H).
Example 47
N- {4-[6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 47 was prepared from Example 41 B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.89 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.22 (s, 1H), 10.55 (s, 1H), 8.43 (d, J=2.0 Hz, 1H), 8.35 - 8.24 (m, 2H), 8.20 (d, J=2.7 Hz, 1H), 8.01 - 7.86 (m, 2H), 7.50 (dd, J=8.8, 3.0 Hz, 1H), 7.12 (d, J=6.1 Hz, 1H), 3.86 (s, 3H), 2.09 (s, 3H).
Example 48
N-{4-[3-(6-Chloropyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 48A was prepared from Example IB and 2-bromo-5-methoxypyridin-3- amine by methods similar to those shown for Example 1C. HPLC: RT = 1.22 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 283 [M+H]+ , ¾ NMR (400 MHz, Chloroform- d) δ 8.34 (s, IH), 8.25 (dd, J=5.2, 0.8 Hz, IH), 7.93 (br. s., IH), 7.82 (d, J=2.4 Hz, IH), 7.20 (dd, J=5.1, 1.3 Hz, IH), 6.56 (d, J=2.6 Hz, IH), 4.36 (br. s., 2H), 3.87 (s, 3H), 2.24 (s, 3H).
48B): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-methoxypyridin-3-yl)-2,2,2- trifluoroacetamide
Example 48B was prepared from Example 48A by methods similar to those shown for Example ID. HPLC: RT = 1.73 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 379 [M+H]+ , ¾ NMR (400 MHz, Chloroform-d) δ ppm 8.78 (br. s., IH), 8.41 (s, IH), 8.36 - 8.27 (m, 2H), 8.24 (d, J=2.6 Hz, IH), 7.94 (br. s., IH), 7.18 (dd, J=5.1, 1.3 Hz, IH), 3.97 (s, 3H), 2.26 (s, 3H).
N-{4-[3-(6-Chloropyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 48 was prepared from Example 48B and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.81 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.07 (s, IH), 10.50 (s, IH), 8.31 (d, J=5.2 Hz, IH), 8.23 (d, J=2.4 Hz, 2H), 8.14 (d, J=7.3 Hz, IH), 7.90 (t, J=7.8 Hz, IH), 7.42 (s, IH), 7.33 (d, J=7.9 Hz, IH), 7.19 (d, J=3.7 Hz, 1H),3.89 (s, 3H), 2.08 (s, 3H).
Example 49
N-{4-[3-(5-Fluoropyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 49 was prepared from Example 48B and 2-bromo-5-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 0.84 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.95 (s, IH), 10.50 (s, IH), 8.44 (d, J=2.4 Hz, IH), 8.28 (d, J=5.0 Hz, IH), 8.23 (d,
J=6.7 Hz, 2H), 8.10 (dd, J=8.6, 4.5 Hz, IH), 7.85 - 7.77 (m, IH), 7.39 (s, IH), 7.15 (d, J=5.0 Hz, IH), 3.89 (s, 3H), 2.08 (s, 3H).
Example 50
N-{4-[3-(5-Chloropyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 50 was prepared from Example 48B and 2-bromo-5-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.95 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.67 (s, IH), 8.56 (d, J=2.0 Hz, IH), 8.36 (d, J=5.0 Hz, IH), 8.31 (d, J=2.4 Hz, IH), 8.26 (br. s., IH), 8.00 - 7.95 (m, IH), 7.94 - 7.89 (m, IH), 7.66 (br. s., IH), 7.22 (d, J=5.0 Hz, IH), 3.94 (s, 3H), 2.10 (s, 3H).
Example 51
N- {4-[3-(5-Fluoro-6-methylpyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
Example 51 was prepared from Example 48B and 6-bromo-3-fluoro-2- methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.91 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 392 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.94 (s, IH), 10.47 (s, IH), 8.33 - 8.23 (m, 2H), 8.21 (d, J=2.0 Hz, IH), 7.90 (dd, J=8.2, 3.2 Hz, IH), 7.66 (t, J=9A Hz, IH), 7.40 (s, IH), 7.20 (d, J=5.0 Hz, IH), 3.89 (s, 3H), 2.29 (d, J=2.4 Hz, 3H), 2.08 (s, 3H).
Example 52
4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-amine
To a solution of Example 14 (38 mg, 0.106 mmol) in MeOH (8 mL) was added IN NaOH (1.057 mL, 1.057 mmol). The mixture was then heated at 80 °C for 1.5 h, and then concentrated. The solid residue was suspended in water, collected by filtration, and dried to give the title product (27.4 mg, 80%) as a white solid. HPLC: RT = 0.87 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 318 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.85 (s, IH), 8.39 (dd, J=4.5, 1.4 Hz, IH), 8.30 (d, J=2.0 Hz, IH), 7.95 (d, J=5.3 Hz, IH), 7.82 (ddd, J=8.4, 3.9, 1.9 Hz, 2H), 7.22 (dd, J=8.3, 4.5 Hz, IH), 6.87 (dd, J=8.5, 0.6 Hz, IH), 6.63 - 6.51 (m, 2H), 6.06 (s, 2H), 3.89 (s, 3H).
Example 53
N-{4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} cyclopropanecarboxamide
To a solution of Example 52 (12.1 mg, 0.038 mmol) and TEA (10.6 μΐ, 0.076 mmol) in THF (0.6 mL) was added a solution of cyclopropanecarbonyl chloride (6.8 mg, 0.065 mmol) in THF (70 μί). The reaction was stirred for 2 h, and then concentrated NH4OH (1 drop) was added. The resulting reaction mixture was stirred at room temperature overnight. The mixture was diluted with DMF and purified by preparative HPLC (Column: Waters XBridge C I 8, 19 x 200 mm, 5-μιη particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-55% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.) to give Example 53 (4.0 mg, 23%). HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 386 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.06 (br. s., IH), 10.93 (s, IH), 8.41 (d, J=3.7 Hz, IH), 8.38 (s, IH), 8.31 (d, J=5.1 Hz, IH), 8.24 (d, J=1.9 Hz, IH), 7.88 (d, J=8.1 Hz, IH), 7.80 (dd, J=8.5, 2.2 Hz, IH), 7.26 (dd, J=8.2, 4.6 Hz, IH), 7.08 (d, J=4.1 Hz, IH), 6.87 (d, J=8.6 Hz, IH), 3.88 (s, 3H), 2.03 (br. s., IH), 0.88 - 0.75 (m, 4H).
Example 54
N- {4-[3-(6-Methoxypyridin-3-yl)-l -methyl-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
To a solution of Example 14 (12 mg, 0.033 mmol) in DMF (0.5 mL) was added CS2CO3 (21.76 mg, 0.067 mmol), followed by a solution of methyl iodide (2.088 μΐ, 0.033 mmol) in DMF (0.5 mL). The reaction mixture was stirred at room temperature for 30 min and then filtered and purified by preparative HPLC (Column: Waters XBridge C18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-65% B over 20 minutes, then a 5 minute hold at 100% B; Flow: 20 mL/min.) to give the title compound (8.2 mg, 66%). HPLC: RT = 0.61 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.73 (s, 1H), 8.46 (dd, J=15.4, 4.7 Hz, 2H), 8.22 - 8.12 (m, 2H), 8.08 (d, J=8.2 Hz, 1H), 7.79 (dd, J=8.6, 2.2 Hz, 1H), 7.34 (dd, J=8.3, 4.6 Hz, 1H), 7.18 (d, J=5.0 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 3.83 (s, 3H), 3.70 (s, 3H), 2.10 (s, 3H).
Example 55
N- {4-[7-(6-Chloropyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}acetamide
Example 55A was prepared from Example IB and 3-chloropyrazin-2-amine by methods similar to those shown for Example 1C. HPLC: RT = 0.906 min
(H20/acetonitrile with 0.1% TFA, Waters Aquity BEH CI 8, 1.7 μιη particles, 2.0 x 50 mm, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 254 [M+H]+ .
55B) N-(3-((2-Acetamidopyridin-4-yl)ethynyl)pyrazin-2-yl)-2,2,2 rifluoroacetamide
Example 55B was prepared from 55A by methods similar to those shown for Example ID. HPLC: RT = 0.998 min (H20/acetonitrile with 0.1% TFA, Waters Aquity BEH C18, 1.7-μηι particles, 2.0 x 50 mm, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 350 [M+H]+ .
N-{4-[7-(6-Chloropyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}acetamide
Example 55 was prepared from Example 55B and 2-bromo-6-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.89 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 365 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.56 (s, IH), 8.56 (d, J=2.4 Hz, IH), 8.42 (d, J=2.4 Hz, IH), 8.37 (d, J=5.1 Hz, IH), 8.27 (s, IH), 8.11 (d, J=7.7 Hz, IH), 7.93 (t, J=7.8 Hz, IH), 7.37 (d, J=7.9 Hz, IH), 7.28 (d, J=5.1 Hz, IH), 2.08 (s, 3H).
Example 56
5-Chloro-2-(2-acetarnidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-N-methyl-lH- pyrrolo[3,2-b]pyridine-7-carboxamide
56A): Ethyl 5-amino-2-chloroisonicotinate
To a solution of ethyl 3-aminoisonicotinate (4.0 g, 24.07 mmol) in DMF (25 mL) was added NCS (3.54 g, 26.5 mmol) at room temperature. The reaction mixture was then heated at 50 °C under nitrogen for 18 h. The reaction mixture was cooled to room temperature and treated with saturated aqueous NaHC03 solution and ethyl acetate. The organic layer was separated and washed with brine, dried (MgS04) and filtered. The filtrate was concentrated in vacuo. The residue was dissolved in DCM and purified by
silica gel flash chromatography, eluting with 30% ethyl acetate in hexane to give the desired product as a light yellow solid (2.0 g, 41%); HPLC: RT = 0.84 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 200.9 [M+H]+; ¾ NMR (400 MHz,CDCb) δ ppm 7.98 (d, J=0.4 Hz, IH), 7.66 (d, J=0.4 Hz, IH), 4.38 (q, J=7.3 Hz, 2H), 1.42 (t, J=7.2 Hz, 3H).
56B): Ethyl 3-amino-2-bromo-6-chloroisonicotinate
To a solution of Example 56A (2.0 g, 9.97 mmol) in DMF (15 mL) was added NBS (1.95 g, 10.97 mmol). The reaction mixture was stirred at room temperature for 20 h. To the reaction mixture was added a saturated aqueous NaHC03 solution and ethyl acetate. The organic layer was separated and washed with saturated NaHC03 solution, dried (MgS04), andfiltered. The filtrate was concentrated in vacuo. The crude product was dissolved in DCM and purified by silica gel flash chromatography, eluting with 10% ethyl acetate in hexane to give the desired product as a light yellow solid (2.4 g, 86%); HPLC RT = 1.01 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 278.9, 280.9 [M+H]+; ¾ NMR (400 MHz,CDCh) δ ppm 7.68 (s, IH), 6.24 (br. s., 2H), 4.40 (q, J=7.0 Hz, 2H), 1.42 (t, J=7.2 Hz, 3H).
56C): Ethyl 2-((2-acetanddopyridin-4-yl)ethynyl)-3-amino-6-chloroisonicotinate
To a solution of Example 56B (2.45 g, 8.77 mmol) and Example IB (1.544 g, 9.64 mmol) in DMF (18 mL) were added Cul (0.134 g, 0.701 mmol) and TEA (12.2 mL, 88 mmol). The reaction mixture was purged with nitrogen, followed bythe addition of PdCl2(PPh3)2 (0.369 g, 0.526 mmol). The resulting mixture was heated at 78 °C for 2 h under nitrogen. The reaction mixture was then cooled to room temperature and diluted with ethyl acetate and saturated aqueous NaHC03 solution. The aqueous layer was extracted with EtOAc (3X) and the combined extracts were washed with saturated NaHC03 solution, and dried over MgS04. The mixture was filtered and then concentrated in vacuo. To the residue were added ethyl acetate and DCM and the precipitate was collected to give a yellow solid as the desired product. The filtrate further was concentrated in vacuo and the residue was purified by silica gel flash chromatography, eluting with 30% ethyl acetate in DCM to give additional desired product as a yellow solid (2.65 g, 84%); MS (ES): m/z = 359.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.65 (s, 1H), 8.40 (dd, J=5.1, 0.7 Hz, 1H), 8.30 (s, 1H), 7.67 (s, 1H), 7.40 (dd, J=5.1, 1.3 Hz, 1H), 6.99 (s, 2H), 4.35 (q, J=7.0 Hz, 2H), 2.12 (s, 3H), 1.34 (t, J=7.2 Hz,
3Η).
56D): Methyl 2-(2-acetamidopyridin-4-yl)-5-chloro-lH-pyrrolo[3,2-b]pyridine-7- carboxylate
A suspension of Example 56C (160 mg, 0.446 mmol) in acetonitrile (6.0 mL) was sonicated and then treated with CS2CO3 (436 mg, 1.338 mmol). The resulting mixture was purged with nitrogen for and Pd(PPh3)4 (51.5 mg, 0.045 mmol) was added. The reaction mixture was heated at 100 °C for 2 h under nitrogen. The reaction mixture was cooled to room temperature and the mixture was filtered. The solid was washed with ethyl acetate and the filtrate was concentrated in vacuo to give a the desired product; MS (ES): m/z =
345.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 1 1.76 (s, IH), 10.64 (s, IH), 8.53 (s, IH), 8.44 (d, J=5.1 Hz, IH), 7.67 (dd, J=5.2, 1.4 Hz, IH), 7.60 (s, IH), 7.23 (d, J=2.0 Hz, IH), 4.02 (s, 3H), 2.15 (s, 3H).
56E): 2-(2-Acetamidopyridin-4-yl)-5-chloro-lH-pyrrolo[3,2-b]pyridine-7-carboxylic acid
To a suspension of Example 56D (0.24 g, 0.696 mmol) in MeOH (1 mL) and 1 ,4- dioxane (6 mL) was added 1 M NaOH solution (3.48 mL, 3.48 mmol) drop wise. The reaction mixture was stirred at room temperature for 1 h. To the reaction mixture was added water and 1 N HC1 solutionwas used to adjust the pH to 1 -2. The reaction mixture was filtered to give a solid as the desired product (0.12 g, 52%); MS (ES): m/z = 331.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 1 1.31 (br. s., IH), 10.60 (s, IH), 8.46 (s, IH), 8.37 (d, .7=5.3 Hz, IH), 7.61 (dd, J=5.3, 1.5 Hz, IH), 7.33 (s, IH), 7.1 1 (s, IH), 2.14 (s, 3H).
56F): 2-(2-Acetamidopyridin-4-yl)-5-chloro-N-methyl-lH-pyrrolo[3,2-b]pyridine-7- carboxamide
To a suspension of Example 56E (90 mg, 0.272 mmol) in DMF (3 mL) was added HATU (124 mg, 0.327 mmol). The reaction mixture was stirred at room temperature for 5 min, followed by the addition of methylamine hydrochloride (0.049 mL, 0.544 mmol) and
4-methylmorpholine (0.06 niL, 0.544 mmol). The resulting mixture was stirred at room temperature for 30 min. The reaction mixture was then concentrated in vacuo and the residue was mixed with MeOH and purified by preparative HPLC (YMC-Pack C-18 30 x 100 mm, eluting with 5% -70% aqueous CH3CN containing 0.1 % TFA over 12 min, 25 mL/min, wavelength = 254 nm). Fractions containing the desired product were combined, concentrated, and lyophilized to give the product (83 mg, 53%); MS (ES): m/z = 344.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.74 (d, J=1.5 Hz, IH), 10.66 (s, IH), 8.93 (d, J=4.6 Hz, IH), 8.50 (s, IH), 8.40 (d, J=5.3 Hz, IH), 7.71 (dd, J=5A, 1.7 Hz, IH), 7.55 (s, IH), 7.20 (d, J=2.2 Hz, IH), 2.89 (d, J=4.6 Hz, 3H), 2.15 (s, 3H).
56G): 2-(2-Acetamidopyridin-4-yl)-3-bromo-5-chloro-N-methyl-lH-pyrrolo[3,2- b]pyridine-7-carboxamide
To a solution of Example 56F (80 mg, 0.140 mmol) in DMF (1.5 mL) was added NBS (29.9 mg, 0.168 mmol). The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was then diluted with a saturated NaHC03 solution and ethyl acetate. The organic layer was separated and dried over MgSCk The mixture wass filtered and the filtrate was concentrated in vacuo. To the residue was added DCM and MeOH and the residue was filtered to give the desired product as a light yellow solid (42 mg, 71%)); MS (ES): m/z = 422.0, 424.0 [M+H]+; ¾ NMR (400MHz, DMSO-de) δ ppm 12.22 (s, IH), 10.66 (s, IH), 8.94 (d, J=4.4 Hz, IH), 8.61 (s, IH), 8.47 (dd, J=5.3, 0.7 Hz, IH), 7.64 (s, IH), 7.52 (dd, J=5.1 , 1.5 Hz, IH), 2.87 (d, J= 4.4 Hz, 3H), 2.14 (s, 3H).
Example 56): 5-Chloro-2-(2-acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-N- methyl-lH-pyrrolo[3,2-b]pyridine-7-carboxamide
A suspension of Example 56G (42 mg, 0.099 mmol), 2-methoxy-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (28.0 mg, 0.119 mmol) and Na2C03 (0.248 mL, 0.248 mmol) in dioxane (2 mL) and was purged with nitrogen, and treated with PdCl2(dppf) (7.27 mg, 9.94 μηιοΐ). The resulting mixture was heated at 90 °C for 2 h. The reaction mixture was concentrated in vacuo. To the residue was added MeOH and DMF, and the mixture was purified by preparative HPLC (Sunfire C-18 19 x 150 mm, eluting with 5% -100% aqueous C¾CN containing 5 mmol NH4OAC over 12 min, 20 mL/min, wavelength = 254 nm). Fractions containing the desired product were combined, concentrated, and lyophilized to give the product as a yellow solid (15 mg, 33%); HPLC: RT = 1.02 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7- μτη particles, gradient = 1.5 min, wavelength = 220 nm)MS (ES): m/z = 451.3 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.32 (dd, J=5.3, 0.7 Hz, 1H), 8.28 (s, 1H), 8.20 (d, J=1.8 Hz, 1H), 7.80 (dd, J=8.6, 2.4 Hz, 1H), 7.56 (s, 1H), 7.21 (dd, J=5.2, 1.7 Hz, 1H), 6.89 - 6.84 (m, 1H), 3.94 (s, 3H), 3.01 (s, 3H), 2.16 (s, 3H).
Example 57
2-(2-Acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-N-methyl-lH-pyrrolo[3,2- b]pyridine-7-carboxamide
To a suspension of Example 56 (8 mg, 0.018 mmol) in methanol (3 mL) and ethyl acetate (1 mL) was added Pd(OH)2 (3.74 mg, 5.32 μηιοΐ). The reaction mixture was stirred under a nitrogen atmosphere over night. The reaction mixture was then diluted with MeOH and ethyl acetate and filtered. The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (Sunfire C-18 19 x 150 mm, eluting with 5% - 100% aqueous CH3CN containing 5 mmol NH4OAC over 12 min, 20 mL/min, wavelength = 220 nm). Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid ( 3 mg, 40%); HPLC: RT = 0.95 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm) MS (ES): m/z = 417.4 [M+H]+; ¾
NMR (400 MHz, MeOH-d4) δ ppm 8.47 (d, J=4.8 Hz, IH), 8.31 (dd, J=5.3, 0.7 Hz, IH), 8.28 (s, IH), 8.18 (dd, J=2.4, 0.7 Hz, IH), 7.80 (dd, J=8.5, 2.3 Hz, IH), 7.54 (d, J=4.8 Hz, IH), 7.24 - 7.18 (m, IH), 6.89 (dd, J=8.6, 0.7 Hz, IH), 3.95 (s, 3H), 3.03 (s, 3H), 2.16
(s, 3H).
Example 58
5-Chloro-N-(l,3-dihydroxypropan-2-yl)-2-(2-acetamidopyridin-4-yl)-3-(6- methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridine-7-carboxamide
58A): 2-(2-Acetamidopyridin-4-yl)-5-chloro-N-(l ,3-dihydroxypropan-2-yl)-lH- pyrrolo[3,2-b]pyridine-7-carboxamide
Example 58A was prepared from Example 56E and 2-aminopropane-l,3-diol by similar method shown for Example 56F. . HPLC: RT = 0.54 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 404.1 [M+H]+
58B): 2-(2-Acetamidopyridin-4-yl)-3-bromo-5-chloro-N-(l,3-dihydroxypropan-2-yl)- lH-pyrrolo[3,2-b]pyridine-7-carboxamide
Example 58B was prepared using similar methods as those shown for Example 56G. HPLC: RT = 0.61 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm). MS (ES): m/z = 482.0, 484.0 [M+H]+. ¾ NMR (400MHz, DMSO-de) δ ppm 12.16 (s, IH), 10.69 (s, IH), 8.68 - 8.57 (m, 2H), 8.46 (d, J=5.1 Hz, IH), 7.81 (s, IH), 7.52 (dd, J=5.3, 1.5 Hz, IH), 4.11 - 4.00 (m, IH), 3.64 - 3.51 (m, 4H), 2.14 (s, 3H).
Example 58): 5-Chloro-N-(l,3-dihydroxypropan-2-yl)-2-(2-acetamidopyridin-4-yl)-3-(6- methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridine-7-carboxamide
Example 58 was prepared from Example 58B by the general method shown for Example 56Η. HPLC: RT = 0.64 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 51 1.2 [M+H]+. ¾ NMR (400 MHz, DMSO-de) δ ppm 1 1.85 (s, IH), 10.58 (s, IH), 8.59 (d, J=8.4 Hz, IH), 8.31 (d, J=5.3 Hz, IH), 8.28 (s, IH), 8.19 (d, J=1.8 Hz, IH), 7.76 (s, IH), 7.72 - 7.66 (m, IH), 7.11 (dd, J=5.3, 1.5 Hz, IH), 6.87 (d, J=8.6 Hz, IH), 4.11 - 4.03 (m, IH), 3.88 (s, 3H), 3.64 - 3.56 (m, 4H), 2.09 (s, 3H).
Example 59
N-(l,3-Dihydroxypropan-2-yl)-2-(2-acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)- lH-pyrrolo[3,2-b]pyridine-7-carboxamide
Example 59 was prepared from Example 58C by similar methods shown for Example 57. HPLC: RT = 0.97 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 477.3 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.48 (d, J=5.1 Hz, IH), 8.30 (d, J=5.7 Hz, IH), 8.27 (s, IH), 8.18 (d, J=2.0 Hz, IH), 7.79 (dd, J=8.6, 2.4 Hz, IH), 7.64 (d, J=5.1 Hz, IH), 7.21 (dd, J=5.3, 1.5 Hz, IH), 6.89 (dd, J=8.6, 0.7 Hz, IH), 4.42 - 4.27 (m, IH), 3.95 (s, 3H), 3.86 - 3.75 (m, 4H), 2.16 (s, 3H).
Example 60
5-Chloro-N-(l,3-dihydroxypropan-2-yl)-2-(2-acetamidopyridin-4-yl)-3-(pyridin-3-yl)- lH-pyrrolo[3,2-b]pyridine-7-carboxamide
Example 60 was prepared from Example 58B by similar methods as shown for Example 56. HPLC: RT = 0.92 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 481.3 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.60 (s, IH), 8.46 (d, J=4.0 Hz, IH), 8.34 - 8.28 (m, IH), 8.25 (s, IH), 8.00 (dt, J=8.0, 1.8 Hz, IH), 7.68 (s,
1H), 7.46 (dd, J=7.8, 5.0 Hz, 1H), 7.16 (dd, J=5.2, 1.7 Hz, 1H), 4.29 (t, J=5.7 Hz, 1H), 3.90 - 3.73 (m, 4H), 2.15 (s, 3H).
Example 61
N- {4-[7-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
A solution of 4-chloropyridin-3 -amine (2.0 g, 15.56 mmol) in TFA (17.98 ml, 233 mmol) was stirred at ice bath temperature and then treated with NBS (3.05 g, 17.11 mmol) slowly.
The reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then concentrated in vacuo to a small volume. To the reaction mixture was added IN NaOH solution and ethyl acetate. The organic layer was separated and washed with a saturated NaHC03 solution, dried over MgS04, and then filtered. The filtrate was concentrated in vacuo. The residue was purified by silica gel flash chromatography, eluting with 15% ethyl acetate in hexane to give the desired product as a white solid (1.65 g, 51 %). HPLC: RT = 1.03 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C 18, 2.0 x 50 mm, 1.7-μπι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 207.1 , 209.1 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 7.70 (d, J=5.1 Hz, 1H), 7.17 (d, J=5.1 Hz, 1H), 4.52 (br. s., 2H).
61B): N-(4-((3-Amino-4-chloropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
To a solution of Example 61 A (1.55 g, 7.47 mmol) and Example IB (1.257 g, 7.85 mmol) in DMF (6 mL) were added Cul (0.142 g, 0.747 mmol) and TEA (10.41 mL, 74.7 mmol). The reaction mixture was purged with nitrogen, and treated with
PdCl2(PPh3)2 (0.367 g, 0.523 mmol). The resulting mixture was heated at 78 °C for 1.5 h under nitrogen. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate and filtered. The brown filtrate was diluted with ethyl acetate and a saturated NaHC03 solution. The aqueous layer was extracted with ethyl acetate (2X) and the combined extracts were washed with a saturated NaHC03 solution, and dried over
MgS04. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was triturated with DCM and filtered to give a yellow solid as the desired product. The filtrate was further purified by silica gel flash chromatography, eluting with 10% MeOH in DCM to give the desired product as a yellow solid (1.55 g, 72%); HPLC: RT = 0.61 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 287.0 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 8.37 (s, 1H), 8.28 (d, J=5.1 Hz, 1H), 7.95 (d, J=5.1 Hz, 2H), 7.24 - 7.19 (m, 2H), 4.71 (br. s., 2H), 2.24 (s, 3H).
61C): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-chloropyridin-3-yl)-2,2,2- trifluoroacetamide
To a suspension of Example 61B (0.95 g, 3.31 mmol) in DCE (12 mL) at ice bath temperature was added TEA (1.62 mL, 11.60 mmol), followed by the addition of trifluoroacetic anhydride (0.74 mL, 5.30 mmol) slowly. The reaction mixture was stirred at 0 °C for 20 min. To the mixture was added more TEA (1.0 mL) and trifluoroacetic anhydride (0.45 mL) and the reaction mixture was stirred at 0 °C for another 40 min. The reaction mixture was quenched with a cold saturated NaHC05 solution and the resulting mixture was extracted with ethyl acetate (2x). The organic layer was separated and washed with a saturated NaHC03 solution, and dried over MgS04. The mixture was filtered and the filtrate was concentrated in vacuo to give a tan solid.The crude product was purified by silica gel flash chromatography, eluting with 70% ethyl acetate in DCM to give the desired product as a yellow solid (0.4 g, 32%); HPLC: RT = 1.04 min
(H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 383.0 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 8.54 (d, J=5.3 Hz, 1H), 8.34 (s, 1H), 8.28 (d, J=5.1 Hz, 1H), 8.17 (br. s., 1H), 7.93 (br. s., 1H), 7.50 (d, J=5.3 Hz, 1H), 7.13 (dd, J=5.1, 1.5 Hz, 1H), 2.24 (s, 3H).
Example 61): N-{4-[7-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
A mixture of Example 61C (30 mg, 0.078 mmol), CS2CO3 (77 mg, 0.235 mmol) and 2-bromo-5-fiuoropyridine (17.93 mg, 0.102 mmol) in acetonitrile (2 mL) in a sealed tube was purged with nitrogen, and treated with Pd(PPh3)4 (9.06 mg, 7.84 μιτιοΐ). The reaction mixture was heated at 100 °C for 1.5 h and then cooled to room temperature. The reaction mixture was diluted with MeOH and ethyl acetate and filtered. The filtrate was
concentrated in vacuo. The residue was purified by preparative HPLC (Column: Waters XBridge C 18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-50% B over 20 minutes, then a 5 minute hold at 100% B; Flow: 20 mL/min.).. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid (1.6 mg, 5.3%); %); HPLC: RT = 0.72 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.53 (br. s., 1H), 10.55 (s, 1H), 8.47 - 8.38 (m, 2H), 8.31 (d, J=5.1 Hz, 1H), 8.22 (br. s., 1H), 8.12 (dd, J=8.7, 4.5 Hz, 1H), 7.81 (td, J=8.8, 2.8 Hz, 1H), 7.44 (d, J=5.0 Hz, 1H), 7.19 (d, J=4.3 Hz, 1H), 2.07 (s, 3H).
Example 62
N- {4-[7-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 62 was prepared from Example 61 C and 2-bromo-5-methoxy pyridine by the general method shown for Example 61. HPLC: RT = 0.73 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.80 - 12.08 (m, 1H), 10.53 (s, 1H), 8.38 (d, J=5.0 Hz, 1H), 8.28 (d, J=5.1 Hz, 1H), 8.26 (br. s., 1H), 8.16 (d, J=2.7 Hz, 1H), 7.95 (d, J=8.7 Hz, 1H), 7.48 (dd, J=8.7, 2.8 Hz, 1H), 7.41 (d, J=5.0 Hz, 1H), 7.14 (d, J=4.9 Hz, 1H), 3.90 - 3.79 (m, 3H), 2.08 (s, 3H).
Example 63
N-{4-[7-Chloro-3-(5-chloropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 63 was prepared from Example 61 C and 2-bromo-5-chloropyridine by the general method shown for Example 61. HPLC: RT = 0.97 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH CI 8, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 398.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.59 (s, IH), 10.56 (s, IH), 8.50 - 8.40 (m, 2H), 8.33 (d, J=5.3 Hz, IH), 8.27 (s, IH), 8.20 (d, J=8.6 Hz, IH), 8.00 (dd, J=8.6, 2.6 Hz, IH), 7.46 (d, J=5.1 Hz, IH), 7.20 (dd, J=5.2, 1.4 Hz, IH), 2.13 - 2.07 (m, 3H).
Example 64
N- {4-[7-Chloro-3-(6-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 64 was prepared from Example 61 C and 2-bromo-6-fluoropyridine by the general method shown for Example 61. . HPLC: RT = 0.71 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 382.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.56 (s, IH), 8.41 (d, J=5.0 Hz, IH), 8.34 (d, J=5.0 Hz, IH), 8.21 (s, IH), 8.12 (d,
J=5A Hz, IH), 8.03 (q, J=8.1 Hz, IH), 7.43 (d, J=5.0 Hz, IH), 7.23 (d, J=5.0 Hz, IH), 6.99 (d, J=6.2 Hz, IH), 2.07 (s, 3H).
Example 65
N- {4-[6-Chloro-3-(6-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 65 was prepared from Example 41 B and 2-bromo-6-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.73 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z= 394.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.57 (s, IH), 8.48 (d, J=2.0 Hz, IH), 8.35 (d, J=5.1 Hz, IH), 8.27 (br. s., IH), 8.02 - 7.90 (m, 2H), 7.76 (t, J=7.8 Hz, IH), 7.19 (d, J=5.0 Hz, IH), 6.62 (d, J=8.2 Hz, IH), 3.48 (br. s., 3H), 2.08 (s, 3H).
Example 66
N-{4-[6-Chloro-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} acetamide
Example 66 was prepared from Example 41 B and 2-bromo-6-methylpyridine by the general methods shown for Example 1. . HPLC: RT = 0.91 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378.0 [M+H]+; ¾ NMR (500 MHz, DMSO- de) δ ppm 12.26 (s, IH), 10.51 (s, IH), 8.42 (d, J=1.9 Hz, IH), 8.35 - 8.23 (m, 2H), 7.96 (d, J=1.9 Hz, IH), 7.85 - 7.77 (m, IH), 7.75 - 7.67 (m, IH), 7.19 (d, J=4.0 Hz, IH), 7.13 (d, J=7.6 Hz, IH), 2.29 (s, 3H), 2.07 (s, 3H).
Example 67
N-(4- {6-Chloro-3-[6-(hydroxymethyl)pyridin-2-yl]-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide
Example 67 was prepared from Example 41 B and (6-bromopyridin-2-yl)methanol by the general methods shown for Example 1. . HPLC: RT = 0.78 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394.3 [M+H]+; ¾ NMR (500 MHz, DMSO- de) 5 ppm 10.65 (s, IH), 8.50 (d, J=1.9 Hz, IH), 8.37 (d, J=5.1 Hz, IH), 8.27 (s, IH), 8.1 1 (t, J=7.8 Hz, IH), 8.07 (d, J=1.7 Hz, IH), 7.87 (d, J=7.9 Hz, IH), 7.57 (d, J=7.7 Hz, IH), 7.25 (d, J=3.2 Hz, IH), 4.59 (s, 2H), 2.08 (s, 3H).
Example 68
N-[4-(6-Chloro-3- {6-[(2-hydroxyethyl)amino]pyridin-2-yl} -lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl]acetamide
Example 68 was prepared from Example 41B and 2-((6-bromopyridin-2- yl)amino)ethanol by the general methods shown for Example 1. HPLC: RT = 0.90 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 423.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.71 (s, 1H), 8.54 (d, J=1.8 Hz, 1H), 8.45 (d, J=5.0 Hz, 1H), 8.31 (s, 1H), 8.11 (s, 1H), 7.82 (br. s., 1H), 7.31 (d, J=4.5 Hz, 1H), 6.96 (br. s., 1H), 6.87 (br. s., 1H), 2.54 (s, 4H), 2.09 (s, 3H).
Example 69
Methyl 5-chloro-2-(2-acetamidopyridin-4-yl)-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2- b]pyridine-7-carboxylate
69 A): Ethyl 2-((2-acetamidopyridin-4-yl)ethynyl)-6-chloro-3-(2,2,2- trifluoroacetamido)isonicotinate
- I l l -
To a suspension of Example 56C (0.2 g, 0.557 mmol) in DCE (4 mL) and diethyl ether (10 mL) was added CaCC (0.223 g, 2.230 mmol) at ice bath temperature. To the reaction mixture was added TFAA (0.17 mL, 1.226 mmol) slowly and the reaction mixture was stirred at ice bath temperature for 2 h. To the reaction mixture was added cold water and ethyl acetate. The organic layer was separated and washed with brine and dried over MgS04. The mixture was filtered and the filtrate was concentrated in vacuo.
To the residue was added DCM and the resulting solid was filtered to give the desired product as a yellow solid (0.15 g, 60%). HPLC: RT = 0.90 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 455.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.90 (s, 1H), 10.70 (s, 1H), 8.48 - 8.39 (m, 1H), 8.26 (s, 1H), 7.99 (s, 1H), 7.22 (dd, J=5.1, 1.5 Hz, 1H), 4.32 (q, J=7.1 Hz, 2H), 2.12 (s, 3H), 1.29 (t, J=7.0 Hz, 3H).
Example 69): Methyl 5-chloro-2-(2-acetamidopyridin-4-yl)-3-(5-fluoropyridin-2-yl)- lH-pyrrolo[3,2-b]pyridine-7-carboxylate
Example 69 was prepared from Example 69A and 2-bromo-5-fluoropyridine by the general methods shown for Example 1. HPLC: RT = 1.13 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH CI 8, 2.0 x 50 mm, 1.7-μιτι particles, gradient = 1.5 min,
wavelength = 220 nm); MS (ES): m/z = 440.3 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.07 (s, IH), 10.59 (s, IH), 8.45 (d, J=3.1 Hz, IH), 8.34 (d, J=5.1 Hz, IH), 8.20 (s, IH), 8.01 (dd, J=8.8, 4.6 Hz, IH), 7.84 (td, J=8.7, 3.0 Hz, IH), 7.70 (s, IH), 7.17 (dd, J=5.1 , 1.5 Hz, IH), 4.02 (s, 3H), 2.09 (s, 3H).
Example 70
Methyl 5-chloro-3-(5-chloropyridin-2-yl)-2-(2-acetamidopyridin-4-yl)-lH-pyrrolo[3,2- b]pyridine-7-carboxylate
Example 70 was prepared from Example 69A and 2-bromo-5-chloropyridine by the general methods shown for Example 1. HPLC: RT = 0.92 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C 18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 456.1 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.14 (s, IH), 10.59 (s, IH), 8.46 (s, IH), 8.34 (d, J=5.1 Hz, IH), 8.23 (s, IH), 8.04 (s, 2H), 7.70 (s, IH), 7.15 (d, J=3.8 Hz, IH), 4.01 (s, 3H), 2.09 (s, 3H).
Example 71
Methyl 2-(2-acetamidopyridin-4-yl)-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridine-
7-carboxylate
Example 71 was prepared from Example 69B by the general methods shown for Example 57. HPLC: RT = 0.96 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 406.3 [M+H]+; ¾ NMR (400 MHz, CDCl3+MeOH-d4) δ ppm 8.15 (br. s., 1H), 8.03 (br. s., 1H), 7.87 (d, J=5.3 Hz, 1H), 7.83 (s, 1H), 7.39 (br. s., 2H), 7.25 - 7.17 (m, 1H), 6.82 - 6.72 (m, 1H), 3.68 (s, 3H), 1.76 (s, 3H).
Example 72
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- hy droxy acetamide
72A): 4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-
Example 72A was prepared from Example 42 by similar method as those shown for Example 52. HPLC: RT = 0.98 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 340.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.15 (br. s., IH), 8.51 (d, J=3.1 Hz, IH), 8.41 (d, J=2.2 Hz, IH), 8.02 (dd, J=9.0, 4.4 Hz, IH), 7.94 - 7.89 (m, 2H), 7.80 (td, J=8.8, 3.1 Hz, IH), 6.57 (s, IH), 6.53 (dd, J=5.3, 1.5 Hz, IH), 6.00 (s, 2H).
72B) 2-((4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)amino)-2-oxoethyl acetate
To a suspension of Example 72A (60 mg, 0.177 mmol) in DCE (3 mL) were added acetoxyacetyl chloride (0.06 mL, 0.54 mmol) and TEA (0.1 mL, 0.71 mmol). The reaction was stirred at room temperature for 2 h. To the reaction mixture was added 0.5 mL of an ammonia hydroxide solution and the mixture was stirred at room temperature for 1 h. The resulting reaction mixture was concentrated in vacuo. The residue was purified by preparative HPLC (Sunfire C-18 19 x 150 mm, eluting with 10% -100% aqueous CH3CN containing 5 mmol NH4OAC over 18 min, 20 mL/min, wavelength = 220 nm). Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid ( 46 mg, 58%); HPLC: RT = 1.04 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 440.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.74 (s, IH), 8.45 (dd, J=4.6, 2.6 Hz, 2H), 8.33 (d, J=5.3 Hz, IH), 8.25 (br. s., IH), 8.12 (dd, J=8.8, 4.6 Hz, IH), 7.97 (d, J=2.2 Hz, IH), 7.82 (td, J=8.8, 3.1 Hz, IH), 7.18 (dd, J=5.3, 1.5 Hz, IH), 4.72 (s, 2H), 2.11 (s, 3H).
N-{4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- hy dr oxy acetami de
A solution of Example 72B (35 mg, 0.08 mmol) in methanol (2 mL) was treated with aqueous NaOH (0.8 mL, 0.80 mmol). The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was then concentrated in vacuo. The residue was purified by preparative HPLC (Sunfire C-18 19 x l50 mm, eluting with 5% - 70% aqueous CLbCN containing 5 mmol NH4OAC over 14 min, 20 mL/min, wavelength = 220 nm). Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid ( 22 mg, 69%); HPLC: RT = 1.0 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 398.2 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.34 (br. s., IH), 9.72 (s, IH), 8.46 (d, J=2.2 Hz, 2H), 8.35 (dd, J=5.3, 0.7 Hz, IH), 8.29 (s, IH), 8.12 (dd, J=8.8, 4.6 Hz, IH), 7.98 (d, J=2.2 Hz, IH), 7.83 (td, J=8.8, 3.1 Hz, IH), 7.23 (dd, J=5.3, 1.5 Hz, IH), 5.73 (t, J=6.1 Hz, IH), 4.03 (d, J=5.9 Hz, 2H).
Example 73
25 -N-{4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}-2-hydroxypropanamide
Example 73 was prepared from Example 72 A and (5 -l-Chloro-l -oxopropan-2-yl acetate by the general methods shown for Example 72. HPLC: RT = 1.1 1 min
(H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3.0 min, wavelength = 220 nm); MS (ES): m/z = 412.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 9.68 (s, 1H), 8.45 (br. s., 2H), 8.33 (d, J=5.1 Hz, 1H), 8.30 (s, 1H), 8.10 (dd, J=8.5, 4.5 Hz, 1H), 7.98 (d, J=\ Hz, 1H), 7.87 - 7.78 (m, 1H), 7.20 (d, J=4.5 Hz, 1H), 5.96 (d, J=5.2 Hz, 1H), 4.27 - 4.16 (m, 1H), 3.45 (s, 1H), 1.29 (d, J=6.7 Hz, 3H).
Example 74
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2-
(morpholin-4-yl)acetamide
74A): 2-Chloro-N-(4-(6-chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a suspension of Example 72A (1 15 mg, 0.338 mmol) in DCE (7 niL) were added chloroacetyl chloride (0.14 mL, 1.70 mmol) and TEA (0.25 mL, 1.70 mmol) slowly. The reaction was stirred at room temperature for 1 h. To the reaction mixture was added 1 mL of ammonia hydroxide solution and the mixture was stirred at room temperature for 0.5 h. The reaction mixture was then diluted with CHC13: 2-propanol
(2.5 : 1) and saturated NaHC03 solution. The organic layer was separated and dried over
MgS04. The mixture was filtered and the filtrate was concentrated in vacuo. To the residue was added DCM and the mixture was filtered to give the desired product (75 mg, 53%). HPLC: RT = 1.09 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 416.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.90 (br. s., IH), 8.45 (d, J=3.1 Hz, 2H), 8.35 (d, J=5.1 Hz, IH), 8.26 (s, IH), 8.12 (dd, J=8.6, 4.6 Hz, IH), 7.98 (d, J=1.5 Hz, IH), 7.82 (td, J=8.7, 2.6 Hz, IH), 7.24 (d, J=4.6 Hz, IH), 4.34 (s, 2H).
N-{4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- (morpholin-4-yl)acetamide
To a mixture of Example 74A (35 mg, 0.084 mmol) in acetonitrile (2 mL) were added morpholine (0.074 mL, 0.841 mmol) and Ag20 (39.0 mg, 0.168 mmol). The reaction mixture was stirred at room temperature for 22 h. The reaction mixture was then diluted with MeOH, and filtered. The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (Column: Waters XBridge CI 8, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15- 100% B over 20 minutes, then a 5 minute hold at 100% B; Flow: 20 mL/min.). Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid (9.1 mg, 23%); HPLC: RT = 0.85 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 467.3 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.37 (s, IH), 8.44 (br. s., 2H), 8.33 (d, J=5.1 Hz, IH), 8.25 (s, IH), 8.07 (dd, J=8.7, 4.5 Hz, IH), 7.99 (s, IH), 7.81 (td, J=8.7, 2.8 Hz, IH), 7.21 (d, J=4.8 Hz, IH), 3.63 (br. s., 2H), 3.57 - 3.36 (m, 4H), 2.54 (br. s., 4H).
Example 75
N-{4 6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-
[(2-hy droxy ethyl)amino] acetamide
Example 75 was prepared from Example 74A and 2-aminoethanol by the general methods shown for Example 74. HPLC: RT = 1.00 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιτι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 441.1 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.46 (d, J=2.9 Hz, IH), 8.37 (d, J=2.0 Hz, IH), 8.33 - 8.26 (m, 2H), 7.95 (d, J=2.0 Hz, IH),
7.84 (dd, J=8.6, 4.6 Hz, IH), 7.72 (td, J=8.5, 3.0 Hz, IH), 7.20 (dd, J=5.3, 1.5 Hz, IH), 3.69 (t, J=5.4 Hz, 2H), 3.48 (s, 2H), 2.80 (t, J=5.4 Hz, 2H).
Example 76
N-(4-(5-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
76A): N-(4-((3-Amino-6-methoxypyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
Example 76 A was prepared from Example IB and 2-bromo-6-methoxypyridin-3- amine following the general procedure for Example 1C. HPLC: RT=0.63 min
(H20/acetonitrile with 0.1 % TFA, Waters Aquity BEH C I 8, 1.7-μηι particles, 2.0x50mm, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z=283 [M+H]+
76B): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-6-methoxypyridin-3-yl)-2,2,2- trifluoroacetamide
To a suspention of Example 76A (80 mg, 0.283 mmol) in Ether:DCM (1 : 1) (4 mL) was added dropwise a solution of 2,2,2-trifluoroacetic anhydride (0.039 mL, 0.283 mmol) in DCM (1 mL) at -10 °C. The reaction mixture was stirred for 30min at -10 °C to 0 °C. The reaction mixture was then diluted with EtOAc, washed with water, and then with satutared aqueous NaCl, dried with MgSCn and concentrated to yield Example 76B (90 mg, 0.238 mmol, 84 % yield) as an off white solid which was used for the next step without further purification. HPLC: RT=0.69 min (H20/acetonitrile with 0.1% TFA, Waters Aquity BEH C18, 1.7-μιτι particles, 2.0x50mm, gradient = 1.5 min, wavelength = 220 nm); m/z=379 [M+H]+.
N-(4-(5-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 76 was preapared from Example 76B and 5-bromo-2-methoxypyridine following the general method for Example 1. HPLC: RT= 1.05 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z=390 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.89 (s, 1H), 10.60 (s, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.31 - 8.23 (m, 2H), 7.95 (s,
IH), 7.80 (d, J=8.8 Hz, IH), 7.76 (dd, J=8.6, 2.2 Hz, IH), 7.07 (d, J=4A Hz, IH), 6.84 (d, J=8.8 Hz, IH), 6.70 (d, J=8.8 Hz, IH), 3.90 - 3.86 (m, 3H), 3.85 (s, 3H), 2.09 (s, 3H).
Example 77
N-(4-(5-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 77 was preapared from Example 76B and 2-bromo-6-chloropyridine following the general method for example 1. HPLC: RT= 1.21 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z=394 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.14 (s, IH), 10.66 (s, IH), 8.34 (d, J=7.7 Hz, IH), 8.31 (d, J=5.4 Hz, IH), 8.20 (s, IH), 7.91 (t, J=7.7 Hz, IH), 7.83 (d, J=8.8 Hz, IH), 7.29 (d, J=7.7 Hz, IH), 7.23 (d, J=4.4 Hz, IH), 6.75 (d, J=8.8 Hz, IH), 3.92 (s, 3H), 2.10 (s, 3H).
Example 78
N-(4-(6-Cyano-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide,
78A): N-(4-((3-Amino-5-bromopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
H
A mixture of 2,5-dibromopyridin-3-amine (2.16 g, 8.57 mmol, from Combi- Blocks, Inc.), N-(4-ethynylpyridin-2-yl)acetamide (1.373 g, 8.57 mmol), copper(I) iodide (0.082 g, 0.429 mmol) in Et3N (20 mL, 143 mmol) and DMF (30 mL) was purged with N2. The resulting mixture was treated with bis(triphenylphosphine)palladium(II) dichloride (0.060 g, 0.086 mmol), purged with N2 and heated at 75 °C for 90 min. The reaction mixture was concentrated in vacuo. To the residue was added 20 mL of iPrOH, the mixture was sonicated and the solid was filtered and washed with iPrOH. The resulting solid was triturated with CH2CI2 and collected by filtration. The filtrate was concentrated and the residue was triturated with CH2CI2 to obtain a second crop of the title compound. Both solids were combined to obtain 2 g of yellow solid. The filtrate was further concentrated in vacuo and the residue was purified by column chromatography on S1O2 (gradient hexane/EtOAc) to obtain 640 mg of the title compound, total 2.64 g (93% yield) as a yellow solid. MS (ES): m/z= 331, 333 [M+H]+ ; ¾ NMR (500 MHz, DMSO- de) δ 10.62(s, 1H), 8.35 (d, J=5.0 Hz, 1H), 8.23 (s, 1H), 7.86 (d, J=1.7Hz, 1H), 7.37-7.33 (m, 2H), 6.13 (s, 1H), 2.11 (s, 3H).
A mixture of Example 78A (300 mg, 0.91 mmol) and Zn(CN)2 (106 mg, 0.91 mmol) in DMF (10 mL) and water (0.5 mL) was purged with N2, and treated with PdCk (dppf) (60 mg, 0.082 mmol) and Pd2dba3 (80 mg, 0.087 mmol). The mixture was again purged with N2 and heated at 85 °C for 6 h. The reaction mixture was partially concentrated in vacuo and the residue was passed through a column of S1O2 (gradient CH2CI2 to 10% MeOH in CH2CI2) to obtain the title compound (135 mg, 0.487 mmol, 54 % yield) as a yellow solid. MS (ES): m/z= 278 [M+H]+ ; ¾ NMR (400 MHz,
METHANOLS) δ 8.33 (br. s., 1H), 8.09 (d, J=1.5 Hz, 1H), 8.05 (br. s., 1H), 7.47 (d, J=1.5 Hz, 1H), 7.46 - 7.43 (m, 1H), 2.24 (br. s., 3H).
78C): N-(4-(6-Cyano-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 78B (530 mg, 1.911 mmol), CS2CO3 (685 mg, 2.103 mmol) and Pd(Ph3P)4 (110 mg, 0.096 mmol) in 12 mL DMF was purged with Ν2 and the mixture was heated 150 °C for 20 minutes, and then cooled to room temperature. The reaction mixture was partially concentrated in vacuo, and the residue was mixed with 15 mL
CH2CI2 and 3 mL water. The solid was filtered and dried to obtain the title compound (350 mg, 1.262 mmol, 66.0 % yield) as a light yellow solid. MS (ES): m/z= 278 [M+H]+ ; ¾ NMR (400 MHz, METHANOLS) δ 8.63 (d, J=1.8 Hz, 1H), 8.57 (s, 1H), 8.42 (d, J=5.3 Hz, 1H), 8.23 (s, 1H), 7.61 (m, 1H), 7.28 (s, 1H), 2.23 (s, 3H).
To a solution of of Example 78C (600 mg, 2.164 mmol) in DMF (15 mL) was added N-iodosuccinimde (487 mg, 2.164 mmol) and the mixture was stirred at room temperature for 1 h. The reaction mixture was partially concentrated in vacuo, and the residue was triturated with water and the solid was filtered to obtain the title compound (620 mg, 1.538 mmol, 71.1 % yield) as a light brown solid. MS (ES): m/z= 403.9
[M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 12.98 (s, 1H), 10.72 (s, 1H), 8.78 (d, J=1.8 Hz, 1H), 8.69 (s, 1H), 8.52 (d, J=5.1 Hz, 1H), 8.37 (d, J=2.0 Hz, 1H), 7.66 - 7.56 (m, 1H), 2.15 (s, 3H).
N-(4-(6-Cyano-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
A mixture of Example 78D (35 mg, 0.087 mmol), 2-methoxy-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine(30.6 mg, 0.130 mmol) and 0.2 mL 3M K3PO4 in DMF (2 mL) was purged with Ν2. The mixture was treated with PdCl2(dppf) (25.4 mg, 0.035 mmol), purged with Ν2 and heated at 80 °C for 60 min. The reaction mixture was concentrated to a volume of 1 mL and 3 mL MeOH was added. The resulting solid was filtered and the filtrate was purified by preparative HPLC (Sunfire C-18 19 x
150 mm, eluting with 5% -100% aqueous G¾CN containing 1% TFA gradient over 12 min, 20 mL/min, wavelength = 254 nm) to obtain the title compound (27 mg, 56%). HPLC: RT = 0.68 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z= 385 [M+H]+ ; ¾ NMR (500 MHz, DMSO-de) δ 10.65 (s, IH), 8.74 (d, J=2.0 Hz, IH), 8.40 (d, J=2.0 Hz, IH), 8.38 - 8.34 (m, 2H), 8.23 (dd, J=2.4, 0.6 Hz, IH), 7.77 (dd, J=8.5, 2.4 Hz, IH), 7.15 (dd, J=5.2, 1.7 Hz, IH), 6.88 (dd, J=8.5, 0.8 Hz, IH), 3.89 (s, 3H), 2.10 (s, 3H).
Example 79
N-(4-(6-(Aminomethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 78 (50 mg, 0.130 mmol) and 20% Pd(OH)2 on carbon (10 mg) in MeOH (12 mL) was stirred under 1 atm of H2 at room temperature. After 4 h additional 20% Pd(OH)2 on carbon (20 mg) was added and stirring was continued under 1 atm H2. After 7 h, the solid was filtered and the filtrate was partially concentrated and the residue was purified by preperative HPLC (Sunfire C-18 19 x 150 mm, eluting with 10% aqueous CH3CN to 60% aqueous CH3CN containing 5 mmol NH4OAC gradient over 8 min, 20 mL/min, wavelength = 254 nm) to obtain the title compound (13 mg, 0.032 mmol, 24.44 % yield) as a light yellow solid. HPLC: RT = 0.49 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z= 389 [M+H]+ ; ¾ NMR (400 MHz,
METHANOLS) δ 8.45 (s, IH), 8.30 (s, IH), 8.26 (d, J=5.1 Hz, IH), 8.17 (d, J=1.8 Hz, IH), 8.05 (s, IH), 7.76 (dd, J=8.6, 2.2 Hz, IH), 7.15 - 7.11 (m, IH), 6.88 (d, J=8.4 Hz, IH), 4.29 (s, 2H), 3.95 (s, 3H), 2.16 (s, 3H).
Example 80 and Example 81 were prepared following similar procedures as described in Examples 78 and 79.
Example 80
N-(4-(7-Cyano-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
HPLC: RT = 0.68 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z= 385 [M+H]+ ; ¾ NMR (400 MHz, METHANOLS) δ 8.60 (d, J=5.1 Hz, IH), 8.37 (d, J=5.9 Hz, IH), 8.30 - 8.28 (m, IH), 7.96 - 7.91 (m, 2H), 7.71 (d, J=5.1 Hz, IH), 7.47 (dd, J=5.7, 1.3 Hz, IH), 7.03 (dd, J=8.7, 0.6 Hz, IH), 4.01 (s, 3H), 2.23 (s, 3H).
Example 81
N-(4-(7-(Aminomethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
HPLC: RT = 0.50 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z= 389 [M+H]+ ; ¾ NMR (500 MHz, DMSO-de) δ 10.61 (s, IH), 8.45 (d, J=4.7 Hz, IH), 8.37 - 8.33 (m, 2H), 8.24 (d, J=1.7 Hz, IH), 7.78 (dd, J=8.5, 2.3 Hz, IH), 7.32 (d, J=4.7 Hz, IH), 7.14 (dd, J=5.1, 1.6 Hz, IH), 6.86 (d, J=8.5 Hz, IH), 4.39 (s, 2H), 3.87 (s, 3H), 2.10 (s, 3H).
Example 82
4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]-N-methylpyridin-2- amine
82A): N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-l-tosyl-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a solution of Example 72A (0.45 g, 1.18 mmol) in DMF (8 mL) were added CS2CO3 (0.85 g, 2.59 mmol) and ^-toluenesulfonyl chloride (0.22 mL, 1.18 mmol). The reaction mixture was stirred at room temperature over night. To the reaction mixture was added ethyl acetate and a saturated NaHC03 solution. The organic layer was extracted
with ethyl acetate (2x) and the combined organic layers were washed with saturated NaHC03 solution, dried over MgS04 and filtered. The filtrate was concentrated in vacuo.
The residue was purified by silica gel flash chromatography, eluting with 0-10% MeOH in DCM to give the desired product as a yellow solid (0.16 g, 25.3%); HPLC: RT = 1.30 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 536.3 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm δ 8.68 (d, J=2.2 Hz, IH), 8.61 (d, J=2.2 Hz, IH), 8.33 (d, J=3.1 Hz, IH), 8.30 (dd, J=5.1 , 0.7 Hz, IH), 7.99 (s, IH), 7.62 (dd, J=8.5, 4.3 Hz, IH), 7.45 (d, J=8.6 Hz, 2H), 7.36 - 7.29 (m, IH), 7.20 (d, J=7.9 Hz, 2H), 7.13 (dd, J=5.2, 1.4 Hz, IH), 2.37 (s, 3H), 2.20 (s, 3H).
82B): N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-l-tosyl-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)-N-methylacetamide
To a suspension of Example 82A (50 mg, 0.093 mmol) in THF (1 mL) was added methyl iodide (0.017 mL, 0.280 mmol) in DMF (0.6 mL) and CS2CO3 (61 mg, 0.187 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with ethyl acetate and saturated NaHC03 solution. The organic layer was separated and dried over MgS04 and filtered. The filtrate was concentrated in vacuo to give the desired product, which was used in the next step without purification. HPLC: RT = 1.43 min (H2O/ACN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μπι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 550.3 [M+H]+.
Example 82): 4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]-N- methylpyridin-2-amine
To a solution of crude Example 82B (30 mg, 0.055 mmol) in MeOH (2 mL) was added an aqueous LiOH solution (0.55 mL, 1.10 mmol). The reaction mixture was then heated at 85 °C for 2 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in DMF and purified by preparative HPLC ( Sunfire C-18 19 x 150 mm, eluting with 10% -100% aqueous CH3CN containing 5 mmol NLUOAc over 12 min, 20 mL/min, wavelength = 220 nm).. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid ( 11 mg, 55%); HPLC: RT = 0.67 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 354.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 8.51 (d, =3.1 Hz, 1H), 8.38 (d, J=2.2 Hz, 1H), 8.05 - 7.95 (m, 2H), 7.90 (d, J=2.2 Hz, 1H), 7.79 (td, J=8.7, 3.0 Hz, 1H), 6.59 (s, 1H), 6.56 - 6.48 (m, 2H), 2.75 (d, J=4.8 Hz, 3H).
Example 83
N-{4-[6-Bromo-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
83A): N-(4-((3-Amino-5-bromopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
Example 83A was prepared from Example IB and 2,5-dibromopyridin-3-amine by methods similar to those shown for Example 1C. HPLC: RT = 1.43 min (EhO/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 331 [M+H]+ , ¾ NMR (400 MHz, DMSO-de) δ 10.61 (s, 1H), 8.36 (dd, J=5.1, 0.7 Hz, 1H), 8.24 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.37 - 7.34 (m, 2H), 3.31 (s, 2H), 2.12 (s, 3H).
83B): N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-bromopyridin-3-yl)-2,2,2- trifluoroacetamide
Example 83B was prepared from Example 83A by methods similar to those shown for Example ID. HPLC: RT = 1.85 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 427
[M+H]+ , ¾ NMR (400 MHz, DMSO-d) δ ppm 11.72 (s, IH), 10.68 (s, IH), 8.79 (d, J=2.0 Hz, IH), 8.41 (dd, J=5.1, 0.9 Hz, IH), 8.36 (d, J=2.2 Hz, IH), 8.25 (s, IH), 7.19 (dd, J=5.1, 1.5 Hz, IH), 2.12 (s, 3H).
Example 83): N- {4-[6-Bromo-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
Example 83 was prepared from Example 83B and 2-bromo-5-methoxy pyridine by the general methods shown for Example 1. HPLC: RT = 0.91 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 438 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.20 (s, IH), 10.56 (s, IH), 8.49 (s, IH), 8.35 - 8.25 (m, 2H), 8.20 (d, J=2.5 Hz, IH), 8.08 (s, IH), 7.93 (d, J=8.7 Hz, IH), 7.50 (dd, J=8.6, 2.7 Hz, IH), 7.13 (d, J=4.9 Hz, IH), 3.86 (s, 3H), 2.10 (s, 3H).
Example 84
Methyl N- {4-[3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} carbamate
To a suspension of Example 52 (28.8 mg, 0.091 mmol) in CH2CI2 (2 mL) was added TEA (0.038mL, 0.272 mmol) and methyl chloroformate (0.014 mL, 0.182 mmol). The mixture was stirred at room temperature overnight, and then MeOH (1 mL) and concentrated NH4OH (1 drop) were added. The resulting reaction mixture was stirred at room temperature ovemight. The mixture was then concentrated, diluted with DMF, and purified by preparative HPLC (Column: Waters XBridge C18, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10- 50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.) to give Example 84 (10.5 mg, 31 %). HPLC: RT = 0.73 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 376 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.07 (br. s., 1H), 10.33 (s, 1H), 8.42 (d, J=4.1 Hz, 1H), 8.34 - 8.17 (m, 2H), 8.08 (s, 1H), 7.94 - 7.71 (m, 2H), 7.27 (dd, J=8.0, 4.5 Hz, 1H), 7.10 (d, J=5.0 Hz, 1H), 6.89 (d, J=8.4 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 2H).
Example 85
Methyl N- {4-[6-chloro-3-(5-fluoropyri din-2 -yl)-lH-pyrrolo[3,2-b]pyri din-2-yl]pyri din-2- yl} carbamate
To a suspension of Example 72A (68 mg, 0.20 mmol) in DCE (3 mL) were added methyl chloroformate (0.04 mL, 0.52 mmol) and 4-methylmorpholine (0.13 mL, 1.20 mmol). The reaction mixture was stirred at room temperature for 1 h. Additional methyl chloroformate (0.04 mL, 0.52 mmol) and 4-methylmorpholine (0.13 mL, 1.201 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for another 0.5 h. To the mixture was added ammonium hydroxide (0.6 mL) and MeOH (3 mL). The resulting mixture was stirred at room temperature for 20 h. The reaction
mixture was then diluted with a saturated NaHC03 solution and CHC13: 2-propanol (2.5 : 1). The layers were separated and the aqueous layer was extracted with CHC13: 2- propanol (2.5 : 1). The combined organic layers were dried over MgS04 and filtered. The filtrate was concentrated in vacuo to give a yellow solid. To the extract was added DCM, the mixture was sonicated and then filtered to give the desired product as a yellow solid (35 mg, 42%). HPLC: RT = 0.72 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 397.9 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.31 (s, 1H), 10.25 (s, 1H), 8.46 (dd, J=6.2, 2.6 Hz, 2H), 8.28 (d, J=5.3 Hz, 1H), 8.1 1 (dd, J=8.8, 4.6 Hz, 1H), 8.02 (s, 1H), 7.97 (d, J=2.2 Hz, 1H), 7.83 (td, J=8.8, 2.9 Hz, 1H), 7.13 (dd, J=5.3, 1.3 Hz, 1H), 3.68 - 3.63 (m, 3H).
Example 86
4-[6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-
Example 86 was prepared from Example 47 by the general methods shown for Example 52. HPLC: RT = 0.86 min (H2O/ACN with 0.1 % TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μπι particles, gradient = 1.5 min, wavelength = 220 nm); MS (ES): m/z = 352.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 8.37 (d, J=2.2 Hz, 1H), 8.24 (d, J=2.6 Hz, 1H), 7.95 - 7.78 (m, 3H), 7.47 (dd, J=8.8, 3.1 Hz, 1H), 6.62 (s, 1H), 6.53 (dd, J=5.3, 1.5 Hz, 1H), 5.97 (s, 2H), 3.86 (s, 3H).
Example 87
Methyl N-{4-[6-chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- y 1] py ridin-2-y 1 } carbamate
Example 87 was prepared from Example 86 by the general methods shown for Example 85. HPLC: RT = 0.98 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 410.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.25 (s, IH), 8.42 (d, J=1.9 Hz, IH), 8.24 (d, J=5.1 Hz, IH), 8.21 (d, J=2.8 Hz, IH), 8.04 (s, IH), 7.95 (d, J=1.9 Hz, IH), 7.92 (d, J=8.6 Hz, IH), 7.50 (dd, J=8.7, 2.9 Hz, IH), 7.09 (d, J=5.1 Hz, IH), 3.85 (s, 3H), 3.65 (s, 3H).
Example 88
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-
(4-methylpiperazin- 1 -yl)acetamide
Example 88 was prepared from 74A and 1 -methylpiperazine by the general methods shown for Example 74. HPLC: RT = 0.85 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 480.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.06 (br. s., IH), 8.45 (br. s., 2H), 8.34 (d, J=5.1 Hz, IH), 8.28 (s, IH), 8.10 (dd, J=8.8, 4.5 Hz, IH), 7.98 (d, J=1.9 Hz, IH), 7.83 (td, J=8.8, 2.9 Hz, IH), 7.22 (d, J=5.0 Hz, IH), 2.63-2.51 (m, 10H), 2.39 (br. s., 3H).
Example 89
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- { [3-(morpholin-4-yl)propyl]amino} acetamide
Example 89 was prepared from 74A and 3-morpholinopropan-l -amine by the general methods shown for Example 74. HPLC: RT = 0.82 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 524.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 8.45 (br. s., 2H), 8.37 - 8.26 (m, 2H), 8.1 1 (dd, J=8.5, 4.5 Hz, 1H), 7.98 (s, 1H), 7.87 - 7.76 (m, 1H), 7.20 (d, J=5.0 Hz, 1H), 3.54-3.4 (br. s., 6H), 3.29 (br. s., 4H), 2.32 (t, J=6.8 Hz, 2H), 1.90 (s, 2H), 1.58 (t, J=6.9 Hz, 2H).
Example 90
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- {[2-^ο ηο1ίη-4^1)6^1^ιώηο} acetamide
Example 90 was prepared from 74A and 2-morpholinoethanamine by the general methods shown for Example 74. HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min,
wavelength = 220 nm);MS (ES): m/z = 510.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.47 (s, 1H), 8.55 - 8.39 (m, 3H), 8.27 - 8.12 (m, 2H), 8.01 (s, 1H), 7.89 - 7.77 (m, 1H), 7.35 (d, J=4.9 Hz, 1H), 4.29 - 3.59 (m, 2H), 3.45 - 2.80 (m, 4H), 2.54 (br.s, 8H).
Example 91
N-{4-[6-Methanesulfonyl-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
91 A): N-(4-(6-Bromo-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-N-((2-(trimethylsilyl)ethoxy)
methyl)acetamide
To a suspension of Example 83 (200 mg, 0.456 mmol) in THF (15 mL)/DMF (7 mL) was added 60% NaH (146 mg, 3.65 mmol), and the mixture was stirred for 15 min. SEM-Cl (0.324 mL, 1.825 mmol) was then added, and the resulting mixture was stirred at room temperature for 1.5h. The reaction was carefully quenched with water, and the mixture was then extracted with EtOAc. The organic layer was separated and washed with 10% LiOH and brine, dried (MgSCn) and concentrated. The residue was purified by
silica gel flash chromatography (24g, MeOH/DCM = 0-5%) to give Example 91 A (196 mg, 62%). HPLC: RT = 3.32 min (H20/MeOH with 0.1% TFA, Chromolith SpeedROD, 4.6 x 50 mm, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 698 [M+H]+.
Example 91): N-{4-[6-Methanesulfonyl-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl]pyridin-2-yl}acetamide
A mixture of Example 91A (25 mg, 0.036 mmol), sodium methanesulfinate (7.30 mg, 0.072 mmol), copper (I) iodide (10.22 mg, 0.054 mmol), L-proline (8.24 mg, 0.072 mmol) and CS2CO3 (23.31 mg, 0.072 mmol) in DMSO (0.7 mL) in a 2 dram vial was purged with nitrogen and then heated at 100 °C overnight. The mixture was cooled to room temperature, and then diluted with MeOH and purified by preparative HPLC (Luna 5u CI 8, 20 x 100 mm, eluting with 20 %- 100 % aqueous acetonitrile over 15 minutes containing 5 mM NH4OAC, 20 mL/min, monitor 254 nm). The desired fractions were combined and concentrated, and the residue was then treated with 50% TFA/DCM (2 mL) and stirred at room temperature for 2h. The mixture was concentrated and purified by preparative HPLC (XBridge CI 8, 5 u, 19 x 200 mm, eluting with 5%-50% aqueous acetonitrile over 20 minutes containing 10 mM ammonium acetate, 20 mL/min, monitor 254 nm) to give Example 91 (3.4 mg, 21%). HPLC: RT = 0.62 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 438 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.62 (s, IH), 8.91 (s, IH), 8.41 - 8.27 (m, 3H), 8.22 (d, J=2.7 Hz, IH), 7.99 (d, J=8.6 Hz, IH), 7.53 (dd, J=8.7, 2.8 Hz, IH), 7.16 (d, J=4.5 Hz, IH), 3.87 (s, 3H), 2.55 (s, 3H), 2.11 (s, 3H).
Example 92
N-{4-[6-Cyano-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
Example 92 was prepared from Example 83 using conditions similar to those described for Example 78B. HPLC: RT = 0.59 min (H2O/ACN with 0.05% TFA, Waters Acquity BEH CI 8, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z= 385 [M+H]+ ; ¾ NMR (400 MHz, DMSO-de) δ 12.75 (s, IH), 10.60 (s, IH), 8.78 (d, J=1.8 Hz, IH), 8.41 (d, J=1.8 Hz, IH), 8.35 - 8.30 (m, 3H), 8.26 (d, J=2.6 Hz, IH), 7.95 (d, J=8.8 Hz, IH), 7.17 (dd, J=5.2, 1.7 Hz, IH), 3.88 (s, 3H), 2.09, 2.07 (s, 3H).
Example 93
N-{4-[6-(Dimethyl-l,2-oxazol-4-yl)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl]pyridin-2-yl} acetamide
A mixture of Example 83 (20 mg, 0.046 mmol), (3,5-dimethylisoxazol-4- yl)boronic acid (9.65 mg, 0.068 mmol), PdCl2(dppf)-CH2Cl2 adduct (1.863 mg, 2.282
μηιοΐ) and 2M potassium phosphate tribasic (0.068 mL, 0.137 mmol) in THF (2 mL) was purged with N2, and then heated in a sealed vial at 85 °C for 30 min. The mixture was cooled to room temperature, then concentrated and purified by preparative HPLC (XBridge C18, 5 u, 19 x 200 mm, eluting with 5%-80% aqueous acetonitrile over 20 minutes containing 10 mM ammonium acetate, 20 mL/min, monitor 254 nm) to give Example 93 (12.3 mg, 59%). HPLC: RT = 0.97 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 455 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.56 (s, IH), 8.44 (s, IH), 8.34 (br. s., IH), 8.30 (d, J=5.0 Hz, IH), 8.21 (d, J=2.8 Hz, IH), 8.04 (d, J=8.7 Hz, IH), 7.84 (s, IH), 7.51 (dd, J=8.7, 2.9 Hz, IH), 7.16 (d, J=5.1 Hz, IH), 3.87 (s, 3H), 2.47 (s, 3H), 2.29 (s, 3H), 2.10 (s, 3H).
Example 94
N- {4-[6-(Dimethyl-lH-l ,2,3-triazol-5-yl)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl]pyridin-2-yl} acetamide
A mixture of Example 84 (20 mg, 0.046 mmol), l,4-dimethyl-5-(tributylstannyl)- lH-l,2,3-triazole (35.2 mg, 0.091 mmol) [Seefeld, M A. et al. PCT Int. Appl, 2008, WO2008098104], Pd(Ph3P)4 (5.27 mg, 4.56 μιηοΐ), copper (I) iodide (1.738 mg, 9.13 μιηοΐ) and TEA (0.013 mL, 0.091 mmol) in DMF (1 mL) was purged with N2, and then heated at 90 °C overnight. The mixture was cooled to room temperature and purified by preparative HPLC (XBridge CI 8, 5 u, 19 x 200 mm, eluting with 10%-50% aqueous acetonitrile over 20 minutes containing 10 mM ammonium acetate, 20 mL/min, monitor 254 nm) to give Example 94 (1.7 mg, 8%). HPLC: RT = 0.75 min (H2O/ACN with 0.1 %
TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 455 [M+H]+.
Example 95
N-(4-(6-(2-Methoxyethoxy)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
95A) N-(4-(6-Bromo-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a suspension of N-(4-(6-bromo-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide (Example 83, 125 mg, 0.285 mmol) and cesium carbonate (139 mg, 0.428 mmol) in DMF (1 mL) and THF (1 mL) was added (2- (chloromethoxy)ethyl) trimethylsilane (57.1 mg, 0.342 mmol). The reaction was stirred at room temperature for lh before it was quenched with brine, and extracted with EtOAc (3x). The combined organic layers were concentrated and purified on ISCO (0-10% MeOH/DCM, 24 g column) to give N-(4-(6-bromo-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyiTolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (143 mg, 0.252 mmol, 88 % yield). MS (ES): m/z = 569.9 [M+H]+.
95B) N-(4-(6-hydroxy-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a vial was added bis(pinacolato)diboron (156 mg, 0.616 mmol), N-(4-(6- bromo-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide (140 mg, 0.246 mmol), Pd2(dba)3 (4.51 mg, 4.92 μηιοΐ), XPhos (4.70 mg, 9.85 μηιοΐ), and potassium acetate (72.5 mg, 0.739 mmol). The vial was evacuated and refilled with N2. Dioxane (3 mL) was then added. The reaction was then heated to 100 °C for 2h.The reaction was then cooled to room temperature, diluted with EtOAC, filtered through a pad of Celite, washing with 10% MeOH/DCM. The combined filtrated was concentrated and taken up in THF (5 mL) and water (2mL). To the mixture was added sodium perborate (100 mg). The resulting suspension was stirred at room temperature overnight before it was diluted with EtOAc, washed with brine, dried and concentrated in vacuo. The crude product was purified on ISCO (0-7% MeOH/DCM, 24 g column) to give N-(4-(6-hydroxy-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl )-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (79 mg, 0.156 mmol, 63.4 % yield). MS (ES): m/z = 506.0 [M+H]+.
95C) N-(4-(6-(2-Methoxyethoxy)-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl) -lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of N-(4-(6-hydroxy-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (32 mg, 0.063 mmol), triphenylphosphine (16.60 mg, 0.063 mmol), and 2-methoxyethanol (14.45 mg, 0.190 mmol) in THF (0.5 mL) at 0 °C was added DIAD (0.012 mL, 0.063 mmol). The reaction was then heated to 50 °C for lh before it was cooled to room temperature and purified on ISCO (0-10% MeOH/DCM, 12 g column) to give N-(4-(6- (2-methoxyethoxy)-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (25 mg, 0.044 mmol, 70.1 % yield). MS (ES): m/z = 564 [M+H]+.
Example 95) N-(4-(6-(2-Methoxyethoxy)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of N-(4-(6-(2-methoxyethoxy)-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (26 mg, 0.046 mmol) in DCM (0.2 mL) was added TFA (0.3 mL). The resulting reaction was stirred at room temperature for 4h before it was concentrated. The resulting mixture was then dissolved in 0.4 M ΝΗ3 in 20% MeOH/DCM (0.5 mL) and stirred at room
temperature for lh. The reaction was then concentrated and purified on ISCO (0-10% MeOH/DCM, 12 g Gold column) to give N-(4-(6-(2-methoxyethoxy)-3-(5- methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (13.5 mg, 0.030 mmol, 64.2 % yield). HPLC: RT = 0.59 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1 min, wavelength = 220 nm); MS (ES): m/z = 434 [M+H]+ ; ¾ NMR (400 MHz, METHANOLS) δ 8.28 (dd, J=3.0, 0.6 Hz, 1H), 8.24 - 8.20 (m, 2H), 8.18 (d, J=2.6 Hz, 1H), 7.63 (dd, J=8.6, 0.6 Hz,
IH), 7.54 (dd, J=8.6, 3.0 Hz, IH), 7.50 (d, J=2.6 Hz, IH), 7.10 - 7.05 (m, IH), 4.38 - 4.22 (m, 2H), 3.97 (s, 3H), 3.88 - 3.77 (m, 2H), 3.48 (s, 3H).
Table 1
The Examples found in Table 1 were prepared according to the general methods shown for Example 95 from the appropriate starting materials.
HPLC/LCMS Column conditions: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μτη particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 1 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 104
104A) 2-Bromo-5-(methoxy-d3)pyridine
To a solution of 6-bromopyridin-3-ol (10.00 g, 57.5 mmol), d4-MeOD (12.44 g, 345 mmol), and triphenylphosphine (15.83 g, 60.3 mmol) in dioxane (80 mL) at 0 °C was added dropwise DIAD (11.73 mL, 60.3 mmol). The reaction was stirred at 0 °C for 10 min before warmed to room temperature and stirred overnight. The reaction was then concentrated and then triturated with DCM (60 mL). The mixture was filtered to remove phosphine oxide by-product. The filtrate was concentrated and purified on ISCO (0-10% MeOH/DCM, 120 g column) to give 2-bromo-5-(methoxy-d3)pyridine (7.1 g, 37.2 mmol, 64.7 % yield). MS (ES): m/z = 191 [M+H]+ ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.08 (dd, J=3.2, 0.4 Hz, 1H), 7.39 (dd, J=8.7, 0.6 Hz, 1H), 7.12 (dd, J=8.7, 3.2 Hz, 1H)
Example 104) N-(4-(3-(5-(Methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example ID (1.2g, 3.45 mmol) and cesium carbonate (2.245 g, 6.89 mmol) was evacuated and backfilled with N2. MeCN (17.23 ml) and 2-bromo-5- (methoxy-d3)pyridine (1.316 g, 6.89 mmol) were added. The mixture was sparged with N2 for 5 min before tetrakis(triphenylphosphine)palladium(0) (0.199 g, 0.172 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110
°C for 2 h. The resulting mixture was cooled to room temperature diluted with 10% MeOH-CH2Cl2 (20 mL) and filtered through Celite (washed with 10% MeOH-CH2Cl2). The filtrate was concentrated in vacuo. The crude material was purified by ISCO (120 g column, 0-8% MeOH/DCM) and dried under vaccum give N-(4-(3-(5-(methoxy- d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (540mg, 1.460 mmol, 42.4 % yield). HPLC: RT = 0.56 min (H20/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 1 min, wavelength = 220 nm); MS (ES): m/z = 363 [M+H]+ ; ¾ NMR (400 MHz, DMSO-de) δ 11.98 (s, 1H), 10.52 (s, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.36 - 8.25 (m, 2H), 8.19 (d, J=2.9 Hz, 1H), 8.03 (d, J=8.7 Hz, 1H), 7.87 (d, J=8.2 Hz, 1H), 7.50 (dd, J=8.7, 2.9 Hz, 1H), 7.26 (dd, J=8.1, 4.6 Hz, 1H), 7.14 (d, J=5.1 Hz, 1H), 2.10 (s, 3H)
Example 105
N-(4-(6-Chloro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
A mixture of Example 41B (110 mg, 0.287 mmol) and cesium carbonate (187 mg, 0.575 mmol) was evacuated and backfilled with N2. MeCN (2874 μΐ) and 2-bromo-5- (methoxy-d3)pyridine (110 mg, 0.575 mmol) were added. The mixture was sparged with N2 for 5 min, then tetrakis(triphenylphosphine)palladium(0) (16.61 mg, 0.014 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110 °C for 2 h. The reaction was then cooled to room temperature, diluted with 10% MeOH- CH2C12 (20 mL), and filtered through Celite (washed with 10% MeOH-CH2Cl2). The filtrate was concentrated in vacuo. The crude material was purified by ISCO (40 g gold column, 0-8% MeOH/DCM, dry-loaed on Celite) and dried under vaccum give the
desired product (48 mg, 0.119 mmol, 41.2 % yield). HPLC: RT = 0.61 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1 min, wavelength = 220 nm); MS (ES): m/z = 397 [M+H]+ ¾ NMR (400 MHz, DMSO-de) δ 12.19 (s, 1H), 10.55 (s, 1H), 8.44 (d, J=2.2 Hz, 1H), 8.32 (s, 1H), 8.29 (d, J=5.3 Hz, 1H), 8.21 (d, J=3.1 Hz, 1H), 7.95 (dd, J=5A, 3.2 Hz, 2H), 7.50 (dd, J=8.7, 3.1 Hz, 1H), 7.13 (dd, J=5.2, 1.5 Hz, 1H), 2.10 (s, 3H)
Example 106
N-(4-(6-Fluoro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
A mixture of Example 38B (110 mg, 0.300 mmol) and cesium carbonate (196 mg, 0.601 mmol) was evacuated and backfilled with N2. MeCN (3003 μΐ) and 2-bromo-5- (methoxy-d3)pyridine (115 mg, 0.601 mmol) were added. The mixture was sparged with N2 for 5 min, then tetrakis(triphenylphosphine)palladium(0) (17.35 mg, 0.015 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110 °C for 2 h. The reaction was then cooled to room temperature, diluted with 10% MeOH- CH2CI2 (20 mL), and filtered through Celite (washed with 10% MeOH-CH2Cl2). The filtrate was concentrated in vacuo. The crude material was purified by ISCO (40 g gold column, 0-8% MeOH/DCM) and dried to give N-(4-(6-fluoro-3-(5-(methoxy-d3)pyridin- 2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (50 mg, 0.125 mmol, 41.6 % yield). HPLC: RT = 0.56 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1 min, wavelength = 220 nm); MS (ES): m/z = 381 [M+H]+; ¾ NMR (400 MHz, METHANOLS) δ 8.33 (t, J=2.2 Hz, 1H),
8.28 (dd, J=3.1, 0.6 Hz, IH), 8.27 - 8.22 (m, 2H), 7.71 (dd, J=9.1 , 2.5 Hz, IH), 7.67 (dd, J=8.7, 0.6 Hz, IH), 7.54 (dd, J=8.7, 3.1 Hz, IH), 7.15 - 7.08 (m, IH), 2.17 (s, 3H).
Table 2
The Examples in the Table 2 were prepared according to the general methods shown for Example 104 from the appropriate starting materials.
hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 114
2-(2-(2-Acetamidopyridin-4-yl)-3-(6-(difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-l -yl)acetamide
To a solution of Example 281 (20 mg, 0.053 mmol) in DMF (0.3 mL) was added potassium carbonate (14.57 mg, 0.105 mmol) and iodomethane (6.59 μΐ, 0.105 mmol). The reaction mixture was stirred overnight at room temperature and then filtered and diluted with MeOH. The crude product was then purified by preparative HPLC to give 2- (2-(2-acetamidopyridin-4-yl)-3-(6-(difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-l -yl)acetamide. HPLC: RT = 0.83 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 437 [M+H]+ ; ¾ NMR (500 MHz, DMSO-de) δ 10.58 (s, 1H), 8.66 (d, J=7.8 Hz, 1H), 8.56 (d, J=4.1 Hz, 1H), 8.37 (d, J=4.8 Hz, 1H), 8.13 (br. s., 1H), 8.01 - 7.93 (m, 2H), 7.56 (br. s., 1H), 7.41 (d, J=7.5 Hz, 1H), 7.35 (dd, J=8.0, 4.5 Hz, 1H), 7.23 (br. s., 1H), 7.08 (d, J=4.6 Hz, 1H), 6.50 - 6.17 (m, 1H), 4.76 (s, 2H), 2.07 (s, 3H).
Example 1 15
2-(Dimethylamino)-N- {4-[6-methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl]pyridin-2-yl} acetamide
115A) N-(4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 48B (0.423 g, 1.118 mmol) and cesium carbonate (0.729 g, 2.236 mmol) was evacuated and backfilled with N2, then MeCN (10.16 mL) and 2- bromo-5-methoxypyridine (0.420 g, 2.236 mmol) were added. The mixture was sparged with N2 for 5 min, then tetrakis(triphenylphosphine)palladium(0) (0.065 g, 0.056 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110 °C for 2 h. The reaction was cooled to room temperature, diluted with 10% MeOH- CH2CI2 (10 mL), and filtered through Celite (washed with 10% MeOH-CmCh). The filtrate was concentrated in vacuo. The crude material was purified by flash
chromatography (40 g silica gel with 25 g prepacked load cartridge; linear gradient 0- 10% MeOH-CH2Cl2) to provide Example 115A (0.216 g, 50%) as an off-white solid. LC- MS m/z 390 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.78 (s, 1H), 10.47 (s, 1H), 8.29 (s, 1H), 8.24 (dd, J=5.3, 0.7 Hz, 1H), 8.20 - 8.17 (m, 2H), 7.96 (d, J=8.7 Hz, 1H), 7.47 (dd, J=8.7, 3.1 Hz, 1H), 7.33 (d, J=2.6 Hz, 1H), 7.10 (dd, J=5.3, 1.6 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 2.09 (s, 3H).
115B) 4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-amine
To a room temperature solution of Example 115A (215 mg, 0.552 mmol) in MeOH (5.52 mL) was added sodium hydroxide (5.52 mL, 1 M solution in H2O, 5.52 mmol). The reaction was sealed and stirred at 80 °C for 2 h, and then it was cooled to room temperature, causing the precipitation of solids, which were collected by vacuum filtration (washed with H2O) to provide Example 1 15B (199 mg, quant.). LC-MS m/z 348 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.62 (s, 1H), 8.24 - 8.22 (m, 1H), 8.16 (d, J=2.7 Hz, 1H), 7.88 - 7.86 (m, 1H), 7.86 - 7.85 (m, 1H), 7.45 (dd, J=8.7, 3.1 Hz, 1H), 7.29 (d, J=2.6 Hz, 1H), 6.60 - 6.57 (m, 1H), 6.51 (dd, J=5.3, 1.5 Hz, 1H), 5.92 (s, 2H), 3.88 (s, 3H), 3.86 (s, 3H).
Example 1 15) 2-(Dimethylamino)-N- {4-[6-methoxy-3-(5-methoxypyridin-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
To a room temperature solution of Example 1 15B (26.2 mg, 0.075 mmol) in DMF (151 μί) was added 2-(dimethylamino)acetic acid (10.89 mg, 0.106 mmol), N,N- diisopropylethylamine (65.7 μί, 0.377 mmol), and HATU (40.1 mg, 0.106 mmol). The reaction was stirred at room temperature for 5 h, and then it was diluted with DMF, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C 18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 115 (26.2 mg, 50%). HPLC Rt = 0.725 min (Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1 % TFA over 3 min; wavelength = 220 nm); LC-MS m/z 433 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 1 1.84 (s, IH), 9.91 (s, IH), 8.30 (s, IH), 8.25 (d, J=5.2 Hz, IH), 8.20 - 8.17 (m, 2H), 7.95 (d, J=8.6 Hz, IH), 7.48 (dd, J=8.7, 2.9 Hz, IH), 7.35 (d, J=2.4 Hz, IH), 7.15 (d, J=5.1 Hz, IH), 3.88 (s, 3H), 3.84 (s, 3H), 3.11 (s, 2H), 2.29 (s, 6H)
Example 1 16
2-(Dimethylamino)-N- {4-[6-methoxy-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl]pyridin-2-yl} acetamide
116A) N-(4-(6-Methoxy-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide
A mixture of Example 48B (0.360 g, 0.952 mmol) and cesium carbonate (0.620 g, 1.903 mmol) was evacuated and backfilled with N2, then MeCN (9.52 mL) and 2-bromo- 6-methylpyridine (0.327 g, 1.903 mmol) were added. The mixture was sparged with N2 for 5 min, then tetrakis(triphenylphosphine)palladium(0) (0.055 g, 0.048 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110 °C for 2 h. The reaction was cooled to room temperature, diluted with 10% MeOH- CH2CI2 (10 mL), and filtered through Celite (washed with 10% MeOH-CH2Cl2). The filtrate was concentrated in vacuo. The crude material was purified by flash
chromatography (24 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-CH2Cl2) to provide Example 116A (172 mg, 48%) as an off-white solid. LC-MS m/z 374 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.83 (s, IH), 10.47 (s, IH), 8.34 (s, IH), 8.25 (dd, J=5.2, 0.7 Hz, IH), 8.21 (d, J=2.7 Hz, IH), 7.88 (d, J=7.7 Hz, IH), 7.71 (t, J=7.7 Hz, IH), 7.34 (d, J=2.6 Hz, IH), 7.19 (dd, J=5.3, 1.6 Hz, IH), 7.10 (d, J=7.6 Hz, IH), 3.89 (s, 3H), 2.30 (s, 3H), 2.09 (s, 3H).
116B) 4-(6-Methoxy-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- amine
To a room temperature solution of Example 116A (171 mg, 0.458 mmol) in MeOH (4579 μί) was added sodium hydroxide (4579 μί, 1 M solution in H2O, 4.58
mmol). The reaction was sealed and stirred at 80 °C for 2 h, and then it was cooled to room temperature and partially concentrated under a stream of N2 to remove most of the MeOH, causing precipitation of solids. The mixture was diluted with H2O (10 mL) and the solids were collected by vacuum filtration (washed with H2O) to provide Example 116B (1 17 mg, 77%) as a yellow solid. LC-MS m/z 332 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.68 (s, 1H), 8.17 (d, J=2.7 Hz, 1H), 7.86 (d, J=5.4 Hz, 1H), 7.79 - 7.76 (m, 1H), 7.69 (t, J=7.7 Hz, 1H), 7.30 (d, J=2.6 Hz, 1H), 7.10 (d, J=7.2 Hz, 1H), 6.68 - 6.64 (m, 1H), 6.56 (dd, J=5.4, 1.5 Hz, 1H), 5.91 (s, 2H), 3.88 (s, 3H), 2.36 (s, 3H).
Example 1 16) 2-(Dimethylamino)-N- {4-[6-methoxy-3-(6-methylpyridin-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} acetamide
To a room temperature solution of Example 116B (30.7 mg, 0.093 mmol) and 2- (dimethylamino)acetic acid (13.37 mg, 0.130 mmol) in DMF (185 μί) was added N,N- diisopropylethylamine (81 μί, 0.463 mmol) and HATU (49.3 mg, 0.130 mmol). The reaction was stirred at room temperature for 18 h, and then it was diluted with DMF, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C 18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 1 16 (19.8 mg, 51 %). HPLC Rt = 0.710 min (Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN- H2O with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS 417 [M+H]+; ¾ NMR
(500 MHz, DMSO-de) δ 1 1.90 (s, IH), 9.97 (br s, IH), 8.34 (s, IH), 8.27 (d, J=5.2 Hz, IH), 8.20 (d, J=2.5 Hz, IH), 7.87 (d, J=7.7 Hz, IH), 7.71 (t, J=7.7 Hz, IH), 7.36 (d, J=2.4 Hz, IH), 7.24 (d, J=4.2 Hz, IH), 7.10 (d, J=7.7 Hz, IH), 3.88 (s, 3H), 3.18 (s, 2H), 2.33 (s, 6H), 2.29 (s, 3H).
Example 1 17
N-(4- {3-[6-(Difluoromethyl)pyridin-2-yl]-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)-2-(dimethylamino)acetamide
117A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 48B (0.360 g, 0.952 mmol) and cesium carbonate (0.620 g, 1.903 mmol) was evacuated and backfilled with N2, then MeCN (9.52 mL) and 2-bromo- 6-(difluoromethyl)pyridine (0.396 g, 1.903 mmol) were added. The mixture was sparged
with N2 for 5 min, then tetrakis(triphenylphosphine)palladium(0) (0.055 g, 0.048 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 110 °C for 2 h. The reaction was cooled to room temperature, diluted with 10% MeOH- CH2CI2 (10 mL), and filtered through Celite (washed with 10% MeOH-CH2Cl2). The filtrate was concentrated in vacuo. The crude material was purified by flash
chromatography (24 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-CH2Cl2) to provide Example 117A (194 mg, 50%) as an off-white solid. LC-MS m/z 410 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 12.00 (s, IH), 10.49 (s, IH), 8.35 - 8.30 (m, 2H), 8.27 (dd, J=5.3, 0.6 Hz, IH), 8.24 (d, J=2.7 Hz, IH), 8.05 (t, J=7.9 Hz, IH), 7.54 (d, J=7.6 Hz, IH), 7.37 (d, J=2.6 Hz, IH), 7.21 (dd, J=5.1, 1.6 Hz, IH), 6.66 (t, J=55.4 Hz, IH), 3.90 (s, 3H), 2.08 (s, 3H).
117B) 4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-amine
To a room temperature solution of Example 117A (193 mg, 0.471 mmol) in MeOH (4714 μί) was added sodium hydroxide (4714 μί, 1 M solution in H2O, 4.71 mmol). The reaction was sealed and stirred at 80 °C for 2 h, and then it was cooled to room temperature, causing the precipitation of solids. The mixture was diluted with H2O (10 mL) and the solids were collected by vacuum filtration (washed with H2O) to provide Example 117B (133 mg, 77%) as an off-white solid. LC-MS m/z 368 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.85 (s, IH), 8.24 - 8.20 (m, 2H), 8.03 (t, J=7.8 Hz, IH), 7.88 - 7.86 (m, IH), 7.54 (d, J=7.5 Hz, IH), 7.33 (d, J=2.6 Hz, IH), 6.70 - 6.68 (m, IH), 6.72 (t, J=55.1 Hz, IH), 6.57 (dd, J=5.4, 1.5 Hz, IH), 5.93 (s, 2H), 3.89 (s, 3H).
Example 1 17) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-6-methoxy-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)-2-(dimethylamino)acetamide
To a room temperature suspension of Example 117B (33.6 mg, 0.091 mmol) and 2-(dimethylamino)acetic acid (13.20 mg, 0.128 mmol) in DMF (183 μί) was added N,N- diisopropylethylamine (80 μΐ,, 0.457 mmol) and HATU (48.7 mg, 0.128 mmol). The reaction was stirred at room temperature for 18 h, and then it was diluted with DMF, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C 18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20-60% B over 20 minutes, then a 3-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 117 (10.7 mg, 26%). HPLC Rt = 0.817 min (Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1 % TFA over 3 min; wavelength = 220 nm); LC-MS m/z 453 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.06 (s, IH), 9.91 (br s, IH), 8.35 (s, IH), 8.32 (d, J=8.0 Hz, IH), 8.29 (d, J=5.2 Hz, IH), 8.25 (d, J=2.4 Hz, IH), 8.05 (t, J=7.8 Hz, IH), 7.54 (d, J=7.7 Hz, IH), 7.39 (d, J=2.5 Hz, IH), 7.27 (d, J=4.3 Hz, IH), 6.66 (t, J=55.3 Hz, IH), 3.90 (s, 3H), 3.10 (s, 2H), 2.29 (s, 6H).
Table 3
Examples 1 18-123 in Table 3 were prepared from either Example 1 15B, Example 1 16B, or Example 1 17B using procedures similar to those used for the preparation of
Example 1 15.
123 N-(4-{3-[6- 0.842 538
(Difluoromethyl)pyridin-
2-yl]-6-methoxy-lH- pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)-2-[4-(2- hy droxy ethy l)piperazin- l-yl]acetamide
a HPLC conditions: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles; 5- 95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm.
Example 124
Methyl N-{4-[6-methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl} carbamate
To a 0 °C suspension of Example 115B (32 mg, 0.092 mmol) in CH2CI2 (921 μί) was added triethylamine (51.4 μί, 0.368 mmol), followed by methyl chloroformate (10.68 μΐ., 0.138 mmol), dropwise. The reaction was stirred at 0 °C for 5 min, then it was warmed to room temperature and stirred for 18 h. Additional methyl chloroformate (3.6 μί, 0.046 mmol) was added and the reaction was stirred at room temperature for 1 h.
Additional methyl chloroformate (3.6 μί, 0.046 mmol) was added and the reaction was stirred at room temperature for 1 h. The reaction was diluted with MeOH (920 μί) and ammonium hydroxide (200 μί), stirred for 3 h, and then concentrated in vacuo. The crude material was triturated with CH2CI2 to provide Example 124 (23.3 mg, 61%) as a white solid. HPLC Rt = 5.27 min (Sunfire C18, 3.0 x 150 mm, 3.5-μηι particles; 5-95% MeCN-H20 with 0.05% TFA over 12 min; wavelength = 220 nm); LC-MS m/z 406
[M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.77 (s, IH), 10.16 (s, IH), 8.22 - 8.18 (m, 3H), 8.03 (s, IH), 7.95 (d, J=8.7 Hz, IH), 7.48 (dd, J=8.7, 3.1 Hz, IH), 7.33 (d, J=2.6 Hz, IH), 7.08 (dd, =5.2, 1.5 Hz, IH), 3.89 (s, 3H), 3.86 (s, 3H), 3.66 (s, 3H).
Example 125
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethoxy-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide
125A) N-(4-(7-Chloro-3-(6-(difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 61C (1.273 g, 3.33 mmol) and cesium carbonate (2.167 g, 6.65 mmol) was evacuated and backfilled with N2, then DMF (13.30 mL) and 2-bromo-6- (difluoromethyl)pyridine (1.384 g, 6.65 mmol) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (0.131 g, 0.166 mmol) was added. The reaction was sparged with N2 for 2 min, then it was sealed and stirred at 120 °C for 2 h. The reaction was cooled to room temperature, diluted with THF (20 mL), filtered through Celite (washed with 60 mL THF followed by 100 mL 20% MeOH- CH2CI2), and concentrated in vacuo. The residue was suspended in CH2CI2 (25 mL) and the solids were collected by vacuum filtration (washed with 10 mL CH2CI2) to provide crude Example 125A, which was used without further purification. LC-MS m/z 414
[M+H]+.
125B) N-(4-(7-Chloro-3-(6-(difluoromethyl)pyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a room temperature solution of crude Example 125 A in THF (26.3 mL) and DMF (26.3 mL) was added cesium carbonate (3.43 g, 10.53 mmol), followed by 2- (trimethylsilyl)ethoxymethyl chloride (1.400 mL, 7.89 mmol), dropwise. The reaction was stirred at room temperature for 1 h, and then it was diluted with EtOAc (400 mL), washed with H2O (400 mL) and sat. aq. NaCl (400 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (40 g silica gel with 5 g prepacked load cartridge; linear gradient 0-100% EtOAc-CH2Cl2) to provide Example 125B (620 mg, 34% over two steps) as a yellow foam. LC-MS m/z 544
[M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.60 (s, IH), 8.50 (d, J=5.1 Hz, IH), 8.43 (dd, J=8.0, 0.8 Hz, IH), 8.38 (dd, J=5.1, 0.7 Hz, IH), 8.22 (s, IH), 8.03 (t, J=7.8 Hz, IH),
7.52 (d, J=5.0 Hz, 1H), 7.49 (d, J=7.6 Hz, 1H), 7.16 (dd, J=5.1, 1.5 Hz, 1H), 6.45 (t, J=55.1 Hz, 1H), 5.65 (s, 2H), 3.33 - 3.27 (m, 2H), 2.07 (s, 3H), 0.75 - 0.66 (m, 2H), -0.14 (s, 9H).
125C) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-hydroxy-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetaniide
A mixture of Example 125B (20 mg, 0.037 mmol) and cesium carbonate (35.9 mg, 0.110 mmol) was evacuated and backfilled with N2, then 1,4-dioxane (331 μί) and H2O (36.8 μί) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (1.446 mg, 1.838 μιτιοΐ) was added. The mixture was sparged with N2 for 1 min, then it was sealed and stirred at 100 °C for 4 h. Additional CS2CO3 (36 mg, 0.11 mmol) and H2O (74 μί) were added and the reaction was sparged with N2 for 5 min, then additional 2nd generation XPhos precatalyst (3 mg, 0.038 mmol) was added. The reaction was sparged with N2 for 1 min, then it was sealed and stirred at 100 °C for 20 h. The reaction was cooled to room temperature, diluted with EtOAc (25 mL), washed with sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-CH2Cl2) to provide Example 125C (5.9 mg, 31%) as a white solid. LC-MS m/z 526 [M+H]+
125D) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-ethoxy-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a 0 °C solution of Example 125C (10.6 mg, 0.020 mmol) in 1,4-dioxane (202 μί) was added triphenylphosphine (6.35 mg, 0.024 mmol) and ethanol (23.55 μί, 0.403 mmol), followed by diisopropyl azodicarboxylate (4.76 μί, 0.024 mmol), dropwise. The reaction was stirred at room temperature for 30 min, then at 50 °C for 1 h. The reaction was cooled to room temperature and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-100% EtOAc-CH2Cl2) to provide Example 125D (8.8 mg, 79%) as a yellow film. LC-MS m/z 554 [M+H]+.
Example 125) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethoxy-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 125D (8.8 mg, 0.016 mmol) in
CH2CI2 (79 μί) was added TFA (79 μΥ . The clear yellow solution was stirred at room temperature for 1 h. Additional TFA (79 μί) was added and the reaction was stirred at room temperature for 5 h. The reaction was concentrated in vacuo. The residue was taken up in 10%) 7 N NEb/MeOH in CH2CI2 (500 μί), stirred at room temperature for 1 h, and
then it was concentrated in vacuo. The crude material was purified by flash
chromatography (4 g silica gel; linear gradient 0-20% MeOH-CfhCh) to provide Example 125 (3.6 mg, 53%) as a white solid. HPLC Rt = 6.03 min (Sunfire C 18, 3.0 x 150 mm, 3.5-μηι particles; 5-95% MeCN-H20 with 0.05% TFA over 12 min;
wavelength = 220 nm); LC-MS m/z 424 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 12.21 (s, IH), 10.47 (s, IH), 8.41 (d, J=7.9 Hz, IH), 8.35 - 8.29 (m, 2H), 8.26 (d, J=5.1 Hz, IH), 8.03 (t, J=7.8 Hz, IH), 7.50 (d, J=7.6 Hz, IH), 7.22 (dd, J=5.2, 1.5 Hz, IH), 6.91 (d, J=5.4 Hz, IH), 6.60 (t, J=55.4 Hz, IH), 4.36 (q, J=7.0 Hz, 2H), 2.07 (s, 3H), 1.49 (t, J=7.0 Hz, 3H).
Example 126
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[2-(pyrrolidin-l-yl)ethoxy]-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
126A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(2-(pyrrolidin-l-yl)ethoxy)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a 0 °C suspension of Example 125C (21.3 mg, 0.041 mmol) in 1,4-dioxane (405 μί) was added triphenylphosphine (13.82 mg, 0.053 mmol) and 2-(pyrrolidin-l- yl)ethanol (9.48 μί, 0.081 mmol), followed by diisopropyl azodicarboxylate (10.37 μί, 0.053 mmol), dropwise. The reaction was stirred at room temperature for 10 min, then at 50 °C for 50 min. The reaction was cooled to room temperature and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-CFhCh) to provide Example 126A (11.0 mg, 44%) as a white solid. LC-MS m/z 623 [M+H]+.
Example 126) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[2-(pyrrolidin-l-yl)ethoxy]- lH-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 126A (11.0 mg, 0.018 mmol) in
CH2CI2 (58.9 μί) was added TFA (118 μί). The reaction was stirred at room temperature for 17 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NFb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, and then concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 126 (15.4 mg). HPLC Rt = 0.818 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 493 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.43 (s, 1H), 8.31 (d, J=4.9
Hz, IH), 8.29 - 8.23 (m, 3H), 8.02 (t, J=8.0 Hz, IH), 7.51 (d, J=8.0 Hz, IH), 7.22 (d, J=5.2 Hz, IH), 6.91 (d, J=5.3 Hz, IH), 6.61 (dd, J=55.4, 54.8 Hz, IH), 4.36 (br t, J=5.3 Hz, 2H), 2.99 - 2.94 (m, 2H), 2.62 - 2.57 (m, 4H), 2.04 (s, 3H), 1.74 - 1.69 (m, 4H).
Example 127
N-(4- {3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethenyl-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide
127A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-l -((2-(trimethylsilyl)ethoxy)methyl)-7- vinyl-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 125B (307 mg, 0.564 mmol), potassium
vinyltrifluoroborate (113 mg, 0.846 mmol), and cesium carbonate (552 mg, 1.693 mmol) was evacuated and backfilled with N2, then 1 ,4-dioxane (5078 μί) and H2O (564 μί) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (22.20 mg, 0.028 mmol) was added. The mixture was sparged with N2 for 1 min, then it was sealed and stirred at 80 °C for 1 h. The reaction was cooled to room
temperature, diluted with EtOAc (50 mL), washed with sat. aq. NaCl (50 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (24 g silica gel with 5 g prepacked load cartridge; linear gradient 0- 100% EtOAc-CH2Cl2) to provide Example 127A (270 mg, 0.504 mmol, 89%) as a yellow foam. LC-MS m/z 536 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.60 (s, IH), 8.56 - 8.50 (m, 2H), 8.37 (dd, J=5.0, 0.7 Hz, IH), 8.22 (s, IH), 8.01 (t, J=7.8 Hz, IH), 7.52 (dd, J=17.3, 10.9 Hz, IH), 7.46 (d, J=7.6 Hz, IH), 7.43 (d, J=4.9 Hz, IH), 7.13 (dd, J=5.1, 1.5 Hz, IH), 6.41 (t, J=55.4 Hz, IH), 6.04 (dd, J=17.2, 1.2 Hz, IH), 5.70 - 5.63 (m, IH), 5.39 (s, 2H), 3.35 - 3.26 (m, 2H), 2.07 (s, 3H), 0.78 - 0.73 (m, 2H), -0.12 (s, 9H).
Example 127) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethenyl-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 127A (17.1 mg, 0.032 mmol) in CH2CI2 (106 μΥ was added TFA (213 μΥ . The reaction was stirred at room temperature for 7 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NH3/MeOH in CH2CI2 (500 μί), stirred at room temperature for 1 h, and then it was concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-20% MeOH-QrhCh). The resulting material was repurified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-QrhCh) to provide Example 127 (7.2 mg, 55%) as a white solid. HPLC Rt = 6.19 min (Sunfire C18, 3.0 x 150 mm, 3.5-μιη particles; 5-95% MeCN-H20 with 0.05% TFA over 12 min; wavelength = 220 nm); LC- MS m/z 406 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 12.15 (s, IH), 10.52 (s, IH), 8.46 (d, J=4.9 Hz, IH), 8.42 (d, J=7.9 Hz, IH), 8.36 - 8.30 (m, 2H), 8.05 (t, J=7.8 Hz, IH),
7.54 - 7.50 (m, 2H), 7.46 (dd, J=17.6, 11.0 Hz, 1H), 7.27 (dd, J=5.1, 1.6 Hz, 1H), 6.62 (t, J=55.1 Hz, 1H), 6.29 (d, J=17.7 Hz, 1H), 5.70 (d, J=11.6 Hz, 1H), 2.08 (s, 3H).
Example 128
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethyl-lH-pyrrolo[3,2-b]pyridin-2-yl}pyridin-
2-yl)acetamide
To a room temperature solution of Example 127A (37.2 mg, 0.069 mmol) in EtOH (694 μί) was added 10% palladium on carbon (7.39 mg, 6.94 μηιοΐ) and ammonium formate (43.8 mg, 0.694 mmol). The reaction was stirred at room temperature for 1 h, then it was filtered through Celite (washed with MeOH) and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (230 μί) and TFA (460 μί). The reaction was stirred at room temperature for 16 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N Nft/MeOH in CH2CI2 (2 mL), stirred at room temperature for 1 h, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-100% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 128 (28.6 mg, quant, over two steps). HPLC Rt = 1.062 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 408
[M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.05 (s, 1H), 10.49 (s, 1H), 8.37 (d, J=4.7 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 8.30 - 8.27 (m, 2H), 8.02 (t, J=7.9 Hz, 1H), 7.51 (d,
J=7.6 Hz, IH), 7.23 (d, J=5.2 Hz, IH), 7.14 (d, J=4.7 Hz, IH), 6.61 (t, J=55.3 Hz, IH), 2.99 (q, J=7.6 Hz, 2H), 2.06 (s, 3H), 1.30 (t, J=7.6 Hz, 3H).
Table 4
Examples 129 and 130 in Table 4 were prepared from Example 125B and, respectively, l -methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole and potassium (3,5-dimethylisoxazol-4-yl)trifluoroborate, using procedures similar to those used for the preparation of Example 127.
a HPLC conditions: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles; 5- 95% MeCN-H20 with 0.1 % TFA over 3 min; wavelength = 220 nm.
Table 5
Examples 131-134 in Table 5 were prepared from Example 125B and the appropriate alkenyl binacol boronate or potassium trifluoroborate using procedures
similar to those used for the preparation of Example 127A and Example 128.
Temperatures ranging from 60 °C to 100 °C were employed for the cross-coupling reaction. Temperatures ranging from room temperature to 60 °C were employed for the hydrogenation reaction.
134 N-(4-{3-[6- 1.284 464
(Difluoromethyl)pyridin-
a HPLC conditions: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles; 5- 95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm.
Example 135
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(oxan-4-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide
and
Example 136
N-{4-[3-(6-Methylpyridin-2-yl)-7-(oxan-4-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide
135A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(3,6-dihydro-2H-pyran-4-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 125B (40 mg, 0.074 mmol), 2-(3,6-dihydro-2H-pyran-4- yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (23.17 mg, 0.110 mmol), and cesium carbonate (71.9 mg, 0.221 mmol) was evacuated and backfilled with N2, then 1,4-dioxane (662 μί) and H2O (73.5 μί) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (2.89 mg, 3.68 μιτιοΐ) was added. The mixture was sparged with N2 for 1 min, then it was sealed and stirred at 60 °C for 2 h. The reaction was cooled to room temperature, diluted with EtOAc (25 mL), washed with sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-100% EtOAc-CmCh) to provide Example 135A (40.2 mg, 92%) as a yellow foam. LC-MS m/z 592 [M+H]+.
Example 135) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(oxan-4-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide and Example 136 N-{4-[3-(6-methylpyridin-2-yl)- 7-(oxan-4-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
To a room temperature suspension of Example 135A (40.2 mg, 0.068 mmol) in EtOH (697 \iL) was added THF (348 μί), followed by 10% palladium on carbon (7.23 mg, 6.79 μπιοΐ) and ammonium formate (42.8 mg, 0.679 mmol). The reaction was stirred at room temperature for 15 h, then at 60 °C for 1 h, and then at 70 °C for 2 h. Additional ammonium formate (22 mg, 0.35 mmol) was added and the reaction was stirred at 70 °C for 4 h. The reaction was cooled to room temperature, filtered through Celite (washed with THF and MeOH), and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (227 μί) and TFA (453 μί). The reaction was stirred at room temperature for 13 h. Additional TFA (0.453 mL) was added and the reaction was stirred at room temperature for 27 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NFb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15- 55% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 135 (9.0 mg, 29% over two steps) and Example 136 (7.7 mg, 27% over two steps). Characterization data for Example 135: HPLC Rt = 1.079 min (Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 464; ¾ NMR (500 MHz, DMSO- de) δ 12.08 (s, 1H), 10.52 (s, 1H), 8.42 (d, J=4.9 Hz, 1H), 8.37 (br d, J=7.7 Hz, 1H), 8.32
- 8.28 (m, 2H), 8.03 (t, J=7.8 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.24 (d, J=5.2 Hz, 1H), 7.19 (d, J=4.8 Hz, 1H), 6.60 (t, J=55.2 Hz, 1H), 4.00 (br d, J=10.8 Hz, 2H), 3.64 - 3.46 (m, 3H), 2.07 (s, 3H), 1.85 - 1.77 (m, 4H). Characterization data for Example 136: HPLC Rt = 0.826 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 428
[M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.90 (br s, 1H), 10.43 (s, 1H), 8.35 (d, J=4.6 Hz, 1H), 8.26 (d, J=4.7 Hz, 1H), 8.20 (br s, 1H), 7.77 - 7.73 (m, 1H), 7.68 (t, J=7.7 Hz, 1H), 7.19 (br d, J=4.5 Hz, 1H), 7.14 (br d, J=4.5 Hz, 1H), 7.08 (br d, J=7.6 Hz, 1H), 4.02
- 3.78 (m, 2H), 3.63 - 3.45 (m, 3H), 2.25 (s, 3H), 2.06 (s, 3H), 1.84 - 1.73 (m, 4H).
Example 137
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(l-methylpiperidin-4-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
and
Example 138
N-{4-[7-(l-Me lpiperidin-4-yl)-3-(6-me lpyridin-2-yl)-lH-pyiTolo[3,2-b]pyridin-2- yl]pyridin-2-yl} acetamide
Example 137 and Example 138 were prepared from Example 125B and 1-methyl-
4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine using procedures similar to those used for the preparation of Example 135 and Example 136. Characterization data for Example 137: HPLC Rt = 0.831 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 477 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.03 (br s, IH), 10.52 (s, IH), 8.43 - 8.37 (m, 2H), 8.32 - 8.26 (m, 2H), 8.02 (t, J=7.9 Hz, IH), 7.50 (d, J=7.7 Hz, IH), 7.24 (d, J=5.0 Hz, IH), 7.16 (d, J=4.7 Hz, IH), 6.59 (t, J=55.3 Hz, IH), 3.30 - 3.20 (m, IH), 2.94 (br d, J=11.4 Hz, 2H), 2.25 (s, 3H), 2.14 (br t, J=11.0 Hz, 2H), 2.07 (s, 3H), 1.90 - 1.75 (m, 4H). Characterization data for Example 138: HPLC Rt = 0.614 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-um particles;
5- 95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 441 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.85 (br s, IH), 10.50 (s, IH), 8.37 (d, J=4.6 Hz, IH), 8.31 - 8.26 (m, 2H), 7.94 (br d, J=7.7 Hz, IH), 7.69 (t, J=7.7 Hz, IH), 7.21 (d, J=5.0 Hz, IH), 7.12 (d, J=4.8 Hz, IH), 7.06 (d, J=7.4 Hz, IH), 3.28 - 3.20 (m, IH), 2.94
(br d, J=10.6 Hz, 2H), 2.27 - 2.23 (m, 6H), 2.13 (br t, J=l l.l Hz, 2H), 2.08 (s, 3H), 1.88 - 1.74 (m, 4H).
Example 139
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(4-methylpiperazin-l-yl)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
A mixture of Example 125B (40 mg, 0.074 mmol), potassium trifluoro((4- methylpiperazin-l-yl)methyl)borate (24.27 mg, 0.110 mmol), and cesium carbonate (71.9 mg, 0.221 mmol) was evacuated and backfilled with N2, then THF (331 μί) and H2O (36.8 μί) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (2.89 mg, 3.68 μιτιοΐ) was added. The mixture was sparged with N2 for 1 min, then it was sealed and stirred at 80 °C for 1 h. The reaction was cooled to room temperature, diluted with EtOAc (25 mL), washed with sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (247 μΥ and TFA (493 μί). The reaction was stirred at room temperature for 42 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N
L/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-100% B over 20 minutes, then a 2-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example
139 (29.3 mg, 81%). HPLC Rt = 0.896 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μτη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 492 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.78 (br s, IH), 10.53 (s, IH), 8.43 (d, J=4.7 Hz, IH), 8.39 (br d, J=8.0 Hz, IH), 8.33 (br s, IH), 8.30 (d, J=5.1 Hz, IH), 8.04 (t, J=7.9 Hz, IH), 7.52 (d, J=7.8 Hz, IH), 7.26 - 7.20 (m, 2H), 6.62 (t, J=55.2 Hz, IH), 3.89 (s, 2H), 3.63 - 3.35 (m, 4H), 2.46 - 2.29 (m, 4H), 2.18 (s, 3H), 2.07 (s, 3H).
Table 6
Example 140 and Example 141 in Table 6 were prepared from Example 125B and, respectively, potassium trifluoro(morpholinomethyl)borate and potassium
((dimethylamino)methyl)trifluoroborate using procedures similar to those used for the preparation of Example 139.
a HPLC conditions: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles; 5- 95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm.
Example 142
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-
2-yl}pyridin-2-yl)acetamide
142A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-formyl-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a room temperature solution of Example 127A (187.8 mg, 0.351 mmol) in 1,4- dioxane (2805 μί) was added H2O (701 μί), 2,6-lutidine (82 μί, 0.701 mmol), osmium tetroxide (111 μί, 4 wt% solution in H2O, 0.018 mmol), and sodium periodate (300 mg, 1.402 mmol). The reaction was stirred at room temperature for 2 h, and then it was diluted with H2O (30 mL) and extracted with CH2CI2 (2 χ 30 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-100% EtOAc-CH2Cl2) to provide Example 142A (179 mg, 95%) as a yellow solid. LC-MS m/z 538 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.64 (s, 1H), 10.60 (s, 1H), 8.81 (d, J=4.6 Hz, 1H), 8.47 (dd, J=7.9, 0.9 Hz, 1H), 8.40 (dd, J=5.1, 0.7
Hz, 1H), 8.23 (s, 1H), 8.04 (t, J=7.8 Hz, 1H), 7.78 (d, J=4.8 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.16 (dd, J=5.1, 1.5 Hz, 1H), 6.46 (t, J=55.3 Hz, 1H), 5.68 (s, 2H), 3.25 - 3.19 (m, 2H), 2.08 (s, 3H), 0.69 - 0.60 (m, 2H), -0.17 (s, 9H).
Example 142) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 142A (19.3 mg, 0.036 mmol) in MeOH (359 μί) was added sodium borohydride (2.72 mg, 0.072 mmol). The reaction was stirred at room temperature for 30 min, and then it was quenched by the addition of H2O (20 mL) and extracted with CH2CI2 (2 χ 20 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (98 μί) and TFA (196 μί). The reaction was stirred at room temperature for 16 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NH3/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 142 (8.6 mg, 71%). HPLC Rt = 0.882 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 410 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.02 (br s, 1H), 10.48 (s, 1H), 8.45 (br d, J=4.6 Hz, 1H), 8.29 (br d, J=5.2 Hz, 1H), 8.27 - 8.24 (m, 2H), 8.02 (t,
J=7.9 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.34 (br d, J=4.4 Hz, 1H), 7.22 (br d, J=5.2 Hz, 1H), 6.63 (t, J=55.5 Hz, 1H), 5.73 (br s, 1H), 4.92 (s, 2H), 2.05 (s, 3H).
Example 143
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-
2-yl}pyridin-2-yl)acetamide
To a 0 °C solution of Example 142A (21.1 mg, 0.039 mmol) in THF (392 μί) was added methylmagnesium bromide (26.2 μί, 3 M solution in Et^O, 0.078 mmol). The reaction was stirred at 0 °C for 1 h, and then it was quenched by the addition of H2O (25 mL) and extracted with EtOAc (25 mL). The organic layer was washed with sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (130 μί) and TFA (260 μΥ . The reaction was stirred at room temperature for 3 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NH3/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-100% B over 20 minutes, then a 2-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 143 (8.3 mg, 50%). HPLC Rt = 1.007 min (Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 424 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.88 (s, 1H), 10.46 (s, 1H), 8.43 (d, J=4.7 Hz, 1H), 8.30 - 8.24 (m, 3H), 8.02 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.6
Hz, IH), 7.33 (d, J=4.7 Hz, IH), 7.22 (br d, J=4.9 Hz, IH), 6.60 (t, J=55.2 Hz, IH), 5.74 - 5.69 (m, IH), 5.39 - 5.33 (m, IH), 2.05 (s, 3H), 1.45 (br d, J=6.4 Hz, 3H).
Table 7
Example 144 and Example 145 in Table 7 were prepared from Example 142 A and, respectively, isopropylmagnesium bromide and methyl-c¾-magnesium iodide, using procedures similar to those used for the preparation of Example 143.
a HPLC conditions: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles; 5- 95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm.
Example 146
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(lR)-l-hydroxyethyl]-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
and
Example 147
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(lS)-l-hydroxyethyl]-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
To a 0 °C solution of Example 142A (82.4 mg, 0.153 mmol) in THF (1533 μΐ) was added methylmagnesium bromide (102 μί, 3 M solution in Et^O, 0.307 mmol). The reaction was stirred at 0 °C for 1 h, and then it was quenched by the addition of H2O (30 mL) and extracted with EtOAc (30 mL). The organic layer was washed with sat. aq. NaCl (30 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in mixture of CH2CI2 (510 μΥ and TFA (1020 μί). The reaction was stirred at room temperature for 5 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NFb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, and concentrated in vacuo. The crude material was purified via preparative SFC with the following conditions: Column: Chiral AD-H 25 x 3 cm ID, 5-μπι particles; Mobile Phase 75:25 CC /MeOH; Flow: 85 mL/min. Fractions containing peak 1 were combined and concentrated in vacuo to provide Example 146 (23.9 mg, 37%). Fractions containing peak 2 were combined and concentrated in vacuo to provide Example 147 (24.0 mg, 35%). The stereochemistry of these two enantiomers was arbitrarily assigned. Characterization data for Example 146: HPLC Rt = 5.43 min (Sunfire C18, 3.0 x 150 mm, 3.5-μπι particles; 5- 95% MeCN-H20 with 0.05% TFA over 12 min; wavelength = 220 nm); LC-MS m/z 424 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.85 (br s, 1H), 10.51 (s, 1H), 8.45 (d, J=4.8 Hz, 1H), 8.43 (d, J=7.9 Hz, 1H), 8.34 (s, 1H), 8.30 (d, J=5.1 Hz, 1H), 8.04 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.7 Hz, 1H), 7.33 (d, J=4.6 Hz, 1H), 7.24 (dd, J=5.2, 1.5 Hz, 1H), 6.61 (t, J=55.0 Hz, 1H), 5.54 - 5.48 (m, 1H), 5.43 - 5.34 (m, 1H), 2.08 (s, 3H), 1.47 (d, J=6.5 Hz, 3H). Characterization data for Example 147: HPLC Rt = 5.42 min (Sunfire C18, 3.0 x 150 mm, 3.5-μιη particles; 5-95% MeCN-H20 with 0.05% TFA over 12 min;
wavelength = 220 nm); LC-MS m/z 424 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 1 1.85 (s, IH), 10.51 (s, IH), 8.46 (d, J=4.8 Hz, IH), 8.43 (d, J=7.2 Hz, IH), 8.34 (s, IH), 8.30 (d, J=5.1 Hz, IH), 8.04 (t, J=7.8 Hz, IH), 7.51 (d, J=7.6 Hz, IH), 7.34 (d, J=4.8 Hz, IH), 7.24 (dd, J=5.1, 1.6 Hz, IH), 6.61 (t, J=55.3 Hz, IH), 5.51 (br d, J=4.2 Hz, IH), 5.42 - 5.35 (m, IH), 2.08 (s, 3H), 1.47 (d, J=6.5 Hz, 3H).
Example 148
N-{4-[7-(2,2-Difluoro-l-hydroxyethyl)-3-[6-(difluoromethyl)pyridin-2-yl]-lH- py rrolo [3,2-b] pyridin-2-y 1] py ridin-2-y 1 } acetamide
148A) N-(4-(7-(2,2-Difluoro-l-hydroxyethyl)-3-(6-(difluoromethyl)pyridin-2-yl)-l -((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a room temperature solution of Example 142A (19.9 mg, 0.037 mmol) in DMF (370 μί) was added (difluoromethyl)trimethylsilane (9.19 mg, 0.074 mmol), followed by cesium fluoride (0.787 mg, 5.18 μηιοΐ). The reaction was stirred at room temperature for
21 h, and then tetrabutylammonium fluoride (185 μί, 1 M solution in THF, 0.185 mmol) was added and the reaction was stirred at room temperature for 1 h. The reaction was diluted with EtOAc (25 mL), washed with H2O (25 mL) and sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0- 100% EtOAc-CH2Cl2) to provide Example 148A (9.5 mg, 44%) as a white film. LC-MS m/z 590 [M+H]+.
Example 148) N-{4-[7-(2,2-Difluoro-l-hydroxyethyl)-3-[6-(difluoromethyl)pyridin-2-yl]- lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide
To a room temperature solution of Example 148A (9.5 mg, 0.016 mmol) in
CH2CI2 (53.7 μί) was added TFA (107 μί). The reaction was stirred at room temperature for 18 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NFb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, and then it was concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 0-100% B over 15 minutes, then a 3-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 148 (7.1 mg, 95%). HPLC Rt = 1.042 min (Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 460 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.06 (s, 1H), 10.46 (s,
1H), 8.49 (d, J=4.6 Hz, 1H), 8.29 (br d, J=5.1 Hz, 1H), 8.27 - 8.23 (m, 2H), 8.03 (t, J=7.8 Hz, 1H), 7.53 (d, J=7.7 Hz, 1H), 7.39 (d, J=4.6 Hz, 1H), 7.22 (br d, J=4.5 Hz, 1H), 6.76 (br d, J=5.0 Hz, 1H), 6.73 - 6.47 (m, 1H), 6.32 - 6.05 (m, 1H), 5.60 - 5.49 (m, 1H), 2.05 (s, 3H).
Example 149
N-{4-[7-(Difluoromethyl)-3-[6-(difluoromethyl)pyridin-2-yl]-lH-pyrrolo[3,2-b]pyridin-
2-yl]pyridin-2-yl} acetamide
To a 0 °C solution of Example 142A (20.9 mg, 0.039 mmol) in CH2CI2 (389 μΐ) was added diethylaminosulfur trifluoride (7.70 μί, 0.058 mmol). The reaction was stirred at 0 °C for 1 h, then at room temperature for 2 h. The reaction was diluted with sat. aq. NaHCC (25 mL) and extracted with CH2CI2 (25 mL). The organic layer was dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (130 μΥ and TFA (260 μί). The reaction was stirred at room temperature for 16 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N
NH3/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 149 (10.3 mg, 62%). HPLC Rt = 1.086 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm);
LC-MS m/z 430 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.50 (br s, 1H), 10.56 (s, 1H), 8.63 (br d, J=3.9 Hz, 1H), 8.34 - 8.26 (m, 3H), 8.06 (br t, J=7.6 Hz, 1H), 7.66 - 7.40 (m, 3H), 7.27 - 7.20 (m, 1H), 6.65 (t, J=55.1 Hz, 1H), 2.07 (s, 3H).
Example 150
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(fluoromethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide
150A) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(hydroxymethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a room temperature solution of Example 142 A (20 mg, 0.037 mmol) in MeOH (372 μΐ) was added sodium borohydride (2.81 mg, 0.074 mmol). The reaction was stirred at room temperature for 15 min, and then it was quenched by the addition of H2O (20 mL) and extracted with CH2CI2 (2 χ 20 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. The aqueous layer was diluted with sat. aq. NH4CI (20 mL) and extracted with CH2CI2 (2 χ 20 mL). The combined organic layers
were dried over Na2S04, filtered, and concentrated in vacuo. Each of the crude isolates was purified by flash chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0-10% MeOH-CFhCh). The product-containing fractions from each column were combined to provide Example 150A (18 mg, 90%) as a white foam. LC-MS m/z 540 [M+H]+
Example 150) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(fluoromethyl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a -78 °C solution of Example 150A (18 mg, 0.033 mmol) in CH2CI2 (334 μί) was added diethylaminosulfur trifluoride (6.61 μί, 0.050 mmol). The reaction was stirred at -78 °C for 10 min, then the reaction was stirred at room temperature for 35 min. The reaction was diluted with sat. aq. NaHCC (25 mL) and extracted with CH2CI2 (25 mL). The organic layer was dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (110 μί) and TFA (220 μΥ . The reaction was stirred at room temperature for 16 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NFb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate;
Gradient: 15-55% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 150 (3.4 mg, 25%). HPLC Rt = 1.007 min (Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1%
TFA over 3 min; wavelength = 220 nm); LC-MS m/z 412 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.28 (br s, IH), 10.52 (s, IH), 8.52 (d, J=4.5 Hz, IH), 8.35 (br d, J=7.8 Hz, IH), 8.33 - 8.29 (m, 2H), 8.05 (t, J=7.8 Hz, IH), 7.54 (d, J=7.7 Hz, IH), 7.34 (br d, J=4.5 Hz, IH), 7.24 (br d, J=5.0 Hz, IH), 6.63 (t, J=55.2 Hz, IH), 5.87 (d, J=46.9 Hz, 2H), 2.07 (s, 3H)
Example 151
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(methylamino)methyl]-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 142A (22.1 mg, 0.041 mmol) in DCE (411 μί) was added methylamine (123 μί, 2.0 M solution in THF, 0.247 mmol), followed by sodium triacetoxyborohydride (13.94 mg, 0.066 mmol). The reaction was stirred at room temperature for 17 h. Additional sodium triacetoxyborohydride (30 mg, 0.14 mmol) was added and the reaction was stirred at room temperature for 3 days. The reaction was diluted with sat. aq. NaHCC (25 mL) and extracted with CH2CI2 (25 mL). The organic layer was dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (137 μί) and TFA (273 μί). The reaction was stirred at room temperature for 2 days, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N Nft/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate;
Gradient: 5-45% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.
Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-35% B over 25 minutes, then a 2- minute hold at 35% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 151 (2.3 mg, 13%). HPLC Rt = 0.764 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 423 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.50 (s, 1H), 8.43 (d, J=4.8 Hz, 1H), 8.36 (d, J=8.1 Hz, 1H), 8.30 (d, J=4.9 Hz, 2H), 8.04 (t, J=7.9 Hz, 1H), 7.52 (d, J=7.8 Hz, 1H), 7.28 (d, J=4.7 Hz, 1H), 7.24 (d, J=5.0 Hz, 1H), 6.75 - 6.47 (m, 1H), 4.09 (s, 2H), 2.35 (s, 3H), 2.06 (s, 3H).
Example 152
N-(4-{7-[(3,3-Difluoroazetidin-l-yl)methyl]-3-[6-(difluoromethyl)pyridin-2-yl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 142A (23.0 mg, 0.043 mmol) in DCE (428 μί) was added 3,3-difluoroazetidine hydrochloride (8.31 mg, 0.064 mmol) and triethylamine (13.42 μί, 0.096 mmol), followed by sodium triacetoxyborohydride (14.51 mg, 0.068 mmol). The reaction was stirred at room temperature for 16 h, and then it was diluted with sat. aq. NaHCC (25 mL) and extracted with CH2CI2 (25 mL). The organic layer was dried over Na2S04, filtered, and concentrated in vacuo. This material was
taken up in a mixture of CH2CI2 (143 μί) and TFA (287 μί). The reaction was stirred at room temperature for 4 days, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N Nfb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20- 60% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 152 (8.7 mg, 42%). HPLC Rt = 1.113 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 485 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.03 (br s, 1H), 10.50 (s, 1H), 8.42 (d, J=4.7 Hz, 1H), 8.33 (br d, J=8.1 Hz, 1H), 8.31 - 8.27 (m, 2H), 8.03 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.6 Hz, 1H), 7.27 - 7.22 (m, 2H), 6.61 (t, J=55.2 Hz, 1H), 4.13 (s, 2H), 3.76 - 3.68 (m, 4H), 2.06 (s, 3H).
Example 153
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(3-hydroxyazetidin-l-yl)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 142A (19.4 mg, 0.036 mmol) in DCE (361 μί) was added azetidin-3-ol hydrochloride (5.93 mg, 0.054 mmol), followed by triethylamine (11.32 μί, 0.081 mmol) and sodium triacetoxyborohydride (12.24 mg, 0.058 mmol). The reaction was stirred at room temperature for 16 h, and then it was
diluted with sat. aq. NaHCC (25 mL) and extracted with CH2CI2 (25 mL). The organic layer was dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (120 μί) and TFA (240 μί). The reaction was stirred at room temperature for 2 days, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N Nfb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: waters xbridge shield rpl 8, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10- 35% B over 25 minutes, then a 2-minute hold at 35% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions:
Column: XBridge C18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10- mM ammonium acetate; Gradient: 0-45% B over 20 minutes, then a 3 -minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 153 (0.7 mg, 4%). HPLC Rt = 0.944 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN- H2O with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 465 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.95 (br s, IH), 10.54 (s, IH), 8.44 - 8.39 (m, 2H), 8.34 - 8.29 (m, 2H), 8.04 (t, J=7.9 Hz, IH), 7.52 (d, J=7.3 Hz, IH), 7.24 (d, J=5.2 Hz, IH), 7.20 (d, J=4.6 Hz, IH), 6.62 (t, J=55.4 Hz, IH), 5.40 (br s, IH), 4.30 - 4.22 (m, IH), 4.05 - 3.97 (m, 2H), 3.68 - 3.57 (m, 2H), 2.97 - 2.86 (m, 2H), 2.08 (s, 3H).
Example 154
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide
154A) N-(4-(7-Acetyl-3-(6-(difluoromethyl)pyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a 0 °C solution of Example 142A (50.3 mg, 0.094 mmol) in THF (936 μΐ) was added methylmagnesium bromide (62.4 μΐ, 3 M solution in Et20, 0.187 mmol), dropwise. The reaction was stirred at 0 °C for 30 min, then it was quenched by the addition of H2O (30 mL) and extracted with EtOAc (30 mL). The organic layer was washed with sat. aq. NaCl (30 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up CH2CI2 (889 μί), and Dess-Martin periodinane (45.2 mg, 0.107 mmol) was added. The reaction was stirred at room temperature for 30 min, and then it was diluted with CH2CI2 (25 mL), washed with sat. aq. NaHCC (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash
chromatography (12 g silica gel with 5 g prepacked load cartridge; linear gradient 0- 100% EtOAc-CH2Cl2) to provide Example 154A (44.5 mg, 91%) as a white foam. LC- MS m/z 552 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.61 (s, IH), 8.71 (d, J=4.9 Hz, IH), 8.49 (d, J=7.9 Hz, IH), 8.38 (d, J=5.0 Hz, IH), 8.17 (s, IH), 8.03 (t, J=7.9 Hz, IH), 7.70 (d, J=4.8 Hz, IH), 7.48 (d, J=7.6 Hz, IH), 7.15 (dd, J=5.1, 1.4 Hz, IH), 6.45 (t,
J=55.1 Hz, 1H), 5.28 (s, 2H), 3.05 - 2.96 (m, 2H), 2.72 (s, 3H), 2.07 (s, 3H), 0.60 - 0.53 (m, 2H), -0.17 (s, 9H).
Example 154) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
To a 0 °C solution of Example 154A (27.2 mg, 0.049 mmol) in THF (493 μί) was added methylmagnesium bromide (32.9 μί, 3 M solution in Et^O, 0.099 mmol), dropwise. The reaction was stirred at 0 °C for 1.25 h, and then additional
methylmagnesium bromide (17 μί, 0.051 mmol) was added and the reaction was stirred at 0 °C for 15 min. Additional methylmagnesium bromide (17 μΐ^, 0.051 mmol) was added and the reaction was stirred at 0 °C for 15 min. The reaction was quenched by the addition of H2O (30 mL) and extracted with EtOAc (30 mL). The organic layer was washed with sat. aq. NaCl (30 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (163 μί) and TFA (327 μΥ . The reaction was stirred at room temperature for 15 h, and then it was concentrated in vacuo. The residue was taken up in 10% 7 N NEb/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge Phenyl, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20-45% B over 25 minutes, then a 2-minute hold at 45% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 154 (7.9 mg, 37%). HPLC Rt = 1.021 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20
with 0.1 % TFA over 3 min; wavelength = 220 nm); LC-MS m/z 438 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 1 1.07 (s, 1H), 10.48 (s, 1H), 8.40 (d, J=4.8 Hz, 1H), 8.30 (d, J=7.9 Hz, 1H), 8.28 - 8.25 (m, 2H), 8.02 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.7 Hz, 1H), 7.23 - 7.18 (m, 2H), 6.61 (t, J=55.3 Hz, 1H), 5.83 (s, 1H), 2.06 (s, 3H), 1.64 (s, 6H).
Example 155
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-
2-yl}pyridin-2-yl)acetamide
155A) (E)-N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(2-ethoxyvinyl)-l -((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 125B (90.0 mg, 0.165 mmol) and cesium carbonate (216 mg, 0.662 mmol) was evacuated and backfilled with N2, then 1,4-dioxane (1489 μί) and H2O (165 μί) were added. The mixture was sparged with N2 for 5 min, then 2nd generation XPhos precatalyst (6.51 mg, 8.27 μιτιοΐ) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-
tetramethyl-l,3,2-dioxaborolane (98 mg, 0.496 mmol) were added. The mixture was sparged with N2 for 1 min, then it was sealed and stirred at 80 °C for 1 h. The reaction was cooled to room temperature, diluted with EtOAc (30 mL), washed with sat. aq. NaCl (30 mL), dried over Na2S04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (24 g silica gel with 5 g prepacked load cartridge; linear gradient 0-100% EtOAc-CH2Cl2) to provide Example 155 A (67.2 mg, 70%) as a light yellow solid. LC-MS m/z 580 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.58 (s, IH), 8.52 (d, J=8.1 Hz, IH), 8.40 (d, J=4.9 Hz, IH), 8.35 (d, J=5.1 Hz, IH), 8.23 (s, IH), 8.00 (t, J=7.9 Hz, IH), 7.44 (d, J=7.7 Hz, IH), 7.40 (d, J=12.7 Hz, IH), 7.30 (d, J=5.0 Hz, IH), 7.11 (dd, J=5.1, 1.5 Hz, IH), 6.57 - 6.26 (m, 2H), 5.40 (s, 2H), 4.02 (q, J=7.0 Hz, 2H), 3.37 - 3.32 (m, 2H), 2.07 (s, 3H), 1.31 (t, J=7.0 Hz, 3H), 0.85 - 0.75 (m, 2H), -0.09 (s, 9H).
Example 155) N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxyethyl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide
A room temperature suspension of Example 155 A (66 mg, 0.114 mmol) in a mixture of CH2CI2 (379 μΥ and TFA (759 μί) was stirred for 6 h, and then H2O (5 drops) was added and the reaction was stirred for 16 h. The reaction was concentrated in vacuo. The residue was taken up in CH2CI2 (20 mL) and washed with sat. aq. NaHCCb (20 mL). The aqueous layer was extracted with CH2CI2 (2 χ 20 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in MeOH (1140 μί) and sodium borohydride (8.63 mg, 0.228 mmol) was added. The reaction was stirred at room temperature for 15 min, and then it was diluted
with sat. aq. NH4CI (25 mL) and extracted with CH2CI2 (2 χ 25 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. The crude material was dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 x 200 mm, 5-μιτι particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-45% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 155 (4.9 mg, 10%). HPLC Rt = 0.929 min (Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1 % TFA over 3 min; wavelength = 220 nm); LC-MS m/z 424 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.04 (br s, 1H), 10.52 (s, 1H), 8.39 - 8.33 (m, 2H), 8.32 - 8.28 (m, 2H), 8.03 (t, J=7.7 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.24 (br d, J=5.0 Hz, 1H), 7.16 (br d, J=4.7 Hz, 1H), 6.63 (t, J=55.5 Hz, 1H), 4.86 (br s, 1H), 3.83 - 3.77 (m, 2H), 3.15 (br t, J=6.6 Hz, 2H), 2.07 (s, 3H).
Example 156
N-(4- {3-[6-(Difluoromethyl)pyridin-2-yl]-7-(pyrrolidin-l -yl)-lH-pyrrolo[3,2-b]pyridin-
2-yl}pyridin-2-yl)acetamide
To a room temperature solution of Example 125B (20 mg, 0.037 mmol) in DMF (184 μί) was added pyrrolidine (61.4 μΐ., 0.735 mmol). The reaction was sealed and stirred at 1 10 °C for 6 h, and then it was cooled to room temperature, diluted with EtOAc (25 mL), washed with H2O (25 mL) and sat. aq. NaCl (25 mL), dried over Na2S04, filtered, and concentrated in vacuo. This material was taken up in a mixture of CH2CI2 (123 μΥ and TFA (247 μΥ . The reaction was stirred at room temperature for 22 h, and
then it was concentrated in vacuo. The residue was taken up in 10% 7 N L/MeOH in CH2CI2 (2 mL), stirred at room temperature for 5 min, concentrated in vacuo, dissolved in DMSO, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge Shield RP18, 19 x 200 mm, 5-μιη particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 20 minutes, then a 4- minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Example 156 (3.6 mg, 21%). HPLC Rt = 1.252 min (Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles; 5-95% MeCN-H20 with 0.1% TFA over 3 min; wavelength = 220 nm); LC-MS m/z 449 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 12.00 (br s, 1H), 10.50 (br s, 1H), 8.35 - 8.26 (m, 2H), 7.91 - 7.83 (m, 1H), 7.81 - 7.75 (m, 1H), 7.47 - 7.32 (m, 2H), 7.26 (br d, J=4.7 Hz, 1H), 7.24 - 6.97 (m, 1H), 6.32 (br d, J=6.2 Hz, 1H), 3.49 - 3.30 (m, 4H), 2.07 (s, 3H), 2.02 - 1.98 (m, 4H).
Example 157
N-(4-(6-Acetamido-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
157A) N-(4-(6-Bromo-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 83 (765 mg, 1.745 mmol), cesium carbonate (1137 mg, 3.49 mmol) and (2-(chloromethoxy)ethyl)trimethylsilane (437 mg, 2.62 mmol) in THF (12 mL) and DMF (12 mL) was stirred at room temperature for 30 min. To the reaction mixture were added CH2CI2 and water, CH2CI2 layer was separated, dried over MgS04, concentrated in vacuo and the residue was purified by flash column on S1O2 (gradient of 100% CH2CI2 to 80% EtOAc in CH2CI2, product was eluted at 30-40% EtOAc in CH2CI2) to obtain 6 (625 mg, 1.099 mmol, 63 %) as a glassy material. MS (ES): m/z = 568, 570 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.65 (d, J=2.0 Hz, IH), 8.33 (s, IH), 8.28 - 8.24 (m, 2H), 8.05 (d, J=2.0 Hz, IH), 7.80 (d, J=8.6 Hz, IH), 7.30 (dd, J=8.7, 3.0 Hz, IH), 7.14 (dd, J=5.2, 1.4 Hz, IH), 5.43 (s, 2H), 3.85 (s, 3H), 3.42 - 3.36 (m, 2H), 2.19 (s, 3H), 0.85 - 0.80 (m, 2H), -0.08 (s, 9H).
Example 157) N-(4-(6-Acetamido-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin- 2-yl)pyridin-2-yl)acetamide
To a solution of N-(4-(6-bromo-3-(5-methoxypyridin-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (40
mg, 0.070 mmol) in dioxane (2 ml) was added acetamide (41.6 mg, 0.704 mmol), xantphos (8.14 mg, 0.014 mmol), cesium carbonate (45.8 mg, 0.141 mmol) and Pd2(dba)3 (12.89 mg, 0.014 mmol). The suspension was purged with nitrogen for 5 minutes and the heated to 110 °C for 1 hr. The reaction mixture was concentrated to dryness and resuspended in lmL EtOAc and filtered through on a small silica gel plug, eluted with Hex:EtOAc (1 : 1) then with EtOAc. The EtOAc fractions were concentrated to give crude product which was treated with 4N HCl in Dioxane 1.5 (mL) for 30 minutes at 60°C. The reaction mixture is concentrated, diluted with DMF and purified by preparative HPLC to give N-(4-(6-acetamido-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide. HPLC: RT = 0.85 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 417 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.50 (s, 1H), 10.27 (s, 1H), 8.42-8.45 (m, 1H), 8.43 (s, 1H), 8.40 (s, 1H), 8.27 (br. s., 1H), 8.24 (d, J=5.05 Hz, 1H), 8.18 (d, J=1.60 Hz, 1H), 7.93 (d, J=8.58 Hz, 1H), 7.48 (dd, J=2.19, 8.50 Hz, 1H), 7.10 (d, J=4.88 Hz, 1H), 3.85 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H)
Example 158
N-(4-(6-(4-Methoxypiperidin-l-yl)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-
2-yl)pyridin-2-yl)acetamide
To a solution of Example 157A (30 mg, 0.053 mmol) in DMSO (2 mL) was added (S)-pyrrolidine-2-carboxylic acid (6.68 mg, 0.058 mmol), K2CO3 (14.59 mg, 0.106 mmol), 4-methoxypiperidine (42.5 mg, 0.369 mmol) and copper (I) iodide (5.33 mg, 0.028 mmol). The reaction mixture was purged with nitrogen for 2 min. and stirred at 100°C for 3h. The reaction mixture was concentrated to dryness over a stream of nitrogen and treated with 4N HCl in dioxane (3mL) at 60°C for 30 minutes. The reaction mixture
was concentrated and redissolved in DMF and purified by preparative HPLC to give N- (4-(6-(4-methoxypiperidin-l-yl)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide. HPLC: RT = 0.92 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 473 [M+H]+; ¾ NMR (500 MHz, DMSO-de) d 12.66 (br. s., 1H), 10.71 (br. s., 1H), 8.42 (s, 1H), 8.40 (d, J=5.55 Hz, 1H), 8.34 (br. s., 1H), 8.30 (br. s., 1H), 7.81 (br. s., 1H), 7.43-7.59 (m, 2H), 7.10-7.31 (m, H), 3.89 (s, 3H), 3.51-3.67 (m, J=5.39 Hz, 2H), 3.42 (br. s., 1H), 3.11 (t, J=9.47 Hz, 2H), 3.10 (s, 3H) 2.10 (s, 3H), 2.00 (br. s., 2H), 1.55-1.72 (m, 2H)
Table 8
Examples in Table 8 were prepared in the same general way as Example 158 and the corresponding amine by the general methods shown.
0.1% tnfluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 167
N-(4-(3-(5-Methoxypyridin-2-yl)-6-(pyrrolidin-l -yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
167 A) tert-Butyl 2-(2-acetamidopyridin-4-yl)-3-(5-methoxypyridin-2-yl)-6-(pyrrolidin-l- yl)-lH-pyrrolo[3,2-b]pyridine-l-carboxylate
To a suspension of Example 83 (100 mg, 0.228 mmol) and DMAP (5.57 mg, 0.046 mmol) in THF (3 mL) was added di-tert-butyl dicarbonate (100 mg, 0.456 mmol). The reaction mixture was stirred at room temperature for overnight. The reaction mixture was diluted water (10 ml) and extract with EtOAc (3x10 ml). The organics were combined, dry over sodium sulfate, filtered and concentrated to give tert-butyl 2-(2- acetanddopyridin-4-yl)-3-(5-methoxypyridin-2-yl)-6-(pyrrolidin-l-yl)-lH-pyrrolo[3,2- b] pyridine- 1-carboxy late as clear yellow oil which was used as is in the next reaction. HPLC: RT = 3.11 min (MeOH/H20 with 0.1% TFA, column: Sun-Fire 5u 4.6 x 30 mm, 1.7-μιη particles, gradient = 4 min, wavelength = 220 nm); MS (ES): m/z = 529 [M+H]+.
Example 167) N-(4-(3-(5-Methoxypyridin-2-yl)-6-(pyrrolidin-l-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution tert-butyl 2-(2-acetamidopyridin-4-yl)-6-bromo-3-(5- methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridine-l-carboxylate (20 mg, 0.037 mmol) in DMSO (2 mL) was added (S)-pyrrolidine-2-carboxylic acid (4.70 mg, 0.041 mmol), K2CO3 (10.27 mg, 0.074 mmol), pyrrolidine (13.21 mg, 0.186 mmol) and copper (I) iodide (3.75 mg, 0.020 mmol). The reaction mixture was purged with nitrogen for 2 min. and stirred at 90°C for over the weekend. The Boc group fell off during the reaction to give the desired product. The reaction mixture was filtered and purified by preparative HPLC to give N-(4-(3-(5-methoxypyridin-2-yl)-6-(pyrrolidin-l-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide. HPLC: RT = 1.01 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 429 [M+H]+.
Table 9
Examples in table 9 were prepared the same way as Example 46 (from Example 41B and heteroaryl bromide by the general methods shown for Example 1)
0.1% tnfluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 172
N-(4-(6-Chloro-3-(4-(difluoromethyl)thiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
172A) 2-Bromo-4-(difluoromethy l)thiazole
To a solution of 2-bromothiazole-4-carbaldehyde (0.3 g, 1.562 mmol) in DCM (10 mL) under a nitrogen atmosphere was added DAST (0.826 mL, 6.25 mmol) dropwise. The reaction mixture was stirred overnight at room temperature and then diluted with EtOAc (lOmL) and quenched with MeOH added dropwise (ImL) until bubbling stopped. The reation mixture was washed with aq. K3PO4. The organic phase was washed with brine, dried over magnesium sulphate, filtered and concentrated under reduced pressure to afford light yellow oil which was and purified by silica gel flash chromatography, eluting with 0-50% ethyl acetate in hexane to afford 2-bromo-4-(difluoromethyl)thiazole (0.2 g, 0.934 mmol, 59.8 % yield) as a yellow oil. ¾ NMR (400 MHz, METHANOLS) δ ppm 7.92 (t, J=1.5 Hz, 1H), 6.75 (t, J=54.6 Hz, 1H) which does not show [M+H]+ under
LCMS.
Example 172) N-(4-(6-Chloro-3-(4-(difluoromethyl)thiazol-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 41B (54 mg, 0.141 mmol), 2-bromo-4- (difluoromethyl)thiazole (60.4 mg, 0.282 mmol) and CS2CO3 (69.0 mg, 0.212 mmol) in Acetonitrile (2 mL) was purged with nitrogen for a few minutes. Xphos (6.73 mg, 0.014 mmol) and Pd2(dba)3 (3.88 mg, 4.23 μηιοΐ) were added and the mixture was heated at 120°C in a sealed vial for lh. The reaction mixture was cooled, filtered and purified by preparative HPLC to give N-(4-(6-chloro-3-(4-(difluoromethyl)thiazol-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide. HPLC: RT = 1.42 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 420 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.63 (s, IH), 8.57 (d, .7=1.94 Hz, IH), 8.53 (s, IH), 8.40 (d, J=5.13 Hz, IH), 8.10 (s, IH), 8.04 (d, J=1.85 Hz, IH), 7.49 (d, .7=5.13 Hz, IH), 6.99 (t, J=54.95 Hz, IH), 6.57 (s, IH), 2.10 (s, 3H).
Example 173
N-(4-(3-(6-Methoxypyridin-3-yl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
N-(4-((3-Amino-5-methylpyridin-2-yl)ethynyl)pyridin-2-yl)acetamide was prepared from Example IB and 2-bromo-5-methylpyridin-3-amine by the methods shown for Example 1C. HPLC: RT = 0.49 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 267 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 10.58 (s, 1H), 8.33 (dd, J=0.77, 5.17 Hz, 1H), 8.21 (s, 1H), 7.64-7.71 (m, 1H), 7.32 (dd, J=1.54, 5.06 Hz, 1H), 6.93 (dd, J=0.88, 1.76 Hz, 1H), 5.72 (s, 2H), 2.20 (s, 3H), 2.11 (s, 3H)
173B) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-methylpyridin-3-yl)-2,2,2- trifluoroacetamide
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-methylpyridin-3-yl)-2,2,2- trifluoroacetamide was prepared by methods shown for Example ID. HPLC: RT = 0.72 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 363 [M+H]+;
Example 173) N-(4-(3-(6-Methoxypyridin-3-yl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
N-(4-(3-(6-Methoxypyridin-3-yl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide was prepared from N-(2-((2-acetamidopyridin-4-yl)ethynyl)-5- methylpyridin-3-yl)-2,2,2-trifluoroacetamide and 5 -iodo-2-methoxy pyridine by the methods shown for Example 172. HPLC: RT = 0.80 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.85 (s, IH), 10.50 (s, IH), 8.28 (d, J=5.19 Hz, IH), 8.24 (s, 2H), 8.19 (d, J=1.83 Hz, IH), 7.75 (dd, J=2.29, 8.39 Hz, IH), 7.65 (s, IH), 7.09 (d, J=5.19 Hz, IH), 6.84 (d, J=8.24 Hz, IH), 3.85 (s, 3H), 2.42 (s, 3H), 2.06 (s, 3H)
Example 174
N-(4-(3-(6-(Difluoromethoxy)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
N-(4-(3-(6-(Difluoromethoxy)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide was prepared from Example ID and 2-bromo-6- (difluoromethoxy)pyridine by the methods shown for Example 172. HPLC: RT = 0.93 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 396; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.26 (s, IH), 10.63 (s, IH), 8.52 (d, J=4.12 Hz, IH), 8.35-8.45
(m, 2H), 8.25 (s, IH), 7.99 (t, J=7.87 Hz, IH), 7.91 (d, J=7.91 Hz, IH), 7.31 (dd, J=4.59, 8.20 Hz, IH), 7.26 (d, J=4.38 Hz, IH), 6.87 (d, J=7.99 Hz, IH), 6.65 (t, J=73.55 Hz, IH), 2.09 (s, 3H)
Table 10
Examples in Table 10 below were prepared from Example 41B or Example 38B or Example ID or from Example 173B and the heteroaryl bromides following the general methods shown for Example 172
LC/MS
Ex. # Structure Name ret. time
(M+H)+ (min)
N-(4-(3-(5-Methoxypyridin-2-
184 yl)-6-methyl-lH-pyrrolo[3,2-
0.67 374 b]pyridin-2-yl)pyridin-2-
HN H yl)acetamide
N-(4-(3-(5-
185 (Difluoromethyl)thiazol-2-yl)-6- methyl-lH-pyrrolo[3,2- 0.92 400 b]pyridin-2-yl)pyridin-2-
HN H yl)acetamide
N-(4-(6-Methyl-3-(2-
186 methylthiazol-4-yl)- 1H-
0.84 364 pyrrolo[3,2-b]pyridin-2-
H ΝNρ¾H yl)pyridin-2-yl)acetamide
187 N-(4-(3-(l-Methyl-lH-pyrazol- 4-y 1)- 1 H-pyrrolo [3 ,2-b] py ridin- 0.51 333 2-yl)pyridin-2-yl)acetamide
188 N-(4-(3-(5-Cyanothiophen-2- yl)-lH-pyrrolo[3,2-b]pyridin-2- 0.76 360 yl)pyridin-2-yl)acetamide
0.1% tnfluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 206
N-(4 3-(5-Chlorothiazol-2-yl)-6-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
A mixture of Example 38B (42 mg, 0.109 mmol), 2-bromo-5-chlorothiazole (43.3 mg, 0.218 mmol) and CS2CO3 (53.4 mg, 0.164 mmol) in acetonitrile (2 mL) was purged with nitrogen for a few minutes. Xphos-Pd-G2 (4.30 mg, 5.46 μηιοΐ) was added and the reaction mixture was heated at 120 °C in a sealed vial for lh. The reaction mixture was cooled, filtered and purified by preparative HPLC to give N-(4-(3-(5-chlorothiazol-2-yl)- 6-fluoro-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide. HPLC: RT = 1.34 min
(H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 388 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.64 (s, 1H), 8.57 (s, 1H), 8.45 (s, 1H), 8.41 (d, J=4.88 Hz, 1H), 7.84 (d, J=9.26 Hz, 1H), 7.71 (s, 1H), 7.48 (d, J=4.96 Hz, 1H), 2.11 (s, 3H).
Table 11
Examples in Table 1 1 below were prepared from Example 38B or Example 48B and heteroaryl bromide using the general methods shown for Example 206.
LC/MS
# Structure Name ret. time
(M+H)+ (min)
211 N-(4-(3-(2-Methylthiazol-4-yl)- 1 H-pyrrolo [3 ,2-b] py ridin-2- 0.76 350 yl)pyridin-2-yl)acetamide
HN H
HPLC/LCMS Column conditions: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μτη particles; Mobile Phase A: 5:95acetonitrile:water with 0.1% tnfluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% tnfluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 212
N-(4-(7-Me l-3-(4-(trifluoromethyl)thiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
212A) N-(4-((4-Methyl-3-nitropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
N-(4-((4-Methyl-3-nitropyridin-2-yl)ethynyl)pyridin-2-yl)acetamide was prepared from Example IB and 2-bromo-4-methyl-3-nitropyridine by the methods shown for
Example 1C. HPLC: RT =0.65 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z =
297 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.72 (s, 1H), 8.73 (d, J=5.06 Hz, 1H), 8.41 (dd, J=0.66, 5.06 Hz, 1H), 8.20 (s, 1H), 7.68 (dd, J=0.66, 5.06 Hz, 1H), 7.22 (dd, J=1.54, 5.06 Hz, 1H), 2.41 (s, 3H), 2.12 (s, 3H).
212B) N-(4-((3-Aniino-4-methylpyridin-2-yl)ethynyl)pyridin-2-yl)acetaniide
To a solution of N-(4-((4-methyl-3-nitropyridin-2-yl)ethynyl)pyridin-2- yl)acetamide (2 g, 6.75 mmol) in (10: 1) EtOH:H20 (1 10 ml) was added iron (1.885 g, 33.8 mmol) and ammonium chloride (3.61 g, 67.5 mmol) and the reaction mixture was heated at 70°C for 2h. The reaction mixture cooled, stirred with celite for 30 min and then filtered. The filter cake was washed with 10% MeOH in DCM and the filterate was concentrated to give a light brown solid which purified on a short silical gel plug eluated with 10-15% MeOH in DCM to yield N-(4-((3-amino-4-methylpyridin-2- yl)ethynyl)pyridin-2-yl)acetamide (1.7 g, 6.38 mmol, 95 % yield) as a light yellow solid. HPLC: RT =0.48 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH CI 8 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 267 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.61 (br. s., 1H), 8.35 (d, J=4.62 Hz, 1H), 8.23 (s, 1H), 7.75 (d, J=4.40 Hz, 1H), 7.23 (br. s., 1H), 7.06 (d, J=3.96 Hz, 1H), 5.55 (br. s., 2H), 2.14-2.26 (m, 3H), 2.17 (s, 3H), 2.12 (s, 3H).
212C) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-methylpyridin-3-yl)-2,2,2- trifluoroacetamide
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-methylpyridin-3-yl)-2,2,2- trifluoroacetamide was prepared from N-(4-((3-amino-4-methylpyridin-2- yl)ethynyl)pyridin-2-yl)acetamide by the methods shown for Example ID. HPLC: RT = 0.67 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH CI 8 2.1x50mm 1.7u, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 363 [M+H]+ , ¾ NMR (400 MHz, DMSO-de) δ ppm 11.52 (s, IH), 10.66 (s, IH), 8.51 (d, J=4.84 Hz, IH), 8.39 (dd, J=0.88, 5.06 Hz, IH), 8.22 (s, IH), 7.50 (dd, J=0.55, 4.95 Hz, IH), 7.14 (dd, J=1.54, 5.06 Hz, IH), 2.26 (s, 3H), 2.12 (s, 3H).
Example 212) N-(4-(7-Methyl-3-(4-(trifluoromethyl)thiazol-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4-methylpyridin-3-yl)- 2,2,2-trifluoroacetamide (40mg, 110 mmole) and 2-bromo-4-(trifluoromethyl)thiazole (51.2 mg, 0.221 mmol) in DMF (2 mL) was added Cs2C03 (53.4 mg, 0.164 mmol) and the reaction mixture was purged with nitrogen for a few minutes. Xphos-Pd-G2 (4.30 mg, 5.46 μηιοΐ) was added and the reaction mixture was heated at 120°C in a sealed vial for lh. The reaction mixture was cooled, filtered and purified by preparative HPLC to give N-(4-(7-methyl-3-(4-(trifluoromethyl)thiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide. HPLC: RT = 1.09 min (H2O/ACN with 0.1% TFA, Waters Acquity SDS BEH CI 8, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 418 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.43 (s, IH), 10.60 (s, IH), 8.46 (br. s., IH), 8.44 (d, J=4.71 Hz, IH), 8.40 (d, J=5.05 Hz, IH), 8.36 (s, IH), 7.46 (d, J=4.96 Hz, IH), 7.18 (d, J=4.63 Hz, IH), 2.60 (s, 3H), 2.09 (s, 3H).
Example 213
N-(4-(7-(Difluoromethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
213 A) (3-Amino-2-chloropyridin-4-yl)methanol
To a solution of methyl 3-amino-2-chloroisonicotinate (0.4 g, 2.144 mmol in THF (5 niL) at -20 °C was added) LAH (2.57 niL, 2.57 mmol) under a nitrogen atmosphere. The mixture was then stirred at 0 °C for 30 min. Ammonium chloride (200 mg) was added and after stirred for 15min. silica gel (3mL) was added to the reaction mixture and concentrated in vacuo. The crude was dry loaded over a 3mL silical gel plug and eluated with 10% MeOH in DCM to give (3-amino-2-chloropyridin-4-yl)methanol (290 mg, 1.829 mmol, 85 % yield) as a white flaky solid. HPLC: RT = 0.44 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C 18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 159 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 7.61 (d, J=4.6 Hz, IH), 7.18 (d, J=4.6 Hz, IH), 5.40 (t, J=5.5 Hz, IH), 5.24 (s, 2H), 4.43 (d, J=5.5 Hz, 2H)
To the solution of (3-amino-2-chloropyridin-4-yl)methanol (0.5 g, 3.15 mmol) in THF (31.5 ml), DCM (31.5 ml) was added Dess-Martin periodinane (2.006 g, 4.73 mmol). The mixture was stirred for 1 h at room temperature. The reaction mixture was diluted with EtOAc (30 mL) and poured into saturated aqueous NaHCC containing Na2S203 (0.4 g). The mixture was stirred for 30 min. and then diluted with EtOAc (10 mL). The organic layer was separated and washed with water, then washed with brine, dried and evaporated. The crude product was purified by silica gel flash chromatography (12 g column, EtOAc/DCM = 0-100%) to yield 3-amino-2-chloroisonicotinaldehyde (260 mg, 1.661 mmol, 52.7 % yield) as a yellow solid. HPLC: RT = 0.61 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 157 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 9.97 (s, 1H), 7.87 (d, J=5.1 Hz, 1H), 7.36 (d, J=4.8 Hz, 1H)
213C) 2-Chloro-4-(difluoromethyl)pyridin-3-amine
2-Chloro-4-(difluoromethyl)pyridin-3-amine was prepared from 3-amino-2- chloroisonicotinaldehyde following the method shown for Example 173 A. HPLC: RT = 0.68 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH CI 8, 2.1 x 50 mm, 1.7- μτη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 179.0, 181.0 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ ppm 7.87 (d, J=4.8 Hz, 1H), 7.15 (d, J=4.8 Hz, 1H), 6.63 (t, J=54.8 Hz, 1H), 4.58 (br. s., 2H)
213D) N-(4-((3-Andno-4-(difluoromethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
To solution of 2-chloro-4-(difluoromethyl)pyridin-3 -amine (0.1 g, 0.560 mmol) in MeCN (5.60 ml) was added K2CO3 (0.232 g, 1.680 mmol). The mixture was bubbled with argon for 5 minutes and then PdCl2(dppf) (0.020 g, 0.028 mmol) was added. After stirring at room temperature for 20 min. Example IB (0.135 g, 0.840 mmol) was added and the reaction mixture was purged with argon then heated at 80 °C for 5h. The reaction mixture was concentrated, suspended in 10% MeOH in DCM and filtered. The filterate was concetrated and purified by silica gel flash chromatography (4 g column, 0-100% gradient; solvent A=DCM; Solvent B: 20% MeOH in DCM) to afford N-(4-((3-amino-4- (difluoromethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide (100 mg, 0.331 mmol, 59.1 % yield). HPLC: RT = 0.63 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 303.1 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.62 (s, 1H), 8.37 (dd, J=0.88, 5.06 Hz, 1H), 8.27 (s, 1H), 7.94 (d, J=4.84 Hz, 1H), 7.38 (dd, J=1.32, 5.06 Hz, 1H), 7.33 (d, J=4.84 Hz, 1H), 7.12 (t, J=54.40 Hz, 1H), 6.04 (s, 2H), 2.12 (s, 3H).
213E) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(difluoromethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(difluoromethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide was prepared from Example 213D using methods similar to example ID. HPLC: RT = 0.73 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18,
2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 399 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ ppm 8.76 (d, J=5.1 Hz, IH), 8.58 (br. s., IH), 8.36 (s, IH), 8.30 (dd, =5.2, 0.8 Hz, IH), 7.99 (br. s., IH), 7.62 (d, J=5.1 Hz, IH), 7.14 (dd, J=5.1, 1.3 Hz, IH), 6.86 (t, J=53.9 Hz, IH), 2.24 (s, 3H)
Example 213) N-(4-(7-(Difluoromethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
N-(4-(7-(Difluoromethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide was prepared from N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4- (difluoromethyl)pyridin-3-yl)-2,2,2-trifluoroacetamide and 5 -bromo-2-methoxy pyridine using the general methods shown for Example 212. HPLC: RT = 0.89 min (H2O/ACN with 0.1% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 410 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.59 (s, IH), 8.54 (d, J=4.46 Hz, IH), 8.33 (d, J=5.13 Hz, IH), 8.27 (s, IH), 8.19 (s, IH), 7.76 (d, J=8.50 Hz, IH), 7.44 (d, J=4.38 Hz, IH), 7.49 (t, J=54.40 Hz, IH), 7.14 (d, J=5.05 Hz, IH), 6.86 (d, J=8.58 Hz, IH), 3.85 (s, 3H), 2.07 (s, 3H).
Example 214
N-(4-(7-(hydroxymethyl)-3-(4-methylthiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
214A) N-(4-((3-Amino-4-(hydroxymethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
N-(4-((3-Amino-4-(hydroxymethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide was prepared from (3-amino-2-chloropyridin-4-yl)methanol and Example IB following the precedure used in Example 213D. HPLC: RT = 0.45 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 283 [M+H]+; ¾ NMR (400 MHz, METHANOL- d4) δ ppm 8.32 (dd, J=0.66, 5.06 Hz, 1H), 8.29 (s, 1H), 7.87 (d, J=4.84 Hz, 1H), 7.30 (dd, J=1.43, 5.17 Hz, 1H), 7.27 (d, J=4.62 Hz, 1H), 4.62 (s, 2H), 2.19 (s, 3H)
214B) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(hydroxymethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(hydroxymethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide was prepared using methods similar to Example ID. HPLC: RT = 0.58
min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7 particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 389 [M+H]+.
Example 214) N-(4-(7-(Hydroxymethyl)-3-(4-methylthiazol-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
Example 214 was prepared from Example 214B and 2-bromo-4-methylthiazole by methods shown for Example 212. HPLC: RT = 0.80 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.62 (s, IH), 8.54 (d, J=4.80 Hz, IH), 8.48 (s, IH), 8.41 (d, J=4.96 Hz, IH), 7.39-7.49 (m, 2H), 7.21 (s, IH), 4.95 (s, 2H), 2.32 (s, 3H), 2.11 (s, 3H)
Table 12
Examples in Table 12 below were prepared from 212C, 213E or 214B or Example 38B or from Example 48B and the heteroaryl bromide using the general methods shown for Example 212.
HPLC/LCMS Column conditions: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μτη particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 230
N-(4-(7-(l-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
23 OA) l-(3-Amino-2-chloropyridin-4-yl)ethanol
To a solution of l-(3-amino-2-chloropyridin-4-yl)ethanone (0.5 g, 2.93 mmol) in anhydrous methanol (20 mL) was added NaBH4 (0.222 g, 5.86 mmol). The mixture was stirred at room temperature for 2h then was quenched with cold water (~1 mL) and concentrated. The crude product was purified on a short flush silica gel plug eluted with 5% MeOH in DCM to yield l-(3-amino-2-chloropyridin-4-yl)ethanol (0.46 g, 2.66 mmol, 91 % yield) as a yellow oil. HPLC: RT = 0.49 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 173 [M+H]+; ¾ NMR (400 MHz, METHANOLS) δ ppm 7.62 (d, J=5.1 Hz, IH), 7.16 (d, J=4.8 Hz, IH), 4.92 (q, J=6.5 Hz, IH), 1.46 (d, J=6.6 Hz, 3H).
230B)
230B) N-(4-((3-Amino-4-(l-hydroxyethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
N-(4-((3-Amino-4-(l -hydroxy ethyl)pyridin-2-yl)ethynyl)pyridin-2-yl)acetamide was prepared from l-(3-amino-2-chloropyridin-4-yl)ethanol and Example IB following the procedure in 213D. HPLC: RT = 0.48 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.6 min, wavelength = 220 nm); MS (ES): m/z = 297 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.60 (s, 1H), 8.35 (dd, J=0.66, 5.06 Hz, 1H), 8.24 (s, 1H), 7.85 (d, J=4.62 Hz, 1H), 7.34 (dd, J=1.32, 5.06 Hz, 1H), 7.20 (d, J=4.62 Hz, 1H), 5.56 (s, 2H), 5.47 (d, J=4.18 Hz, 1H), 4.88 (dq, J=4.40, 6.38 Hz, 1H), 2.12 (s, 3H), 1.32 (d, J=6.38 Hz, 3H)
230C) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(l-hydroxyethyl)pyridin-3-yl)-2,2,2- trifluoroacetami de
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(l-hydroxyethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide was prepared from N-(4-((3-amino-4-(l -hydroxy ethyl)pyridin-2- yl)ethynyl)pyridin-2-yl)acetamide (230B) following the produre in example ID. HPLC: RT = 0.61 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.6 min, wavelength = 220 nm); MS (ES): m/z = 393 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.52 (s, 1H), 10.66 (s, 1H), 8.64 (d,
J=5.1 Hz, IH), 8.39 (dd, J=5.1, 0.7 Hz, IH), 8.21 (s, IH), 7.69 (d, J=4.8 Hz, IH), 7.13 (dd, J=5.1, 1.5 Hz, IH), 4.83 (q, J=6.4 Hz, IH), 2.11 (s, 3H), 1.26 (d, J=6.6 Hz, 3H).
Example 230) N-(4-(7-(l-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
N-(4-(7-(l-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide was prepared N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4-(l - hydroxyethyl)pyridin-3-yl)-2,2,2-trifluoroacetamide (230C) following procedure used for Example 212. HPLC: RT = 0.79 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 404 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 1 1.68 (s, IH), 10.56 (s, IH), 8.37 (d, J=4.63 Hz, IH), 8.31 (d, J=5.05 Hz, IH), 8.25 (s, IH), 8.18 (s, IH), 7.76 (dd, J=1.77, 8.58 Hz, IH), 7.28 (d, J=4.63 Hz, IH), 7.13 (d, J=5.05 Hz, IH), 6.84 (d, J=8.50 Hz, IH), 5.34 (br. s., IH), 3.85 (s, 3H), 1.90 (s, 3H), 1.45 (d, J=6.40 Hz, 3H).
Table 13
Examples in Table 13 below were prepared from Example 230C and heteroaryl bromides using the general methods shown for Example 212
HPLC/LCMS Column conditions: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μτη particles; Mobile Phase A: 5:95acetonitrile:water with 0.1% tnfluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% tnfluoroacetic acid; Temperature: 50°C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Example 233
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(l-fluoroethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a solution of N-(4-((3-amino-4-(l-hydroxyethyl)pyridin-2-yl)ethynyl)pyridin- 2-yl)acetamide (0.1 g, 0.337 mmol) in CH2CI2 (334 μΐ) at -20 °C was added DAST (0.045 ml, 0.337 mmol). The reaction was stirred at -20°C for 10 min, then stirred warm to room temperature for 45 min. The reaction was quenched with MeOH and concentrated. The crude material was purified by silica gel flash chromatography (4 g column,
EtOAc/hexanes = 0-100%) to give N-(4-((3-amino-4-(l-fluoroethyl)pyridin-2- yl)ethynyl)pyridin-2-yl)acetamide. HPLC: RT = 0.57 min (H2O/ACN with 0.05% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.6 min, wavelength = 220 nm). MS (ES): m/z = 299 [M+H]+; ¾ NMR (400 MHz,
CHLOROFORM-d) δ ppm 8.37 (s, 1H), 8.27 (dd, J=0.77, 5.17 Hz, 1H), 8.07 (dd, J=1.32, 4.84 Hz, 1H), 7.21 (dd, J=1.43, 5.17 Hz, 1H), 7.03 (dd, J=0.66, 4.84 Hz, 1H), 5.70 (dq, J=6.60, 46.97 Hz, 1H), 4.69 (br. S., 2H), 2.23 (s, 3H), 1.75 (dd, J=6.38, 17.61 Hz, 3H).
233B) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(l-fluoroethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide
N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-(l-fluoroethyl)pyridin-3-yl)-2,2,2- trifluoroacetamide was prepared from N-(4-((3-amino-4-(l-fluoroethyl)pyridin-2- yl)ethynyl)pyridin-2-yl)acetamide (233A) by methods similar to those used in example ID. HPLC: RT = 0.74 min (H2O/ACN with 0.05% TFA, Waters Acquity UPLC BEH
C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.6 min, wavelength = 220 nm).
m/z = 395 [M+H]+;
Example 233) N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(l-fluoroethyl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-(l-fluoroethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide was prepared from N-(2-((2-acetamidopyridin-4- yl)ethynyl)-4-(l-fluoroethyl)pyridin-3-yl)-2,2,24rifluoroacetarnide (233B) and 2-bromo- 6-(difluoromethyl)pyridine using the general methods shown for Example 212. HPLC: RT = 1.01 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 426 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.13 (s, IH), 10.53 (s, IH), 8.52 (d, J=4.63 Hz, IH), 8.35 (d, J=7.91 Hz, IH), 8.32 (br. s., IH), 8.31 (d, J=5.22 Hz, IH), 8.05 (t, J=7.83 Hz, IH), 7.53 (d, J=7.66 Hz, IH), 7.33 (d, J=4.71 Hz, IH), 6.57 (t, J=55.29 Hz, IH), 6.35 (dq, J=6.60, 46.95 Hz, IH), 2.07 (s, 3H), 1.73 (dd, J=6.65, 24.66 Hz, 3H).
Example 234
N-(4-(7-Methoxy-3-(4-methylthiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide was prepared from N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4- methoxypyridin-3-yl)-2,2,2-trifluoroacetamide and 2-bromo-4-methylthiazole following the same methods shown for Example 212. HPLC: RT = 0.90 min (H2O/ACN with 0.1 % TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 426 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.54 (s, IH), 8.50 (s, IH), 8.39 (d, J=5.30 Hz, IH), 8.33 (d, J=5.13 Hz, IH), 7.44 (d, J=5.05 Hz, IH), 7.20 (s, IH), 6.95 (d, J=5.30 Hz, IH), 4.04 (s, 3H), 2.27 (s, 3H), 2.10 (s, 3H).
Example 235
N-(4-(6-Chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)- 2-(4-(2-hydroxyethyl)piperazin-l -yl)acetamide
Example 235 was prepared from Example 290A and 2-(piperazin-l-yl)ethanol by the general methods shown for Example 286. HPLC: RT = 1.02 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 522 [M+H]+
Example 237
N-(4-(3-(5-Methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
To a solution of N-(4-(6-chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (25 mg, 0.061 mmol) (Example 236) and sodium formate (25.01 mg, 0.368 mmol) in MeOH (2 mL) was purged with argon for several minutes. PdOAc2 (5.50 mg, 0.025 mmol) was added and the reaction mixture was purge briefly with argon then heated at 75 °C for 2.5 h in a sealed tube. The reaction mixture was filtered and purified by preparative HPLC to yield N-(4-(3-(5-methoxy-6- methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide. HPLC: RT = 0.70 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm). MS (ES): m/z = 374 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.96 (s, 1H), 10.48 (s, 1H), 8.41 (d, J=3.95 Hz, 1H), 8.34 (br. s., 1H), 8.25 (d, J=5.13 Hz, 1H), 7.86 (d, J=8.16 Hz, 2H), 7.40 (d, J=8.50 Hz, 1H), 7.24 (dd, J=4.50, 8.12 Hz, 1H), 7.18 (d, J=4.96 Hz, 1H), 3.83 (s, 3H), 2.20 (s, 3H), 2.08 (s, 3H).
Example 238
N-(4-(6-Chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- y l)pyridin-2-y l)-2-(4-methy lpiperazin- 1 -y l)acetamide
238A) 4-(6-Chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-amine
4-(6-Chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-amine was preapred from N-(4-(6-chloro-3-(5-methoxy-6-methylpyridin-2- yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (Example 236) by the general methods shown for Example 52. HPLC: RT = 0.39 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH CI 8 2.1x50mm 1.7 u, gradient = 1.75 min, wavelength = 220 nm); MS (ES): m/z = 366 [M+H]+.
238B) 2-Chloro-N-(4-(6-chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
2-Chloro-N-(4-(6-chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide was prepared from 4-(6-chloro-3-(5-methoxy-6- methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-amine by the general methods shown for Example 74A. HPLC: RT = 0.56 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.75 min, wavelength = 220 nm); MS (ES): m/z = 442 [M+H]+.
Example 238) N-(4-(6-Chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide
A solution of 2-chloro-N-(4-(6-chloro-3-(5-methoxy-6-methylpyridin-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (60.6 mg, 0.137 mmol) and 1- methylpiperazine (41.2 mg, 0.411 mmol) in DMF (0.5 mL) was added K2CO3 (56.8 mg, 0.411 mmol) and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with EtOAc (~3 mL) and filtered through Celite. The celite was washed with 10% MeOH/DCM (~3 mL). The filtrate was concentrated, redissolved in DMF (2 mL) and purified by preparative HPLC to give N-(4-(6-chloro-3-(5-methoxy-
6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-(4-methylpiperazin- l-yl)acetamide. HPLC: RT = 0.90 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH CI 8 2.1x50mm 1.7u, gradient = 1.75 min, wavelength = 220 nm); MS (ES): m/z = 506 [M+H]+. ¾ NMR (500 MHz, DMSO-de) δ ppm 9.97 (s, IH), 8.41 (s, IH), 8.36 (s, IH), 8.30 (d, J=5.13 Hz, IH), 7.94 (d, J=1.60 Hz, IH), 7.81 (d, J=8.41 Hz, IH), 7.41 (d, J=8.50 Hz, IH), 7.23 (d, J=4.63 Hz, IH), 3.84 (s, 3H), 3.16 (s, 2H), 2.54 (br. s., 8H), 2.20 (s, 6H).
Example 239
N-(4-(6-Chloro-3-(5-methoxythiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
N-(4-(6-Chloro-3-(5-methoxythiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide was prepared from Evample 41B and 2-bromo-5-methoxythiazole by the methods shown for Example 172. HPLC: RT = 1.25 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 400: ¾ NMR (500 MHz, DMSO-de) δ 10.64 (s, IH), 8.52 (d, J=1.68 Hz, IH), 8.45 (s, IH), 8.39 (d, J=5.05 Hz, IH), 7.98 (d, J=1.94 Hz, IH), 7.47 (dd, J=1.01, 5.13 Hz, IH), 7.13 (s, IH), 3.94 (s, 3H), 2.12 (s, 3H).
Example 240
240A) N-(4-(5-Bromo-7-cyano-3-(4-methylthiazol-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetaniide
A solution of 2-bromo-4-methylthiazole (145 mg, 0.814 mmol), 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(l ,3,2-dioxaborolane) (248 mg, 0.977 mmol) in 1,4-dioxane (5 ml) was added potassium acetate (120 mg, 1.222 mmol). The reaction mixture was purged with argon for several minutes and PdCl2(dppf)-CH2Cl2Adduct (20.81 mg, 0.041 mmol) was added. The reaction mixture was bubbled argon for 2min and heated in a sealed vial at 90 °C for 2 h. To the cooled reaction mixture was added N-(4-(5-bromo-7-cyano-3-iodo-l - ((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (499mg, 0.814 mmol) and tripotassium phosphate (0.679 ml, 2.036 mmol). The reaction mixture was bubbled with argon for 5min and heated at 1 10 °C for overnight. The reaction mixture was cooled, diluted with EtOAc and washed with water then with brine. The organic phase was dried with MgS04, concentrated and purified by silica gel flash chromatography (12 g column, EtO Ac/hex = 0-50%) to give N-(4-(5-bromo-7-cyano-3- (4-methylthiazol-2-yl)-l -((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide. HPLC: RT = 1.20 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH CI 8 2.1x50mm 1.7u, gradient = 1.75 min, wavelength = 220 nm); MS (ES): m/z = 583, 585 [M+H]+.
Example 240) N-(4-(7-Cyano-3-(4-methylthiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A solution of N-(4-(5-bromo-7-cyano-3-(4-methylthiazol-2-yl)-l -((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide (80 mg, 0.137 mmol) (Example 240A) in methanol (3 mL) was added sodium formate (55.9 mg, 0.823 mmol) and the reaction mixture was purged with argon for several minutes. Pd(OAc)2 (18.47 mg, 0.082 mmol) added and the reaction mixture was stirred at 70°C in a sealed vial for 16h. The reaction mixture was filtered and concetrated and then treated with (1 : 1) DCM:TFA (3mL) and heated at 50°C for 2h. The reaction mixture was then concentrated and dissolved in DMF and purified by prepative HPLC to give N-(4-(7- cyano-3-(4-methylthiazol-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide. HPLC: RT = 1.34 min (H20/MeOH with 0.05% TFA, Waters Acquity SDS BEH C18 2.1x50mm 1.7u, gradient = 1.75 min, wavelength = 220 nm); MS (ES): m/z = 375
[M+H]+. ¾ NMR (500 MHz, DMSO-de) δ ppm 10.64 (s, IH), 8.58 (s, IH), 8.44 (d, J=5.13 Hz, IH), 8.24 (s, IH), 7.71 (d, J=4.97 Hz, IH), 7.42 (s, IH), 7.40 (s, IH), 2.45 (s, 3H), 2.15 (s, 3H).
Example 241
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl} -2- {[2-(mo holin-4-yl)ethyl]amino} acetamide
Example 241 was prepared from Example 74 A and 2-morpholinoethanamine by the general methods shown for Example 74. HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 510.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.47 (s, 1H), 8.55 - 8.39 (m, 3H), 8.27 - 8.12 (m, 2H), 8.01 (s, 1H), 7.89 - 7.77 (m, 1H), 7.35 (d, J=4.9 Hz, 1H), 4.29 - 3.59 (m, 2H), 3.45 - 2.80 (m, 4H), 2.54 (br.s, 8H).
Example 242
4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)-N-ethylpyridin-2- amine
Example 242 was prepared by the general methods shown for Example 82.
HPLC: RT = 1.08 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 379.9 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.17 (br. s., 1H), 8.41 (br. s., 1H), 8.26 (br. s., 1H), 7.93 (br. s., 2H), 7.87 (d, J=7.0 Hz, 1H), 7.50 (d, J=7.5 Hz, 1H), 6.75 (br. s., 1H), 6.59 (d, J=4.8 Hz, 1H), 3.86 (s, 3H), 2.54 (m, 2H), 1.13 (t, J=7.0 Hz, 3H)
Example 243
4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)-N- isobutylpyridin-2-amine
Example 243 was prepared by the general methods shown for Example 82.
HPLC: RT = 1.01 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 408.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.13 (br. s., IH), 8.40 (br. s., IH), 8.25 (br. s., IH), 7.92 (br. s., 2H), 7.86 (d, J=8.4 Hz, IH), 7.49 (d, J=8.3 Hz, IH), 6.69 (br. s., IH), 6.56 (br. s., IH), 3.86 (s, 3H), 3.00 (br. s., 2H), 1.83 - 1.71 (m, IH), 0.88 (d, J=6.4 Hz, 6H.
Example 244
N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-
Example 244 was prepared from 74A and piperidin-4-ol by the general methods shown for Example 74. HPLC: RT = 0.84 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 481.1 [M+H]; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.48 (br. s., 1H), 8.46 (br. s., 2H), 8.42 (d, J=4.5 Hz, 1H), 8.23 (br. s., 1H), 8.12 (dd, J=8.6, 4.5 Hz, 1H), 8.01 (s, 1H), 7.89 - 7.75 (m, 1H), 7.33 (br. s., 1H), 4.23 - 3.1 1 (m, 3H), 2.54 (s, 4H), 1.91 (br. s., 2H), 1.68 (br. s., 2H).
Example 245
N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2- (4-(dimethylamino)piperidin-l -yl)acetamide
Example 245 was prepared from 74A and N,N-dimethylpiperidin-4-amine by the general methods shown for Example 74. HPLC: RT = 0.83 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min,
wavelength = 220 nm);MS (ES): m/z = 508.3 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.43 (s, 1H), 8.44 (br. s., 2H), 8.36 (d, J=5.0 Hz, 1H), 8.22 (br. s., 1H), 8.07 (dd, J=8.7, 4.5 Hz, 1H), 8.01 (s, 1H), 7.87 - 7.71 (m, 1H), 7.28 (br. s., 1H), 3.87 - 3.52 (m, 13H), 2.04 (br. s., 2H), 1.76 (br. s., 2H).
Example 246
N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2- (4-(2-hydroxyethyl)piperazin-l -yl)acetamide
Example 246 was prepared from example 74A and 2-(piperazin-l -yl)ethanol by the general methods shown for Example 74. HPLC: RT = 0.86 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 510.2 [M+H]; ¾ NMR (500 MHz, DMSO- de) δ ppm 12.44 (s, 1H), 10.34 (br. s., 1H), 8.46 (br. s., 2H), 8.36 (d, J=5.0 Hz, 1H), 8.27 (br. s., 1H), 8.16 - 8.07 (m, 1H), 8.00 (s, 1H), 7.83 (t, J=8.6 Hz, 1H), 7.25 (d, J=4.9 Hz, 1H), 3.73 (br. s., 4H), 3.19 (br. s., 4H), 3.11 - 2.63 (m, 4H), 2.54 (s, 2H).
Example 247
N-(4-(6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-
(piperazin- 1 -y l)acetamide
Example 247 was prepared from 74 A and ter /-butyl piperazine-l -carboxylate by the general methods shown for Example 74. HPLC: RT = 0.86 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 466.0 [M+H]; ¾ NMR (500MHz, DMSO- de) 5 ppm 10.13 (s, 1H), 8.46 (br. s., 2H), 8.34 (d, J=5.1 Hz, 1H), 8.28 (s, 1H), 8.15 - 8.07 (m, 1H), 7.99 (s, 1H), 7.88 - 7.77 (m, 1H), 7.22 (d, J=5.0 Hz, 1H), 3.23 (s, 2H), 2.98 (br. s., 4H), 2.63 (br. s., 4H).
Example 248
2-(4-Acetylpiperazin-l-yl)-N-(4-(6-chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
Example 248 was prepared from 74A and l-(piperazin-l -yl)ethanone by the general methods shown for Example 74. HPLC: RT = 0.86 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 508.2 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ
10.12 (s, IH), 8.46 (s, 2H), 8.34 (d, J=5.2 Hz, IH), 8.29 (s, IH), 8.10 (dd, J=8.5, 4.3 Hz, IH), 7.99 (s, IH), 7.88 - 7.79 (m, IH), 7.21 (d, J=4.9 Hz, IH), 3.47 (d, J=4.3 Hz, 4H), 3.41 - 3.35 (m, 4H), 3.22 (s, 2H), 1.99 (s, 3H).
Example 249
N-(4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-
2-(4-methy lpiperazin- 1 -y l)acetamide
249 A) 2-Chloro-N-(4-(6-chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a suspension of 4-(6-chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-amine (210 mg, 0.597 mmol) (Example 86) in DCE (8 mL) (sonicated) was added chloroacetyl chloride (0.214 mL, 2.69 mmol) and TEA (0.42 mL, 2.98 mmol) slowly at ice bath temperature. The reaction mixture was stirred at rt for 0.5 h. Then to the reaction mixture was added 2 mL of aqueous ammonia hydroxide solution and the mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted
with saturated NaHC03 solution and the mixture was filtered to give the desired product
(255 mg, 99%); HPLC: RT = 0.69 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 427.9 [M+H]+; ¾ NMR (400MHz, DMSO-d6) δ ppm 12.22 (s, 1H), 10.87 (s, 1H), 8.43 (d, J=2.2 Hz, 1H), 8.37 - 8.28 (m, 2H), 8.20 (d, J=2.9 Hz, 1H), 7.99 - 7.91 (m, 2H), 7.50 (dd, J=8.8, 3.1 Hz, 1H), 7.20 (dd, J=5.2, 1.4 Hz, 1H), 4.35 (s, 2H), 3.86 (s,
3H).
Example 249) N-(4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)-2-(4-methylpiperazin- 1 -yl)acetamide
To a mixture of Example 249 A (60 mg, 0.140 mmol) in acetonitrile (4 mL) was added 1-methylpiperazine (168 mg, 1.681 mmol) and silver oxide (64.9 mg, 0.280 mmol). The reaction mixture was stirred at room temperature for 3.5 h. The reaction mixture was concentrated in vacuo and the residue was mixed with TFA/MeOH, then concentrated in vacuo. To the residue was added small amount of TFA/MeOH. The mixture was filtered through a syringe filter, and purified by preparative HPLC. Fractions containing the desired product were combined, and mixed with CHCl3/2-propanol (3 : 1) and NaHC03 solution. The organic layer was separated and dried over MgS04. The filtrate was concentrated in vacuo and lyophilized to give the desired product (43 mg, 61 %); HPLC: RT = 0.57 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C 18, 2.1 x 50 mm, 1.7- μτη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 492.0 [M+H] ; ¾ NMR (400MHz, MeOH-d4) δ ppm 8.35 (d, J=2.2 Hz, 1H), 8.31 (d, J=0.7 Hz, 1H), 8.28 - 8.23 (m, 2H), 7.94 (d, J=2.0 Hz, 1H), 7.67 (d, J=8.8 Hz, 1H), 7.52 (dd, J=8.7, 3.0
Hz, 1H), 7.16 (dd, J=5.3, 1.5 Hz, 1H), 3.94 (s, 3H), 3.20 (s, 2H), 2.83 - 2.46 (m, 8H), 2.33 (s, 3H).
Example 250
N-(4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-
2-morpholinoacetamide
Example 250 was prepared from Example 249A and morpholine by the general methods shown for Example 249. HPLC: RT = 0.77 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 479.0 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.06 (br. s., 1H), 8.42 (br. s., 1H), 8.31 (br. s., 2H), 8.19 (br. s., 1H), 7.95 (br. s., 1H), 7.91 (d, J=8.6 Hz, 1H), 7.49 (d, J=7.4 Hz, 1H), 7.17 (br. s., 1H), 3.84 (br. s., 3H), 3.62 (br. s., 2H), 2.54 (s, 8H).
Example 251
N-(4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-
2-(4-ethylpiperazin- 1 -yl)acetamide
Example 251 was prepared from Example 249A and 1 -ethylpiperazine by the general methods shown for Example 249. HPLC: RT = 0.85 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 506.1 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ 12.27 (s, IH), 10.21 (br. s., IH), 8.42 (s, IH), 8.35 - 8.27 (m, 2H), 8.18 (br. s., IH), 7.97 (s, IH), 7.91 (d, J=8.7 Hz, IH), 7.50 (dd, J=8.7, 2.8 Hz, IH), 7.18 (d, J=4.9 Hz, IH), 3.84 (s, 3H), 3.53 (m, 10H), 3.20 - 2.92 (m, 2H), 1.20 (t, J=7.2 Hz, 3H).
Example 252
N-(4-(6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)- 2-(4-(2-hydroxyethyl)piperazin-l -yl)acetamide
Example 252 was prepared from Example 249A and 2-(piperazin-l-yl)ethanol by the general methods shown for Example 249. HPLC: RT = 0.85 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 522.3 [M+H]; ¾ NMR (500 MHz, DMSO- de) δ ppm 9.98 (s, IH), 8.42 (br. s., IH), 8.36 - 8.27 (m, 2H), 8.18 (br. s., IH), 8.01 - 7.84
(m, 2H), 7.50 (d, J=8.5 Hz, IH), 7.17 (d, J=5.0 Hz, IH), 3.85 (s, 3H), 3.16 (s, 2H), 2.54 (br. s., 6H), 2.43 (br. s., 3H), 1.90 (s, 3H).
Example 253
N-(4-(6-Chloro-3-(5-ethoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 253 was prepared from Example 41B and 2-bromo-5-ethoxypyridine by the general methods shown for Example 1. HPLC: RT = 1.05 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.20 (s, IH), 10.56 (s, IH), 8.42 (d, J=1.8 Hz, IH), 8.35 - 8.24 (m, 2H), 8.18 (d, J=2.6 Hz, IH), 8.01 - 7.85 (m, 2H), 7.48 (dd, J=8.6, 2.7 Hz, IH), 7.11 (d, J=4.5 Hz, IH), 4.13 (q, J=6.9 Hz, 2H), 2.09 (s, 3H), 1.36 (t, J=6.9 Hz, 3H)
Example 254
N-(4-(6-Chloro-3-(5-isopropoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 254 was prepared from Example 41B and 2-bromo-5- isopropoxy pyridine by the general methods shown for Example 1. HPLC: RT = 1.16 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 422.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.56 (br. s., IH), 10.64 (s, IH), 8.57 - 8.47 (m, IH), 8.35 (d, J=5.0 Hz, 2H), 8.21 (br. s., IH), 8.03 (d, J=1.7 Hz, IH), 7.93 (d, J=8.8 Hz, IH), 7.79 (d, J=7.1 Hz, IH), 7.22 (d, J=5.4 Hz, IH), 4.81 (dt, J=l 1.9, 5.8 Hz, IH), 2.07 (s, 3H), 1.34 (d, J=6.0 Hz, 6H)
Example 255
N-(4-(6-Chloro-3-(6-isopropoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 255 was prepared from Example 41B and 2-bromo-6- isopropoxy pyridine by the general methods shown for Example 1. HPLC: RT
(H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 422.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.24 (br. s., IH), 10.59 (br. s., IH), 8.44 (s, IH), 8.32 (d, J=4.7 Hz, IH), 8.23 (br. s., IH), 7.97 (d, J=7.3 Hz, IH), 7.91 (s, IH), 7.68 (t, J=7.7 Hz, IH), 7.13 (d, J=4.7 Hz, IH), 6.48 (d, J=8.1 Hz, IH), 4.47 - 4.26 (m, IH), 2.04 (s, 3H), 0.88 (d, J=6.1 Hz, 6H)
Example 256
N-(4-(6-Chloro-3-(6-ethoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 256 was prepared from Example 41B and 2-bromo-6-ethoxypyridine by the general methods shown for Example 1. HPLC: RT = 1.23 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.29 (br. s., IH), 10.61 (s, IH), 8.48 (s, IH), 8.35 (d, J=5.0 Hz, IH), 8.28 (br. s., IH), 8.00 (d, J=7.4 Hz, IH), 7.95 (s, IH), 7.74 (t, J=7.8 Hz, IH), 7.18 (d, J=5.0 Hz, IH), 6.58 (d, J=8.2 Hz, IH), 3.64 (q, J=6.9 Hz, 2H), 2.09 (s, 3H), 1.00 (t, J=7.0 Hz, 3H)
Example 257
Example 257 was prepared from 2-bromo-6-methylpyridine by the general methods shown for Example 266. HPLC: RT = 0.66 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.46 (s, IH), 8.31 (d, J=5.0 Hz, 2H), 8.24 (d, J=5.2 Hz, IH), 7.93 (d, J=7.7 Hz, IH), 7.69 (t, J=7.7 Hz, IH), 7.20 (d, J=5.0 Hz, IH), 7.07 (d, J=7.6 Hz, IH), 6.90 (d, J=5.4 Hz, IH), 4.04 (s, 3H), 2.26 (s, 3H), 2.11 - 2.03 (m, 3H).
Example 258
N-(4-(6-Chloro-3-(6-ethoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 258 was prepared from Example 41B and 5 -bromo-2-ethoxy pyridine by the general methods shown for Example 1. HPLC: RT = 1.18 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.23 (br. s., IH), 10.60 (s, IH), 8.39 (s, IH), 8.35 - 8.27 (m, 2H), 8.20 (s, IH),
7.95 (br. s., 1H), 7.74 (d, J=7.2 Hz, 1H), 7.11 (d, J=4.7 Hz, 1H), 6.83 (d, J=8.5 Hz, 1H), 4.31 (q, J=6.8 Hz, 2H), 1.32 (t, J=6.9 Hz, 3H)
Example 259
N-(4-(6-Chloro-3-(3-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 259 was prepared from Example 41B and 2-bromo-3-methylpyridine by the general methods shown for Example 1. HPLC: RT = 1.16 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.61 (br. s., 1H), 10.51 (s, 1H), 8.54 (br. s., 1H), 8.34 (s, 1H), 8.26 (d, J=5.0 Hz, 1H), 8.10 - 7.95 (m, 3H), 7.59 (br. s., 1H), 7.05 (d, J=5.1 Hz, 1H), 2.09 (s, 3H), 1.99 (s, 3H)
Example 260
N-(4-(6-Chloro-3-(6-isopropylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 260 was prepared from Example 41B and 2-bromo-6-isopropylpyridine by the general methods shown for Example 1. HPLC: RT = 1.06 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 406.1 [M+H]+; ¾ NMR (500 MHz, DMSO- de) δ ppm 12.28 (br. s., 1H), 10.53 (br. s., 1H), 8.46 (s, 1H), 8.30 (d, J=4.2 Hz, 1H), 8.23 (br. s., 1H), 8.01 (d, J=7.6 Hz, 1H), 7.97 (s, 1H), 7.77 (t, J=7.5 Hz, 1H), 7.18 (d, J=4.7 Hz, 1H), 7.09 (d, J=7.2 Hz, 1H), 2.87 - 2.73 (m, 1H), 2.06 (s, 3H), 0.94 (d, J=6.6 Hz, 6H)
Example 261
N-(4-(3-(6-Fluoropyridin-3-yl)-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
261 A) l-(3-Amino-2,6-dibromopyridin-4-yl)ethanone
To a solution of l-(3-aminopyridin-4-yl)ethanone (0.9 g, 6.61 mmol) in DMF (10 mL) was added NBS (2.53 g, 14.21 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with ethyl acetate and saturated NaHC03 solution. The organic layers (extracted two times) were washed with saturated
NaHC03 solution, dried over MgS04 The filtrate was concentrated in vacuo. The
residue was purified by flash chromatography. The product was eluted with 0-20% ethyl acetate in hexane to give the desired product as a white solid (1.55g, 80%); HPLC: RT = 0.88 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 292.8, 294.8
[M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 7.65 (s, 1H), 6.73 (br. s., 2H), 2.62 (s, 3H).
261B) N-(4-((4-Acetyl-3-andno-6-bromopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
To a solution of l-(3-amino-2,6-dibromopyridin-4-yl)ethanone (6.2 g, 21.09 mmol) in DMF (30 mL) were added TEA (29.4 mL, 211 mmol), Cul (0.20 g, 1.055 mmol) and N-(4-ethynylpyridin-2-yl)acetamide (3.72 g, 23.20 mmol). The reaction mixture was purged with nitrogen stream for 3 min, followed by addition of
bis(triphenlphosphine)Palladium (II) chloride (0.888 g, 1.266 mmol) The reaction mixture was heated at 80 °C for 2 h.The reaction mixture was cooled down and diluted with ethyl acetate and saturated NaHC03 solution. The ethyl acetate extracts (two times) were combined, washed with saturated NaHC03 solution, dried over MgS04. The filtrate was concentrated in vacuo. To the residue was added DCM, and the mixture was filtered to give light tan solid and filtrate. The filtrate was purified by flash chromatography. The product was eluted with DCM to 20% of 10% MeOH in DCM to give the desired product as brown solid, total (3.4 g, 43.2%); HPLC: RT = 0.78 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 372.8, 374.8 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.64 (s, 1H), 8.39 (dd, J=5.1, 0.9 Hz, 1H), 8.29 (s, 1H), 7.94 (s, 1H), 7.44 - 7.31 (m, 3H), 2.63 (s, 3H), 2.12 (s, 3H).
261C) N-(2-((2-Acetarnidopyridin-4-yl)ethynyl)-4-acetyl-6-bromopyridin-3-yl)-2,2,2- trifluoroacetamide
To a suspension of N-(4-((4-acetyl-3-amino-6-bromopyridin-2-yl)ethynyl)pyridin- 2-yl)acetamide (2.0 g, 5.36 mmol) in DCE (35 mL) (sonicated) were added TEA (3.73 mL, 26.8 mmol) and trifluoroacetic anhydride (1.29 mL, 9.11 mmol) dropwise at ice bath temperature. The reaction mixture was stirred at 0 °C for 40 min. To the reaction mixture was added more TEA (2.5 ml) and trifluoroacetic anhydride (0.7 mL) and the reaction mixture was stirred at 0 °C for another 40 min. The reaction mixture was diluted with ethyl acetate and saturated NaHC03 solution. The organic layer was separated and washed with saturated NaHC03 solution, dried over MgS04. The filtrate was
concentrated in vacuo. The residue was dissolved in DCM and filtered through a syringe filter, purified by flash Chromatography. The product was eluted with DCM to 20% of 10% MeOH in DCM to give the desired product as yellow solid (0.8 g, 32%); HPLC: RT = 0.82 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 470.7 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ ppm 9.46 (br. s., 1H), 8.37 (s, 1H), 8.30 (d, J=5.1 Hz, 1H), 7.94 (br. s., 1H), 7.75 (s, 1H), 7.15 (dd, J=5.1, 1.3 Hz, 1H), 2.68 (s, 3H), 2.23 (s, 3H).
261D) N-(4-(7-Acetyl-5-bromo-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
The reaction mixture of N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4-acetyl-6- bromopyridin-3-yl)-2,2,2-trifluoroacetamide (150 mg, 0.320 mmol),
bis(dibenzylideneacetone)palladium (18.4 mg, 0.032 mmol), 2-(dicyclohexylphosphino)- 2',4',6'-triisopropylbiphenyl (10.67 mg, 0.022 mmol) and Cs2C03 (208 mg, 0.639 mmol) in acetonitrile (5 mL) in a sealed tube was pureged with nitrogen stream for 2 min, then heated at 110 °C for 2 h. The reaction mixture was cooled down and extracted with ethyl acetate. The residue was dissolved in MeOH/TFA solution, purified by preparative HPLC. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid (31 mg, 26%); HPLC: RT = 0.67 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS CI 8, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 373.1 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.82 (s, IH), 10.66 (s, IH), 8.51 (s, IH), 8.41 (d, J=5.3 Hz, IH), 7.89 (s, IH), 7.70 (dd, J=5.3, 1.5 Hz, IH), 7.23 (d, J=2.0 Hz, IH), 2.76 (s, 3H), 2.15 (s, 3H).
261E) N-(4-(7-(l-Hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To the reaction mixture of N-(4-(7-acetyl-5-bromo-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide (90 mg, 0.241 mmol) in MeOH (6 mL) was added Pd(OH)2-C (16.93 mg, 0.024 mmol) . The mixture was sonicated, vacuumed, then hydrogenated with hydrogen balloon for 2 h.The reaction mixture was diluted with MeOH, filtered. The filtrate was concentrated in vacuo to give the desired product as yellow solid (60 mg, 84%); HPLC: RT = 0.46 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 297.1 [M+H]+.
261F) N-(4-(7-(l-Hydroxyethyl)-3-iodo-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
To a solution of N-(4-(7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide (60 mg, 0.202 mmol) in DMF (2 mL) was added NIS (54.7 mg, 0.243 mmol). The reaction mixture was stirred at room temperature for 1 h.The reaction mixture was extracted with ethyl acetate and brine. The organic layer was separated and concentrated in vacuo. The crude was used in the next step reaction without purification. HPLC: RT = 0.50 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C 18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 423.1 [M+H]+.
Example 261) N-(4-(3-(6-Fluoropyridin-3-yl)-7-(l -hydroxyethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
The solution of N-(4-(7-(l-hydroxyethyl)-3-iodo-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide (30 mg, 0.071 mmol) and 2-fiuoropyridine-5-boronic acid (12.0 mg, 0.085 mmol) in dioxane (2 mL) in a sealed tube. 1.0 M Na2CCb solution (0.18 mL, 0.18 mmol) was added and the mixture was purged with nitrogen stream for 3 min, followed by addition of PdCl2(dppf) (5.2 mg, 7.1 1 μιτιοΐ). The resulting mixture was heated at 90 °C for 2 h.The reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH+ 2 drop of TFA and filtered through a syringe filter, purified by preparative HPLC. Fractions containing the desired product were combined,
concentrated, and lyophilized to give the desired product 2 TFA salt as a yellow solid (5.3 mg, 12 %); HPLC: RT = 0.69 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 3 min, wavelength = 220 nm); MS
(ES): m/z = 392.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.65 (s, IH), 8.53 (d, J=5.3 Hz, IH), 8.38 (d, J=5.1 Hz, IH), 8.28 (s, IH), 8.23 (s, IH), 8.04 (td, J=8.2, 2.2 Hz, IH), 7.57 (d, J=5.0 Hz, IH), 7.27 (br. s., IH), 7.20 (d, J=5.0 Hz, IH), 5.49 (q, J=6.2 Hz, IH), 2.07 (s, 3H), 1.50 (d, J=6.4 Hz, 3H).
Example 262
N-(4-(3-(6-Fluoropyridin-2-yl)-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 262 was prepared from 2-bromo-6-fiuoropyridine by the general methods shown for Example 261. HPLC: RT = 0.79 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 392.1 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.88 (s, IH), 10.57 (s, IH), 8.46 (d, J=4.7 Hz, IH), 8.34 (d, J=5.0 Hz, IH), 8.28 - 8.17 (m, 2H), 8.02 (q, J=8.2 Hz, IH), 7.33 (d, J=4.7 Hz, IH), 7.22 (d, J=4.1 Hz, IH), 6.96 (dd, J=8.0, 2.3 Hz, IH), 5.55 (d, J=4.4 Hz, IH), 5.43 - 5.26 (m, IH), 2.08 (s, 3H), 1.45 (d, J=6.4 Hz, 3H).
Example 263
N-(4-(3-(6-Chloropyridin-2-yl)-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 263 was prepared from 2-bromo-6-chloropyridine by the general methods shown for Example 261. HPLC: RT = 0.86 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408.2 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.68 (s, IH), 8.61 (d, J=5.4 Hz, IH), 8.42 (d, J=5.0 Hz, IH), 8.28 (s, IH), 7.92 - 7.84 (m, IH), 7.74 (br. s., IH), 7.64 (d, J=5.3 Hz, IH), 7.43 (d, J=7.9 Hz, IH), 7.26 (s, IH), 5.49 (d, J=6.5 Hz, IH), 2.09 (s, 3H), 1.49 (d, J=6.5 Hz, 3H)
Example 264
N-(4-(3-(6-Chloropyridin-3-yl)-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 264 was prepared from 5-bromo-2-chloropyridine by the general methods shown for Example 261. HPLC: RT = 0.77 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 408.2 [M+H] ; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.67 (s, IH), 8.53 (d, J=5.2 Hz, IH), 8.46 (d, J=2.0 Hz, IH), 8.39 (d, J=5.1 Hz, IH), 8.26 (s, IH), 7.94 (dd, J=8.2, 2.2 Hz, IH), 7.68 - 7.51 (m, 2H), 7.18 (d, J=4.9 Hz, 2H), 5.47 (q, J=6.2 Hz, IH), 3.00 - 2.84 (m, IH), 2.08 (s, 3H), 1.49 (d, J=6.4 Hz, 3H).
Example 265
N-(4-(3-(5-Fluoropyridin-2-yl)-7-(l-hydroxyethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 265 was prepared from 2-bromo-5-fiuoropyridine by the general methods shown for Example 261. HPLC: RT = 0.60 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 392.2 [M+H] ; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.45 (d, J=2.9 Hz, IH), 8.38 (d, J=5.1 Hz, IH), 8.27 (dd, J=5.3, 0.4 Hz, IH), 8.19 (s, IH), 7.81 - 7.66 (m, 2H), 7.36 (d, J=5.1 Hz, IH), 7.18 (dd, J=5.3, 1.5 Hz, IH), 5.44 (q, J=6.6 Hz, IH), 2.15 (s, 3H), 1.62 (d, J=6.6 Hz, 3H).
Example 266
N-(4-(7-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
The solution of 4-methoxypyridin-3 -amine (3.1 g, 24.97 mmol) in TFA (38.5 ml, 499 mmol) was stirred at ice bath temperature and to the mixture was added NBS (4.89 g, 27.5 mmol) in several batches. The reaction mixture was stirred at room temperature over night. The reaction mixture was concentrated in vacuo and the residue was diluted with satuarted NaHC03 solution and ethyl acetate. The organic layers (twice extracts) were combined and washed with saturated NaHC03 solution, dried over MgS04. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography. The product was eluted with 0-20% ethyl acetate in hexane to give the desired product as a white solid (3.9 g, 77%); HPLC: RT = 0.47 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 202.8, 204.8 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 7.75 (d, J=5.5 Hz, 1H), 6.69 (d, J=5.5 Hz, 1H), 4.11 (d, J=6.2 Hz, 2H), 3.92 (s, 3H).
266B) N-(4-((3-AiTiino-4-methoxypyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
To a solution of 2-bromo-4-methoxypyridin-3-amine (2.1 g, 10.34 mmol), N-(4- ethynylpyridin-2-yl)acetamide (1.82 g, 11.38 mmol) in DMF (15 mL) was added TEA (21.62 mL, 155 mmol) and Cul (0.12 g, 0.62 mmol). The reaction mixture was purged
with nitrogen for 2 min, followed by addition of Pd(PPh3)2Ch (0.73 g, 1.03 mmol). The reaction mixture was then heated at 100 °C for 3 h. The reaction mixture was cooled down and diluted with ethyl acetate and saturated NaHC03 solution. The organic layer
(two times extracts) were combined, washed with saturated NaHC03 solution, dried over MgS04. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography. The product was eluted with DCM to 50% of 10% MeOH in DCM to give the desired product as a light yellow (1.0 g, 34%); HPLC: RT = 0.48 min
(H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 283.1 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 10.59 (s, IH), 8.34 (dd, J=5.1, 0.7 Hz, IH), 8.22 (s, IH), 7.79 (d, J=5.3 Hz, IH), 7.34 (dd, J=5.2, 1.4 Hz, IH), 6.91 (d, J=5.3 Hz, IH), 5.35 (s, 2H), 4.03 (q, J=7.2 Hz, IH), 3.88 (s, 3H), 2.11 (s, 3H).
266C) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-4-methoxypyridin-3-yl)-2,2,2- trifluoroacetamide
To a suspension of N-(4-((3-amino-4-methoxypyridin-2-yl)ethynyl)pyridin-2- yl)acetamide (0.6 g, 2.13 mmol) in DCE (14 mL) (sonicated) in ice bath temperature was added TEA (1.19 mL, 8.50 mmol), followed by addition of trifluoroacetic anhydride (0.53 mL, 3.83 mmol) slowly. The reaction mixture was stirred at 0 °C for 15 min and it turned into clear solution. The reaction mixture was quenched with cold saturated NaHC03 solution and the resulting mixture was extracted with ethyl acetate three times.
The organic layer was separated and washed with saturated NaHC03 solution, dried over
MgS04. The filtrate was concentrated in vacuo to give to give brown solid. To the residue was added ether and the solid was filtered to give the desired product as a brown solid (0.42 g, 70%); HPLC: RT = 0.63 min (H2O/ACN with 0.05% TFA, Waters Acquity
SDS C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 379.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.32 (s, IH), 10.66 (s, IH), 8.52 (d, J=5.7 Hz, IH), 8.42 - 8.36 (m, IH), 8.20 (s, IH), 7.32 (d, J=5.7 Hz, IH), 7.13 (dd, J=5.1, 1.5 Hz, IH), 3.93 (s, 3H), 2.1 1 (s, 3H).
Example 266) N-(4-(7-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a suspension of N-(2-((2-acetamidopyridin-4-yl)ethynyl)-4-methoxypyridin-3- yl)-2,2,2-trifluoroacetamide (70 mg, 0.185 mmol), 2-bromo-5-methoxy pyridine (70 mg, 0.37 mmol) in DMF (2 mL) was added Cs2C03 (121 mg, 0.37 mmol). The reaction mixture was purged with nitrogen and followed by addition of 2nd generation Xphos precatalyst (7.5 mg, 9.3 μηιοΐ). The resulting mixture was heated at 120 °C for 3 h.The reaction mixture was cooled down. The residue was concentrated in vacuo and filtered and purified by preparative HPLC. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid (15.3 mg, 20.4%); HPLC: RT = 0.77 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7-μπι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 390.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.45 (s, IH), 8.29 (d, J=5.3 Hz, IH), 8.22 (d, J=5.3 Hz, 2H), 8.13 (d, J=2.9 Hz, IH), 7.96 (d, J=8.7 Hz, IH), 7.46 (dd, J=8.7, 3.0 Hz, IH), 7.1 1 (d, J=5.1 Hz, IH), 6.89 (d, J=5.4 Hz, IH), 4.03 (s, 3H), 3.83 (s, 3H), 2.07 (s, 3H).
Example 267
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-7-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 267 was prepared from 2-bromo-6-(difluoromethyl)pyridine by the general methods shown for Example 266. HPLC: RT = 0.94 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 410.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.72 (s, IH), 8.65 (d, J=6.6 Hz, IH), 8.43 (d, J=5.0 Hz, IH), 8.34 (s, IH), 7.98 (t, J=7.9 Hz, IH), 7.66 (d, J=7.7 Hz, IH), 7.54 (d, J=6.6 Hz, IH), 7.40 (d, J=6.5 Hz, IH), 7.28 (d, J=4.5 Hz, IH), 7.23 - 6.97 (m, IH), 4.27 (s, 3H), 2.09 (s, 3H).
Example 268
N-(4-(3-(5-Fluoropyridin-2-yl)-7-methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 268 was prepared from 2-bromo-5-fluoropyridine by the general methods shown for Example 266. HPLC: RT = 0.80 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ
ppm 10.46 (s, IH), 8.38 (d, J=2.9 Hz, IH), 8.31 (d, J=5.3 Hz, IH), 8.25 (d, J=5.1 Hz, IH), 8.18 (br. s., IH), 8.1 1 (dd, J=8.5, 4.6 Hz, IH), 7.77 (td, J=8.8, 2.9 Hz, IH), 7.16 (d, J=5.1 Hz, IH), 6.91 (d, J=5.4 Hz, IH), 4.03 (s, 3H), 2.06 (s, 3H).
Example 269
N-(4-(7-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 269 was prepared from 5 -bromo-2-methoxy pyridine by the general methods shown for Example 266. HPLC: RT = 0.76 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 390.3 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.11 (s, IH), 10.54 (s, IH), 8.28 (dd, J=5.0, 2.7 Hz, 3H), 8.19 (d, J=2.0 Hz, IH), 7.75 (dd, J=8.5, 2.3 Hz, IH), 7.12 (d, J=6.1 Hz, IH), 6.89 (d, J=5.4 Hz, IH), 6.83 (d, J=8.5 Hz, IH), 4.03 (s, 3H), 3.85 (s, 3H), 2.07 (s, 3H).
Example 270
N-(4-(3-(4-(Difluoromethyl)thiazol-2-yl)-7-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 270 was prepared from 2-bromo-4-(difluoromethyl)thiazole by the general methods shown for Example 266. HPLC: RT = 0.94 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 416.0 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.59 (s, 1H), 10.56 (s, 2H), 8.50 (s, 2H), 8.44 (d, J=5.4 Hz, 2H), 8.35 (d, J=5.2 Hz, 2H), 8.04 (s, 2H), 7.46 (d, J=4.0 Hz, 2H), 7.00 (d, J=5.5 Hz, 2H), 7.12 - 6.80 (m, 2H), 4.06 (s, 3H), 2.10 (s, 3H).
Example 271
N-(4-(7-Chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 271 was prepared from 6-methoxypyridin-3-ylboronic acid by the general methods shown for Example 266. HPLC: RT = 0.57 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394.1 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.38 (br. s., 1H), 10.59 (s, 1H), 8.36 (d, J=5.1 Hz, 1H), 8.35 - 8.28 (m, 2H), 8.25 -
8.15 (m, IH), 7.76 (dd, J=8.6, 2.4 Hz, IH), 7.41 (d, J=5.1 Hz, IH), 7.16 (dd, J=5.3, 1.5 Hz, IH), 6.85 (dd, J=8.6, 0.7 Hz, IH), 3.87 (s, 3H), 2.09 (s, 3H)
Example 272
N-(4-(6-Bromo-3-(6-(difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 272 was prepared from 2-bromo-6-(difluoromethyl)pyridine by the general methods shown for Example 1. HPLC: RT = 0.75 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 458, 460.1 [M+H]+; ¾ NMR (400 MHz, DMSO- de) δ ppm 12.39 (s, IH), 10.53 (s, IH), 8.54 (d, J=2.2 Hz, IH), 8.35 (s, IH), 8.32 - 8.25 (m, 2H), 8.1 1 (d, J=2.0 Hz, IH), 8.07 (t, J=7.9 Hz, IH), 7.56 (d, J=7.7 Hz, IH), 7.23 (dd, J=5.2, 1.7 Hz, IH), 6.85 - 6.51 (m, IH), 2.08 (s, 3H)
Example 273
Example 273 was prepared from 2-bromo-6-fluoropyridine by the general methods shown for Example 266. HPLC: RT = 0.80 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.51 (s, IH), 8.35 (d, J=5.3 Hz, IH), 8.30 (d, J=5.1 Hz, IH), 8.20 (s, IH), 8.15 (d, J=5.7 Hz, IH), 8.01 (q, J=8.1 Hz, IH), 7.20 (d, J=5.1 Hz, IH), 7.04 - 6.88 (m, 2H), 4.04 (s, 3H), 2.07 (s, 3H).
Example 274
N-(4-(7-(Hydroxymethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a solution of ethyl 3-aminoisonicotinate (7.0 g, 42.1 mmol) in DMF (40 mL) was added NBS (15.74 g, 88 mmol). The reaction mixture was stirred at room
temperature for 20 h. The reaction mixture was diluted with saturated NaHC03 solution and ethyl acetate. The organic layer was separated and washed with saturated NaHC03 solution, dried over MgS04. The filtrate was concentrated in vacuo. The crude product was dissolved in DCM and purified by flash chromatography. The product was eluted with 0-15% ethyl acetate in hexane to give the desired product as a white solid (9.6 g, 70%); HPLC: RT = 1.02 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 278.9, 280.9 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 7.81 (s, 1H), 6.26 (br. s., 2H), 4.39 (q, J=7.0 Hz, 2H), 1.42 (t, J=7.2 Hz, 3H).
274B) Ethyl 2-((2-acetanddopyridin-4-yl)ethynyl)-3-amino-6-bromoisonicotinate
To a solution of ethyl 3-amino-2,6-dibromoisonicotinate (4.0 g, 12.35 mmol) and N-(4-ethynylpyridin-2-yl)acetamide (2.18 g, 13.6 mmol) in DMF (20 mL) were added Cul (0.19 g, 0.99 mmol) and TEA (17.21 mL, 123 mmol). The reaction mixture was purged with nitrogen stream for 3 min, followed by addition of Pd(PPh3)2Ch (0.52 g, 0.74 mmol). The resulting mixture was heated at 80 °C for 2 h under nitrogen stream. The reaction mixture was cooded down and diluted with ethyl acetate and saturated NaHC03 solution. The ethyl acetate extracts (two times) were combined, washed with saturated NaHC03 solution, dried over MgS04. The filtrate was concentrated in vacuo. To the residue was added DCM, and the mixture was filtered to give light tan solid as the desired
prodicut (3.5 g). The filtrate was purified by flash chromatography. The product was eluted with 0-30% ethyl acetate in DCM to give the desired product as a yellow solid, total weight (4.0 g, 80%); HPLC: RT = 0.92 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 402.9, 404.9 [M+H]+; ¾ NMR (400 MHz, CDCh) δ ppm 8.37 (s, IH), 8.29 (d, J=5.1 Hz, IH), 8.01 (s, IH), 7.85 (s, IH), 7.20 (dd, J=5.2, 1.4 Hz, IH), 6.36 (br. s., 2H), 4.41 (q, J=7.0 Hz, 2H), 2.24 (s, 3H), 1.43 (t, J=7.2 Hz, 3H).
274C) Ethyl 2-(2-acetamidopyridin-4-yl)-5-bromo-lH-pyrrolo[3,2-b]pyridine-7- carboxylate
To a suspension of ethyl 2-((2-acetamidopyridin-4-yl)ethynyl)-3-amino-6- bromoisonicotinate (2.0 g, 4.96 mmol) and CS2CO3 (2.42 g, 7.44 mmol) in CH3CN (30 mL) was purged with nitrogen stream for 2 min, was added Pd(PPh3)4 (0.344 g, 0.298 mmol). The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was diluted with ethyl acetate and filtered to give black filtrate. The solid on the funnel was washed with ethyl acetate. The total filtrate was concentrated in vacuo to give black solid. To the solid on the funnel was added water. The mixtrue was stirred with a spatura and filtered to give black solid 2, dried on high vacuum. The black solid 2 was mixed with THF+MeOH, sonicated and filtered. The filtrate was concentrated in vacuo to give black solid 3 as the desired product of ethyl and methyl ester mixture (1.0 g, 50%); HPLC: RT = 0.80 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 403.0, 405.0
[M+H]+; ¾ NMR (400MHz, DMSO-de) δ ppm 11.70 (s, IH), 10.62 (s, IH), 8.55 (s, IH), 8.43 (d, J=5.3 Hz, IH), 7.76 - 7.62 (m, 2H), 7.25 (s, IH), 4.49 (q, J=7.2 Hz, 2H), 2.14 (s, 3H), 1.43 (t, J=7.2 Hz, 3H).
274D) Methyl 2-(2-acetamidopyridin-4-yl)-lH-pyrrolo[3,2-b]pyridine-7-carboxylate
To the reaction mixture of methyl 2-(2-acetamidopyridin-4-yl)-5-bromo-lH- pyrrolo[3,2-b]pyridine-7-carboxylate (1 10 mg, 0.283 mmol) in MeOH (8 mL) and THF (4 mL) was added Pd-C (20 mg, 0.028 mmol) and the mixture was sonicated, evacuated, then hydrogenated with hydrogen balloon for 4 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was extracted with CHCl3:2-propanol
(2.5 : 1). The organic layer was washed with saturated NaHC03 solution, dried over
MgS04. The filtrate was concentrated in vacuo to give yellow solid as the desired product
(60 mg, 68%); HPLC: RT = 0.51 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 31 1.0 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 1 1.44 (s, 1H), 10.60 (s, 1H), 8.60 - 8.51 (m, 2H), 8.42 (d, J=5.3 Hz, 1H), 7.69 (dd, J=5.3, 1.5 Hz, 1H), 7.64 (d, J=4.8 Hz, 1H), 7.25 (d, J=2.0 Hz, 1H), 4.07 - 4.00 (m, 3H), 2.15 (s, 3H).
274E) N-(4-(7-(Hydroxymethyl)-lH-pyiTolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of methyl 2-(2-acetamidopyridin-4-yl)-lH-pyrrolo[3,2-b]pyridine-7- carboxylate (0.6 g, 1.93 mmol) in MeOH (15 mL) and THF (15 mL) was added LiBr (0.34 g, 3.87 mmol) and NaBH4 (0.37 g, 9.67 mmol) in several batches. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated in vacuo. The residue was extracted with CHCl3:2-propanol (2: 1). The organic layer was
washed with saturated NaHC03 solution, dried over MgS04, concentrated in vacuo to give the desired product as a yellow solid (0.28 g, 51 %). HPLC: RT = 0.44 min
(H2O/ACN with 0.05% TFA, Waters Acquity SDS C 18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 283.1 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.58 (d, J=5.9 Hz, IH), 8.48 (d, J=5.3 Hz, IH), 7.84 (d, J=6.2 Hz, IH), 7.70 (dd, J=5.4, 1.7 Hz, IH), 7.37 (s, IH), 5.27 (s, 2H), 2.25 (s, 3H).
274F) N-(4-(7-(Hydroxymethyl)-3-iodo-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
To a solution of N-(4-(7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide (25 mg, 0.089 mmol) in DMF (1 mL) was added NIS (22 mg, 0.097 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was purified by preparative HPLC. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid ( 13 mg, 36%); HPLC: RT = 0.48 min (H2O/ACN with 0.05% TFA, Waters Acquity SDS C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 1.8 min, wavelength = 220 nm); MS (ES): m/z = 408.8 [M+H]+; ¾ NMR (400 MHz, MeOH-d4) δ ppm 8.64 (s, IH), 8.60 (d, J=6.2 Hz, IH), 8.52 (d, J=5.3 Hz, IH), 7.89 (d, J=6.2 Hz, IH), 7.59 (dd, J=5.2, 1.7 Hz, IH), 5.23 (s, 2H), 2.24 (s, 3H).
Example 274 N-(4-(7-(Hydroxymethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
The suspension of N-(4-(7-(hydroxymethyl)-3-iodo-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide (60 mg, 0.147 mmol) and (6-methoxypyridin-3-yl)boronic acid
(27.0 mg, 0.176 mmol) in dioxane (2 mL) and aqueous Na2C03 solution (0.37 mL, 0.37 mmol) was purged with nitrogen stream for 3 min, followed by addition of PdCl2(dppf) (10.8 mg, 0.015 mmol). The resulting mixture was heated at 90 °C for 2 h. The reaction mixture was concentrated in vacuo. The residue was purified by preparative HPLC. Fractions containing the desired product were combined, concentrated, and lyophilized to give the desired product as a yellow solid (23 mg, 39%); HPLC: RT = 0.71 min
(H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιη particles, gradient = 3 min, wavelength = 220 nm);MS (ES): m/z = 390.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.75 (s, IH), 10.58 (s, IH), 8.38 (d, J=4.6 Hz, IH), 8.31 (d, J=5.1 Hz, IH), 8.28 (s, IH), 8.21 (d, J=1.9 Hz, IH), 7.77 (dd, J=8.5, 2.3 Hz, IH), 7.28 (d, J=4.5 Hz, IH), 7.12 (d, J=4.0 Hz, IH), 6.85 (d, J=8.5 Hz, IH), 5.55 (t, J=5.7 Hz, IH), 4.90 (d, J=5.6 Hz, 2H), 3.86 (s, 3H), 2.08 (s, 3H).
Example 275
N-(4-(3-(6-Fluoropyridin-2-yl)-7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 275 was prepared from 2-bromo-6-fluoropyridine by the general methods shown for Example 274. HPLC: RT = 0.72 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 377.9 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.57 (s, IH), 8.46 (d, J=4.7 Hz, IH), 8.34 (d, J=5.1 Hz, IH), 8.24 (d, J=4.2 Hz, 2H), 8.03 (q, J=8.1 Hz, IH), 7.32 (d, J=4.6 Hz, IH), 7.22 (d, J=5.1 Hz, IH), 6.97 (dd, J=8.1, 2.4 Hz, IH), 4.91 (s, 2H), 2.08 (s, 3H).
Example 276
N-(4-(3-(6-Chloropyridin-2-yl)-7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 276 was prepared from 2-bromo-6-chloropyridine by the general methods shown for Example 274. HPLC: RT = 0.80 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.59 (s, IH), 8.49 (d, J=4.8 Hz, IH), 8.35 (d, J=5.1 Hz, IH), 8.28 (s, IH), 8.22 (d, J=6.9 Hz, IH), 7.90 (t, J=7.8 Hz, IH), 7.38 (d, J=4.6 Hz, IH), 7.33 (d, J=7.8 Hz, IH), 7.23 (d, J=5.1 Hz, IH), 4.94 (s, 2H), 2.09 (s, 3H).
Example 277
N-(4-(3-(6-Fluoropyridin-3-yl)-7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 277 was prepared from 5-bromo-2-fluoropyridine by the general methods shown for Example 274. HPLC: RT = 0.63 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 378.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.61 (s, IH), 8.45 - 8.33 (m, 2H), 8.27 (br. s., 2H), 8.13 - 7.99 (m, IH), 7.31 (d, J=4.5 Hz, IH), 7.25 - 7.12 (m, 2H), 4.92 (s, 2H), 2.08 (s, 3H).
Example 278
N-(4-(3-(6-Chloropyridin-3-yl)-7-(hydroxymethyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 278 was prepared from 5-bromo-2-chloropyridine by the general methods shown for Example 274. HPLC: RT = 0.71 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 394.1 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 13.01 (br. s., IH), 10.70 (s, IH), 8.60 (d, J=5.6 Hz, IH), 8.47 (d, J=2.1 Hz, IH), 8.40 (d, J=5.0 Hz, IH), 8.26 (s, IH), 7.92 (dd, J=8.2, 2.3 Hz, IH), 7.68 (d, J=5.4 Hz, IH), 7.61 (d, J=8.2 Hz, IH), 7.17 (d, J=3.5 Hz, IH), 5.10 (s, 2H), 2.08 (s, 3H).
Example 279
N-(4-(7-(Hydroxymethyl)-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 279 was prepared from 2-bromo-6-methylpyridine by the general methods shown for Example 274. HPLC: RT = 0.58 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374.2 [M+H]+
Example 280
N-(4-(7-(Hydroxymethyl)-3-(6-methylpyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 280 was prepared from 5-bromo-2-methylpyridine by the general methods shown for Example 274. HPLC: RT = 0.47 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374.2 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.66 (s, 1H), 8.68 (br. s., 1H), 8.48 (d, J=4.9 Hz, 1H), 8.36 (d, J=5.0 Hz, 1H), 8.27 (br. s., 1H), 8.03 (br. s., 1H), 7.54 (d, J=8.2 Hz, 1H), 7.45 (br. s., 1H), 7.16 (d, J=4.5 Hz, 1H), 4.98 (s, 2H), 2.59 (s, 3H), 2.08 (s, 3H).
Example 281
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 281 was prepared from Example ID and 2-bromo-6- (difluoromethyl)pyridine by the general methods shown for Example 1. HPLC: RT = 0.83 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 380 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.56 (s, 1H), 8.49 (d, J=4.3 Hz, 1H), 8.44 - 8.26 (m, 3H), 8.07 (t, J=7.8 Hz, 1H), 7.93 (d, J=8.1 Hz, 1H), 7.55 (d, J=7.7 Hz, 1H), 7.38 - 7.22 (m, 2H), 6.84 - 6.48 (m, 1H), 2.09 (s, 3H)
Example 282
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 282A was prepared from Example IB and 2-bromo-5-methoxypyridin-3- amine by similar methods as shown for Example 1C. HPLC: RT = 0.80 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 283 [M+H]+.
282B):N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-methoxypyridin-3-yl)-2,2,2- trifluoroacetamide
Example 282B was prepared from Example 282A by methods similar to those shown for Example ID. HPLC: RT = 0.97 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.0 x 50 mm, 1.7-μηι particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 379 [M+H]+ .
Example 282 was prepared from Example 282B and 2-bromo-6- (difluoromethyl)pyridine by the general methods shown for Example 1. HPLC: RT = 0.94 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 410 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.65 (s, 1H), 8.46 - 8.24 (m, 4H), 8.14 (br. s., 1H), 8.09 - 7.99 (m, 1H), 7.79 - 7.49 (m, 3H), 7.25 (d, J=4.9 Hz, 2H), 6.97 - 6.56 (m, 2H), 3.94 (s, 3H), 2.09 (s, 3H)
Example 283
N-(4-(6-Methoxy-3-(6-methylpyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 283 was prepared from Example 282B and 2-bromo-6-methylpyridine by the general methods shown for Example 1. HPLC: RT = 0.74 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 374 [M+H]+; ¾ NMR (500 MHz, DMSO- de) δ ppm 10.67 (s, IH), 8.42 (d, J=5.0 Hz, IH), 8.38 - 8.26 (m, 2H), 8.19 (br. s., IH), 7.84 (d, J=7.9 Hz, IH), 7.71 (d, J=6.8 Hz, IH), 7.53 (s, IH), 7.30 (d, J=4.7 Hz, IH), 3.94 (s, 3H), 2.66 (s, 3H), 2.08 (s, 3H)
Example 284
N-(4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
Example 284 was prepared from Example 282B and 2-bromo-5-methoxypyridine by the general methods shown for Example 1. HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 390 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ
ppm 1 1.81 (br. s., IH), 10.51 (br. s., IH), 8.40 - 8.07 (m, 4H), 7.95 (d, J=4.8 Hz, IH), 7.49 (br. s., IH), 7.35 (br. s., IH), 7.1 1 (br. s., IH), 3.99 - 3.76 (m, 6H), 2.09 (br. s., 3H)
Example 285
N-(4-(6-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
285 A): N-(4-(6-Methoxy-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of 282A in THF (4 mL) was added 1M potassium tert-butoxide in THF (2.1 mL, 2.1 mmol). The mixture was heated to 70°C and stirred for 2.5 h, then cooled to room temperature. The semi-solid was dissolved in MeOH, and dry loaded on celite, and then purified by silica gel chromatography (24 g, MeOH/DCM=0-10%) to give 285A (187 mg, 94%). HPLC: RT = 0.82 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C 18, 2.0 x 50 mm, 1.7-μτη particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 283 [M+H]+ ; ¾ NMR (400 MHz, DMSO-de) δ ppm 11.84 (s, IH), 10.53 (s, IH), 8.46 (s, IH), 8.35 (dd, J=5.3, 0.7 Hz, IH), 8.15 (d, J=2.6 Hz, IH), 7.54 (dd, J=5.3, 1.5 Hz, IH), 7.33 - 7.26 (m, IH), 7.11 (d, J=1.5 Hz, IH), 3.87 (s, 3H), 2.15 (s, 3H).
Example 285B was prepared from Example 285A by the general methods shown for Example 14B. HPLC: RT = 0.84 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μτη particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 361 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.10 (s, IH), 10.62 (s, IH), 8.73 (s, IH), 8.49 - 8.39 (m, IH), 8.23 (d, J=2.4 Hz, IH), 7.57 (dd, J=5.3, 1.8 Hz, IH), 7.33 (d, J=2.4 Hz, IH), 3.90 (s, 3H), 2.15 (s, 3H)
Example 285 was prepared from Example 285B and (6-methoxypyridin-3- yl)boronic acid by the general methods shown for Example 14. HPLC: RT = 1.19 min (H2O/CAN with 10 mM ammonium acetate, Waters Acquity UPLC BEH CI 8, 2.0 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 390 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 11.86 (s, IH), 10.56 (s, IH), 8.29 (d, J=5.0 Hz, 2H), 8.23 (s, IH), 8.17 (s, IH), 7.77 (d, J=8.5 Hz, IH), 7.36 (s, IH), 7.09 (d, J=5.1 Hz, IH), 6.86 (d, J=8.5 Hz, IH), 3.88 (br. s., 3H), 3.87 (br. s., 3H), 2.09 (s, 3H)
Example 286
286A): 2-Chloro-N-(4-(3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 286A was prepared from Example 52 by the general methods shown for Example 74A. HPLC: RT = 0.87 min (H2O/CAN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 394 [M+H]+
N-(4-(3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2- morpholinoacetamide
A mixture of 286A (30 mg, 0.076 mmol), morpholine (19.91 mg, 0.229 mmol) and K2CO3 (31.6 mg, 0.229 mmol) in DMF (0.5 mL) was stirred at room temperature for 3.h. Diluted with EtOAc, the resulting mixture was filtered through celite, and eluted with 10% MeOH/DCM. The filtrate was concentrated. The residue was purified by preparative HPLC (Column: Waters XBridge C I 8, 19 x 200 mm, 5-μιη particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-60% B over 15 minutes, then a 5 minute hold at 100% B; Flow: 20 mL/min.) to give Example 286 (19.6 mg, 58%). HPLC: RT = 0.62 min (H2O/CAN with 0.1 % TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μιτι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 445 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.08 (br. s., IH), 10.12 (s, IH), 8.50 - 8.30 (m, 4H), 8.25 (br. s., IH), 7.88 (d, J=8.2 Hz, IH), 7.80 (d, J=8.5 Hz, IH), 7.26 (dd, J=7.8, 4.5 Hz, IH), 7.18 (d, J=4.8 Hz, IH), 6.87 (d, J=8.4 Hz, IH), 3.88 (s, 3H), 3.63 (br. s., 3H), 3.44 (br. s., 4H), 3.20 (s, 2H)
Example 287
N-(4-(3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-(4- methy lpiperazin- 1 -y l)acetamide
Example 287 was prepared from Example 286A and 1 -methylpiperazine by the general methods shown for Example 286. HPLC: RT = 0.59 min (H2O/ACN with 0.1 % TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 458 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 10.04 (s, IH), 8.50 - 8.31 (m, 3H), 8.26 (s, IH), 7.88 (d, J=8.2 Hz, IH), 7.84 - 7.74 (m, IH), 7.26 (dd, J=8.1 , 4.5 Hz, IH), 7.18 (d, J=5.0 Hz, IH), 6.87 (d, J=8.5 Hz, IH), 3.88 (s, 3H), 2.53 - 2.36 (m, 10H), 2.21 (s, 3H)
Example 288
2-(4-(2-Hydroxyethyl)piperazin-l -yl)-N-(4-(3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
Example 288 was prepared from Example 286A and 2-(piperazin-l-yl)ethanol by the general methods shown for Example 286. HPLC: RT = 0.62 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 488 [M+H]+; ¾ NMR (500 MHz, DMSO- de) δ ppm 8.41 (d, J=4.0 Hz, IH), 8.37 - 8.30 (m, 2H), 8.24 (s, IH), 7.88 (d, J=7.9 Hz, IH), 7.83 - 7.70 (m, IH), 7.26 (dd, J=8.1, 4.5 Hz, IH), 7.18 (d, J=5.5 Hz, IH), 6.87 (d, J=8.5 Hz, IH), 3.88 (s, 3H), 3.51 (br. s., 2H), 2.51 (br. s., 12H), 1.91 (s, 2H)
Example 289
4-(6-Chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-
Example 289 was prepared from Example 43 by the general methods shown for Example 14. HPLC: RT = 0.91 min (H2O/CAN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 352 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ ppm 12.07 (s, IH), 8.39 (d, J=2.2 Hz, IH), 8.28 (d, J=1.8 Hz, IH), 7.96 (d, J=5.3 Hz, IH), 7.89 (d, J=2.2 Hz, IH), 7.79 (dd, J=8.6, 2.4 Hz, IH), 6.88 (d, J=8.6 Hz, IH), 6.62 - 6.50 (m, 2H), 6.09 (s, 2H), 3.89 (s, 3H).
Example 290
N-(4-(6-Chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-
290A): 2-Chloro-N-(4-(6-chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 290A was prepared from Example 289 by the general methods shown for Example 74A. HPLC: RT = 0.98 min (H2O/CAN with 0.1% TFA, Waters Acquit UPLC BEH C18, 2.0 x 50 mm, 1.7-μτη particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 428 [M+H]+
Example 290 was prepared from Example 290A and morpholine by the general methods shown for Example 286. HPLC: RT = 1.01 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 479 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ ppm 12.28 (s, IH), 10.14 (br. s., IH), 8.42 (s, IH), 8.38 - 8.30 (m, 2H), 8.23 (s, IH), 7.97 (s, IH), 7.77 (d, J=8.5 Hz, IH), 7.17 (d, J=5.0 Hz, IH), 6.88 (d, J=8.6 Hz, IH), 3.88 (s, 3H), 3.63 (br. s., 4H), 3.24 - 3.13 (m, 2H).
Example 291
N-(4-(6-chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-
(4-ethy lpiperazin- 1 -y l)acetamide
Example 291 was prepared from Example 290A and 1 -ethylpiperazine by the general methods shown for Example 286. HPLC: RT = 1.05 min (H2O/ACN with 0.1% TFA, Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 506 [M+H]+.
Example 292
N-(4-(6-chloro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-
(4-methy lpiperazin- 1 -yl)acetamide
Example 292 was prepared from Example 290A and 1 -methylpiperazine by the general methods shown for Example 286. HPLC: RT = 1.03 min (H2O/ACN with 0.1% TFA, Waters Acquit UPLC BEH CI 8, 2.1 x 50 mm, 1.7-μηι particles, gradient = 3 min, wavelength = 220 nm); MS (ES): m/z = 492 [M+H]+
Example 293
N-(4-(3 5-Methoxypyridin-2-yl)-6-((methylamino)methyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
293A) N-(4-((3-Amino-5-bromopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
A mixture of 2,5-dibromopyridin-3-amine (6.89 g, 27.3 mmol, from Combi- Blocks, Inc.), N-(4-ethynylpyridin-2-yl)acetamide (3.98 g, 24.85 mmol), copper(I) iodide (0.237 g, 1.242 mmol) in triethylamine (90 mL) and DMF (70 mL) was purged with Ν2. Solid PdCh(PPh3)2 (0.174 g, 0.248 mmol)was added and the reaction mixture was purged with Ν2. The reaction mixture was heated at 75 °C for 90 min under a N2 atm and then concentrated in vacuo. To the residue was added 100 mL of CH2CI2 and the resulting mixture was sonicated briefly and stirred at room temperature for 10 minutes. The solid
was filtered and washed with CH2CI2 to obtain the desired compound (5.1 g,) after drying. The filtrate was concentrated and residue was mixed with Celite which was passed through a flash column on S1O2 (solid load, gradient of 100% CH2CI2 to 10% MeOH in CH2CI2) to obtain additional desired product (0.9 g). Total 6 g (73 %).MS (ES): m/z= 331, 333 [M+H]+ ; ¾ NMR (500MHz, DMSO-de) δ 10.62(s, 1H), 8.35 (d, J=5.0 Hz, 1H), 8.23 (s, 1H), 7.86 (d, J=1.7Hz, 1H), 7.37-7.33 (m, 2H), 6.13 (s, 1H), 2.11 (s, 3H).
293B) N-(2-((2-Acetamidopyridin-4-yl)ethynyl)-5-bromopyridin-3-yl)-2,2,2- trifluoroacetamide
To a heterogeneous mixture of 293 A (4 g, 12.08 mmol) and Et3N (6 mL) in CH2CI2 (100 mL) at ice bath temperature was added 2,2,2-trifluoroacetic anhydride (1.4 mL, 10.07 mmol) slowly and it was stirred at the ice bath temperature for 1 h. The reaction mixture was mixed with di-basic phosphate buffer (4.5 g of K2HPO4 in 30 mL water), the organic layer was separated, dried over MgS04, concentrated in vacuo and the residue was passed through a flash column on S1O2 (gradient of 100% CH2CI2 to 100% EtOAc, product was eluted at 40-55% EtOAc) to obtain 293B (2.8 g, 6.55 mmol, 54 %) as a white solid. MS (ES): m/z = 427, 429 [M+H]+ ; ¾ NMR (400MHz,
CHLOROFORM-d) δ 8.94 (d, J=2.0 Hz, 1H), 8.69 (br. s., 1H), 8.58 (d, J=2.0 Hz, 1H), 8.50 (br. s., 1H), 8.31 (d, J=4.6 Hz, 1H), 2.27 (s, 3H).
A mixture of 293B (1.5 g, 3.51 mmol), 2-bromo-5-methoxy pyridine (1.651 g, 8.78 mmol) and cesium carbonate (2.86 g, 8.78 mmol) in MeCN (13 mL) in a sealed tube was purged with N2. Pd(Ph3P)4 (0.406 g, 0.351 mmol) was added and the mixture was purged with N2 again. The reaction mixture was put in a preheated heater at 110 °C, stirred at that temperature for 3h and cooled to room temperature. To the reaction mixture was added 15 mL water, the mixture was stirred and then the solid was collected by filtration, washed with water and then CH2CI2 to obtain 293C (1 g, 2.282 mmol, 65 %). MS (ES): m/z = 438, 440 [M+H]+; ¾ NMR (400MHz, DMSO-de) δ 12.16 (s, IH), 10.53 (s, IH), 8.49 (d, J=2.0 Hz, IH), 8.31 (s, IH), 8.28 (d, J=5.3 Hz, IH), 8.20 (d, J=2.9 Hz, IH), 8.06 (d, J=2.0 Hz, IH), 7.95 - 7.92 (m, IH), 7.49 (dd, J=8.6, 3.1 Hz, IH), 7.12 (dd, J=5.1, 1.5 Hz, IH), 3.86 (s, 3H), 2.09 (s, 3H).
293D) N-(4-(6-Bromo-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of 293C (765 mg, 1.745 mmol), cesium carbonate (1137 mg, 3.49 mmol) and (2-(chloromethoxy)ethyl)trimethylsilane (437 mg, 2.62 mmol) in THF (12 mL) and DMF (12 mL) was stirred at room temperature for 30 min. To the reaction mixture were added CH2CI2 and water. The CH2CI2 layer was separated, dried over MgS04, concentrated in vacuo and the residue was purified by flash column on S1O2 (gradient of 100% CH2CI2 to 80% EtOAc in CH2CI2, product was eluted at 30-40% EtOAc in CH2CI2) to obtain 294D (625 mg, 1.099 mmol, 63 %). MS (ES): m/z = 568, 570 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.65 (d, J=2.0 Hz, 1H), 8.33 (s, 1H), 8.28 - 8.24 (m, 2H), 8.05 (d, J=2.0 Hz, 1H), 7.80 (d, J=8.6 Hz, 1H), 7.30 (dd, J=8.7, 3.0 Hz, 1H), 7.14 (dd, J=5.2, 1.4 Hz, 1H), 5.43 (s, 2H), 3.85 (s, 3H), 3.42 - 3.36 (m, 2H), 2.19 (s, 3H), 0.85 - 0.80 (m, 2H), -0.08 (s, 9H).
293E) N-(4-(6-Formyl-3-(5-methoxypyridin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of 293D (740 mg, 1.302 mmol) in THF (8 mL) at -78 °C was added 1 mL of 1.6M MeLi in ether under Ν2 with stirring. In 15 minutes was added 0.8 mL of 2M nBuLi solution at -78 °C, stirred for 15 minutes. To the resulting heterogeneous mixture was added 1 mL DMF and it was stirred for 40 minutes. HO Ac (1 mL) was added, and the mixture was concentrated to a volume of ~4 mL and then the residue was passed through a flash column on S1O2 eluting with a gradient of 100% CH2CI2 to 10% MeOH in CH2CI2 (product was eluted at -50% of 10% MeOH in CH2CI2) to obtain 293E (130 mg, 0.251 mmol, 19 %). MS (ES): m/z = 518 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 10.18 (s, 1H), 9.43 (s, 1H), 9.04 (d, J=1.5 Hz, 1H), 8.42-8.40 (m, 2H), 8.32-8.38 (m, 2H), 7.84 (d, J=8.6 Hz, 1H), 7.18 (dd, J=8.7, 3.0 Hz, 1H), 7.04 (dd,
J=5.2, 1.2 Hz, 1H), 5.53 (s, 2H), 3.81 (s, 3H), 3.44 - 3.37 (m, 2H), 2.09 (s, 3H), 0.86 - 0.77 (m, 2H), -0.45 (s, 9H).
Example 293) N-(4-(3-(5-Methoxypyridin-2-yl)-6-((methylamino)methyl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of 293E (40 mg, 0.077 mmol) and 0.6 mL of 2M MeNH2 in THF in CH2CI2 (2 mL) and iPrOH (2 mL) was stirred at room temperature for 20 min. The reaction mixture was cooled in an ice bath and NaBH4 (-50 mg) was added. The reaction mixture was stirred for 30 min. Acetone (5 mL) was added, and the mixture was stirred for 10 minutes. TFA (~1 mL) was added and the mixture was concentrated in vacuo and the residue was purified by Prep HPLC to obtain -17 mg of the SEM-protected methylaminomethyl intermediate as a TFA salt. Prep HPLC: Column #1, 20% B to 100% B over 8 min, RT = 3.6 min. Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-O. /0 TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. MS (ES): m/z = 533 [M+H]+; ¾ NMR (400MHz, METHANOLS) δ 8.84 (d, J=1.5 Hz, 1H), 8.64 (d, J=1.8 Hz, 1H), 8.59 (dd, J=5.1, 0.9 Hz, 1H), 8.55 (d, J=2.6 Hz, 1H), 8.35 (s, 1H), 7.76 (dd, J=9.1, 3.0 Hz, 1H), 7.38 (d, J=9.0 Hz, 1H), 7.34 (dd, J=5.1, 1.5 Hz, 1H), 4.55 (s, 2H), 3.99 (s, 3H), 3.48 (dd, J=8.8, 7.7 Hz, 2H), 2.84 (s, 4H), 2.18 (s, 3H), 0.88 - 0.67 (m, 2H), -0.07 (s, 9H).
The SEM-protected methylaminomethyl intermediate obtained above was mixed with 1.5 mL CH2CI2 and 1.5 mL TFA at room temperature and was stirred for 1 h at room temperature. The mixture was concentrated in vacuo and the residue was purified by prep HPLC to obtain Example 294 (1.6 mg, 5% overall yield). Prep HPLC: Column #1, 10% B to 60% B over 8 min, RT = 2.7-4 min. Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H20-5mmol NH4OAc; Solvent B = 90% CH3CN/10% H20~5mmol NH4OAc. Analytical HPLC: RT = 0.48 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιτι particles, gradient = 1.5 min, wavelength = 220 nm). MS (ES): m/z = 403 [M+H]+; ¾ NMR (400MHz, METHANOLS) δ 8.47 (d, J=2.0 Hz, 1H), 8.28 (d, J=2.6 Hz, 1H), 8.27 - 8.24 (m, 2H), 8.08 (d, J=2.0 Hz, 1H), 7.63 (dd, J=8.6, 0.4 Hz, 1H), 7.53 (dd, J=8.7, 3.0 Hz, 1H), 7.11 - 7.08 (m, 1H), 4.37 (s, 2H), 3.95 (s, 3H), 2.77 (s, 3H), 2.16 (s, 3H).
Example 294
N-(4-(3-(5-methoxypyridin-2-yl)-6-((propylamino)methyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
Example 294 was prepared in a similar way as Example 293. HPLC: RT = 0.55 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C 18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm). MS (ES): m/z = 431 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.54 (s, IH), 8.43 (s, IH), 8.31 (br. s., IH), 8.27 (d, J=5.0 Hz, IH), 8.18 (d, J=2.5 Hz, IH), 8.00 (d, J=8.7 Hz, IH), 7.88 (s, IH), 7.49 (dd, J=8.5, 2.7 Hz, IH), 7.12 (d, J=4.9 Hz, IH), 4.04 ( s., 2H), 3.44 (br. s., 3H), 2.66 (t, J=7.3 Hz, 2H), 2.54 (s, 2H), 2.09 (s, 3H), 1.58 - 1.48 (m, 2H), 0.89 (t, J=7.4 Hz, 3H).
Example 295
3-(2-(2-Acetamidopyridin-4-yl)-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-6- yl)-2,2-difluoro-3-hydroxypropanamide
(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-6-yl)-2,2-difluoro-3- hydroxypropanamide
To a solution of aldehyde 293E (100 mg, 0.193 mmol) in THF (3 mL) was added 7 mL of (2-ethoxy-l,l-difluoro-2-oxoethyl)zinc(II) bromide (0.5 M solution in THF from Rieke Metals, RiekeMetals.com) under a N2 atm. The reaction mixture was stirred at room temperature for 4 h. 7N NH3 in MeOH solution (4 mL) was added at room temperature. The resulting solid was filtered and the filtrate was concentrated in vacuo. The residue was passed through a flash column on S1O2 eluting with a gradient of 10% MeOH in CH2CI2- CH2CI2 solvent system to obtain Example 295A (20 mg, 0.033 mmol, 17 %). MS (ES): m/z = 613 [M+H]+; ¾ NMR (400M Hz, METHANOLS) δ 8.56 (d, J=5.1 Hz, 1H), 8.54 (br. s., 1H), 8.34 (br. s., 1H), 8.02 (br. s., 1H), 7.94 (s, 1H), 7.34 (dd, J=9.2, 2.9 Hz, 1H), 7.28 (d, J=4.0 Hz, 1H), 7.10 (d, J=9.2 Hz, 1H), 5.58 (s, 2H), 3.77 (s, 3H), 3.45 - 3.39 (m, 2H), 3.27 (dt, J=3.2, 1.6 Hz, 1H), 2.17 (s, 3H), 0.81 - 0.75 (m, 2H), - 0.12 (s, 9H).
Example 295) 3-(2-(2-Acetamidopyridin-4-yl)-3-(5-methoxypyridin-2-yl)-lH- pyrrolo[3,2-b]pyridin-6-yl)-2,2-difluoro-3-hydroxypropanamide
To a solution of 295A (20 mg, 0.033 mmol) in CH2CI2 (5 mL) was added 1 mL of TFA at room temperature and it was stirred for 3 h. The reaction mixture was concentrated, and to the residue was added 0.3 mL Et3N. The mixture was concentrated and the residue was mixed with 0.3 mL of Et3N and then passed through a flassh column
on SiC eluting with CH2CI2- 10% MeOH in a CH2CI2 gradient. Followed by elution with 20% MeOH and 1% EtsN in CH2CI2 to provide -24 mg of the slightly impure product. This material was repurified by prep HPLC (RT = 2.7-3.4 min) to obtain Example 295 (4.5 mg, 8.39 μπιοΐ, 26 %). Prep HPLC: Column #1, 20% B to 100% B over 8 min; Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10%
CH3CN/90% H20-5mmol NH4OAc; Solvent B = 90% CH3CN/10% H20~5mmol
NH4O Ac. Analytical HPLC: RT = 0.54 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm). MS (ES): m/z = 483 [M+H]+; ¾ NMR (400 MHz, METHANOLS) δ 8.45 (s, 1H), 8.27 (d, J=2.9 Hz, 1H), 8.25 - 8.22 (m, 2H), 8.05 (d, J=l. l Hz, 1H), 7.64 (d, J=8.6 Hz, 1H), 7.53 (dd, J=8.6, 2.9 Hz, 1H), 7.12 - 7.09 (m, 1H), 5.37 (dd, J=16.3, 8.6 Hz, 1H), 3.95 (s, 3H), 2.15 (s, 3H).
Example 296
N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoroacetyl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
296A) N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoroacetyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide, 2 (99893-307)
To a solution of Example 293D (300 mg, 0.528 mmol) in THF (5 mL) at -78 °C was added 0.4 mL of 1.6M MeLi solution in ether. After 10 minutes was added 0.25 mL of 2.5M nBuLi solution in hexane and the mixture was stirred for 30 min at -78 °C. 2,2,2- trifluoro-N-methyl-N-(2,2,2-trifluoroacetyl)acetamide (0.2 mL, 0.528 mmol) (from TCI company) was added and the mixture was stirred for 1 h.To the reaction mixture was added MeOH and 100 uL of TFA. The mixture was warmed to room temperature and directly purified by prep HPLC to obtain a partially purified product, which was used for the next step as it is. Prep HPLC: Column #1, 20% B to 100% B over 8 min, RT = 5.2-6 min. Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-0.1% TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. LCMS shows a hydrated mass, MS (ES): m/z = 604 [M+H20+H]+
Example 296) N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoroacetyl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
The partially purified material obtained above (Example 296A) was mixed with 5 mL CH2CI2 and 2 mL TFA at room temperature and stirred for 7.5 h. The reaction mixture was then concentrated in vacuo and the residue was purified by prep HPLC: RT = 3.1 min. Prep HPLC: Column #1, 20% B to 100% B over 8 min, Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-0.1% TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. The material obtained was repurified by prep HPLC to afford Example 297 (9 mg, 0.018 mmol, 3 %). Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H20-5mmol NH4OAc; Solvent B = 90% CH3CN/10% H20~5mmol NH4OAc, 9 mg, (0.018 mmol, 3.37 % yield). Analytical HPLC: RT = 0.63 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιτι particles, gradient = 1.5 min, wavelength = 220 nm).LCMS shows a
hydrated mass, MS (ES): m/z = 474 [M+H20+H]+; ¾ NMR (400M Hz, METHANOL- d4) δ 8.70 (d, J=l . l Hz, IH), 8.31 - 8.23 (m, 4H), 7.67 - 7.60 (m, IH), 7.55 - 7.50 (m, IH), 7.13 (dd, J=5.2, 1.7 Hz, IH), 3.94 (s, 3H), 2.14 (s, 3H).
Example 297
N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoro-l-hydroxyethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
297A) N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoro-l-hydroxyethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a partially purified Example 296A (110 mg) in MeOH (5 mL) at ice bath temp was added 50 mg of NaBH4 in small portions with stirring. After 1 h, the reaction mixture was treated with 3 mL acetone, stirred for 10 min, and quenched with 0.4 mL HO Ac. The mixture was concentrated in vacuo and the residue was purified by prep HPLC to obtain 65 mg of the alcohol as a TFA salt. Prep HPLC: Column #1, 20% B to 100% B over 8 min, RT = 5.6 min Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-0.1% TFA; Solvent B = 90% CH3CN/10% H2O-O. /0 TFA MS (ES): m/z = 588 [M+H]+; ¾ NMR (400 MHz, METHANOLS) δ 8.86 (s, IH), 8.78 (s, IH), 8.59 (dd, J=5.1, 0.4 Hz, IH), 8.51 (d, J=2.6 Hz, IH), 8.36 (s, IH), 7.58 (dd, J=9.1, 3.0 Hz, IH), 7.35 (dd, J=5.1, 1.5 Hz, IH), 7.23 (d, J=9.0 Hz, IH), 5.63 (s, 2H), 5.55 (q, J=6.8 Hz, IH), 3.94 (s, 3H), 3.52 - 3.47 (m, 2H), 2.20 (s, 3H), 0.87 - 0.81 (m, 2H), -0.09 (s, 9H).
Example 297: N-(4-(3-(5-Methoxypyridin-2-yl)-6-(2,2,2-trifluoro-l-hydroxyethyl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of the TFA salt of Example 297A (65 mg, 0.093 mmol) in CH2CI2 (4 mL) at room temperature was added 2 mL TFA. After 4 h at rt the mixture was concentrated in vacuo and the residue was purified by prep HPLC to obtain Example 297 (23 mg, 0.048 mmol, 52 % yield). Prep HPLC: Column #1, 20% B to 100% B over 8 min, RT = 4.8 min; Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H20-5mmol NH4OAc; Solvent B = 90% CH3CN/10% H20~5mmol
NH4OAC. Analytical HPLC: RT = 0.64 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιτι particles, gradient = 1.5 min, wavelength = 220 nm). MS (ES): m/z = 458 [M+H]+; ¾ NMR (400 MHz, METHANOLS) δ 8.46 (d, J=l. l Hz, IH), 8.27 (d, J=2.9 Hz, IH), 8.23 (d, J=4.8 Hz, 2H), 8.08 (s, IH), 7.65 (d, J=8.6 Hz, IH), 7.52 (dd, J=8.7, 3.0 Hz, IH), 7.12 - 7.09 (m, IH), 5.29 (q, J=7.0 Hz, IH), 3.94 (s, 3H), 2.15 (s, 3H).
Example 298
N-^4-(7-Acetyl-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
To a solution of 3-aminoisonicotinonitrile (9 g, 76 mmol) in MeOH (120 mL) at room temperature was added solid N-bromosuccinimide (26.9 g, 151 mmol) in several portions over 45 min with stirring. The reaction mixture was stirred at room temperature for 2 h. To the reaction mixture was added an additional 5 g of NBS and stirring continued at room temperature for 1 h. The reaction mixture was concentrated in vacuo and to the residue was added iPrOH (-120 mL). The resulting solid was filtered and washed with Et20 to obtain 15 g of a yellow solid. The solid was mixed with water (45 mL), sonicated and stirred. Then the resulting solid was collected by filtration and washed with water to obtain 10 g of the desired product. The original iPrOH filtrate was concentrated in vacuo and the residue was mixed with water, the solid was filtered, washed with Et20 to obtain brownish black solid. It was suspended in CHCh, the insoluble black solid was removed by filtration and the fitrate was concentrated. The residue was mixed with water, sonicated, stirred, and the solid was collected by filtration to obtain 2.78 g of a second crop of Example 298A. Total 12.8 g (61 %). MS (ES): m/z= 276. 278, 280 [M+H]+; ¾ NMR (400MHz, CDCh) δ 7.29 (s, 1H), 2.80 (s, 2H).
298B) N-(4-((3-Andno-6-bromo-4-cyanopyridin-2-yl)ethynyl)pyridin-2-yl)acetamide
A mixture of Example 298A (7.4 g, 26.7 mmol), Example IB (3.85 g, 24.05 mmol) and copper(I) iodide (0.254 g, 1.336 mmol) in DMF (60 mL) and EtsN (60 mL) was purged with N2. Solid PdCh(Ph3P)2 (0.938 g, 1.336 mmol) was added and the
mixture was heated at 75 °C for 30 min under a N2 atm. The resulting solid was filtered, washed with CH2CI2 and dried to obtain the 1st crop of Example 298B (6.8 g). The filtrate was concentrated to a volume of 25 mL. Water (100 mL) and CH2CI2 (100 mL) were added and the mixture was stirred for 20 minutes. The resulting solid was filtered and washed successively with water, CH2CI2 and iPrOH to obtain an impure product (~2.1 g). This impure material was triturated again with CH2CI2 to obtain the 2nd crop of the product (900 mg). Total 7.7 g (81 %). MS (ES): m/z= 356, 358 [M+H]+ ; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.38 (s, 1H), 8.31 (dd, J=5.2, 0.8 Hz, 1H), 7.97 (br. s., 1H), 7.46 (s, 1H), 7.21 (dd, J=5.1, 1.5 Hz, 1H), 5.10 (br. s., 2H), 2.25 (s, 3H).
298C) N-(4-(5-Bromo-7-cyano-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A heterogeneous mixture of Example 298B (6.4 g, 17.97 mmol) and cesium carbonate (6.44 g, 19.77 mmol) in DMF (100 mL) was purged with Ν2 and treated with Pd(Ph3P)4 (1.038 g, 0.898 mmol). The mixture was purged with Ν2 again and heated at 80 °C under Ν2 atm for 1 h. It was then concentrated to a volume of -60 mL and water (350 mL) and 40 mL CH2CI2 (40 mL) were added. The mixture was stirred at rt, and the resulting solid was collected and washed with a small amount of iPrOH, and then CH2CI2 to obtain Example 298C (5.3 g, 14.88 mmol, 83 %) after drying.MS (ES): m/z= 356, 358 [M+H]+ ; ¾ NMR (400MHz, DMSO-de) δ 13.08 (br. s., 1H), 10.65 (br. s., 1H), 8.57 (br. s., 1H), 8.44 (br. s., 1H), 7.92 (br. s., 1H), 7.72 (s., 1H), 7.32 (s., 1H), 2.15 (s., 3H).
298D) N-(4-(5-Bromo-7-cyano-3-iodo-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide
A heterogeneous mixture of Example 298C (600 mg, 1.685 mmol) and N- iodosuccinimide (379 mg, 1.685 mmol) in THF (10 mL) was stirred at room temperature for 1 h. The reaction mixture was mostly concentrated in vacuo, and the residue was mixed with CH2CI2 and water and the solid was filtered. The solid was washed with water and CH2CI2 to obtain Example 298D (670 mg, 1.390 mmol, 83 %). MS (ES): m/z= 482, 484 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 13.49 (s, 1H), 10.72 (s, 1H), 8.65 (s, 1H), 8.51 (d, J=5.1 Hz, 1H), 8.05 (s, 1H), 7.55 (dd, J=5.1, 1.5 Hz, 1H), 2.15 (s, 3H).
298E) N-(4-(5-Bromo-7-cyano-3-iodo-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A heterogeneous mixture of Example 298D (4.5 g, 9.33 mmol), Hunig's Base (2.119 mL, 12.14 mmol) and (2-(chloromethoxy)ethyl)trimethylsilane (1.712 g, 10.27 mmol) in CH2CI2 (70 mL) was stirred at room temperature. It slowly became a homogeneous solution and the reaction was complete in 1 h. To the reaction mixture was added water, the CH2CI2 layer was separated, dried over MgS04, and concentrated in vacuo. The resulting residue was passed through a flash column on S1O2 eluting with hexane-EtOAc gradient to obtain Example 298E (4.2 g, 6.86 mmol, 74 %). The desired product was eluted at 40-55% EtOAc in hexane. MS (ES): m/z= 612, 614 [M+H]+ ; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.51 (br. s., 1H), 8.46 (d, J=5.3 Hz, 1H), 7.69 (s, 1H), 7.34 (d, J=4.4 Hz, 1H), 7.28 - 7.28 (m, 1H), 5.65 (s, 2H), 3.56 - 3.35 (m, 2H), 2.29 (s, 3H), 0.97 - 0.77 (m, 2H), 0.00 - -0.19 (m, 9H).
298F) N-(4-(5-Bromo-7-cyano-3-(6-methoxypyridin-3-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 298E (1.8 g, 2.94 mmol), (6-methoxypyridin-3-yl)boronic acid (0.899 g, 5.88 mmol) and 0.25 mL of 3M K3PO4 in dioxane (20 mL) was purged with N2. PdC12(dppf) (0.215 g, 0.294 mmol) was added, the reaction was purged with N2 again and the mixture was put into a preheated heater at 100 °C. It was stirred at 100 °C under N2 for 60 min., and then cooled to rt. The reaction mixture was mixed with CH2CI2 and anhydrous Na2S04, stirred, the solid was filtered, washed with CH2CI2 and the filtrate was concentrated in vacuo. The residue was purified by flash column on S1O2 eluting with gradient (Hexane-EtOAc) to obtain Example 298F (800 mg, 1.348 mmol, 46 %). MS (ES): m/z= 593, 595 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.32 (br. s., IH), 8.03 (s, IH), 7.95 (d, J=4.6 Hz, IH), 7.77 (d, J=2.2 Hz, IH), 7.33 (dd, J=8.6, 2.2 Hz, IH), 6.89 (s, IH), 6.66 (d, J=4.4 Hz, IH), 6.36 (d, J=8.6 Hz, IH), 5.27 (s, 2H), 3.54 (s, 3H), 3.16 - 3.10 (m, 2H), 1.85 (s, 3H), 0.56 - 0.50 (m, 2H), -0.43 (s, 9H).
298G) N-(4-(7-Acetyl-3-(6-methoxypyridin-3-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of Example 298F (45 mg, 0.076 mmol) in THF at -78 °C under N2 was added a MeLi solution (0.5 mL of 1.6M in ether) and it was stirred for 30 min.
nBuLi solution (0.2 mL of 2.5M in hexane) was added and the mixture was stirred for 6 min. To the reaction mixture was added 0.5 mL of HO Ac, and it was stirred for 5 min. CH2CI2 and water were added, organic layer was separated, concentrated in vacuo and prep HPLC provided Example 298G (7 mg, 0.013 mmol, 17 %). Prep HPLC: Column #1, 20% B to 100% B over 8 min, Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-O. /0 TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. MS (ES): m/z= 532 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 12.01 (br. s., 1H), 8.81 (d, J=4.2 Hz, 1H), 8.67 (s, 1H), 8.27 (br. s., 1H), 8.18 (br. s., 1H), 7.98 (d, J=7.0 Hz, 1H), 7.61 (d, J=3.3 Hz, 1H), 7.22 (br. s., 1H), 7.00 (d, J=6.2 Hz, 1H), 5.44 (s, 2H), 4.04 (s, 3H), 3.26 - 3.19 (m, 2H), 2.80 (s, 3H), 2.33 (s, 3H), 0.80 - 0.73 (m, 2H), -0.05 (s, 9H).
Example 298) N- 4-(7-Acetyl-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 298G (7 mg, 0.013 mmol) and TFA (0.5 mL) in CH2CI2 (7 mL) was stirred at room temperature for 5 h, and then concentratyed in vacuo. The residue was purified by prep HPLC to obtain the TFA salt of Example 298 (4 mg, 6.98 μιηοΐ, 53 %). Prep HPLC: Column #1, 20% B to 100% B over 8 min, RT = 2.5 min.; Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O- 0.1% TFA; Solvent B = 90% CH3CN/10% H2O-O. /0 TFA. Analytical HPLC: RT = 0.62 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm).MS (ES): m/z= 402 [M+H]+; ¾ NMR (400 MHz, DMSO-de) δ 11.74 (br.s., 1H), 10.58 (s, 1H), 8.66 - 8.60 (m, 1H), 8.34 - 8.27 (m, 2H), 8.22 (d, J=2.0 Hz, 1H), 7.81 (d, J=5.1 Hz, 1H), 7.77 (dd, J=8.5, 2.3 Hz, 1H), 7.14 (d, J=4.0 Hz, 1H), 6.85 (d, J=8.6 Hz, 1H), 3.87 (s, 3H), 2.77 (s, 3H), 2.09 (s, 3H).
Example 299
N-(4-(7-(2-Hydroxypropan-2-yl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
To a solution of TFA salt of Example 298 (50 mg, 0.097 mmol) in THF (2.5 mL) at ice bath temp under N2 atm was added MeMgCl (0.8 mL of 3M solution in THF) slowly with stirring. After 40 minutes, was added TFA in MeOH (0.4 mL in 3 mL MeOH) slowly and the reactionmixture was concentrated in vacuo. The residue was mixed with EtOAc (15 mL), concentrated in vacuo and was purified by preparative HPLC to obtain Example 299 (10.9 mg, 0.026 mmol, 27 %). Prep HPLC: Column: XBridge C18, 19 x 200 mm, 5-μπι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Analytical HPLC: RT = 0.55 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μπι particles, gradient = 1.5 min, wavelength = 220 nm). MS (ES): m/z= 418 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 10.96 - 10.91 (br. s, 1H), 10.60 (s, 1H), 8.34 (d, J = 4.8 Hz, 1H), 8.30 (m, 1H), 8.27 (s., 1H), 8.19 (, 1H), 7.80 - 7.74 (m, 1H), 7.18 (d, J=4.8 Hz, 1H), 7.10 (d, J=4.5 Hz, 1H), 6.84 (d, J=8.5 Hz, 1H), 3.85 (s, 3H), 2.54 (s, 1H), 2.08 (s, 3H), 1.64 (s, 6H).
Example 300
N-(4-(7-(l-Hydroxy-2-methylpropyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
300A) N-(4-(5-Bromo-7-cyano-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
A mixture of Example 298F (100 mg, 0.168 mmol) and TFA (1 mL) in CH2CI2 (5 mL) was stirred at room temperature for 8 h. The mixture was concentrated in vacuo to obtain -100 mg of the crude product. This material was used directly in the next step. HPLC: RT = 0.86 min (H2O/CAN with 0.1% TFA, Waters Acquity UPLC BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 2 min, wavelength = 220 nm); MS (ES): m/z = 462.9, 464.9 [M+H]+.
300B) N-(4-(5-Bromo-7-isobutyryl-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin- 2-yl)pyridin-2-yl)acetamide
To a solution of Example 300A TFA salt (110 mg, 0.191 mmol) in THF (3 mL) at -78 °C was added 2 mL of 2 M iPrMgCl solution in THF with stirring. After 2 h, the mixture was slowly warmed to room temperature over 2 h. The reaction mixture was again cooled to -78 °C and additional 2 mL of 2M iPrMgCl solution was added and then the mixture was warmed to rt over 1 h. To the reaction mixture were added EtOAc (5 mL) and HO Ac (2 mL) and it was stirred for 10 min. The mixture was mixed with CH2CI2 and aq NaHCCb. The CH2CI2 layer was separated, then aq layer was washed with CH2CI2 and the combined CH2CI2 layers were concentrated in vacuo. The residue was purified by prep HPLC to obtain the TFA salt of Example 300B (25 mg, 21%) as a yellow solid. Column #1, 20% B to 100% B over 8 min, RTt = 6.8 min. Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-O. /0 TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. MS (ES): m/z= 508, 510 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 12.65 (br. s., IH), 10.59 (br. s., IH), 8.91 (s, IH), 8.29 (br. s., IH), 8.08 (br. s., IH), 7.89 - 7.85 (m, IH), 7.84 (s, IH), 7.29 (d, J=4.2 Hz, IH), 6.92 (d, J=8.6 Hz, IH), 4.01 (s, 3H), 3.66 (hept, J=6.6 Hz, IH), 2.35 (s, 3H), 1.33 (d, J=6.6 Hz, 6H)
Example 300) N-(4-(7-(l -Hydroxy -2-methylpropyl)-3-(6-methoxypyridin-3-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of bromoketone Example 300B (25 mg) and 20% Pd(OH)2/C (25 mg) in MeOH (10 mL) was stirred under 1 atm H2 gas at room temperature for 1.5 h. The solid was filtered, washed with MeOH, and the filtrate was concentrated in vacuo. The residue was purified by prep HPLC to obtain Example 300 (14.9 mg, 0.035 mmol, 86 %). Prep HPLC: Column: XBridge C18, 19 x 200 mm, 5-μιη particles; Mobile Phase A: 5:95
acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5- minute hold at 100% B; Flow: 20 mL/min. Analytical HPLC: RT = 0.61 min (H20/MeCN with 0.1 % TFA, Waters Acquity BEH C 18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm).MS (ES): m/z= 432 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 1 1.63 (s, 1H), 10.60 (br. s., 1H), 8.37 (d, J=4.6 Hz, 1H), 8.32 (d, J=5.1 Hz, 1H), 8.27 (br. s., 1H), 8.21 (br. s., 1H), 7.78 (d, J=8.3 Hz, 1H), 7.23 (d, J=4.6 Hz, 1H), 7.12 (d, J=4.6 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 5.45 (br. s., 1H), 4.96 (t, J=5.0 Hz, 1H, should be a dd, but shows it as if it is a triplet), 3.85 (s, 3H), 2.08 (s, 3H), 1.90 (m, 1H), 0.89 (t, J=6.5 Hz, 6H, should be d or dd, but shows it as if it is a triplet).
Example 301
N-(4-(7-(l -Hydroxypropyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
301A) N-(4-(5-Bromo-3-(6-methoxypyridin-3-yl)-7-propionyl-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of Example 298F (358 mg, 0.603 mmol) in THF (3 mL) at room temperature was added 3 mL of 1 M EtMgBr solution in THF slowly with stirring. After
30 min, the reaction mixture was cooled to -78 °C and an additional 2 mL of 2M iPrMgCl solution was added. The mixture was warmed to room temperature over 1 h. To the reaction mixture were added EtOAc (5 mL) and HO Ac (2 mL), and it was stirred for 10 min. The reaction mixture was mixed with CH2CI2 and aq NaHCC , the organic layer was separated, and the aq layer was washed with CH2CI2. The combined CH2CI2 layers were concentrated in vacuo. The residue was purified by prep HPLC to obtain Example 301A (80 mg, 0.155 mmol, 26 %). Column #1, 20% B to 100% B over 8 min, RT = 11 min. Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O- 0.1% TFA; Solvent B = 90% CH3CN/10% H2O-O. /0 TFA. MS (ES): m/z= 624, 626 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 11.92 (br.s., 1H), 8.71 (s, 1H), 8.17 (d, J=5.7 Hz, 1H), 8.08 (d, J=2.2 Hz, 1H), 7.82 (dd, J=8.6, 2.4 Hz, 1H), 7.46 (s, 1H), 7.13 (dd, J=5.7, 1.3 Hz, 1H), 6.85(d, J = 8.6 Hz, 1H), 5.33 (s, 2H), 3.95 (s, 3H), 3.15 - 3.13 (m, 2H), 3.06 (q, J=7.2 Hz, 2H), 2.31 (s, 3H), 1.29 (t, J=7.2 Hz, 3H), 0.74 - 0.69 (m, 2H), - 0.08 (s, 9H).
301B) N-(4-(5-Bromo-3-(6-methoxypyridin-3-yl)-7-propionyl-lH-pyrrolo[3,2-b]pyridin- 2-yl)pyridin-2-yl)acetamide
To a solution of Example 301 A (40 mg, 0.064 mmol) in CH2CI2 (5 mL) at room temperature was added 1 mL TFA. The mixture was stirred for 6 h, and then concentrated in vacuo and the residue was purified by prep HPLC to obtain the TFA salt of Example 301B (20 mg, 0.033 mmol, 51 %).Column #1, 20% B to 100% B over 8 min, RT = 6.3 min.; Column #1 = Waters Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-O. P/0 TFA; Solvent B = 90% CH3CN/10% H2O-O. P/0 TFA. MS (ES): m/z= 494, 496
[M+H]+; ¾ NMR (400 MHz, METHANOL-cU) δ 8.35 (br. s., 1H), 8.29 (d, J=1.8 Hz, 1H), 8.00 (s, 1H), 7.94 (dd, J=8.7, 2.3 Hz, 1H), 7.78 (br. s., 1H), 7.52 (br. s., 1H), 7.03 (d, J=8.8 Hz, 1H), 4.01 (s, 3H), 3.22 (q, J=7.1 Hz, 2H), 2.26 (s., 3H), 1.28 (t, J=7.0 Hz, 3H).
Example 301) N-(4-(7-(l-Hydroxypropyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide
A mixture of Example 301B (20 mg, 0.033 mmol) and 12 mg of 20% Pd(OH)2/C in MeOH (10 mL) was stirred at rt under 1 atm of H2 for 3.5 h. The reaction mixture was filtered, and the solid was washed with MeOH. The filtrate was concentrated in vacuo and the residue was purified by prep HPLC to obtain Example 301 (9.5 mg, 67%). Prep HPLC: Column: XBridge C18, 19 x 200 mm, 5-μιη particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5- minute hold at 100% B; Flow: 20 mL/min. Analytical HPLC: RT = 0.57 min (H20/MeCN with 0.1 % TFA, Waters Acquity BEH C 18, 2.0 x 50 mm, 1.7-μιη particles, gradient = 1.5 min, wavelength = 220 nm).MS (ES): m/z= 418 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 1 1.66 (s, 1H), 10.61 (s, 1H), 8.37 (d, J=4.7 Hz, 1H), 8.33 (d, J=5.0 Hz, 1H), 8.29 (br. s., 1H), 8.21 (s, 1H), 7.80 - 7.76 (m, 1H), 7.26 (d, J=4.6 Hz, 1H), 7.12 (d, J=4.8 Hz, 1H), 6.84 (d, J=8.5 Hz, 1H), 5.46 (d, J=4.4 Hz, 1H), 5.13 (br. s., 1H), 3.86 (s, 3H), 2.09 (s, 3H), 1.84-1.69 (m, 2H), 0.92 (t, J=7.2 Hz, 3H).
Example 302
l-(2-(2-Acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-7- yl)propyl carbamate
302A) N-(4-(3-(6-Methoxypyridin-3-yl)-7-propionyl-l-((2-
(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of Example 298F (1.6 g, 2.70 mmol) in THF (30 mL) at -78 °C under Ν2 atm was added an EtLi solution (30 mL of 0.5M solution in benzene- cyclohexane, Aldrich) with stirring. After 1.5 h, the mixture was warmed to -20 °C and 3 mL HO Ac was added, along with 15 mL methanol and 1.5 mL water. The mixture was stirred, mostly concentrated in vacuo and the residue was passed through a flash column on S1O2 eluting with heanae-EtOAc gradient to obtain Example 302A (400 mg, 0.733 mmol, 27%). MS (ES): m/z= 546 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 8.85 (s, 1H), 8.64 (d, J=4.8 Hz, 1H), 8.35 (br. s., 1H), 8.29 (d, J=5.1 Hz, 1H), 8.15 - 8.13 (m, 1H), 7.81 (dd, J=8.6, 2.4 Hz, 1H), 7.28 (s, 1H), 6.98 (dd, J=5.1 , 1.5 Hz, 1H), 6.76 (dd, J=8.6, 0.4 Hz, 1H), 5.38 (s, 2H), 3.91 (s, 3H), 3.1 1 - 3.05 (m, 4H), 2.20 (s, 3H), 1.29 (t, J=7.0 Hz, 3H), 0.69 - 0.64 (m, 2H), -0.1 1 (s, 9H).
303B) N-(4-(7-(l-Hydroxypropyl)-3-(6-methoxypyridin-3-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide
To a solution of Example 302A (400 mg, 0.733 mmol) in MeOH (15 mL) at ice bath temp was added NaBH4 solid (160 mg) in several portions. The mixture was stirred for 2 h and 2 mL of acetone was added. The mixture was stirred for 10 min. and 2 mL HOAc was added. The mixture was concentrated in vacuo and the residue was passed through a flash column on S1O2 eluting with CLhCh-EtOAc gradient (product was eluted at 80-100% EtOAc in CH2CI2) to obtain Example 302B (310 mg, 0.566 mmol, 77 %). MS (ES): m/z= 548 [M+H]+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 9.34 (br. s., IH), 8.47 (d, J=4.8 Hz, IH), 8.34 (br. s., IH), 8.22 - 8.19 (m, IH), 8.04 (d, J=2.2 Hz, IH), 7.76 (dd, J=8.6, 2.4 Hz, IH), 7.36 (d, J=5.4 Hz, IH), 6.95 (dd, J=5.2, 1.2 Hz, IH), 6.70 (d, J=8.6 Hz, IH), 5.53 - 5.41 (m, 2H), 5.30 (dd, J=7.9, 4.6 Hz, IH), 3.86 (s, 3H), 3.19 (dd, J=9.2, 7.5 Hz, 2H), 2.15 (s, 3H), 1.99 - 1.86 (m, 2H), 1.07 (t, J=7.4 Hz, 3H), 0.73 (t, J=8.5, 2H), -0.14 (s, 9H).
302C) l-(2-(2-Acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[3,2-b]pyridin-7-yl)propyl carbamate
To a solution of Example 302B (165 mg, 0.301 mmol) in CH2CI2 (5 mL) at ice bath temp was added 200 uL of trichloroacetylisocyanate slowly with stirring. In 30 min a solution of aq NH3 in MeOH (0.6 mL of 28% NH3 in water + 4 mL MeOH) was added, stirring continued for 30 minutes at ice bath temp and then 5 h at room temperature. The mixture was mostly concentrated in vacuo and the residue was purified by prep HPLC to obtain the TFA salt of Example 302C (124 mg, 0.151 mmol, 50.3 % yield). Prep HPLC: Column#l, 20% A to 100% B over 8 min, RT = 5.2 min; Column #1 = Waters Sunfire C- 18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-O. /0 TFA; Solvent B = 90% CH3CN/10% H2O-O. /0 TFA. MS (ES): m/z= 591 [M+H1+; ¾ NMR (400 MHz, CHLOROFORM-d) δ 10.91 (br. s., 1H), 8.67 (s, 1H), 8.64 (d, J=5.7 Hz, 1H), 8.19 (d, J=5.7 Hz, 1H), 8.01 (d, J=2.2 Hz, 1H), 7.65 (dd, J=8.6, 2.4 Hz, 1H), 7.61 (d, J=5.7 Hz, 1H), 7.09 (dd, J=5.6, 1.4 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.30 (dd, J=7.9, 5.1 Hz, 1H), 6.06 (d, J=10.8 Hz, 1H), 5.25 (d, J=10.6 Hz, 1H), 5.11 (br. s, 2H), 3.93 (s, 3H), 3.50 (dd, J=9.1, 8.3 Hz, 2H), 2.27 (s, 3H), 2.04 - 1.95 (m, 2H), 1.12 (t, J=7.3 Hz, 3H), 1.07 - 0.90 (m, 2H), -0.01 (s, 9H).
Example 302) l-(2-(2-Acetamidopyridin-4-yl)-3-(6-methoxypyridin-3-yl)-lH- pyrrolo[3,2-b]pyridin-7-yl)propyl carbamate
To a solution of 2 TFA salt of Example 302C (124 mg, 0.151 mmol) in CH2CI2 (5 mL) at room temperature was added 2.3 mL of TFA. The mixture was stirred for 7 h, and then concentrated and the residue was purified by prep HPLC to obtain partially purified material. Prep HPLC: Column#l, 20% A to 100% B over 8 min; Column #1 = Waters
Sunfire C-18, 19x150 mm; Solvent A = 10% CH3CN/90% H2O-0.1% TFA; Solvent B = 90% CH3CN/10% H2O-0.1% TFA. This material was repurified by prep HPLC to obtain Example 302 (13 mg, 0.028 mmol, 18.64 % yield). Prep HPLC: Column: XBridge C18, 19 x 200 mm, 5-μηι particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Analytical HPLC: RT = 0.59 min (H20/MeCN with 0.1% TFA, Waters Acquity BEH C18, 2.0 x 50 mm, 1.7-μηι particles, gradient = 1.5 min, wavelength = 220 nm).MS (ES): m/z= 461 [M+H]+; ¾ NMR (500 MHz, DMSO-de) δ 11.87 (s, IH), 10.57 (s, IH), 8.35 (d, J=4.7 Hz, IH), 8.30 (d, J=5.1 Hz, IH), 8.27 (s, IH), 8.18 (d, J=1.9 Hz, IH), 7.74 (dd, J=8.5, 2.1 Hz, IH), 7.11 (d, J=4.8 Hz, 2H), 6.81 (d, J=8.6 Hz, IH), 6.07 (m, IH), 3.82 (s, 3H),), 2.05 (s, 3H), 1.91 - 1.75 (m, 2H), 0.91 (t, J=7.2 Hz, 3H).
Biological Assays
Assays are conducted in 1536-well plates and 2 reactions are prepared from addition of HIS-TGF Rl T204D or HIS-TGF R2 WT, anti-HIS detection antibody, a labeled small molecule probe (Kd = <100 nM; k0ff = O.001 s"1) and test compounds in assay buffer (20 mM HEPES pH 7.4, 10 mM MgCh, 0.015% Brij35, 4 mM DTT, and 0.05 mg/ml BSA). The reaction is incubated for 1 hour at room temperature and the HTRF signal was measured on an Envision plate reader (Ex:340nm; Em:520nm/495nm). Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentration of reagents in the assay are 1 nM HIS-TGF Rl T204D or HIS-TGF R2 WT, 0.2 nM anti- HIS detection antibody, labeled small molecule prode (at Kd) and 0.5% DMSO. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations. IC50 values were derived by non-linear regression analysis.
Table 14 shows the TGF Rl and TGF R2 IC50 values for the Examples of this invention.
Table 14
47 0.004 >15
48 0.001 0.076
49 0.003 0.24
50 0.003 6.57
51 0.002 0.61
52 0.041 0.45
53 0.002 0.005
54 0.021 3.61
55 0.003 0.069
56 0.017 1.1
57 0.019 0.11
58 0.017 9.23
59 0.021 6.37
60 0.32 6.65
61 0.005 0.98
62 0.009 >15
63 0.019 >15
64 0.009 0.3
65 0.01 >15
66 0.002 3.72
67 0.037 0.36
68 0.96 >15
69 0.76 >15
70 7.73 >15
71 0.27 4.38
72 0.008 1.55
73 0.019 15.5
74 0.001 2.6
75 0.005 1.03
76 0.016 0.93
77 0.033 >15
78 0.003 0.16
79 0.007 0.16
80 0.007 0.083
81 0.014 0.26
82 0.006 4.05
83 0.002 >15
84 0.002 0.13
85 0.01 4.05
86 0.008 >15
87 0.002 >15
88 0.001 9.92
89 0.003 4.81
90 0.004 3.67
91 0.019 >15
92 0.002 >15
Example # TGFpRl (μΜ) TGF0R2 (μΜ)
93 0.003 >15
94 0.004 >15
95 0.002 >15
96 0.001 >15
97 0.001 >15
98 0.002 >15
99 n/a 2.75
100 n/a 2.62
101 n/a 4.29
102 n/a 3.45
103 n/a 4.92
104 0.002 6.29
105 0.005 >15
106 0.003 >15
107 0.001 8.14
108 0.145 >15
109 0.011 14.1
110 0.053 >15
111 0.002 2.42
112 0.001 8.75
113 0.003 14.6
114 0.55 >15
115 0.001 8.68
116 0.005 7.35
117 0.003 11.3
118 0.002 >15
119 O.001 >15
120 0.001 >15
121 0.001 >15
122 0.001 >15
123 O.001 >15
124 0.001 12.8
125 0.003 >15
126 0.009 >15
127 0.001 6.65
128 n/a 5.26
129 0.007 >15
130 0.004 >15
131 0.001 3.84
132 0.001 >15
133 0.001 >15
134 0.004 8.66
135 0.003 >15
136 0.006 >15
137 0.058 >15
138 0.200 >15
Example # TGFpRl (μΜ) TGF0R2 (μΜ)
139 0.001 8.47
140 0.001 7.60
141 0.003 27.3
142 0.001 7.81
143 0.001 2.53
144 0.001 0.361
145 0.002 2.94
146 0.001 1.78
147 0.002 0.750
148 0.001 0.484
149 0.002 8.37
150 0.001 6.08
151 0.010 >15
152 0.002 4.09
153 n/a n/a
154 0.001 1.77
155 0.001 3.47
156 0.188 >15
157 0.0013 >15
158 0.0163 >15
159 0.0311 >15
160 0.0110 >15
161 0.0126 >15
162 0.0279 >15
163 0.0304 >15
164 0.0053 >15
165 0.0353 >15
166 0.0132 >15
167 0.0171 >15
168 0.0138 1.188
169 0.0023 0.882
170 0.0320 > 15
171 0.0010 10.763
172 0.0004 3.982
173 0.1498 1.352
174 0.0034 > 15
175 0.0004 > 15
176 0.0005 0.037
177 0.0014 > 15
178 0.0035 0.176
179 0.0580 > 15
180 0.0274 > 15
181 n/a 1.068
182 0.1822 > 15
183 0.0030 0.407
184 6.5186 > 15
Example # TGFpRl (μΜ) TGF0R2 (μΜ)
185 7.0006 > 15
186 0.0029 0.821
187 0.0587 0.424
188 0.0104 0.240
189 0.2489 0.089
190 0.0443 7.556
191 0.0939 1.996
192 0.1095 > 15
193 0.0006 > 15
194 0.0050 4.309
195 0.0048 > 15
196 0.0951 1.211
197 3.5430 > 15
198 0.0011 1.478
199 0.0006 0.041
200 0.0007 0.548
201 0.0275 1.533
202 0.0015 0.225
203 0.7743 > 15
204 0.0055 0.111
205 0.0029 0.147
206 0.0068 0.325
207 n/a 5.655
208 0.0006 0.044
209 0.0009 0.218
210 0.0025 0.815
211 0.0049 1.043
212 0.0005 8.822
213 0.0061 0.118
214 0.0014 0.173
215 0.0885 0.999
216 0.0013 3.773
217 > 15 > 15
218 0.0017 0.594
219 0.0006 0.082
220 0.0005 1.379
221 0.0037 1.357
222 0.0015 0.129
223 0.0008 0.043
224 0.0012 0.544
225 0.0007 0.057
226 0.0041 1.551
227 0.0006 0.725
228 n/a 4.241
229 0.0014 10.934
230 0.0024 0.037
Example # TGFpRl (μΜ) TGF0R2 (μΜ)
231 0.0010 9.108
232 0.0030 0.115
233 0.0014 4.062
234 0.0016 0.572
235 0.001 0.176
237 0.1112 > 15
238 0.0882 > 15
239 0.0746 3.276
240 0.5942 > 15
241 0.004 3.67
242 0.033 15
243 0.361 15
244 0.003 7.82
245 0.002 4.07
246 0.001 5.99
247 0.003 15
248 0.002 14.45
249 0.007 > 15
250 0.007 > 15
251 0.005 > 15
252 0.001 > 15
253 0.004 > 15
254 0.065 > 15
255 0.433 > 15
256 0.020 > 15
257 0.003 6.21
258 0.002 6.29
259 0.535 > 15
260 0.049 > 15
261 0.005 0.011
262 0.002 0.267
263 0.001 0.279
264 0.001 0.681
265 0.004 1.054
266 0.005 > 15
267 0.002 > 15
268 0.005 2.45
269 0.067 1.038
270 n/a 7.545
271 0.002 0.352
272 0.001 1.85
273 n/a 1.359
274 0.001 0.114
275 0.003 0.637
276 0.001 0.503
277 0.006 0.010
Example # TGFpRl (μΜ) TGF0R2 (μΜ)
278 0.011 0.709
279 0.006 9.90
280 0.023 4.12
281 0.001 0.984
282 0.001 1.850
283 0.001 1.122
284 0.003 5.222
285 0.002 0.016
286 0.001 0.253
287 0.001 0.668
288 0.002 0.487
289 0.002 0.794
290 0.002 1.124
291 0.001 1.664
292 0.001 1.514
293 0.016 > 15
294 0.063 > 15
295 0.001 > 15
296 0.002 7.780
297 0.004 4.328
298 0.008 0.120
299 0.002 0.038
300 0.003 0.017
301 0.001 0.031
302 0.001 0.723
Claims
WHAT IS CLAIMED IS:
The compound of the formula
(I)
wherein:
a heterocylic or heterobicyclic group substituted with 0-4 R2; X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-; R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1 , 2, 3, or 4;
n is 0, 1 , 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
2. A compound according to claim 1 of formula (II)
wherein:
X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
3. A compound according to claim 2 of the formula
(R2)trv -^: X1
wherein:
X1, X2, X3 and X4 are independently -CR4 or -N-, wherein at least one is -N-;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
4. A compound according to claim 3 of the formula
(Π)
wherein:
X1 and X2 are independently -CH or -N-;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4,-S02R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
Ry is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C3)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN; R8 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1, 2, 3, or 4;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
5. A compound according to claim 4 of the formula
(II)
wherein:
X1 and X2 are independently -CH or -N-;
R1 is hydrogen, (Ci-C3)alkyl, (C4-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
Ry is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN; R8 is hydrogen, (Ci-C3)alkyl, or -COR9;
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
m is 0, 1 or 2;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
6. A compound according to claim 1 of formula (III)
(III)
wherein:
R is a heterocylic or heterobicyclic group substituted with 0-4 R2;
R1 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C6)alkyl, (C2-C6)alkenyl, (Ci-C6)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C6)alkylamino-, (Ci-C6)alkylamino(Ci-C6)alkyl, 5-6 membered heteroaryl, heterocyclyl,
O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or (Ci-C6)alkyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl; or
R5 and R6 can be taken together with the nitrogen atom to which they are attached to form a 5-7 membered heterocyclo ring;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN; R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
7. A compound according to claim 6 of the formula
(III)
wherein:
R is a heterocylic or heterobicyclic group substituted with 0-4 R2;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-Ce)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C6)alkyl or -CN;
R8 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C6)alkyl, (C3-C8)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
8. A compound according to claim 7 of the formula
(III)
wherein:
R is thiazole, thiadiazole, thiophene, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R2;
R1 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or - SO2R9, any of which except the hydrogen is substituted with 0-3 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C6)alkyl, (Ci-C6)alkoxy or -SO2 (Ci-C6)alkyl;
R3 is independently one or more hydrogen, CD3, OCD3, halogen, -CN, (Ci- C3)alkyl, (C2-C6)alkenyl, (Ci-C3)alkoxy, (C3-C8)cycloalkyl, hydroxy(Ci-C3)alkyl, (Ci- C3)alkylamino-, (Ci-C3)alkylamino(Ci-C3)alkyl, 5-6 membered heteroaryl, heterocyclyl, O-heterocyclyl, -NR5R6, -CONR5R6, -COOR4, -COR4, -SO2R4, -CHCF2COOCH2OH or - CHCF2CONH2, any of which except the hydrogen is substituted with 0-4 Ry;
W is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, -CONHR9, -COOR9, -COR9 or -
R9 is hydrogen, (Ci-C3)alkyl, (C3-C6)cycloalkyl, heterocyclylalkyl-,
heterocyclyl(Ci-C3)alkylamino(Ci-C3)alkyl- or (Ci-C3)alkylamino(Ci-C3)alkyl;
n is 0, 1, 2 or 3;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
9. A compound according to claim 8 of the formula
(III)
wherein:
R is thiazole, pyrazole, isoquinoline, indole or quinoline substituted with 0-4 R2; R1 is -COR9 substituted with 0-2 Rx;
Rx is hydrogen, halogen, -OH, halo(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, -amino(Ci- C3)alkyl, or -CN;
R2 is independently one or more hydrogen, -CD3, OCD3, halogen, -CF3, -CHF2, - CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, halogen, -CN, (Ci-C3)alkyl, (Ci- C3)alkoxy, (C3-C6)cycloalkyl, 5-6 membered heteroaryl, heterocyclo, -NR5R6, - CONR5R6, -COOR4, -SO2R4 or (Ci-C3)alkylamino substituted with 0-2 R^;
Ry is hydrogen, halogen, -OH, (Ci-C3)alkyl, halo(Ci-C3)alkyl, hydroxy(Ci- C3)alkyl, -amino(Ci-C3)alkyl, -NHCOOH, or -CN;
R4 is hydrogen or methyl;
R5 and R6 are independently hydrogen, -C(0)alkyl or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is -COR9;
R9 is hydrogen, (Ci-C3)alkyl or (C3-C6)cycloalkyl;
n is 0, 1 or 2;
and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
10. A compound according to claim 9 of the formula
(III)
wherein:
R is thiazole, isoquinoline, indole or quinoline substituted with 0-4 R2;
R1 is -COR9;
R2 is independently one or more hydrogen, halogen, -CF3, -CN, (Ci-C3)alkyl, (Ci-C3)alkoxy or -SO2 (Ci-C3)alkyl;
R3 is independently one or more hydrogen, halogen, -CN or (Ci-C3)alkyl;
R7 is independently one or more hydrogen, halogen, halo(Ci-C3)alkyl or -CN;
R8 is hydrogen;
R9 is hydrogen or (Ci-C3)alkyl;
n is 0, 1 or 2;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
11. A compound according to claim 1 selected from the following
N- {4-[6-Fluoro-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin- 2-yl}acetamide,
N- {4-[6-Chloro-3-(5-fluoropyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl} -2- { [3-(morpholin-4-yl)propyl] amino} acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-(methoxy-d3)-lH-pyrrolo[3,2- b]pyridin-2-yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-ethoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-ethoxy-lH-pyrrolo[3,2-b]pyridin-2- yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(dimethylamino)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(hydroxymethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(l-hydroxyethyl)-lH-pyrrolo[3,2- b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(lR)-l -hydroxyethyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(l S)-l-hydroxyethyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-[(methylamino)methyl]-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-{3-[6-(Difluoromethyl)pyridin-2-yl]-7-(2-hydroxypropan-2-yl)-lH- pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)acetamide,
N-(4-(7-(l-Hydroxyethyl)-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-6-methoxy-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide, or
N-(4-(6-Methoxy-3-(6-methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
12. A compound according to claim 1 selected from the following
N-{4-[3-(6-Methoxypyridin-3-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2- yl}acetamide,
N-{4-[6-Chloro-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl}acetamide,
N-(4-(3-(5-(Methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2- yl)acetamide,
N-(4-(6-Chloro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(6-Fluoro-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide, 106
N-(4-(6-Methoxy-3-(5-(methoxy-d3)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide,
N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2-yl)pyridin- 2-yl)acetamide, or
N-(4-(6-Methoxy-3-(5-methoxypyridin-2-yl)-lH-pyrrolo[3,2-b]pyridin-2- yl)pyridin-2-yl)acetamide
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
13. A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
14. A combination pharmaceutical product comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents.
15. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.
16. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases or conditions for which a TGFBR antagonist is indicated.
17. A compound or a pharmaceutically acceptable salt thereof for use according to claim 16, wherein the disease or condition is cancer.
18. The use according to claim 17 wherein the cancer is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.
19. The use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of diseases or conditions for which a TGFBR antagonist is indicated.
20. A method of treating diseases or conditions for which a TGFBR antagonist is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580076649.4A CN107257798A (en) | 2014-12-22 | 2015-12-22 | TGF β R antagonists |
JP2017552007A JP2018501315A (en) | 2014-12-22 | 2015-12-22 | TGFβ receptor antagonist |
EP15823892.3A EP3237415A1 (en) | 2014-12-22 | 2015-12-22 | Tgf receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462095328P | 2014-12-22 | 2014-12-22 | |
US62/095,328 | 2014-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016106266A1 true WO2016106266A1 (en) | 2016-06-30 |
Family
ID=55135542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/067252 WO2016106266A1 (en) | 2014-12-22 | 2015-12-22 | TGFβ RECEPTOR ANTAGONISTS |
Country Status (7)
Country | Link |
---|---|
US (1) | US9708316B2 (en) |
EP (1) | EP3237415A1 (en) |
JP (1) | JP2018501315A (en) |
CN (1) | CN107257798A (en) |
AR (1) | AR103232A1 (en) |
TW (1) | TW201630907A (en) |
WO (1) | WO2016106266A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068759A1 (en) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
WO2018086609A1 (en) | 2016-11-14 | 2018-05-17 | 江苏恒瑞医药股份有限公司 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof |
WO2018226846A1 (en) * | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
JP2021506858A (en) * | 2017-12-18 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 4-azaindole compound |
US12049439B2 (en) | 2018-05-22 | 2024-07-30 | Orsobio, Inc. | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2813875T3 (en) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compounds and procedures for use |
WO2018171611A1 (en) * | 2017-03-22 | 2018-09-27 | 江苏恒瑞医药股份有限公司 | 6-pyrazole-[1,2,4]triazolo[4,3-a]pyridine-3-amide derivative, preparation method therefor and use thereof in medicine |
CN112694477B (en) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | Pyrazolo ring compound, pharmaceutical composition containing pyrazolo ring compound, preparation method and application of pyrazolo ring compound |
CN110885329B (en) * | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | Synthetic method of 1, 7-naphthyridine derivative |
WO2023147015A1 (en) * | 2022-01-27 | 2023-08-03 | The Broad Institute, Inc. | Substituted heterocyclic csnk1 inhibitors |
WO2023150793A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Inhibitors of malic enzyme 1 |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040176390A1 (en) * | 2003-03-04 | 2004-09-09 | Pfizer Inc | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors |
US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007075598A2 (en) | 2005-12-20 | 2007-07-05 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036653A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008098104A1 (en) | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009044273A2 (en) | 2007-10-05 | 2009-04-09 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
US20110207732A1 (en) * | 2008-10-23 | 2011-08-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Azaindole derivatives |
WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2011109400A2 (en) | 2010-03-04 | 2011-09-09 | Macrogenics,Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2011140249A2 (en) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
WO2012032433A1 (en) | 2010-09-09 | 2012-03-15 | Pfizer Inc. | 4-1bb binding molecules |
WO2012142237A1 (en) | 2011-04-15 | 2012-10-18 | Newlink Geneticks Corporation | Fused imidazole derivatives useful as ido inhibitors |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2013119716A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
WO2013132044A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and uses thereof |
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100378937B1 (en) | 1997-10-20 | 2003-05-09 | 에프. 호프만-라 로슈 아게 | Bicyclic kinase inhibitors |
SE0202463D0 (en) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
GB0708141D0 (en) * | 2007-04-26 | 2007-06-06 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
EP2245936A1 (en) * | 2009-04-27 | 2010-11-03 | Bayer CropScience AG | Use of 4-aza indole derivatives for the reduction of mycotoxin contamination |
GB201304527D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
-
2015
- 2015-12-21 TW TW104142991A patent/TW201630907A/en unknown
- 2015-12-21 AR ARP150104241A patent/AR103232A1/en unknown
- 2015-12-22 CN CN201580076649.4A patent/CN107257798A/en active Pending
- 2015-12-22 JP JP2017552007A patent/JP2018501315A/en active Pending
- 2015-12-22 WO PCT/US2015/067252 patent/WO2016106266A1/en active Application Filing
- 2015-12-22 EP EP15823892.3A patent/EP3237415A1/en not_active Withdrawn
- 2015-12-22 US US14/977,709 patent/US9708316B2/en active Active
Patent Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
US20040176390A1 (en) * | 2003-03-04 | 2004-09-09 | Pfizer Inc | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors |
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007075598A2 (en) | 2005-12-20 | 2007-07-05 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036653A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008098104A1 (en) | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009044273A2 (en) | 2007-10-05 | 2009-04-09 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
US20110207732A1 (en) * | 2008-10-23 | 2011-08-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Azaindole derivatives |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
WO2011109400A2 (en) | 2010-03-04 | 2011-09-09 | Macrogenics,Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2011140249A2 (en) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
WO2012032433A1 (en) | 2010-09-09 | 2012-03-15 | Pfizer Inc. | 4-1bb binding molecules |
WO2012142237A1 (en) | 2011-04-15 | 2012-10-18 | Newlink Geneticks Corporation | Fused imidazole derivatives useful as ido inhibitors |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2013119716A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
WO2013132044A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and uses thereof |
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
Non-Patent Citations (20)
Title |
---|
"Design of Prodrugs", 1985, ELSEVIER |
"Medicinal Chemistry: Principles and Practice", 2006, THE ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, UK |
"Methods in Enzymology", vol. 112, 1985, ACADEMIC PRESS, pages: 309 - 396 |
"The Peptides: Analysis, Synthesis, Biology", vol. 3, 1981, ACADEMIC PRESS |
"The Practice of Medicinal Chemistry", 2008, ACADEMIC PRESS |
BERNABEU ET AL., BIOCHEM BIOPHYS ACTA, vol. 1792, 2009, pages 954 - 973 |
BUIJS ET AL., CURR PHARMACEUTICAL BIOTECH, vol. 12, 2011, pages 2121 - 2137 |
BUNDGAARD, H. ET AL., J. PHARM. SCI., vol. 77, 1988, pages 285 |
BUNDGAARD, H. ET AL.: "A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, article "Design and Application of Prodrugs", pages: 113 - 191 |
BUNDGAARD, H., ADV. DRUG DELIV. REV., vol. 8, 1992, pages 1 - 38 |
GREENE; WUTS: "Protective Groups In Organic Synthesis", 1999, WILEY AND SONS |
HARRADINE ET AL., ANNALS OF MEDICINE, vol. 38, 2006, pages 403 - 414 |
KAKEYA, N. ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692 |
LING; LEE, CURRENT PHARMACEUTICAL BIOTECH., vol. 12, 2011, pages 2190 - 2202 |
RAUTIO, J: "Prodrugs and Targeted Delivery (Methods and Principles in Medicinal Chemistry)", vol. 47, 2011, WILEY-VCH |
REMINGTON: "The Science and Practice of Pharmacy", 2012, PHARMACEUTICAL PRESS |
SHI; MASSAGUE, CELL, vol. 113, 2003, pages 685 - 700 |
TESTA, B. ET AL.: "Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology", 2003, VCHA AND WILEY-VCH, ZURICH, SWITZERLAND |
WEISS; ATTISANO, WIRES DEVELOPMENTAL BIOLOGY, vol. 2, 2013, pages 47 - 63 |
WUTS, P. G. M.; GREENE, T.W.: "Protecting Groups in Organic Synthesis", 2007, WILEY |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068759A1 (en) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
CN108779115B (en) * | 2016-10-14 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine |
CN108779115A (en) * | 2016-10-14 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | Five yuan of hetero-aromatic rings and bridged ring analog derivative, preparation method and its application in medicine |
US10906905B2 (en) | 2016-10-14 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
US10899741B2 (en) | 2016-11-14 | 2021-01-26 | Jiangsu Hengrui Medicine Co., Ltd. | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof |
WO2018086609A1 (en) | 2016-11-14 | 2018-05-17 | 江苏恒瑞医药股份有限公司 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2018226846A1 (en) * | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
JP2021506858A (en) * | 2017-12-18 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 4-azaindole compound |
JP7289301B2 (en) | 2017-12-18 | 2023-06-09 | ブリストル-マイヤーズ スクイブ カンパニー | 4-azaindole compound |
US11820768B2 (en) | 2017-12-18 | 2023-11-21 | Bristol-Myers Squibb Company | 4-azaindole compounds |
US12049439B2 (en) | 2018-05-22 | 2024-07-30 | Orsobio, Inc. | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
US11618747B2 (en) | 2018-06-28 | 2023-04-04 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
US11970484B2 (en) | 2018-06-28 | 2024-04-30 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
Also Published As
Publication number | Publication date |
---|---|
CN107257798A (en) | 2017-10-17 |
AR103232A1 (en) | 2017-04-26 |
US9708316B2 (en) | 2017-07-18 |
TW201630907A (en) | 2016-09-01 |
US20160176871A1 (en) | 2016-06-23 |
JP2018501315A (en) | 2018-01-18 |
EP3237415A1 (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9708316B2 (en) | TGFβR antagonists | |
US12037323B2 (en) | Uracil derivatives as Mer-AXL inhibitors | |
US9725449B2 (en) | Tricyclic compounds as anticancer agents | |
WO2017015425A1 (en) | Tgf beta receptor antagonists | |
WO2020021024A1 (en) | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) | |
CN107207504B (en) | Phthalazinone derivatives, preparation method and use thereof | |
WO2016183115A1 (en) | 5h-pyrido[3,2-b]indole compounds as anticancer agents | |
WO2018017633A1 (en) | TGF Beta RECEPTOR ANTAGONISTS | |
JP2021527654A (en) | Pyrazole derivative as a MALT1 inhibitor | |
WO2017035118A1 (en) | Tgf beta receptor antagonists | |
CA3185649A1 (en) | Indole compounds as androgen receptor modulators | |
US10292985B2 (en) | TGF beta receptor antagonists | |
EP3390406A1 (en) | Cxcr4 receptor antagonists | |
US10961239B2 (en) | TGF beta receptor antagonists | |
US10399987B2 (en) | TGF beta receptor antagonists | |
WO2022169921A1 (en) | Benzofuran compounds as sting agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15823892 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015823892 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017552007 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |